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1 Introduction 
1.1 The History of Taxus and Paclitaxel* 
The genus Taxus, which is distributed over the temperate zones of the northern hemisphere, has 
ten species' including the European yew (T boccata), Japanese yew (T Cuspidata), and Pacific 
yew (T brevifoha) These different species are often considered to be simple geographic varieties so 
that the classification of the genus Taxus is very complicated The various species are 
morphologically almost indistinguishable because the principal characteristics such as shape, 
sharpness and color of the needles, are often difficult to interpret Classification is even further 
complicated by the existence of cultivated varieties (cultivars, over 100 for Τ boccata Linn ) which 
have been developed for desirable traits in gardening 
The yew is often called the tree of death Its poisonous nature has been known since antiquity 
Julius Caesar2 speaks of it in the sixth book of "De bello Gallico" in connection with Catuvolcus, 
the old Chief of the Celtic tribe of Eburones, who killed himself with the yew rather than surrender 
to the Romans 
There used to be yew forests in Europe, but now the plant is almost extinct in the wild state, 
because the wood, which is very strong and resistant to insects and woodworm, was used for many 
purposes In the Middle Ages yew was used to make spears, bows and arrows 3 Yew wood was also 
used for making art objects and musical instruments The yew was little used for making furniture, 
probably due to the toxicity of the dust The development of the yew long-bow ( 180-200 cm) was a 
technological revolution, the so called atom bomb of that time, which led to the initial successes of 
the English in the Hundred Years' war (1337-1475) The fact that at Agincourt 4,000 English 
archers defeated 65,000 French cavalrymen (the English had 26 dead and the French 40,000)" gives 
an idea of the military impact of the long bow Centuries of war nearly led to the extinction of the 
yew in Europe Today there are plenty of yews in parks and cemeteries, mainly for the following 
reasons It grows slowly, it needs little clipping, it is very strong and resists pollution and it is eye 
pleasing because of the intense green color of the needles which contrasts, in the female plants, with 
the red color of lb berries 
The medicinal use of the yew has been very limited Emperor Claudius recommended it to the 
Roman Senate as an antidote to adder bites In the 18th century it was used as an antimalarial and 
antirheumatic In more recent time its activity on the heart has been recognized and the possibility 
of using the yew as a cardiotoxic tonic has been suggested 5 
The berries of the yew are not poisonous, but the seeds in the berries are If the seeds are not 
" The INN (International Nonproprietary Name) of taxol is paclitaxel Taxol is a trademark of the Bristol-Meyers 
Squibb Company (since the end of 1993) Therefore, the name paclitaxel is used instead of taxol 
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chewed, no effect is observed, because their outer integument is resistant to gastric juices. The 
needles of the yew are poisonous for all animals. The lethal dose is about 0.5 g/kg in monogastric 
animals and about 5 g/kg in ruminants. No such precise data are known for man, but four or five 
handfuls of needles, corresponding to about 150 needles are generally considered lethal.6 Poisoning 
is rapid and lethal, no specific antidote is known. The first poisoning symptoms are mydriasis, 
nausea, vomiting, abdominal cramp and arrhythmia. Death occurs through cardiac arrest from three 
to twenty-four hours after ingestion of the plant (extract). 
Yew is poisonous mainly because of a mixture of at least eleven alkaloids, known collectively as 
taxine, which comprises the main taxane type compounds present in the needles. In the rat the LD50 
by oral route is 20-25 mg/kg. The composition of taxine varies with the method of extraction, the 
period of harvesting the needles and the method of drying them. Two known constituents are taxine 
A (1) and taxine В (2) (figure 1.1). The LD50 of pure taxine В by oral route in the rat is 4-5 mg/kg at 
which dose taxine A is not toxic.7 
Figure 1.1 Chemical structures of taxine A (1), taxine В (2) and paclitaxel (3) 
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Paclitaxel (3) (figure 1.1) is not a constituent of taxine, since its nitrogen atom is benzoylated and 
therefore has no basic properties. The story of this molecule started in the sixties, when the National 
Cancer Institute (NCI) launched a very ambitious project for the discovery of anticancer compounds 
from plants. Between 1950 and 1980 extracts of over 30,000 plants were systematically analyzed. 
Paclitaxel was not an accidental discovery, but was an outcome of the investigation of over 12,000 
natural compounds for anticancer activity.8 
In 1963, the botanist Barclay first isolated a crude extract from the bark of the Pacific yew 
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(Taxus brevi/olia). In 1964 it was discovered that this extract was toxic for cultured murine 
leukemia cells. The isolation of the compound responsible for this activity began the following year 
in the laboratories of Monroe Wall of the Research Triangle Institute (North Carolina).9 Paclitaxel 
was obtained in the pure form in 1969 and its structure was published in 1971. The crystal structure, 
which will be discussed in section 2.3, was recently determined.10 Figure 1.2 shows a 3D-view of 
paclitaxel, which clearly shows that the molecule has the shape of an inverted cup. 
Figure 1.2 3D-view of paclitaxel 
Paclitaxel was not patented, mainly for two reasons: 1 ) The market was flooded, in those years, 
with anticancer drugs isolated from plants, and paclitaxel was simply one of many; 2) There was no 
renewable source of the product, as the concentration in the bark is very low, about 100 ppm (100 
mg/kg). A century old tree contains about 3 kg bark; extraction of 3 kg bark yields 300 mg 
paclitaxel implying that for one kg paclitaxel more than 3,000 trees are needed. 
The Taxus brevi/olia is a very slow growing tree which needs about 100 years to attain 
dimensions which allow exploitation of the bark (diameter: 25 cm, height: 6-9 meters). The pacific 
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yew grows in the forest of northwestern Canada (British Columbia) and the United States (southern 
Alaska, northern California, Washington, Oregon, Montana and Idaho) and it mostly forms 
populations of 5 to 10 trees per acre. 
Because of the difficulty of obtaining paclitaxel and its insolubility in water, the pharmacological 
importance of paclitaxel was not recognized until the late seventies, when its mechanism of action 
was discovered. 
In 1979, Susan Horwitz and co-workers discovered that paclitaxel blocks cell replication due to 
its ability to stabilize microtubules, thereby inhibiting the depolymerization of tubulin. In this way 
the cell loses control of assembling and disassembling the microtubules and can no longer divide. 
Because of this unique mechanism of action, paclitaxel became a major subject in many 
biochemical investigations. In the seventies NCI had developed new biological tests, based on 
human tumors transplanted in mice (xenografts).13 Paclitaxel proved to be more active on human 
than on murine tumors or neoplastic cells cultured in vitro. Phase I clinical trials started in 1983 and 
ended almost immediately, because one of the first patients died suddenly of hypotensive collapse 
and others had severe allergic reactions.14 However, the cause of the trouble was the large quantity 
of solvent (Cremophor EL, polyoxyethylated castor oil) used to make the drug soluble in water. 
Paclitaxel was then administered by slow infusion (24 h) and after premedication with 
antihistamines. As the first results were very promising, phase II trials started in 1985 and it was 
demonstrated that paclitaxel is active against ovarian, breast and lung cancer. In 1990, phase III 
trials started and are still going on. 
The supply of paclitaxel became a problem. Over 250,000 kg of bark was required in 1989 to 
obtain more than 25 kg of paclitaxel (a course of treatment requires 2 g of paclitaxel; for the 
treatment of 12,000 patients per year, 24 kg paclitaxel was needed). Such a large-scale use of 
paclitaxel would result in the disappearance of the Pacific yew within a few years. Moreover the 
yew grows in forests which are the nesting place of the spotted owl, which is a protected species 
and a symbol of the American environmentalists. 
In 1989 NCI admitted that it was not in a position to develop paclitaxel as a drug and sought a 
partner in the pharmaceutical industry.' In January 1991 the franchise for the development of 
paclitaxel was awarded to Bristol-Meyers Squibb. This company would supply NCI with all needed 
paclitaxel for clinical studies, search for alternative ways of obtaining the product and file a New 
Drug Application for regulatory approval at the FDA (Food and Drug Administration). In exchange 
the company would obtain a five-year exclusivity on the marketing of paclitaxel in the US. The 
harvesting of Pacific yew bark is now strictly regulated in the United States. The monopoly has 
been granted to Hauser Chemical Research.17 Harvesting takes place during the months of May to 
August. 
In 1992 in the US18" and in 1993 in Europe186 the use of paclitaxel (isolated from the bark of 
Taxus brevi/olia) for the treatment of patients with advanced ovarian cancer was approved and in 
1994 also the treatment of patients with breast cancer was approved in the US as well as in 
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Europe.19 In 1995 the FDA approved, in the US, the use of paclitaxel in a combination therapy with 
cisplatin (also a well known drug for the treatment of ovarian cancer) for the treatment of patients 
with ovarian cancer. 
The bark of the Pacific yew, Taxus brevi/olia can never be a permanent solution to the problem 
of paclitaxel supply, because the trees grow too slowly to provide a fast enough turnover between 
sowing and utilization. The remaining trees might provide a supply of paclitaxel for not more than 
5-10 years. Clearly paclitaxel can only be used in medicine if a method is developed for obtaining it 
from other renewable sources. Possible approaches are: semisynthetic, synthetic, phytochemical and 
biotechnological approaches. These approaches will be discussed in the next section. 
1.2 Alternative Sources for Paclitaxel 
1.2.1 Biotechnical Approaches 
The Occurrence of Various Taxanes in Taxus species 
More then two hundred taxoids have been isolated from plants of the genus Taxus.21 The 
structure of some of those are depicted in figure 1.3: Taxine A (1), isolated from Taxus baccalà22; 
Taxusin (4), isolated from Taxus baccalà23; taxinine A (5), isolated from Taxus cuspidata24 and 
Taxus chinensis; taxine В (2), isolated from Taxus baccata;2225 O-cinnamoyl-taxicin I (6), 
isolated from Taxus baccata; taxacin (7), isolated from Taxus cuspidata21 spicatine (8), isolated 
from Austrotaxus spicata2t brevifoliol (9) from Taxus brevi/olia29; baccatin III (10) and 10-
deacetylbaccatin III (11), both isolated from Taxus baccata20 and Taxus wallichiana^ baccatin VII 
(12), isolated from Taxus baccata;2 lO-deacetyl-lO-oxo-7-epi-paclitaxel (13), isolated from Taxus 
33 30 brevi/olia; 10-(ß-hydroxybutyryl)-10-deacetylpaclitaxel (14), isolated from Taxus boccata. 
These examples illustrate the structural variation of the isolated taxoids. Taxine В (2) is the main 
constituent in the needles of Taxus baccata. Another important constituent is 10-deaceteylbaccatin 
III (11), whereas the others are present in quantities of less than 100 mg/kg of dried needles. 
Figure 1.3 Some taxoids, isolated from different Taxus species 
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Biosvnthetic Pathways 
The biosynthesis of these taxoids is not known in detail, however Lythgoe et al. and others 
proposed a biosynthetic pathway in which the Л, В and С rings of the taxoids are formed by the 
6 
Introduction 
sequential intramolecular cychzations of the double bonds of geranylgeranyl pyrophosphate (15) via 
cation 16 to l(s)-verticilene (17) and then to taxa-4(20),l l(12)-diene (19) via cation 18 (figure 1 4) 
Figure 1.4 Biosynthesis of pachtaxel 
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These bioorganic pathways were studied by isolating intermediates, which were subsequently 
incubated with extracts of the yew stem. From 19, baccatin III (10) was produced by enzymatic 
oxidations and acylations. As shown by Fleming et al., attachment of either ß-phenylalanine or 
phenylisoserine gives 21 (it is uncertain when R is oxidized from H to OH) and after benzoylation 
of the amino group, paclitaxel (3) was formed. 
Croteau et al. have isolated the C-ring double bond isomer taxa-4(5),l l(12)-diene (20), from yew 
bark extract and demonstrated that this substance, when incubated with yew stem sections, was 
converted into paclitaxel, 10-deacetylbaccatin III and other highly functionalized taxanes. 
Recently they have found in their biosynthetic studies that 15 is converted into 20 and not 19 by 
taxadiene synthase, a diterpcne cyclase that catalyzes the first step of paclitaxel biosynthesis in 
pacific yew.36c 
Rubenstein et al. have synthesized both 19 and 20 and in ongoing studies they will examine 
37 
which compound is actually involved in the biosynthesis of paclitaxel. 
Paclitaxel from Taxus-Tissue Culture 
38 
Large-scale plant cell culture may be a cost effective technology to produce paclitaxel. To 
make paclitaxel production from Taxus cell culture commercially viable, large amounts of 
paclitaxel must be produced in a relatively short period of time. Therefore, a rapid-growing cell line 
that produces large amounts of paclitaxel is desired. Screening for high paclitaxel-producing trees 
may be a first step to the development of high yielding cell lines. Under appropriate conditions, 
plant tissue cells, preferably bark or cambial tissue cells, may undergo dedifferentiation to cells that 
form a tissue known as callus. Callus may be grown either as solid tissue or as a cell suspension of 
single cells or small groups of cells in a culture medium. 
Christen et al. reported the development of a method of producing taxane ring-containing 
alkaloid compounds from cell cultures of Taxus brevi/olia. The compounds produced by the cell 
cultures are paclitaxel and a number of additional taxoids, some of which may not be present in the 
plant. The identification and concentration were performed by HPLC. The concentration of 
paclitaxel is 1.0-3.0 mg/L from cell suspension cultures. Paclitaxel-producing cell suspension 
cultures established from Taxus media Hicksii and Taxus cuspidata have also been reported. 
Further manipulation of cell cultures, strong optimization of yield and continuous culture is needed 
for the economic production of paclitaxel.''2 
Production of Paclitaxel by a Fungus of Pacific Yew 
Production of bioactive substances by microbial fermentation can have several advantages: (a) 
microbes can be grown in tank fermentators, producing an inexhaustible supply of paclitaxel. (b) 
Microorganisms respond favorably to routine culture techniques, (c) Enlargement of the production 
scale is relatively easy, (d) Different bioactive compounds can be produced by altering culture 
conditions. 
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In the past two to three years Stierle et al. have isolated more than 300 fungi from the bark and 
needles of yews growing in Montana, Washington, Idaho and Oregon. They were motivated for 
this study by a discovery made forty years ago by Yabuta, a Japanese plant pathologist. Yabuta 
determined in his study of 'foolish rice seedling disease' that gibberellins (highly functionalized 
diterpenes that are responsible for the disease symptoms) are produced by a phytopathogenic fungus 
Gibberella fujikuroi and by higher plants. This finding suggests the possibility of genetic exchange 
between higher plants and fungi. Therefore, a search for a paclitaxel-producing organism was begun 
in the tissues of Taxus species. 
Of the 300 microbes screened to date only one, Taxus andreanae, has demonstrated the ability to 
produce paclitaxel. Stierle et al. have demonstrated that the paclitaxel found in cultures of Taxus 
andreanae is produced de novo by this fungus and that this paclitaxel is identical to the paclitaxel 
isolated from Taxus brevi/olia. Unfortunately the yield is rather low, about 24-50 ng of paclitaxel 
are produced per liter. Stierle et al. also demonstrated that this yield can be scaled up by adding yew 
extract, sugars or plant growth regulators. 
Improved culturing techniques, the addition of 'activators' and the application of genetic 
engineering methods may ultimately permit the commercialization of Taxus andreanae for the 
production of paclitaxel. 
1.2.2 Phytochemical Approach 
A phytochemical approach without killing the plant is based on the extraction of paclitaxel from 
parts of Taxus brevi/olia and of other Taxus species, which are renewable sources (e.g.: needles, 
seeds,4 ). The paclitaxel content in the needles shows great variation, depending on the Taxus 
species, ' '4 and is, anyway, much lower (10 to 1000 times) than in the bark of Taxus brevi/olia. 
Another problem seems to be the extreme complexity of the composition of the diterpene fraction of 
the needles. Also the very toxic alkaloid derivatives, present in much larger quantities, may cause 
problems of contamination. 
A possible solution has been offered by Hess et al. They have shown that it is possible to 
stimulate paclitaxel production in Taxus brevi/olia by the variation of growth conditions. This fits 
in the proposal by Bailey et al. of setting up a plantation system, using Taxus species with the 
most desirable paclitaxel characteristics. This plantation would allow the use of modern plant-
growing methods, it would be located for optimal climate, drainage, soil conditions and so on, and it 
would allow a less costly and more manageable harvest. Disadvantages are that it would take many 
years to obtain a continuous yield of paclitaxel, a plantation may be vulnerable to crop disasters and, 
in addition Paclitaxel from alternative species will also require FDA approval. 
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1.2.3 Synthetic Approaches 
Total synthesis 
In 1994 two groups, viz. Holton et al. and Nicolaou et al., published a total synthesis of 
paclitaxel at almost the same time. In 1995 Danishefsky et al. also reported a total synthesis of 
paclitaxel. The three different synthetic routes will be discussed briefly here. 
Holton et al. started their total synthesis with the commercially available'' compound patchino 
(23), which can also be synthesized from (-)-camphor (22) (figure 1.5). Patchino was converted into 
the dihydroxy compound 24, which then underwent epoxy alcohol fragmentation, after protection at 
C-13 compound 25 was isolated. Next, 26, synthesized in 5 steps from 25, was converted into 27 in 
36 % overall yield from patchino. Via 28, compound 27 was converted into paclitaxel (3) in 24 
steps. The overall yield of paclitaxel from patchino was 4-5 %. This is very reasonable for a 
synthetic route of 42 steps. 
Figure 1.5 Total synthesis of paclitaxel by Holton et al. 
3 steps 
" f r * 
(-)-Camphor (22) patchino (23) 24 
2 steps 
^ » - TBDMSO""foA У ^ В 
25 
О 8 steps 
TBDMSO 
Nicolaou et al. performed their total synthesis50 via the compounds 33 and 37, which were coupled 
by a Shapiro reaction and further converted into compound 38 (figure 1.6). However, 33 had to be 
synthesized from 29 in 11 steps with an overall yield of 28 % and 37 had to be synthesized from 34 
(obtained from acetone and ethyl acetoacetate) in 7 steps with an overall yield of 33 %. Furthermore 
31 was prepared in one step from galactaric (or mucic) acid in 19 % yield. The epoxide 38 was 
10 
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opened with LiAH4. The formed diol was converted to the cyclic carbonate. After desilylation and 
oxidation to the corresponding di-aldehyde, a McMurry cyclization led to compound 39. In 17 steps 
39 was converted into paclitaxel (3). The overall yield starting from 33 and 37 was 0.13 % (0.012 % 
from 29 and 34). 
Figure 1.6 Total synthesis of paclitaxel by Nicolaou et al. 
2 s , e P s Et02C. 
о OH. 
л^ 
EtOjC. 
II 
34 
OH OH 
30 31 
I 3 steps I 
35 
4 steps 
Τ 
36 
и' &Y 
OTBDMS 
2 steps 
* • 
TBDMSO 
oxidation and 
McMurry 
coupling 
5 steps 17 steps О Ph О 
 χ XTX 1 N 
oxidation [ΓΓ° 
0
 V 39 V 
-PhLi 
Η OH 
paclitaxel (3) 
Danishefsky et al. started their total synthesis ' from the commercially available Wieland-
Miescher ketone (40), (figure 1.7). This ketone was converted via 41 into compound 42 in 19 
steps. Compound 42 was coupled with 43 and then further converted into 44 in 11 steps. Ring 
closure of compound 44 by a Heck-reaction and further conversion gave paclitaxel (3). The 
synthesis of paclitaxel starting from the Wieland-Miescher ketone (40) took 51 steps and the overall 
yield was less than 0.014 %. 
The routes of Nicolaou and Danishefsky are so-called convergent routes, using chemical 
pathways for the production of both paclitaxel and a variety of its derivatives. Whereas the synthetic 
route of Holton (giving the best yields) is linear and therefore has less possibilities for the synthesis 
of derivatives. 
11 
It is not the purpose of this section to discuss which of the three syntheses is the most effective or 
most practical one. Despite the fact that all three are chemical masterpieces, commercially they will 
be of no interest. Long-term benefits may be the development of derivatives of paclitaxel that 
cannot be obtained from nature or semisynthesis, but that have a higher therapeutic index. Also, a 
total synthesis allows for greater structural variations than does semisynthesis, and in this way it 
may contribute in obtaining more insight in the mechanism of action. 
Figure 1.7 Total synthesis of paclitaxel by Danishefsky et al. 
7 steps 
OSi'BuMe- , 0 M e OSitBuMe, 
ОБіМез 6 steps 
(s)-Wieland-Miescher 
ketone (40) 
О Ph О 
phAN4-4A0.....Z; 
paclitaxel (3) 
Semisynthesis 
The discovery by Potier et al. that 10-deacetylbaccatin III (11) (scheme 1.1) can be isolated in 
significant quantities from a renewable source, i.e., the needles of the European yew Taxus baccalà, 
may be one of the most important findings in the attempt to secure the long term supply of 
paclitaxel through semi-synthesis. Extraction of the fresh needles yields 10-deacetylbaccatin III in 
amounts of up to lg/kg,3 which is about ten times the amount of paclitaxel isolated from the bark 
(0.1g/kg). 
Potier et al. reported the first successful semisynthesis of 10-deacetylpaclitaxel (48) starting 
from 10-deacetylbaccatin III (11) (scheme 1.1). This compound was converted into 45 by treatment 
with trichloroethyl chloroformate and reaction with cinnamoyl chloride in the presence of silver 
cyanide. Next, compound 46, together with its regio- and diastereo-isomers, was synthesized from 
45 by application of the Sharpless hydroxyammination procedure using N-chloro-N-sodio-tert-
butylcarbamate as the amine component. The yield of the desired diastereomers could be 
improved by adding dihydroquinine acetate or chlorobenzoate. Under the best conditions 46 and its 
regioisomer were obtained as a 1:1 mixture in 67 %. Cleavage of the ЛЧ-ВОС group, followed by 
benzoylation and removal of the trichloroethyl carbonyl protecting groups yielded 10-
deacetylpaclitaxel (48) in an overall yield of 10 % starting from 10-deacetylbaccatin III (11). This 
12 
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route also led to the synthesis of JV-debenzoyl-jV-t-butoxycarbonyl-10-deacetylpaclitaxel (47) 
(docetaxef ), which has been shown to be somewhat more active than paclitaxel in clinical phase II 
and phase III studies.56 It is expected that docetaxel will receive the FDA-approval in a short period 
of time for use in the treatment of breast cancer. 
Scheme 1.1 
HO" 
a,b 
(10 R = Ac) 
11 R = H 
PIT ^ O 
45 R = COOCH2CCI3 
Pri ^ O 
10-deacetylpaclitaxel (48) 46 R = COOCH2CCI3 
ι— 4в к = u< 
d U.47 R = H 
(a) CIC02CH,CCl,, 94 % (b) PhCH=CHCOCl/AgCN, 71 % (c) t-Bu02CNNaCl/AgN03/Os04, 25 % (d) 
Zn/MeOH/AcÒH/бО °C, 90 % (e) Me3SiI/0 °C, 75 %. (f) PhCOCl/pyridme, 100 %. (g) Zn/AcOH, 90 % 
In a similar way, Potier et al. were also able to synthesize paclitaxel in an overall yield of 7 %, 
starting from baccatin III (10). The low overall yield of the synthesis described above is mainly 
due to the unsatisfactory stereochemical control in the oxyamination reaction. 
In 1986 Greene et al. developed the first synthesis of the protected paclitaxel side chain (50) 
(scheme 1.2), and improved it through the years. ' First the C7-hydroxyl of 10-deacetylbaccatin 
III (11) was protected with triethylsilyl chloride and then the 10-hydroxyl was acetylated, yielding 
7-tnethylsilylbaccatin III 49. Treatment of 49 with excess protected side chain (50) in the presence 
of di-2-pyridyl carbonate (DPC) and 4-dimethylaminopyridine (DMAP) at 73 °C in toluene for 100 
hours gave the protected paclitaxel derivative 51. Removal of the protecting groups yielded 
The INN (International Nonproprietary Name) of taxotere is docetaxel. Taxotere is a trademark of Rhône-Poulenc 
Rorer Therefore the name docetaxel is used instead of taxotere. 
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paclitaxel (3) in an overall yield of 52 %, starting from 10-deacetylbaccatin III (11). 
AcO о 
OSiEt3 
H O 
11 49 
OSEt3 
О 
χ 
Ρ Ι Γ Α Ν Η О 
- РгГ ^ о -
OH 
51 PrT ^ O 
Ó AcO 
paclitaxel (3) P h ' ^ O 
(a) Et3SiCl/Et3N, 85 % (b) CH3COCl/Et3N/0 °C, 86 % (c) DPC/DMAP/73 °C, 80 % (at 50 % conversion) (d) 0 5 
% HCl/ethanol/ 0 °C, 89 % 
The acylation of the Cl3-hydroxyl of 7-triethylsilylbaccatin III (49), which was the weak point 
in the semisynthesis described above, was improved by using reactive side chain precursors 52 and 
53 by Holton et al. and 54 by Greene et al. (scheme 1.3). 
OSiEta 
О 
χ 
P h ^ ^ N H О 
AcO о 
52, S3 or 54 
-*• P h - ^ N ^ n / Pri > " "0" 
OH 
paclitaxel (3) 
OH 
E E 0
- , / h P r w ^ O ^ O Ph 
оДгРЬ
 N
' 
О Ph 
52 53 54 
(a) For 52/53 DMAP/pyndine, 92 % for 52, 100 % (at 77 % conversion) for 53, For 54 54, DCC/toluene/20 "C/5 min 
then 49, DMAP/75 °C/18 h, 94 % (b) 0 5 % HCl/ethanol/ 0 °C, 90 % for both 52 and 53, 92 % for 54 
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Holton et al. synthesized ß-lactam 5260 and coupled it to 7-triethylsilylbaccatin III (49) in 92 % 
yield. Removal of the protecting groups afforded paclitaxel in an overall yield of 83 % from 49 (61 
% from 10-deacetylbaccatin III (11)). The overall yield from 11 in this method was even improved 
to 69 % by using lithium hexamethyldisilazide in THF instead of DMAP in pyridine in order to 
activate the C13-hydroxyl by creating an anion which facilitates the attack on the ß-lactam 52 . 
The synthesis of this ß-lactam has been improved by Ojima et al. 
The second precursor synthesized by Holton et al. was oxazinone 53 which was coupled to 49 in 
100 % yield at 77 % conversion.63 Removal of the protecting groups yielded paclitaxel (3) in an 
overall yield of 90 % starting from 49 (66 % from 10-deacetylbaccatin III (11)). 
The third precursor, oxazolidine 54, developed by Greene et al. was coupled to 49 in 94 % 
yield.64 Hydrolysis of the protecting p-methoxybenzylidene group and the triethylsilyl group gave 
paclitaxel (3) in an overall yield of 87 % from 49 (64 % from 10-deacetylbaccatin III (11)). 
In evaluating the five semisynthetic approaches, it appears that the Holton-Ojima ß-lactam, the 
Holton oxazinone, and the Greene oxazolidine approach, all are good strategies for the preparation 
of paclitaxel (3). The conversion of 10-deacetylbaccatin III (11) into paclitaxel is very high yielding 
which is important because 10-deacetylbaccatin HI is relatively expensive compared to the side 
chain (precursors). On the other hand, the synthesis of these side chain precursors is less efficient 
(lower overall yields) than that of Greene's side chain 50 (scheme 1.2). 
Very recently semisynthetic paclitaxel from 10-deacetylbaccatin III has been approved by the 
FDA and it is now commercially available for the treatment of patients who have breast or ovarian 
56c 
cancer. 
Whereas baccatin III and 10-deacetylbaccatin III have been used in the synthesis of paclitaxel, 
some other precursors, such as brevifoliol,65 13-acetyl-9-dihydrobacatin HI66 and 14-ß-hydroxy-10-
desacetylbaccatin, isolated from the needles of different Taxus species, have been applied in the 
synthesis of analogs. 
Taxine В (2, figure 1.8), the most abundant precursor present in the needles of Taxus boccata, 
has hardly been investigated as a precursor for either the synthesis of paclitaxel or for the synthesis 
of its analogs. 
To our knowledge, to date only two investigations have been carried out using taxine В as a 
starting material. These syntheses, however, did not lead to analogs that possess the ß-aminoacid 
side chain that is necessary for cytotoxic activity. Ettouati et al. have synthesized compound 5. 
Investigations in the Department of Organic Chemistry in Nijmegen, were started by van 
*25d 
Rozendaal and have led to a mixture of compounds 56a-c (both syntheses will be discussed in 
chapter 3). 
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он 
taxine В (2) 
R30""(« 
"OR, 
TUPO I "но OSitBuMe2 
ΤΉΡΟ 
66a R3 = Η , Kt = Ms 
56b R3 = Ms , R, = Ms 
66c R3 = Ms , R, = Η 
1.3 Aim of the Research described in this Thesis 
In his thesis, van Rozendaal described starting from taxine В some semisynthetic approaches 
in which paclitaxel (and also 7-deoxypaclitaxel) was the target compound. However, a 
retrosynthetic analysis showed that the semisynthesis of paclitaxel from taxine В would require 
more than 20 steps. The incorporation of the C7-hydroxyl group was expected to be an especially 
difficult task. Because the supply of paclitaxel is no longer crucial, due to the above-described 
semisynthesis starting from 10-deacetylbaccatin III, as well as the fact that the C7-hydroxyl group 
apparently had no effect on the cytotoxic activity,69 the efforts were concentrated on the 
semisynthesis of 7-deoxypaclitaxel (57) and analogs thereof, that have structural variations at CI, 
C2 and C4 (figure 1.9), starting from (crude) taxine B. At the start of this study nothing was known 
about the importance of the functional groups at these positions in paclitaxel, in relation to the 
cytotoxic activity. 
Figure 1.9 
AcO о 
О Ph О 
phAN4\p^0,J$n 
Η он 
R = ОН 57 ( 7-deoxypaclitaxel) 
R = H 58 ( 1,7-dideoxypaclitaxel) 
Ph О 
P h ^ r T V ^ O 
R1O OR2 
H OH 
R,Ô 
O R / " 5 " 
7-deoxypaclitaxel analogs 
R-i = R2 - H or Ri,R2 = isopropyhdene 
R3, R4 and R5 are variable substituents 
In a later stage when the importance of the C2-benzoyl and the importance of the C4-acetyl for 
the cytotoxic activity became known (1994-1995), the synthetic routes were directed toward the 
incorporation of these functional groups. 
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During this study it was discovered that the isolated taxine В actually is a mixture of several 
taxanes (figure 1.10). Two of these are 1-deoxytaxine В analogs (2e-f), which cannot be separated 
from the taxine В analogs (2a-d). At a certain stage in the synthetic route, however, the analogs 
with and without the CI-hydroxy 1 group can be separated. In the literature 1-deoxy- or 1,7-dideoxy-
paclitaxel derivatives have never been reported. Therefore, another target of this study is the 
development of a synthetic route for 1,7-dideoxypaclitaxel (58) (figure 1.9) and analogs thereof, 
starting from 1-deoxytaxine B. 
Figure 1.10 
2a, 
2b, 
R2O OR3 
= Г Ч ^ о ^ 
rC 1  1 
R 1
 OR. [ 
R1 = OH, R2 = Ac, R3 = R4 = H 
R' = OH, R2 = H, R3 = R4 = Ac 
2d, R1 = OH, R3 = H, R2 = R4 = Ac 
2e, R ' = H , R 2 = A C , R 3 = R 4 = H 
2f, R1 = H, R3 = Ac, R2 = R4 = H 
1.4 Outline of this Thesis 
Chapter 2 gives a literature survey on the unique mechanism of action, Structure Activity 
Relationship studies and the conformation in aqueous solutions (the so called "Hydrophobic 
Collapse" model) of paclitaxel. 
In chapter 3, the initial approaches to the synthesis of 7-deoxypaclitaxel analogs, starting from 
taxine B, a precursor isolated from the dried needles of the Taxus baccata, are presented. The 
synthesis and (biological) evaluation of some new 7-deoxypaclitaxel analogs are described. 
In chapter 4, preliminary studies concerning the synthesis of 7-deoxypaclitaxel analogs, 
possessing the C2-benzoate group are reported. Several methods are explored to incorporate this 
benzoate group via cyclic protection functions at the Cl,C2-diol unit that are stable to base and that 
can be converted directly into the desired benzoate group. 
Chapter 5 describes the application of the most suitable method for the incorporation of the C2-
benzoate group, in several different strategies/synthetic routes, leading to 7-deoxypaclitaxel 
analogs. In addition to the synthesis, the biological evaluation of these analogs is also reported and 
discussed. 
In chapter 6, some approaches to the conversion of 1-deoxytaxine B, also isolated from the dried 
needles of Taxus baccata, into 1,7-dideoxypaclitaxel analogs are presented. 
This thesis is concluded with a summary in English and Dutch. 
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2 Mechanism of Action, Structure Activity 
Relationship and the 'Hydrophobic 
Collapse1 Model of Paclitaxel 
2.1 Unique Mechanism of Action 
2.1.1 The Mechanics of Cell Division 
For a better understanding of the mechanism of action of paclitaxel, the process of cell division 
will first be outlined briefly. Cells have a characteristic life cycle' as depicted in figure 2.1. 
Figure 2.1 The cell division cycle 
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Some cells in the human body, for instance the neurons, have no ability to replicate. Other cells in 
different tissues find themselves most of the time in the G0-phase, where no replication takes place. 
Skeletal muscle cells replicate less then once a year, liver cells about once a year, and cells of the 
intestinal stem, twice a day. Cells in the G0-phase can enter the G,-phase of the cell division cycle 
under the influence of tissue specific growth factors. After re-entering the cell cycle, the cells go 
through the G,-phase via complex enzymatic processes and enter the S-phase. In this phase DNA, 
histones and Microtubule-Organizing Centers (MOTCs) are replicated, after which the cell enters 
the G2-phase. In this phase the cell is prepared to enter the mitotic phase (M-phase) e.g. by the 
synthesis of extra tubulin. The M-phase includes the five stages of nuclear division (mitosis) and 
23 
Chapter 2 
cytoplasmic division (cytokinesis). The five nuclear division stages are: 1) Prophase; the chromatin 
condenses into well-defined chromosomes. The bipolar mitotic spindle, composed of microtubules 
and associated proteins, begins to form. 2) Prometaphase; disruption of the nuclear envelope, 
spindle microtubules enter the nucleus. 3) Metaphase; the chromosomes are aligned in one plane, 
halfway the spindle poles. 4) Anaphase; separation of the daughter chromatids. The two poles of the 
spindle move further apart. 5) Telophase; the chromatids arrive at the poles, nuclear envelopes are 
re-formed around each group of daughter chromosomes, the nucleoli re-appear, mitosis ends. In the 
stage of cytokinesis the cytoplasm is divided after which two daughter cells are formed. These cells 
grow further and produce new proteins before either entering the G0-phase or the G !-phase. 
For normal cells, the cell division is a controlled process. At high population density the process 
is slowed down. Such a control mechanism is generally not present for cancer cells, so their 
replication goes on even under conditions where normal cells would go into the G0-phase. 
2.1.2 Interaction of Paclitaxel with Microtubules 
In 1978 Fuchs and Johnson reported that paclitaxel produced a time-dependent increase in the 
size of interphase P388 leukemia cells.2 They thought that paclitaxel had antimitotic activity similar 
to that observed for vinca alkaloids and maytansine, but that it had less activity in vivo than other 
mitotic spindle poisons. Vinblastine, colchicine, maytansine, podophyllo-toxin and steganacine are 
drugs that can bind to tubulin, but they all enhance the disassembly of microtubules. 
Horwitz and co-workers3 discovered in 1979 that paclitaxel acts as a promoter of calf brain 
microtubule assembly in vitro, in contrast to the drugs mentioned above, which inhibit assembly. 
Microtubules are an integral component of eukaryotic cells. They have a role in many different 
cellular functions, including chromosome movement, regulation of cell form, anchorage of surface 
receptors in the plasma membrane and cellular motility. Microtubules are absolutely necessary for 
cell division. Therefore, microtubules are described as the most strategic subcellular targets of 
anticancer chemotherapeutics. 
Microtubules are built up from two subunits: a- and ß-tubulin. The first step of the microtubule 
assembly is the formation of a heterodimer from one molecule of α-tubulin and one molecule of ß-
tubulin, with a dissociation constant KD » 10' (figure 2.2).c' In the presence of magnesium ions, 
GTP (Guanosine 5'-TriPhosphate) and MAP's (Microtubule Associated Proteins) the heterodimers 
form nucleation centers in a head to tail arrangement for the building of the protofilaments. The 
growth goes on along the axis from the first protofilament as well as perpendicular to that, until the 
growing molecule turns itself around the axis from the protofilament so that the side filaments fuse 
together during the formation of a microtubule. From this moment on growth only takes place at the 
ends of the tubule. 
A normal microtubule consists of 13 protofilaments and has a diameter of 24 nm. It has a fast 
growing end, called the plus-pole, and a slow growing end, the minus-pole. The microtubules are 
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self-assembling and self-disassembling structures that are in dynamic equilibrium with the tubulin 
dimers, but the total mass of the tubules is constant. When the tubulin concentration is lower than 
the critical concentration, no spontaneous microtubule assembly takes place. Horwitz et al. showed 
that paclitaxel has an influence on the tubulin/microtubules equilibrium. Maximal effects are 
achieved at an equimolar ratio of paclitaxel/tubulin.6 Paclitaxel lowers the critical tubulin 
concentration to almost 0 mg ml"1 and shortens the induction time of the microtubule assembly, 
even in the absence of magnesium ions, GTP and MAP'S.7 Compared to normal microtubules, the 
paclitaxel induced microtubules are shorter, they consist of 12 protofilaments instead of 13 and they 
have a smaller diameter, 22 nm instead of 24 nm. Normal microtubules depolymerize under the 
influence of calcium ions or by decreasing the temperature. Paclitaxel induced microtubules are 
stable to these conditions. Therefore, paclitaxel is a potent inhibitor of eukaryotic cell replication. 
Figure 2.2 The formation of microtubules and the mechanism of action of paclitaxel 
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In their studies on the influence of paclitaxel on in vitro cell culture systems, Horwitz et al. 
discovered that HeLa8 cells incubated with paclitaxel are blocked in the late G2- and/or M-phase.
9 
Morphologically these cells differ from normal cells in the G2-/M-phase because they possess an 
unnatural bundle of microtubules instead of the mitotic spindle. From that time on, many 
investigations10 have been published by different research groups, in which it is shown that 
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paclitaxel has an influence on the microtubules in all phases of the cell cycle. In mitosis, arrested 
cells show microtubule asters. These are star-shaped bundles of microtubules that are reversibly 
formed. In the other phases of the cell cycle paclitaxel causes irreversible formation of arrays of 
disorganized microtubules that are often aligned in parallel bundles. In general, the interactions of 
paclitaxel with the microtubules block the formation of a normal mitotic spindle. It is possible that 
cancer cells are not able to check for the missing spindle, so that the cell tries to continue the cell 
cycle which then causes cell death. Other investigations have shown that paclitaxel also inhibits 
cells leaving the G0-phase. 
2.1.3 The Paclitaxel Binding Site(s) of ß-tubulin 
Very little is known about the binding site of microtubules and its molecular interaction with 
paclitaxel. In order to obtain more insight into the molecular mechanism of action of paclitaxel, 
several research groups have used various techniques to visualize the paclitaxel binding site. For 
this purpose Sengupta et al. and Souto et al. used fluorescent analogs of paclitaxel. Sengupta et al. 
have suggested that these analogs can be used for determining the environment of both the 
paclitaxel and tubulin molecules, but so far they have reported very little useful information. 
More successful are the in vitro [ H]labeling experiments carried out by Rao et al., showing that 
paclitaxel binds specifically to cellular microtubules and preferentially to the ß-tubulin subunit. The 
observed stoichiometry approaches one mole of paclitaxel bound per mole of tubulin-dimer in the 
13a 
polymer. The binding is reversible because unlabeled paclitaxel readily displaces the 
[ H]paclitaxel. These studies with [ H]paclitaxel demonstrated that direct labeling of tubulin results 
in preferential labeling of ß-tubulin. Because of the low extent of incorporation of drug, however, 
[ HJpaclitaxel cannot be used in mapping the drug binding sites. To overcome this problem they 
used [3H]3'-(p-azidobenzamido)paclitaxel (1) (figure 2.3) to photolabel ß-tubulin5a and they 
demonstrated that the final 31 amino acids at the N-terminal of ß-tubulin5b'f are involved in the 
binding of paclitaxel. 
Figure 2.3 Structures of [3H]3'-(p-azidobenzamido)- and [3H]2-(m-azidobenzoyl)paclitaxel 
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Dasgupta et al. who carried out similar experiments with compound 1, found that 80 % of the 
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incorporated label was present in the ß-subunit and 20 % in the ct-subunit.14 According to Dasgupta 
et al., this difference in labeling pattern could be due to the fact that Rao et al. photolabeled tubulin 
in the presence of microtubule-associated proteins (MAP's). 
In another study Rao et al. used [3H]2-(m-azidobenzoyl)paclitaxel (2) (figure 2.3) as a C2-
modified photoaffinity analog of paclitaxel.15 Their results demonstrated that 2-(m-
azidobenzoyl)paclitaxel photolabels a peptide consisting of the amino acid residues 217-231 of ß-
tubulin. 
The two paclitaxel contact domains identified in these studies have also been shown to be a part 
of the colchicine binding site, highlighting the functional importance of these domains in tubulin 
assembly-disassembly reactions. 
Another technique that can be used to obtain more information about the binding site is electron 
microscopy. Nogales et al. have recently published electron microscopy experiments on tubulin 
with and without bound paclitaxel.16 The resolution, however, was too low to indicate a possible 
binding site. Nogales et al. claim to have improved their techniques and that they will soon obtain a 
three dimensional density map at sufficient resolution to traee the tubulin peptide chain and possibly 
acquire more information about the mechanism by which paclitaxel effects the tubulin 
polymerization. 
2.2 Structure Activity Relationship of Paclitaxel and Analogs 
In this section an overview of the Structure Activity Relationship (SAR) studies of paclitaxel and 
analogs will be given. SAR data are available for a large number of paclitaxel analogs, modified 
either in the side chain or in the taxane part. The purpose of these studies has been to determine 
which substituents on the side chain or taxane part could be modified, substituted or eliminated 
without loss of biological activity. The biological activity of the analogs is determined by tubulin 
assembly assays and in vitro cytotoxicity assays, using well characterized cell cultures. 
For a better understanding of the research described in this thesis a distinction is made between 
the SAR studies carried out before and after the start of the investigation. In 1992, very little was 
known about the SAR of paclitaxel (analogs). The original strategy for the synthesis of paclitaxel 
(analogs) was based on these studies. During the course of the investigations several new SAR 
studies appeared. Based on these new results the strategy of making bioactive analogs had to be 
adapted. 
2.2.1 SAR Studies of Paclitaxel Analogs at the Start of the Investigation 
Until 1992, a small number of paclitaxel analogs, listed in table 2.1, were isolated and/or 
synthesized and biologically evaluated. The in vitro cytotoxicity of paclitaxel and these analogs was 
determined quantitatively using P388 cells (murine lymphocytic leukemia cells), J774.2 cells 
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(murine macrophage-like cells) and KB cells (human carcinoma of the nasopharynx). The tubulin 
assembly was determined qualitatively, a plus sign (+) means that tubulin assembly is induced and a 
minus sign (-) stands for no induction of tubulin assembly by that analog. By carefully examining 
table 2.1 some conclusions can be drawn with respect to the importance of several functional groups 
for the biological activity of paclitaxel. First of all, the paclitaxel side chain (3) is absolutely 
necessary for the activity, since baccatin III (4, entry 2) and 10-deacetylbaccatin III (5, entry 3) 
(figure 2.4) have no cytotoxic activity and no influence on the tubulin assembly.17<a,b)'18 
Figure 2.4 
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The benzoyl group in the side chain seems of less importance for the activity, since 
cephalomannine (6, entry 4), where the benzoyl is replaced by a 2-(2-butene)carbonyl group, | 7 М ) ' ' 8 
has about the same activity as paclitaxel (figure 2.5). Docetaxel (7, entry 5), having a t-
butyloxycarbonyl group instead of a benzoyl group in the side chain, is even more active than 
paclitaxel. 
Figure 2.5 
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The hydroxyl group at C2' is also important for the activity, as can be deduced from the 
experiment with 2'-0-(/-butyldimethylsilyI)paclitaxel (entry 6), which is a factor 30,000 less active 
than paclitaxel.20 However 2'-0-acetylpaclitaxel (entry 7) is almost as active as paclitaxel, probably 
due to the fact that the 2'-(9-acetyl group is either hydrolized under the conditions of the bioassay18 
or converted intracellularly to paclitaxel. It is also known that at C2' the R- and at C3' the S-
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configuration is required, since 2'-epi,3'-epi-paclitaxel (entry 8) and 2'-epi,3'-epi-docetaxel (entry 9) 
are much less active than paclitaxel and docetaxel, respectively. These results indicate that the 
C2'-hydroxyl group is directly involved in the binding of paclitaxel to the microtubules. 
Table 2.1 The in vitro cytotoxicity and tubulin assembly of paclitaxel and its analogs 
ED 50 tubulin Reference 
assembly 
Entry Compound P388 J774.2 
(ng/ml) (μΜ) 
KB 
(ng/ml) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
paclitaxel 
baccatin III (4) 
10-deacetylbaccatin III (5) 
cephalomannine (6) 
docetaxel (7) 
2'-0-(i-butyldimethyl-
silyl)paclitaxel 
2'-0-acetylpaclitaxel 
2'-epi,3 '-epi-paclitaxel 
2'-epi,3'-epi-docetaxel 
2',7-di-O-acetylpaclitaxel 
2'-0-acetyl-7-deoxy-7-
oxopaclitaxel 
2',7-dideoxy-2',7-
dioxopaclitaxel 
7-0-acetyl-2'-deoxy2'-
oxopaclitaxel 
2',7-di-O-acetyl-lO-
deacetylpaclitaxel 
secopaclitaxel (8) 
(9) 
7-O-acetylpaclitaxel 
7-deoxy-7-oxopaclitaxel 
7-epi-paclitaxel 
10-deacetyl-7-epi-paclitaxel 
10-deacetoxy-10-
oxopaclitaxel 
10-deacetylpaclitaxel 
270 
-
-
-
130 
-
-
7000 
>10000 
-
-
-
-
-
-
-
-
-
-
-
-
-
" ED50: Drug concentration that inhibits cell division by 50 % after 72 hr 
0.08 
>10 
-
0.15 
-
-
0.3 
-
-
0.8 
-
-
-
0.2 
-
-
0.09 
-
0.12 
0.28 
. 
0.9 
0.010 
2000 
1000 
0.038 
-
300 
0.020 
-
-
30 
1500 
12000 
20 
10 
200 
2300 
4.0 
500 
0.030 
-
20 
-
+ 
-
-
+ 
+ 
. 
-
-
-
-
-
-
-
-
-
-
+ 
+ 
+ 
+ 
+ 
+ 
17-23 
17(a,b),18 
18 
17(a,d),18 
19 
20 
17(b-d), 18,20 
19 
19 
17(a-d), 18,20 
17c 
17c,18 
17c 
17(a,d),18 
17c 
21 
17(b-d), 18,20 
17c,18 
18,22 
22 
18 
17(a,d),18 
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,17c The low activity of secopaclitaxel (8, entry 15) and 20-acetoxy-4-deacetyl-5-epi-20-O-
secopaclitaxel21 (9, entry 16) (figure 2.6), suggests that the oxetane ring at C4.C5 is indispensable 
for high activity of paclitaxel and its analogs. Part of the explanation of the low activity may be that 
opening of the oxetane ring makes the remaining ring system more flexible; it loses the inverted cup 
shape. The molecule is, therefore, unable to fit onto the binding site at the tubulin. It could also be 
that the oxygen atom in the oxetane ring is directly involved in the binding of the microtubules.21 
Figure 2.6 
AcO о 
Ph 
О Ph О 
H он 
secopaclitaxel (8) Ri = Ac, R2 = H 
20-acetoxy-4-deacetyl-5-epi-20-O-secopaclitaxel (9) R, = H, R2 = Ac 
Analogs with structural variation at C7 have also been synthesized. 7-O-Acetyl- and 7-deoxy-7-
oxopaclitaxel (entries 17 and 18, respectively) are less active than paclitaxel itself. I 7 ' 8 · 2 0 Whereas 
7-epi-paclitaxel (entry 19) possesses activity comparable to that of paclitaxel.18'22 It seems, 
therefore, that a free hydroxyl group at C7 is important for the activity, while the configuration at 
C7 is not which may suggest that this hydroxyl group is not directly involved in the binding of 
paclitaxel to the microtubules. 
Oxidation of the hydroxyl group at CIO of paclitaxel leads to the inactive compound 10-
deacetoxy-10-oxopaclitaxel (entry 21).18 On the other hand, 10-deacetylpaclitaxel (entry 22) is 
slightly less active than paclitaxel, suggesting that some modifications at CIO are allowed and that 
the C10-acetoxy group is also not directly involved in the binding to the microtubules. 
All SAR data mentioned sofar are summarized in figure 2.7. 
Figure 2.7 Diagram of SAR data of paclitaxel prior to 1992 
¡AcO: 
paclitaxel 
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| less important j 
[to be investigated! 
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2.2.2 SAR Studies of Paclitaxel Analogs During the Past Four Years 
SAR studies carried out prior to 1992 were mainly performed by the research groups of Kingston 
et al. and Horwitz et al. From 1992 onward, many research groups became involved in these SAR 
studies, leading to a tremendous increase of publications in this area. Many of these studies are an 
extension of earlier studies, involving the C7- and C10-positions and the side chain of paclitaxel, 
but several studies also deal with the C2-, C4-, C9- and C13-position of paclitaxel. 
2.2.2.1 SAR Studies involving the C7-, C9- and C10-position of Paclitaxel 
In section 2.2.1 it was indicated that the C7-hydroxyl group may not be directly involved in the 
binding of paclitaxel to the microtubules. This now has been confirmed, because 7-
deoxypaclitaxel24 (entry 2) is more cytotoxic than is paclitaxel to P-388 cells (table 2.2). In other 
cell systems the activity of this analog is comparable to paclitaxel. 
Table 2.2 The cytotoxic activity of some paclitaxel analogs, modified at C7 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Compound 
paclitaxel 
7-deoxypaclitaxel 
7-deoxy-7-a-fluoropaclitaxel 
7-deoxy-7-a-azidopaclitaxel 
7-O-chloromethyl-
oxycarbonylpaclitaxel 
7-O-ethoxycarbonylpaclitaxel 
7-epi-paclitaxel 
7-deoxy-7-7V-
butyloxycarbonylpaclitaxel 
7-0-a-trimethylsilylether 
7-0-a-dimethylphenylsilylether 
7-O-P-triethylsilylether 
HCT116b 
(nM) 
4.0 
4.0 
7.0 
-
7.0 
6.0 
2.0 
46 
>60 
>78 
>78 
i<V 
P-388b 
(ng/ml) 
4.0 
0.1 
-
-
-
-
-
-
-
-
-
CA46b 
(nM) 
10 
30 
-
10 
-
-
-
-
-
-
-
Reference 
24-26 
24,25a 
25 
26 
25a 
25a 
25a 
25a 
25a 
25a 
25a 
'IC50: Drug concentration required to inhibit cell proliferation to 50 % vs untreated cells(37 °C, 72h). "HCT116: human 
colon carcinoma; P-388: mouse lymphocytic leukemia; CA46: human Burkitt lymphoma. 
The other analogs (entries 3-7) in table 2.2 show that replacement of the C7-hydroxyl group by 
other substituents has little or no effect on the activity,25,26 with the exception of the four last-
mentioned analogs. The inactivity of 7-deoxy-7-N-butyloxycarbonylpaclitaxel (entry 8) is ascribed 
31 
to the incapability of this analog of getting into the cell.25" The low activity of the three silylether 
analogs (entries 9-11) is attributed to the bulkiness of these substituents. 
There have been a few investigations involving the carbonyl at C9. Reduction of this carbonyl 
leads to 9(R)-dihydropaclitaxel (entry 2), which is slightly less active than paclitaxel27'28 (table 2.3), 
whereas 9-0-methyl-9(R)dihydropaclitaxel27 (entry 3) and 9-deoxopaclitaxel29 (entry 4) are slightly 
more active than paclitaxel, illustrating that some modifications at C9 are allowed. 
Currently, about 20 analogs of paclitaxel with structural variations at CIO, have been synthesized 
and biologically evaluated. 10-Epi-pacIitaxel30 (entry 5) is slightly more active than paclitaxel. In 
section 2.2.1 it was indicated seen that 10-deacetylpaclitaxel is slightly less active than paclitaxel. 
Surprisingly, 10-epi-10-deacetylpaclitaxel (entry 6), however, is even more active than 10-epi-
paclitaxel (entry 5, table 2.3). 
Table 2.3 The cytotoxic activity of some paclitaxel analogs, modified at C9 or CIO 
icso icw 
IÍ-50 padiL 
Entry Compound P-388b HCT116b B16b 
(ng/ml) (nM) 
Ref. 
9.0 
49 
7.8 
5.5 
-
-
12 
. 
2.0 
-
-
-
-
-
7.0 
3.4 
1 
-
-
-
0.73 
0.62 
-
. 
27-33 
27,28 
27 
29 
30 
30 
31 
32 
1 paclitaxel 
2 9(R)-dihydropaclitaxel 
3 9-0-methyl-9(R)-dihydropaclitaxeI 
4 9-deoxopaclitaxel 
5 10-epi-paclitaxel 
6 10-epi-lO-deacetylpaclitaxel 
7 10-deacetoxypaclitaxel 
8 10-deacetyl-lO-butyrylpaclitaxel 
9 10-deacetyl-10-0-
cyclopropylcarbonylpaclitaxel - 2.3 - 32 
10 10-deacetyl-10-
dimethylaminocarbamoylpaclitaxel 
11 10-deacetyl-10-0-methy Ipaclitaxel 
12 10-deacetyl-10-0-
methyloxycarbonylpaclitaxel 
13 10-deacetyl-10-0-benzoylpaclitaxel 
aIC50 Drug concentration required to inhibit cell proliferation to 50 % vs untreated cells(37 °C, 72 h) "P-388 mouse 
lymphocytic leukemia, HCT116 human colon carcinoma, Bl6 melanoma. 
Whereas 10-deacetoxypaclitaxel31 (entry 7) is slightly less active than paclitaxel, the С10-
carbamoyl analog (entry 10) is more active and the C10-methyl ether and С10-0-
1.1 
12.0 
3.0 
2.2 
32 
32 
32 
32,33 
32 
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methyloxycarbonyl analogs (entries 11 and 12, respectively) are slightly less active than 
paclitaxel.32 The other C10-analogs in table 2.3 (entries 8, 9 and 13) are all esters of 10-
deacetylpaclitaxel, which have about the same activity as paclitaxel.32 The results confirm earlier 
findings that some modifications at CIO are allowed and that the C10-acetoxygroup is probably not 
directly involved in the binding of paclitaxel to the microtubules. 
The paclitaxel analogs in the tables 2.2 and 2.3 are all analogs modified at one position, the C7, 
C9 or C10-position respectively. The question arises whether it would be possible to predict on the 
basis of these results the activity of analogs modified at more than one position. For example, is the 
activity caused by a substituent at one position additive to the activity caused by a substituent at 
another position? Unfortunately, this additivity principle does not apply. For example, 7-deoxy-9-
deoxopaclitaxel should be more active than paclitaxel in the P-388 cell culture, because 7-
deoxypachtaxel (entry 2, table 2.2) and 9-deoxopaclitaxel (entry 4, table 2.3) are both more active 
than paclitaxel against these cells. But table 2.4 shows that 7-deoxy-9-deoxopachtacel (entry 2) is 
only as active as paclitaxel.29 The same holds for 7-deoxy-10-deacetoxypaclitaxel, which should be 
more active than 10-deacetoxypaclitaxel (entry 7, table 2.3) against HCT116 cells, while table 2.4 
shows that 7-deoxy-l O-deacetoxypaclitaxel (entry 4) is less active. ' 
Table 2 
Entry 
.4 The cytotoxic activity of some 
Compound 
paclitaxel analogs, 
HCT116b 
(nM) 
modified at C7, C9 and/or CIO 
IC50" 
A549b 
(ng/ml) 
P-388" 
(ng/ml) 
ICso/ 
IC50 рас 
B16b 
Ref. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
paclitaxel 
7-deoxy-9-deoxopaclitaxel 
7-epi-1 O-deacetoxypaclitaxel 
7-deoxy-1 O-deacetoxypaclitaxel 
7-deoxy-9-deoxo-10-
deacetoxypaclitaxel 
10-deacetyl-9(R)-dihydropaclitaxel 
10-epi-9(R)-dihydropaclitaxel 
10-epi-10-deacetyl-9(R)-
dihydropaclitaxel 
10-deacetoxy-10-oxo-9(R)-
dihydropaclitaxel 
10-deacetoxy-9(R)-
dihydropaclitaxel 
4.0 
-
40 
29 
-
-
-
-
-
-
2.5 9.0 
9.0 
-
-
57 
140 
-
1 
-
-
-
. 
14 
3.6 
27 
29 
34 
24b,34 
29 
27 
30 
11 
4.5 30 
1 2 30 
- 12 35 
"IC50 Drug concentration required to inhibit cell proliferation to 50 % vs untreated cells(37 °C, 72 h) "HCT116 human 
colon carcinoma, A549 human breast cancer, P-388 mouse lymphocytic leukemia, BI6 melanoma 
33 
The same holds for 7-deoxy-9-deoxo-10-deacetoxypaclitaxel (entry 5), which is expected to be 
more active than 10-deacetoxypaclitaxel (entry 7, table 2.3) against P-388 cells. Again, table 2.4 
shows that 7-deoxy-9-deoxo-10-deacetoxypaclitaxel is less active than 10-deacetoxypaclitaxel. 10-
Deacetoxy-10-oxo-9(R)-dihydropaclitaxel (entry 9) is as active as paclitaxel (table 2.4), whereas 10-
deacetoxy-10-oxopaclitaxel (entry 21, table 2.1) and 9(R)-dihydropaclitaxel (entry 2, table 2.3) both 
are less active than paclitaxel. It is clear that it is almost impossible to predict the activity for multi-
modified analogs by combining results of single-modified analogs. 
Analyzing the tables 2.1,2.2, 2.3 and 2.4, reveals that some modifications at C7, C9 and/or CIO are 
allowed. These modifications increase or decrease the activity of the analogs in general with no 
more than a factor 10 to 20, with respect to paclitaxel. Therefore, it is believed that the 
functionalities at C7, C9 and CIO are not directly involved in the binding of paclitaxel to the 
microtubules. 
2.2.2.2 SAR Studies involving the C2-, C4- and C13-position of Paclitaxel 
SAR studies involving the C2-, C4- or C13-position of paclitaxel started in 1993. 
Chen et al. reported that 2-de(benzoyloxy)paclitaxel (10, entry 2) is about a hundred times less 
active than paclitaxel (table 2.5), therefore, implying that the C2-benzoate group is indispensable for 
the activity. 
In 1994 and 1995 several research groups reported some systematic investigations on the 
influence of aromatic substitution on the bioactivity of paclitaxel analogs. ~* These results are 
summarized in table 2.5. The para-substituted analogs (12-15, entries 4-7) are all less active than 
paclitaxel, whereas most meta-substituted analogs (16-19, entries 8-11) are more active than 
paclitaxel, independent of the electronic effect of the substituents. Therefore it is evident that the 
effect of aromatic substitution at the C2-benzoate group is not an electronic effect. This agrees well 
with studies on the conformation of paclitaxel in aqueous solution by NMR spectroscopy and 
molecular modeling (section 2.3),which show the importance of hydrophobic interactions between 
the C2-benzoate and the СЗ'-phenyl group for active analogs. The results above suggest that para 
substituents may disrupt these interactions, whereas meta substituents enhance them. 
Figure 2.8 
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Table 2.5 SAR studies involving the C2-position ofpaclitaxel 
HV IC5P/IC.S0 pachiaitl References 
Entry HCT116b(nM) P-388" HL-ÓO" В16" 
1 OC(0)Ph 
2 H (10) 
3 OC(0)C 6H„(ll) 
4 OC(0)Ph-OCH3(p) (12) 
5 OC(0)Ph-N02(p) (13) 
6 OC(0)Ph-CN(p) (14) 
7 OC(0)Ph-CH3(p) (15) 
8 OC(0)Ph-CN(m) (16) 
9 OC(0)Ph-OCH3(m) (17) 
10 OC(0)Ph-CH3(m) (18) 
11 0C(O)Ph-NO2(m) (19) 
12 OC(0)Ph-CH3(o) (20) 
40 
480 
>91 
>88 
>85 
-
-
-
-
-
-
1 
-
-
-
-
> 100 
-
0 20 
0 0013 
-
-
1 
-
-
-
-
> 100 
-
1 
0 33 
-
-
1 
-
-
22 
-
-
5 1 
-
-
16 
0 73 
36 
36 
37 
37,39 
37 
38 
39 
38 
38 
39 
39 
0 84 39 
"ICS0 Drug concentration required to inhibit cell proliferation to 50 % vs untreated cells(37 °C, 72 h) "HCT116 human 
colon carcinoma, P-38S mouse lymphocytic leukemia, HL-60 Human promyetocytic leukemia, В16 melanoma 
In their attempt to prepare 1-deoxypaclitaxel, Chaudhary et al synthesized the compounds 21 
and 2241 (figure 2 9) 
Figure 2.9 
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23 2-epi-paclitaxel 
In order to remove the Cl-hydroxy 1 group they wanted to introduce the xanthyl group at this 
position Before the xanthate was formed, however, the benzoyl group migrated from the C2- to the 
CI-hydroxy 1 group and the xanthyl group was attached to the C2-hydroxyl group, yielding 
compound 21 Under radical deoxygenation conditions, 21 was converted into l-benzoyl-2-
de(benzoyloxy)pachtaxel (22) The analogs 21 and 22 are the first Cl-acylated pachtaxel analogs 
reported Against P388 cells, both compounds are less active than pachtaxel, they have an ED50 of 
0 28 and 1 70 μg/ml, respectively, whereas pachtaxel has an ED50 of 0 03 μg/ml 
Very recently, Chordia et al have synthesized 2-epi-paclitaxel42 (23) (figure 2 9) In an HCT116 
35 
cytotoxicity assay this compound was not active, when compared to paclitaxel. 
Currently, the performed SAR studies involving the C2-position of paclitaxel, indicate the 
importance of the nature and stereochemistry of the C2-aroyl group for the bioactivity of paclitaxel 
(analogs). Thus far, meta-substitution of the benzoate group at C2 seems to be the only modification 
that is allowed in order to retain (or in some cases even increase) the activity of paclitaxel (analogs). 
Another very important functionality for the activity of paclitaxel appeared to be the C4-acetate 
group. Recent SAR studies involving structural modifications at the C4-position, are summarized in 
table 2.6. 
Figure 2.10 
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Table 2.6 SAR studies on the C4-position of paclitaxel 
I C
w
a
 References 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
R 
OAc 
OH (24) 
Η (25) 
OCH3 (26) 
OC(0)C6H5 (27) 
OC(0)CH=CH2 (28) 
ОС(0)СН(СН3)2 (29) 
ОС(0)С3Н5-с (30) 
ОС(0)ОСН3 (31) 
ОС(0)ОСН2СН3 (32) 
OC(0)NHC4H7-c (33) 
OC(0)imidazole (34) 
CA46b (μΜ) 
0.03 
>10 
0.7 
0.04 
-
-
-
-
-
-
-
-
HCT116b(nM) 
2.4-4.0 
> 1000 
-
-
410 
6.0 
5.0 
1.0 
2.0 
1.0 
9.2 
803 
43 
43,44,45 
43 
46 
45,47 
45 
45,40 
45,47,48 
45 
45 
45 
45 
ICS0: Drug concentration required to inhibit cell proliferation to 50 % vs untreated cells(37 C, 72 h). 
bCA46: human Burkitt lymphoma; HCT116: human colon carcinoma. 
This table shows that 4-deacetylpaclitaxel43ivM'45 (24, entry 2) and the C4-benzoate analog (27, 
entry 5) are more than 100 times and 4-deacetoxypaclitaxel (25, entry 3) is about 20 times less 
active than paclitaxel. The C4-methyl ether paclitaxel analog (26, entry 4) possesses the same 
36 
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activity as that of paclitaxel. Also, the C4-acyl compounds (28-30, entries 6-8, respectively) exhibit 
about the same activity as that of paclitaxel (some are slightly more and others are slightly less 
active than paclitaxel). The two C4-carbonate analogs (31 and 32, entries 9 and 10, respectively) are 
slightly more active than paclitaxel. Whereas the two C4-carbamate analogs (33 and 34, entries 11 
and 12, respectively) are (slightly) less active than paclitaxel. 
Finally, 4-deacetyl-9(R)-dihydropaclitaxel27 (35) (figure 2.11) was tested against four cell lines 
and appeared to be not active in none of them (table 2.7). 
The results of the SAR studies involving the C4-position of paclitaxel, show that an ester, ether 
or carbonate substituent at this position is indispensable for the activity of paclitaxel (analogs). The 
fact that both the 4-deacetoxy analog 25 (entry 3, table 2.6) and the C4-methyl ether analog (26, 
entry 4) appear to be more active than 4-deacetylpaclitaxel, suggests that polarity changes at C4 also 
have an effect on activity. 
Figure 2.11 
Table 2.7 Evaluation of compound 35 
paclitaxel 
35 
A549D 
2.5 
>1000 
I<V (ng/ml) 
HT29- B16F10° 
1.8 3.4 
>1000 >1000 
Ref. 
P388ü 
8 8 27 
>1000 27 
"1C50 Drag concentration required to inhibit cell proliferation to 50 
% vs untreated cells(37 °C, 72 h) bA549 human breast cancer, 
HT-29 human colon adenocarcinoma, B16F,0 mouse melanoma, 
P388 mouse lymphocytic leukemia 
Recently it was shown that the stereochemistry at C13 is important for the activity of 
paclitaxel49 Both 13-epi-paclitaxel (36) and 4-deacetyl-13-epi-pacIitaxel (37) (figure 2 12) are 
much less active than paclitaxel in a tubulin binding assay (table 2 8). 
Table 2.8 Evaluation of compounds 36 and 37 
Tubulin assembly Reference 
IC5oa 
paclitaxel 1.04 49 
36 > 20 49 
37 > 2 0 49 
IC50 The drug concentration in mM which reduces the 
supernatant protein concentration by 50 % 
AcO OH 
О Ph О 
P h ^ K T V ^ O · " / 
H OH 
35 4-deacetyl-9(R)-dihydropachtaxel 
О" "Ph 
36 R = Ac(13-epi-pachtaxel) 
37 R = H (4-deacetyl-13-epi-paclitaxel) 
37 
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2.1.13 SAR Studies involving the Side Chain of Paclitaxel 
For the studies described in this thesis the SAR studies performed on the paclitaxel side chain are 
of less importance. In order to provide a SAR picture as complete as possible, some concluding 
results of the side chain SAR studies will be given. 
As mentioned before, the hydroxyl function at C2' is important for the biological activity of 
paclitaxel. To retain the activity, this hydroxyl group should either be free or functionalized with 
groups that can easily be removed by hydrolysis (ги vitro or in vivo), like ester18 or carbonate50 
functionalities. 
The JV-benzoyl group in the side chain is of less importance for the activity. As shown in table 
2.1, docetaxel is more active and cephalomannine has the same activity as paclitaxel. Furthermore, 
aromatic substitution at this benzoyl group has little effect on the activity. Also, replacement of 
the ЛГ-benzoyl group by another acyl52 or even carbamate function526 has little effect. 
On the other hand, the СЗ'-phenyl group seems to be important. Paclitaxel analogs in which the 
phenyl group is replaced by a hydrogen are at least 100 times less active than paclitaxel.52b 
Replacement of the СЗ'-phenyl group by a cyclohexyl53 or a f-butyl group54 slightly increases the 
activity. Replacement by a furyl- or pyridyl group also seems to be allowed.55 Aromatic substitution 
at the СЗ'-phenyl has only a slight effect on the activity of paclitaxel.56 The observed high activity 
for apolar substituents, together with the relative flat response in the biological assay to the changes 
in electronic and steric effects, suggests that the СЗ'-substituent is involved in hydrophobic 
interactions at the binding site of microtubules. 
2.2.2.4 Summary of the SAR Studies of the Main Investigated Positions in Paclitaxel 
In figure 2.13, the results of SAR studies carried out thus far are summarized. 
Figure 2.13 Diagram of all available SAR studies 
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2.2.2.5 Evaluation of Some Other Paclitaxel Analogs 
The paclitaxel analogs, discussed until now, all are derived from paclitaxel by simple 
modification of its substituents at the taxane part or at the side chain. Figure 2.14 depictures other 
types of analogs. These analogs are either obtained from more elaborate modifications at the taxane 
part of paclitaxel (e.g. 38," 39,58 40,59 412 6 and 4226) or from other taxane precursors than paclitaxel 
(e.g. 43,60 44,61 4562 and 4663). None of these analogs appeared more active than paclitaxel. In 
biological assays, the analogs 38, 39, 43, 44, 45 and 46 appeared to be much less active than 
paclitaxel, whereas the analogs 40,41 and 42 possess activity similar to that of paclitaxel. 
Figure 2.14 
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2.3 'Hydrophobic Collapse' Model of Paclitaxel and Analogs 
Although the affinity of paclitaxel for its receptor seems to be high, the structural nature of 
pachtaxel's binding site at the microtubules is still not known. It is known from some compounds 
with high binding affinities that they have the same conformation m solution as in the bound state. 
This suggests that knowledge of the conformation in aqueous solution could be used to design new 
paclitaxel analogs or biological mimics of the drug. 
In polar solvents (docetaxel in methanol, 5 paclitaxel in DMSO/water ) the side chain 
conformation differs from the conformation in apolar solvents. 
Water strongly induces the same conformation in both docetaxel and paclitaxel. 2D-NMR studies 
carried out by Vander Velde et al. and Paloma et al. together with solvated molecular modeling 
39 
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studies by Williams et al. show that the key interaction in this conformation is hydrophobic 
clustering of the C2-benzoyl, СЗ'-phenyl and C4-acetyl groups. The nonpolar side chain amide 
groups (benzoyl for paclitaxel, /-BOC for docetaxel) do not seem to be involved. This 
conformational change is a nonpeptide example of 'hydrophobic collapse'. This is a process in 
which bioactive compounds dramatically change their conformation in aqueous solvents (compared 
to organic solvents) as a consequence of hydrophobic clustering of nonpolar groups and loss of 
intramolecular hydrogen bonds. Since no active paclitaxel analogs are known without C2-benzoyl 
or without СЗ'-phenyl (or an apolar substituent at this position), these groups seem to be responsible 
for the supposed 'preorganization' of the side chain conformation, which is most relevant for binding 
to the microtubules. 
Very recently the same hydrophobic clustering was found in the crystal structure of paclitaxel a 
and of 10-deacetyl-7-epi-paclitaxel. Figure 2.15 depictures the crystal structure of paclitaxel71 
(the crystals were obtained by crystallization of paclitaxel from methanol/water), showing that the 
C2-benzoyl, the СЗ'-phenyl and the C4-acetyl are close together. 
The pharmacological significance of this clustering is still unknown. 
40 
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2.4 State of Affairs regarding the Molecular Mechanism of 
Action 
The 'hydrophobic collapse' model of paclitaxel suggested by NMR studies in polar solvents and 
by crystal structure studies is supported by the results from SAR studies. The SAR studies show 
that the groups that are involved in hydrophobic clustering, viz. the C2-benzoyl, C3'-phenyl and C4-
acetyl groups are also the functionalities that are absolutely indispensable for the bioactivity of 
paclitaxel (section 2.2.2). Further studies as mentioned above (for instance a crystal structure of the 
paclitaxel-microtubule complex) together with photolabeling and high-resolution electron 
microscopy experiments (section 2.1.3) will provide more detailed information about the nature of 
the paclitaxel binding site at microtubules. Moreover, these studies might also elucidate the 
mechanism of action of paclitaxel at the molecular level. Detailed knowledge of the binding site and 
the molecular mechanism of action will enable the design of new, more active paclitaxel analogs 
and/or biological mimics of the drug. 
Thus far, the state of affairs regarding the mechanism of action of paclitaxel is clearly 
summarized in a statement made by Horwitz in 1992:72 "The ability of paclitaxel to polymerize 
tubulin into stable microtubules in the absence of any cofactors and to induce the formation of 
stable microtubule bundles in cells are the unique characteristics of this drug. Paclitaxel is thus a 
prototype for a new class of antitumor drugs and has focused attention on microtubules as a worthy 
target for cancer chemotherapeutic drugs. However, at the molecular level, the mechanism by which 
paclitaxel interacts with microtubules and blocks cells in mitosis is still poorly understood." 
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3 Initial Approaches for the Conversion of 
Taxine В into 7-Deoxypaclitaxel Analogs 
3.1 Introduction 
3.1.1 General Strategy 
Taxine В (figure 3.1) the most abundant and most readily available precursor of paclitaxel with a 
taxane skeleton, has received scarce attention in the synthesis of paclitaxel and its analogs. The 
synthesis of paclitaxel from taxine В would require more than 20 steps, as has been shown in a 
retro-synthetic analysis by van Rozendaal.' The introduction of the 7-hydroxyl group, in particular, 
was expected to be difficult. Therefore, it was decided to concentrate the effort of this study on the 
synthesis of 7-deoxypaclitaxel analogs, after in vitro assays had shown that the 7-hydroxyl group 
had practically no effect on the activity (7-deoxypaclitaxel is even more active than paclitaxel).2 
From SAR-studies it appeared that the oxetane ring, the paclitaxel side chain, and the C21-
hydroxyl group are important for the cytotoxic activity of paclitaxel,3 whereas the functional groups 
at the upper side of paclitaxel at positions C9 and CIO, are of less importance.3*'1·"' The bottom side 
of paclitaxel, positions CI, C2 and C4, was a "black box" at the start of this study; their importance 
had not been established at that time. For this reason the prime focus was on the synthesis of 
analogs of 7-deoxypaclitaxel that possess the oxetane ring and the ß-amino acid side chain and that 
have structural variations in the functionalities at CI, C2 and C4. At the positions C9 and CIO, these 
analogs will have either free or protected hydroxyl groups. Among these analogs the most 
challenging one is 7-deoxy-10-deacetyl-9(R)-dihydropaclitaxel. This compound is expected to be 
more water soluble than paclitaxel because of the two free hydroxyl groups at C9 and CIO. In 
addition, it can be easily converted further into C9- and ClO-functionalized analogs. 
The conversion of taxine В into 7-deoxy-10-deacetyl-9(R)-dihydropaclitaxel is schematically 
depicted in figure 3.1. The netto conversions that are needed are outlined in the boxes, А, В and C. 
The removal of the side chain in box A, the construction of the oxetane ring in box A, and the 
reduction of the C13-carbonyl in box С are carried out under basic conditions. The hydroxyl groups 
at CI, C2, C9 and CIO, therefore, must be protected by base-stable protective groups, after the 
acetyl group at CIO has been removed. The side chain can be subsequently removed, followed by 
construction of the oxetane ring. The synthesis of this CI-, C2-, C9- and C10-protected oxetane 
compound is expected to proceed without serious complications. 
Problems are foreseen, however, when the acetyl at C4 (box A) and the benzoyl at C2 (box B) 
are introduced before the reduction of the C13-carbonyl (box C), because this will limit the number 
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of reducing agents that can be used for the stereoselective reduction of the C13-carbonyl. Probably 
the most convenient approach will be to begin with the reduction of the C13-carbonyl followed by 
coupling of the formed hydroxyl group to the paclitaxel side chain. Next, the acetate at C4 can be 
introduced, after which the deprotected C2-hydroxyl group can be benzoylated. Removal of the 
protecting groups will then lead to 7-deoxy-10-deacetyl-9(R)-dihydropaclitaxel. A more detailed 
description of this strategy is outlined in section 3.1.4. 
Figure 3.1 
AcO OH 
taxine В 
но OH 
Ph 
О Ph О 
Η он 
7-deoxy-10-deacetyl-9(R)-dihydropaclitaxel 
3.1.2 Synthetic Route by van Rozendaal 
In his thesis,1 van Rozendaal described the first approach to convert taxine В (1) into 7-
deoxypaclitaxel analogs (scheme 3.1). 
Scheme 3.1 Conversion of taxine В by van Rozendaal 
AcO он 
THPO I HO OSiteuMe, 
THPO 
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(a) Mel/ether; 91 %. (b) K2C03/ethanol; 89 %. (c) NaOMe/MeOH; 98 %. (d) Acetone/CuSO,,; 75 
%. (e) Dihydropyran/PTS/CH2Cl2; 82 %. (f) DIBALH/CH2CI2/0 °C; 75 %. (g) OsOfl/NMO; 75 
%. (h) r-BuMe2SiCl/ET3N/DMF; 73 %. (i) MsCI/pyridine/O °C; 24 % 5a, 46 % 5b, 22 % 5c. (j) 
TBAF/THF. (k) Bu4N*OAc/butanone. 
Taxine В was easily converted into compound 2, which was stereoselectively reduced with 
DIBALH to give compound 3 in 75 % yield.5 Next, the double bond at C4-C20 was cis-
dihydroxylated, followed by silylation of the primary alcohol, leading to compound 4. In order to 
synthesize oxetane compound 6, the hydroxyl group at C5 had first to be selectively mesylated, so 
that it can act as a leaving group in the formation of the oxetane ring. Unfortunately, this mesylation 
was not successful. A mixture of 5a, 5b and 5c in a 1:2:1 ratio was formed. For that reason this 
strategy was abandoned. 
3.1.3 Synthetic Route by Ettouati et al. 
To our knowledge only one other investigation starting from taxine В has been carried out to 
date. While van Rozendaal was working on the first route to 7-deoxypaclitaxel and analogs thereof, 
Ettouati et al.6 published a semi-synthetic route toward compound 15 (scheme 3.2). 
From taxine В (1), the first steps of their synthesis involved the formation of Ocinnamoyl-
taxicin-I triacetate (7). For the removal of the side chain, the construction of the oxetane ring and 
the reduction of the СІЗ-carbonyl, it is necessary to protect the hydroxyl groups at CI, C2, C9 and 
CIO with base-stabile protective groups, after the hydrolysis of the acetate groups with sodium 
methoxide. Ettouati et al. protected the Cl- and C2-hydroxyl groups, as well as the C9- and С10-
hydroxyl groups, as an isopropylidene acetal, affording the diisopropylidene protected compound 8. 
Hydrolysis of the cinnamate ester yielded 9. O'i-dihydroxylation with osmium tetroxide (10), 
protection of the formed primary hydroxyl with a f-butyldimethylsilyl group (11), mesylation of the 
secondary hydroxyl group (12) and deprotection of the primary hydroxyl group gave 13. Treatment 
of 13 with tetrabutylammonium acetate gave the oxetane compound 14. Next, the carbonyl at C13 
had to be reduced. Ettouati and co-workers obtained the best results with DIBALH, affording a 3:1 
mixture of the С 13a- and C13ß-hydroxyl isomers. The СІЗсс-hydroxyl compound was acylated 
with cinnamic acid,7 yielding 15, which was not converted further. They also acetylated the C4-
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hydroxy 1 of 14 yielding 16, which was also not converted further either 
Scheme 3.2 Conversion of Taxine В by Ettouati et al 
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It was presumed that Ettouati et al did not further investigate the compounds 15 and 16, because 
they were not able to remove the two isopropylidene protective functions at C1,C2 and at C9,C10, 
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respectively, independently from each other, as is necessary for the selective introduction of the 
benzoate group at C2. 
3.1.4 Strategy for the Synthesis of 7-Deoxy-10-deacetyl-9(R)-dihydro-
paclitaxel 
Taking into account the results of van Rozendaal and Ettouati et al., a strategy for the synthesis 
of 7-deoxypaclitaxel analogs by combining both of these routes was developed. The resulting 
reaction sequence, depicted in scheme 3.3, starts with compound 2 from the route of van Rozendaal, 
in which the CI- and C2-hydroxyl groups are protected as THP-acetals and the C9- and С10-
hydroxyl groups as an isopropylidene acetal. It was expected that the THP-acetals could be removed 
independently from each other, and, in particular, independently from the isopropylidene acetal, 
since THP-acetals are generally more acid labile than isopropylidene acetáis.8 
Scheme 3.3 Strategy for the Synthesis of 7-Deoxy-10-deacetyl-9(R)-dihydropaclitaxel 
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The next step in the synthesis, however, is not the reduction of 2 with DIBALH. Instead, 
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following the synthetic route of Ettouati et al., the cinnamoyl side chain at C5 is removed, yielding 
compound 17. In an analogous way as described for the conversion of 9 to 14, compound 17 will be 
transformed into oxetane compound 18. With DIBALH, 18 can be reduced to 19. In the next step, 
the protected paclitaxel side chain will be coupled to the C13-hydroxyl group of 19, leading to 20, 
after which acetylation of the C4-hydroxyl group will give 21. 
For the introduction of the benzoyl group, the CI- and C2-hydroxyl groups of 21 have to be 
selectively deprotected, yielding 22 (scheme 3.4). In the next step, the cyclic carbonate function can 
be introduced, leading to 23. Opening of this cyclic carbonate with phenyllithium, followed by 
hydrolysis of the isopropylidene acetal will yield 7-deoxy-10-deacetyl-9(R)-dihydro-paclitaxel (24). 
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3.2 The Synthesis of the 7-Deoxypaclitaxel Analogs 65-68 
3.2.1 A Closer Look at Taxine В 
Taxine В (la, figure 3.3) is easily isolated from the leaves of the common European yew, Taxus 
taccata L., as reported by van Rozendaal, yielding 2-3 g per kg of dried leaves.1 
Actually, the crude extract from the needles (with a 0.5 % v/v sulfuric acid solution) is not pure 
taxine В but a mixture of at least 11 taxines, called taxine. The major alkaloid of this mixture, 
however, is taxine В (20 %). Isotaxine В (le) also occurs in appreciable concentrations, while the 
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other taxines are only minor constituents.9 The isolation of this crude taxine fraction (9-12 g per kg 
of dried leaves) is clearly outlined in the thesis of van Rozendaal.' Pure taxine В was obtained from 
this fraction by a pH-controlled acid/base extraction procedure as described by Lucas and Graf et 
al., in a yield of 2-3 g per kg of dried leaves10 and this pure taxine В was the starting material in the 
synthetic route by van Rozendaal as well as by Ettouati et al. 
In this study it was found that this pH-controlled extraction step can be omitted and that it is 
possible to use the crude taxine fraction (12 g per kg of dried leaves) in the synthesis of 7-
deoxypaclitaxel and its analogs. In a collaboration program with the Agricultural University of 
Wageningen, it was found that 60 % of the crude taxine fraction consists of unknown compounds 
that do not have a taxane skeleton." The other 40 % of this fraction (4.8 g per kg of dried leaves) 
consists of compounds that do possess a taxane skeleton.12 For the major part, this 40 % contains 
four taxine В analogs, la-d, and two 1-deoxytaxine В analogs, le-f, figure 3.3. The taxine B, as 
well as the 1-deoxytaxine В analogs, differ from each other in the number and position(s) of the 
acetyl groups. 
Figure 3.3 
reo ORÍ 
la, R' = OH,R2 = Ac,RJ = R4 = H 
lb, R'=OH,R2 = H, RJ = R4 = Ac 
lc, R' = OH, R3 = Ac, R2 = R4 - H 
ld, R1 = OH,R1 = H,R2 = R4 = Ac 
le, R' = H,R2 = Ac,R3 = R4 = H 
If, R' = H,R3 = Ac, R2 = R4 = H 
No further purification of the crude taxine fraction is necessary, because in the first step of the 
synthesis, the compounds with the taxane skeleton (40 %) are easily separated from the other 
compounds. The taxine B- and the 1-deoxytaxine В analogs are separated in a later stage of the 
synthesis. 
3.2.2 Preparation of Key Intermediate 32 
In the first step of the synthesis the taxine fraction was treated with methyl iodide (scheme 3.5). 
The compounds with the taxane skeleton la-f, see figure 3.3, crystallized as ammonium salts, the 
other compounds remained in the solution. The purified taxines la-f were collected as the 
corresponding ammonium salts by filtration. The next step was elimination of trimethyl ammonium 
iodide with K2C03, yielding a mixture of 25a-f.
13
 The number of taxines was reduced to two by 
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removal of the acetyl groups with 1.2 equivalents of sodium methoxide, yielding a mixture of 
tetraol 26a and triol 26b. 
Scheme 3.5 
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26a Ri = OH 
26b R' = H 
27a R' = OH 
27b R' = H 
(a) CH,I. (b) K2COj/H20/MeOH. (c) 1.2 eq NaOMe/MeOH; 85 % from (a), (d) Acetone/CuSO,; 55 % from (a). 
These two compounds were indistinguishable by Thin Layer Chromatography, Gas 
Chromatography and common High Pressure Liquid Chromatography.14 In collaboration with the 
University of Wageningen the presence of 26b was established with special HPLC-techniques. 
From that time on it was possible to isolate the 1-deoxy analog, as will be described in chapter 4. 
Before hydrolysis of the cinnamoyl ester at C5, the hydroxyl groups CI, C2, C9 and CIO were 
protected. Ettouati et al. used acetone in the presence of H2S04, which gave the diisopropylidene 
compound 8 (scheme 3.2). In the present study it was decided to use the method described by 
Harrison et al., who used acetone in the presence of anhydrous CuS04.
15
 In this way the mono-
acetonide 27a (mixed with 27b) was prepared (scheme 3.5). At this stage of the synthetic route, the 
first purification by column chromatography was carried out. Compound 27a (mixed with 27b) was 
isolated in a yield of 55 %, starting from the ammonium salt. 
Treatment of 27a,b with dihydropyran in the presence ofp-toluenesulfonic acid (PTS) yielded 
2a,b (scheme 3.6). In this step, compound 2b was removed by chromatography.16 Treatment of 
27a,b with 2-methoxypropene in the presence of PTS gave the diacetonide 8 while 27b was again 
removed by chromatography,16 (scheme 3.6). This diacetonide was synthesized for two reasons. 
Firstly, it was used as a reference compound and compared with the diacetonide of Ettouati et al. 
(scheme 3.2). Secondly to prepare an analog similar to compound 15 described by Ettouati et al., 
but with the paclitaxel side chain instead of cinnamic acid attached to the СІЗ-hydroxyl group. 
Since all hydroxyl groups were protected as acetáis, the cinnamoyl side chain at C5 could be 
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removed with 20 N NaOH, yielding compounds 9 and 28 (scheme 3.6). 
Scheme 3.6 
OH 
27a Ri = OH 
27b R< = Η 
OR* 
2a Ri = OTHP , R5 = THP 
2b R1 = Η , Rs = THP 
8 R1 = ORs, R6,R5 = isopropylidene 
-*• О: 
-х-
/ ORs 
28 RS = Re = THP 
9 Rs,R6 = isopropy lidene 
"OMs 
OR5 
29 Rs = Re = THP 
ORs' 
30 Rs = Rs = JHP 
10 R5.R6 = isopropyhdene 
'OR7 
OTBDMS 
Ζ 
'iZ 
OR5 
31 Rs = Rs = THP, R7 = H 
32 Rs = Re = JHP, R7 = Ms 
11 R5.R6: 
12RS.R6: 
•H 
:MS 
:
 isopropyhdene, R7 : 
:
 isopropyhdene, R7 = 
(a) Dihydropyran/PTS, 82 % for 2 2-Methoxypropene/PTS, 73 % for 8 (b) 20 N NaOH, 93 % for 9, 95 % for 
28 (c) Methanesulfonyl chlonde/pyndine, no reaction (d) Os04/NMMO, 87 % for 10, 75 % for 30 (e) r-
Butyldimethylsilyl chloride/imidazole, 94 % for 11, 95 % for 31 (0 As (c), 86 % for 12, 89 % for 32 
Next, it was tried to mesylate the C5-hydroxyl group to give 29. When this compound 29 could 
be obtained the same strategy as described by van Rozendaal could be followed. Instead of the 
cirmamoyl side chain, in this case the mesyl group would shield the rear side of the C13-carbonyl 
and the reduction will take place from the front side, yielding the desired α-isomer (with the mesyl 
group still present).5 In this way the problems faced by van Rozendaal, who was unable to 
selectively mesylate the C5-hydroxyl group (scheme 3.1), can be circumvented. Unfortunately, this 
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plan did not meet with success because the C5-hydroxyl group of 28 could not be mesylated. 
Therefore, the conversion of the allylic alcohol into an oxetane ring starting with 9 and 28, 
respectively, was carried out using established methods.617 In the first step, the C4-C20 double bond 
was stereoselectively c/j-dihydroxylated, using osmium tetroxide in the presence of N-
methylmorpholine-N-oxide monohydrate, giving 10 and 30.18 Before the secondary hydroxyl group 
at C5 can be converted into a good leaving group, the primary hydroxyl group at C20 must first be 
temporarily protected using i-butyldimethylsilyl chloride in the presence of imidazole, affording 11 
and 31. Mesylation of 11 and 31 gave 12 and 32, respectively. Instead of using the mesyl group, the 
introduction the tosyl group was also attempted. Unfortunately, no reaction took place when 31 was 
treated with tosyl chloride instead of mesyl chloride in pyridine. 
3.2.3 Formation of the Oxetane Ring, the Reduction, and the Initial Attempts 
to Introduce the C2-benzoyl and C4-acetyl Functions 
Two different routes were followed for the synthesis of compound 35 from 32. In the first route 
(scheme 3.7) the oxetane ring was synthesized prior to the reduction of the C13-carbonyl. In the 
second route (scheme 3.8) the oxetane ring was synthesized after the reduction of the C13-carbonyl. 
Scheme 3.7 
12 R5.R6 = isopropylidene 14 Rs.Re = isopropyhdene 
I* 
35 R5 = R6 = THP 36 R5 = R« = THP 
38 R5,R<> = isopropyhdene 39 R5,R« = isopropylidene 
(a) Tetrabutylammomum fluoride, 98 % (b) Tetrabutylammonium acetate, 77 % for 33, 56 % for 14 (c) 
Ac20/DMAP, 83 % (d) DIBALH/-10 °C, 49 % (35), 11 % (36) and 44 % (38), 12 % (39). 
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The first route (32-»33-»35) is analogous to that of Ettouati et al.6 in the preparation of 
compound 14 from 12 (scheme 3.2). Treatment of compound 32 with TBAF, in order to remove the 
f-buryldimethylsilyl group, followed by ring closure under the influence of Bu4N
+
 OAc, gave 
oxetane compound 33 (scheme 3.7). In order to study the C4-acylation, compound 33 was treated 
with Ac20 in the presence of DMAP, affording compound 34." 
The next step in the route is the selective reduction of the C13-carbonyl of compound 33. 
Ettouati et al. have shown that several reducing agents are not applicable in the reduction of 14.6 By 
using NaBH4 in the presence of CeCl3 the starting material was destroyed. In the absence of СеСЦ 
two compounds were formed; one in which the Cl 1-C12 double bond, as well as the carbonyl, was 
reduced (45 %) and another in which the СІЗ-carbonyl was reduced to the C13ß-isomer, the wrong 
isomer (25 %). Also, reduction with LiAlH4 in ether gave the undesired C13ß-isomer (39 %). The 
best results were obtained with DIBALH, yielding 13 % of the C13ß-, but also 39 % of the С 13a-
isomer. 
Based on these results of Ettouati et al., it was decided to use DIBALH in the reduction of the 
C13-carbonyl of compound 33.20 The desired C13a-isomer 35 was isolated in 49 % (37 % from 32) 
and the undesired C13ß-isomer 36 in 11 % yield. 
In order to find a more selective reduction of the СІЗ-carbonyl in the other route (32->37-»35), 
first the carbonyl of 32 was reduced by DIBALH. Use of models and calculations indicated that the 
mesyloxy group at C5 can shield the rear side of the carbonyl at C13,21 (figure 3.4). 
Figure 3.4 3D-view of compound 32 demonstrating the hydride attack 
Front Side Attack 
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Therefore, the attack of the hydride can only take place from the front side, analogous to the 
reduction of 29 (scheme 3.6). Indeed, only the СІЗсс-isomer, 37, was isolated while the C13ß-
isomer was not detected (scheme 3.8). Unfortunately, 37 was isolated in only 45 % yield. From the 
remaining mixture, about 30 % was lost during column chromatography. The other 25 % consisted 
of several products, which were not identified. The reduction was not further studied in this stage, 
although it may be optimized by using other (leaving) groups instead of the mesyl group. 
Desilylation of 37 with tetrabutylammonium fluoride, followed by treatment with 
tetrabutylammonium acetate, yielded 35 in 36 % from 32 (scheme 3.8). 
Scheme 3.8 
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(a) DIBALH/-10 °C; 45 %. (b) ) Tetrabutylammonium fluoride, (c) Tetrabutylammonium acetate; 79 % from 37. 
Thus, the overall yield of 35, starting from 32, was about the same for both routes. Nevertheless 
purification by column chromatography after each step, appeared to be more difficult for the second 
route. For this reason, compound 38 was synthesized via 14 by the first route in 24 % from 12 
(scheme 3.7). 
For the introduction of the benzoyl group at C2 and the acetyl at C4, compound 33 was the 
starting material of choice (scheme 3.9). 
Scheme 3.9 
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(a) H20/HOAc/THF : 2/2/1; 89 %. (b) Benzoyl chloride/pyridine; 96 %. 
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41 
In the first step, the hydroxyl groups at CI and C2 of 33 had to be deprotected, after which the 
benzoate group could be introduced at C2. However, it appeared to be impossible to hydrolyze both 
THP groups under mild acidic conditions. The use of stronger acidic conditions was not possible 
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because this would lead to the hydrolysis of the isopropylidene acetal at C9 and CIO. Only the THP 
group at CI was hydrolyzed, giving 40, which became clear when the free hydroxyl group was 
benzoylated, yielding 41. The 400 MHz 'H-NMR spectrum of compound 41 showed no downfield 
shift of the proton at C2 as was expected when the benzoate group is attached to C2 (4.14 ppm in 40 
and 4.15 ppm in 41). Compound 41 provided the possibility of synthesizing analogs with a benzoate 
group at CI instead of at C2. These types of analogs, substituted at CI, were not known in the 
literature and it would be interesting to investigate their biological activity.22 
In order to achieve selective reduction of the C13-carbonyl, while at the same time avoiding 
reduction of the benzoyl group of compound 41 several reducing agents were tried, e.g. BH3.THF,23 
NaBH4,6 LiBH4,6 diphenylsilane,24 9-BBN25 and K-selectride.26 The best results were obtained with 
BHj.THF. Unfortunately, the yield of C13a-isomer 42 was only 21 % (scheme 3.10). The C13ß-
isomer was isolated in 4% (not completely pure). There were also many side products formed which 
were not identified, among them are probably products in which concomitant reduction of the СП-
СП double bond had taken place. 
Scheme 3.10 
(a)BH,.THF;21%. 
Na- and LiBH,, gave the undesired C13ß-isomer, according to TLC. Diphenylsilane, 9-BBN and 
K-selectride gave no reaction, probably due to the size of these agents which makes it impossible to 
approach the C13-carbonyl because of steric hindrance. 
For the introduction of the C4-acetyl group, compound 41 was treated with acetic anhydride in 
the presence of DMAP, affording compound 43 (scheme 3.11). 
Scheme 3.11 
(a) Ac20/DMAP; 88 %. (b) BH3.THF; 13 %. 
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Reduction of the C13-carbonyl of 43 with BHj.THF yielded 44 (the C13ß-isomer was not 
isolated). Again, this reduction with BH3.THF resulted in a very low yield of the desired product 
and formation of side products. However, the compounds 42 and 44 were isolated in a sufficient 
amount to be coupled to the paclitaxel side chain. Therefore, no further studies were carried out to 
optimize this reduction step. 
The next step in the synthetic route was the coupling of 35,38, 42 and 44 with the paclitaxel side 
chain. 
3.2.4 Synthesis of the Paclitaxel and Docetaxel Side Chain 
Until 1993, only Denis et al.27lb had reported a synthesis of the protected paclitaxel side chain 45 
(figure 3.5). After 1993, there was an explosion of publications involving this synthesis from many 
research groups.28,2' The coupling of side chain 45 to the taxane skeleton, which was a weak point in 
the semi-synthesis of paclitaxel,l2b was improved by using side chain precursors such as oxazinone 
46,30 ß-lactam 4731 and oxazolidine 4832 (see also section 1.2.3). Currently, a great variety of 
methods is available for the synthesis of both the paclitaxel side chain,28 as well as its precursors.29 
Figure 3.5 
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The method of Denis et al. was slightly modified and used for the synthesis of the paclitaxel and 
docetaxel side chain (scheme 3.12), because the starting methyl ester of cinnamic acid, is cheap and 
available in large quantities. This route allowed us to produce the side chain on a multigram scale 
with high enantioselectivity. Furthermore, protected side chain 45 can be converted into the side 
chain precursor oxazinone 46, which gave excellent results in coupling reactions.30 
In the first reaction step, methyl cinnamate (49) is stereoselective^ m-dihydroxylated to diol 50. 
For this purpose, Denis et al. used an enantioselective c/'s-dihydroxylation method of Sharpless from 
1988.27c Denis et al. were able to isolate the pure enantiomer 50 in a yield of 51 %.27a A slight 
adaptation to this reaction was made by using the improved method reported by Sharpless.33ab 
Under the influence of Ad-mix-ß [a mixture of K2Os02(OH)4, (DHQD)2-Phal, K3Fe(CN)6 and 
K2C03)] in the presence of methanesulfonamide, c/i-diol 50 was synthesized and isolated in 88 % 
yield. Monotosylation of 50 afforded compound 51, from which epoxide 52 was formed after 
treatment with K2C03. Epoxide 52 was opened with sodium azide in the presence of methyl 
formate, necessary to capture the sodium hydroxide formed, yielding compound 53. 
For the formation of the docetaxel side chain the azide 53 was hydrogenated in the presence of 
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di-f-butyl carbonate (BOC20), yielding the docetaxel side chain methyl ester 54. Protection of the 
free hydroxyl group with ethyl vinyl ether in the presence of PTS, followed by saponification of the 
methyl ester, led to the protected docetaxel side chain 55. 
For the formation of the paclitaxel side chain, the hydroxyl group of azide 53 was first 
benzoylated, affording compound 56. Under hydrogénation conditions the benzoyl group migrated 
to the amino group, yielding 57. In this case protection and saponification led to the protected 
paclitaxel side chain, 45. 
Scheme 3.12 
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(a) Ad-mix-p/r-BuOH/H20; 88 %. (b) p-Toluenesulfonyl chloride/Et,N/0 °C; 83 %. (c) K2COj/H20/DMF; 93 %. 
(d) Sodium azide/methyl formate; 96 %. (e) BOC20/EtOAc/H2/Pd-C; 98 %. (f) Ethyl vinyl ether/PTS; 93 %. (g) 
K2COj/MeOH/H20; 95 %. (h) Benzoyl chloride/Et>N/DMAP. (i) H^Pd-C/EtOAc; 81 % from S3. 
The conversion of the protected paclitaxel side chain 45 into the corresponding oxazinone 46, 
according to the protocol of Holton,30 is depicted in scheme 3.13. 
Scheme 3.13 
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(a) KOí-Bu/methanesulfonyl chloride; 41 % 
In the syntheses of paclitaxel analogs described in this thesis both protected paclitaxel side chain 
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45 and oxazinone 46 were used. 
3.2.5 7-Deoxypaclitaxel Analogs From Crude Taxine 
Coupling of the compounds 35,38,42 and 44 with the paclitaxel side chain will lead to protected 
paclitaxel analogs. It is known from the literature that the coupling reaction with the protected side 
chain 45 in the presence of DCC and DMAP, proceeds in low yield (80 % with 50 % conversion).12b 
Therefore, in these coupling reactions the activated side chain oxazinone 46 was used. The 
advantage is that the conversion with respect to the taxane-part, which is more difficult to obtain 
than the paclitaxel side chain, is higher with oxazinone 46 (100 % with 77 % conversion).30 A 
general disadvantage of these reactions is that the amount of side chain needed is about 4-5 times as 
much as when using the protected side chain 45. 
The coupling of 35 and 38 with oxazinone 46 gave the protected 7-deoxypaclitaxel analogs 58 
and 59, respectively (scheme 3.14). 
Scheme 3.14 
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(a) DMAP/pyridine; 89 % for 58; 75 % for 59. (b) Ac20/DMAP; no reaction. 
Before the deprotection of the compounds 58 and 59, the acetylation of the C4-hydroxyl group of 
analog 58 was attempted. Treatment of 58 with Ac20 in the presence of DMAP, however, gave no 
conversion. The reason for this might be stabilization of 58 by the formation of a hydrogen bond 
between the C4-hydroxyl and the ester carbonyl of the side chain.34 
In an analogous way as described for compound 58, the protected analog 60 was synthesized 
from compound 42 (scheme 3.15). The coupling reaction between compound 44 and oxazinone 46 
in order to obtain analog 61 occurred less smoothly. First of all, the reaction proceeded very slowly, 
which can be attributed to the formation of a hydrogen bond between the СІЗ-hydroxyl group and 
the carbonyl of the C4-acetate group.12b A more serious problem was the purification of compound 
61. Only one new spot was seen on TLC (even with different eluents e.g.: EtOAc/Hex ; 1/1 and 
CH3CI/CH3OH ; 95/5). After purification by column chromatography 'H-NMR showed, however, a 
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mixture of two compounds from which 61 was the minor product. The major product could not be 
identified, although the NMR spectrum suggested an ester of the paclitaxel side chain, as was 
deduced from the proton signals in the aromatic area (7.00-7.50 ppm). Also in the area of 0.85-1.75 
ppm, where normally the methyl protons of the taxane skeleton are located, a complicated pattern 
was observed. 
Scheme 3.15 
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(a) DMAP/pyridine; 90 % for 60; ? % for 61. 
Ph 
46 
A further elaboration of this synthetic route to 61 will depend on the results of the cytotoxic 
activity tests of the other analogs, when not active further work will not be considered. 
Removal of the protecting groups. 
An alternative method for the introduction of the C2-benzoyI group is depicted in scheme 3.16. 
Scheme 3.16 
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(a) AcOH/H20/THF : 2/2/1, RT. (b) Ν,Ν'-Carbonyldiimidazole. (c) Phenyllithium. 
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Treatment of compound 58 with a 2/2/1 mixture of AcOH/H20/THF was originally expected to 
give compound 62. Introduction of the carbonate bridge to 63 and selective opening of this bridge 
with phenyllithium would give the benzoate compound M.u' Unfortunately, analogous to the 
deprotection of 33 (scheme 3.9) the THP-acetal at the C2-hydroxyl group was not hydrolyzed. 
Under the conditions used, compound 58 was converted into compound 65 (scheme 3.17). 
When the concentration of acetic acid was increased and the solution was heated to 40 °C the 
isopropylidene acetal at C9, CIO was also hydrolyzed, affording 66 and 67, respectively (scheme 
3.17). 
Scheme 3.17 
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(a) AcOH/H20/THF : 2/2/1, RT; 76 %. (b) AcOH/H20/THF : 4/2/1,40 °C; 63 % for 66; 66 % for 67. 
Treatment of 58 with 0.1 N HC1/THF gave 66 (45 %), with partial hydrolysis of the paclitaxel 
side chain (39 %). The same effect was achieved by treatment with PTS/MeOH. Other agents that 
were used for the cleavage of acetáis, such as magnesium bromide35 (MgBr2) or sodium 
cyanoborohydride36 (NaCNBH3) also did not lead to the deprotection of the C2-hydroxyl group of 
compound 67. With NaCNBH3 several products were formed which were not identified because of 
the small scale at which this reaction was performed. With MgBr2 no reaction took place. 
Removal of the C9,C10-O-isopropylidene group of compound 61 appeared to be even more 
difficult. With a 4/2/1 mixture of AcOH/H20/THF at 50 °C the isopropylidene functionality was not 
hydrolyzed. A 12/2/1 mixture of AcOH/H20/THF at 50 °C was needed and under these conditions 
63 
the paclitaxel side chain was split off for 32 %. Nevertheless, compound 68, with the THP group at 
the C2-hydroxyl still present, was isolated in 61 % yield (scheme 3.18). 
Scheme 3.18 
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Finally, treatment of 61 with 0.1 N НС1ЯНР or PTS/MeOH did not lead to the hydrolysis of the 
THP group, rather the paclitaxel side chain was split off completely. 
3.3 Evaluation of 7-DeoxypaclitaxeI Analogs 58, 59, 65-68 
During the completion of the synthetic routes toward these analogs, it became known from SAR 
studies that the benzoyl function at C2 is indispensable for the cytotoxic activity of Paclitaxel.37 
Despite the fact that the analogs above do not have the crucial benzoate function at C2, they were 
still tested for their activity for the following reasons: 
- The analogs have functionalities in least at five positions, which are different from that positions 
in paclitaxel. These types of analogs had not been evaluated in SAR studies of paclitaxel before. 
It was hoped that the effect of the missing C2-benzoyl group would be compensated by the other 
functions. 
- It was also hoped that the THP group at C2 would be a substitute for the benzoate group at C2, 
because the two acetal oxygens are in about the same spatial position as the two oxygens of the 
benzoate group. 
- For compound 68 it was hoped that the benzoate group at CI might have a related effect on the 
activity in the same way as does this group at C2 (At that time compound 68 was also the first 
CI-substituted paclitaxel analog). 
To determine the activity the analogs were tested for their in vitro cytotoxicity against seven 
well-characterized human tumor cell lines: MCF7 (breast cancer), EVSA-T (breast cancer), WIDR 
(colon cancer), IGROV (ovarian cancer), Ml9 MEL (melanoma), A498 (renal cancer), H226 (Non-
small cell lung cancer). The determination of the cytotoxicity was carried out by Kolker H.J.; 
Verweij, J.; Stoter, G. and Schellens, J.H.M, from the laboratory of Experimental Chemotherapy 
and Pharmacology, Department of Medical Oncology. Rotterdam Cancer Institute (Dr. Daniel den 
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Hoed Kliniek).38 
Unfortunately, all the analogs showed very low cytotoxic activity against these cell lines. 
Paclitaxel has an IDS0 < 3 ng/ml in all cell lines whereas the ID50-values of the analogs are 10,000-
20,000 times higher. The inactivity must be attributed thus to the missing benzoate group at C2, 
which is in agreement with the SAR studies. 
3.4 Conclusions 
In this chapter it was shown that it is possible to use the crude taxine fraction, instead of pure 
taxine B, for the synthesis of 7-deoxypaclitaxel derivatives. 
The selective protection of the CI- and C2-hydroxyl groups as THP-acetals, whereby they can be 
removed independently from each other as well as from the isopropylidene group, was not 
successful. It was possible, however, to remove the THP-acetal at CI without removing the THP-
acetal at C2 and/or the isopropylidene functionality at C9.C10. The THP-acetal at C2 or the 
isopropylidene acetal at C1.C2, however, could not be hydrolyzed without destroying the rest of the 
molecule. Recently, analogous problems with the hydrolysis of the isopropylidene acetal at C1,C2 
of a related taxane compound 69 (figure 3.6) have been reported by Nicolaou et al.35 
Figure 3.6 
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According to these investigators it was also not possible to remove the isopropylidene acetal clip 
in compound 69 without destroying the molecule. 
Since it was noi possible to hydrolyze the THP-acetal at C2 and the isopropylidene group at CI, 
C2, introduction of the C2-benzoate group could not be accomplished. Consequently, 7-
deoxypaclitaxel analogs possessing this C2-benzoate group, which is necessary for cytotoxic 
activity, could not be synthesized. 
Introduction of the acetate group at C4, after coupling of the paclitaxel side chain, appeared not 
to be possible, probably due to the formation of a hydrogen bond between the C4-hydroxyl group 
and the carbonyl group of the side chain. 
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Introduction of a benzoyl and acetyl group, respectively, before the reduction of the С13-
carbonyl complicated this reduction reaction. The most satisfying, but still poor, results were 
obtained using BH3.THF as a reducing agent. 
By combining the improved Sharpless stereoselective cw-dihydroxylation reaction13" and the 
method of Denis et al.,27" both the paclitaxel and docetaxel side chain were prepared on a multi-
gram scale in high yields and with high enantioselectivity. 
3.5 Experimental Section 
Proton magnetic resonance spectra were measured on a Bruker AC-100 or a Bruker AM-400 
spectrometer. Chemical shift values are reported as δ-values relative to tetramethylsilane as an 
internal standard; deuterochloroform was used as solvent Mass spectra were obtained with a double 
focusing VG 7070E spectrometer Elemental analyses were carried out on a Carlo Erba Instruments 
CHNSO EA 1108 element analyzer. For the determination of optical rotations a Perkin-Elmer 241 
Polarimeter was used. Melting points were determined with a Reichert Thermopan microscope and 
are uncorrected Thin layer chromatography (TLC) was carried out on Merck precoated silica gel 60 
F-254 plates (thickness; 0.25 mm). All reactions mentioned were monitored by TLC. Spots were 
visualized with UV or a 6 2 % H2S04 aqueous solution, (IL) containing ammonium molybdate (42 
g) and eerie ammonium sulfate (3 6 g), followed by charring. Column chromatography was carried 
out using silica 60 or silica 60H (Merck). Unless otherwise stated, materials were obtained from 
commercial sources and used without further purification. When necessary, solvents were distilled 
and dried according to standard procedures. 
Extraction procedure for crude taxine 
Dried leaves (17 kg) of Тахич boccata were soaked in an aqueous solution of H2S04 (100 liter, 0 5 % v/v) for three 
days The sulfuric acid solution was separated from the leaves and extracted (in portions of 20 L) with diethyl ether (3 
L) in a continues extraction apparatus for 1 day, to remove the major part of the undesired neutral organic compounds 
The sulfuric acid solution then was brought to pH 9 by addition of aqueous ammonia This solution was extracted twice 
with diethyl ether (3 L) in a continuous extraction apparatus for I day The combined ether layers were dried over 
anhydrous sodium sulfate, filtered and concentrated in vacuo, yielding crude taxine (150-200 g from 17 kg, depending 
on the quality of the leaves) as a light yellow colored amorphous powder 
Preparation of the Mixture of 25a-f. To a solution of crude taxine В (containing 40 % of la-f) (25 0 g, 42 9 
mmol) in ether (150 ml) methyl iodide (12 5 ml) was added After one day the pale yellow amorphous iodide salt of la-
f was collected, washed with ether and dried in a dessicator (13 4 g, s 18 3 mmol) A solution of this salt (13 4 g) in 
ethanol (50 ml) was added to a solution of potassium carbonate (15 g) in water (750 ml) The reaction mixture was 
stirred for 2 hours The precipitated mixture of 25a-f was collected, washed with water and dried (9 50 g, 17 7 mmol) 
Preparation of the Mixture of 5a-cinnamoyltaxicin-I (26a) and Sa-cinnamoyltaxicin-II (26b). A solution of 
sodium methoxide prepared from 0 49 g sodium (0 021 g-atoms), in methanol (550 ml) was cooled to 0 °C under an 
argon atmosphere After addition of 25a-f (9 50 g, 17 7 mmol), the mixture was stirred for 16 hours at 0 °C Then the 
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reaction mixture was acidified with glacial acetic acid and concentrated Water (500 ml) was added This solution was 
extracted twice with ether (200 ml) The combined ether layers were washed with a NaHCCysaturated solution, dried 
and concentrated m vacuo, yielding a mixture of 26a,b (7 45 g, 15 0 mmol, 85 %) 
Preparation of the mixture of 9,10-O-(Propane-2,2-diyl)-5a-cinammoyltaxicin-I (27a) and 9,10-O-(Propane-2,2-
diyl>5a-cinnamoyltaxicin-H (27b). To a suspension of anhydrous copper sulfate (35 g, 0 22 mmol) in dry acetone 
(750 ml) the mixture of 26a,b (7 45 g, 15 0 mmol) and a catalytic amount of p-toluenesulfonic acid were added After 2 
days at rt the solution was filtered The filtrate was concentrated in vacuo The residue was purified via chromatography 
(EtOAc/hexane 2/5) to give a mixture of 27a and 27b (5 23 g, 9 8 mmol, 65 %) mp 112 °C, [a],,20 + 233 4° (c=l 05 in 
chloroform), 'H-NMR (400 MHz, CDCI,) δ 7 71-7 42 (5H, m, H-Ph), 7 63 (IH, d, J6 5 = 15 9 Hz, H6'), 6 35 (IH, d, Js 
6 = 15 9 Hz, H5·), 5 46 (IH, bs, H20), 5 37 (IH, bs, H20), 5 33 (IH, bs, H5), 4 90 (IH, d, J10_, = 9 Hz, HI0), 4 30 (IH, 
d, J, ,„ = 9 Hz, H9), 4 08 (IH, t, J „ = 7 5 Hz, J 2 0 H 2 = 7 5 Hz, H2), 3 25 (IH, d, J 3 2 = 7 5 Hz, H3), 2 66 (2H, q, J,„ = 
21 4 Hz, H14), 2 50 (IH, d, J O H 2 2 = 7 5 Hz, OH2), 2 12 (3H, s, H18), 2 04 (IH, s, H6), 1 75 (2H, m, H6 and H7), 1 64 
(3H, s, H16), 1 62 (IH, m, H7), 1 51 (ЗН, s, acetonide), 1 44 (ЗН, s, acetonide), 1 37 (3H, s, H17), 1 10 (3H, s, H19), 
FAB-MS, 537 [M+H]* 
l,2-Di(tetrahydropyran-2-yl)-9,10-O-(Propane-2,2-diyl)-5a-cinammoyltaxicin-I (2a). To a solution of 27a,b (5 0 g, 
9 4 mmol) andp-toluenesulfonic acid (PTS) (10 mg, 0 05 mmol) m CH2C12 (75 ml), dihydropyran (2 3 g, 27 mmol) in 
CH,CL2 (10 ml) was slowly added at rt After one day the reaction mixture was washed with a NaHCOj-saturated 
solution, then washed with brine, dried over Na2SO„ and concentrated in vacuo The residue was purified via 
chromatography (EtOAc/hexane 2/5), yielding 2a (5 4 g, 7 7 mmol, 82 %) mp 66 °C, [a]d2° + 257 9° (c=l 00 m 
chloroform), 'H-NMR (400 MHz, CDC13) δ 7 73 (2H, m, H-Ph), 7 41 (ЗН, m, H-Ph), 7 61 (IH, d, J 6 , = 15 9 Hz, H6'), 
6 33 (IH, d, ibJ¡ = 15 9 Hz, H5'), 5 58 (IH, bs, H20), 5 33 (IH, s, H5), 5 27 (IH, bs, H20), 4 91 (IH, m, H11"), 4 90 
(IH, d, J,o, = 92 Ηζ,ΗΙΟ), 4 56 (IH, m, Hl Γ), 4 26 (IH, d, J<M„ = 9 2 Hz, H9), 4 14 (IH, d, J 2 , = 5 6 Hz, H2), 3 85 
(IH, m, H12"), 3 73 (IH, m, H12"), 3 49 (IH, m, H12'), 3 39 (IH, m, H12'), 3 09 (IH, d, J3 2 = 5 6 Hz, H3), 2 67 (2H, s, 
H14), 2 12 (3H, s, H18), 1 59 (3H, s, H16), I 50 (3H, s, acetonide), 1 44 (3H, s, acetonide), 1 36 (3H, s, H17), 1 10 
(3H, s, H19), FAB-MS, 705 [M+H]+, Anal Caled forC^H^O, C, 7157, H, 8 01 Found С, 71 91, H, 7 95 
l,2-9,10-bis-O-(Propane-2,2-diyl)-5a-cinammoyltaxicin-I (8). The same procedure was followed as for 2a 
Instead of dihydropyran, 2-methoxypropene (1 30 g ml, 18 1 mmol) was added Compound 8 was isolated in 73 % 
yield (3 95 g, 6 86 mmol) 'H-NMR (400 MHz, CDC13) δ 7 72 (2H, m, H-Ph), 7 42 (ЗН, m, H-Ph), 7 62 (IH, d, J6 s = 
15 9 Hz, H6'), 6 33 (IH, d, ¡S4 = 15 9 Hz, H5'), 5 57 (IH, bs, H20), 5 32 (bs, IH, H20), 5 27 (IH, bs, H5), 4 90 (IH, d, 
J1M = 92 Hz, H10),4 27 (IH, d, J, ,0 = 9 2 Hz, H9),4 23 (IH, d, J23 = 5 7 Hz, H2), 3 06 (IH, d, J32 = 5 6 Hz, H3), 2 78 
(IH, d,JH 1 4=19 5, H14),2 69(lH,d, J „ M = I 9 5, H14),2 13 (3H, s, H18), 1 59 (3H, s, H16), 1 51 (3H, s, acetonide), 
1 44 (3H, s, acetonide), 1 40 (3H, s, acetonide), 1 38 (3H, s, acetonide), I 34 (3H, s, H17), 1 09 (3H, s, H19) 
Hydrolysis of 2a -> 28. To a solution of 2a (5 4 g, 7 7 mmol) in dry THF (60 ml), 20 N NaOH (aq) (25 ml) was 
added The reaction mixture was stirred at reflux temperature for 2 days The reaction mixture was then diluted with 
water (50 ml) and extracted twice with CH2CI2 (150 ml) The combined organic layers were washed with brine, dried 
over Na2SO< and concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), yielding 
28 (4 20 g, 7 32 mmol, 95 %) mp 66-69 °C, [a]d2° + 195 1° (c=l 00 in chloroform), 'H-NMR (400 MHz, CDC13) δ 
5 47 (IH bs, H20), 5 09 (IH, bs, H20), 4 91 (IH, d, J 1 0 , = 9 2 Hz, НЮ), 4 89 (IH, m, Hl 1"), 4 58, (IH, m, HI Г), 4 22 
(IH, d, J, ,0 = 9 2 Hz, H9), 4 17 (IH, bs, H5), 4 10 (IH, d, J „ = 5 4 H A H2),3 87 (IH, m, H12"), 3 74 (IH, m, H12"), 
3 50 (IH, m, Η12·), 3 40 (IH, m, H12'), 3 23 (IH, d, J 3 2 = 5 4 Hz, НЗ), 2 60 (2Н, bs, 2Н14), 2 06 (ЗН, s, Н18), 1 58 
(ЗН, s, HI6), 1 49 (ЗН, s, acetonide), 1 45 (ЗН, s, acetonide), 1 32 (ЗН, s, HI7), 1 05 (ЗН, s, HI9), CIMS, 574 [Mf, 
Anal Caled for C33HS0O8 С, 68 95, H, 8 79 Found С, 69 17, H, 8 63 
Hydrolysis of 8 -> 9. The same procedure was followed as for 28, using 8 (3 95 g, 6 86 mmol) Compound 9 was 
isolated in 93 % yield (2 84 g, 6 37 mmol) 'H-NMR (400 MHz, CDCI3) δ 5 46 (IH, bs, H20), 5 10 (IH, bs, H20),4 90 
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(IH, d, J1 ( W = 9 2 Hz, H10), 4 24 (IH, d, J, ,„ = 9 2 Hz, H9), 4 18 (IH, d, J „ = 5 7 Hz, H2), 4 15 (IH, bs, H5), 3 19 
(IH, d, J,
 2 = 5 7 Hz, H2), 2 75 (IH, d, J,4 , 4 = 19 5, H14), 2 69 (IH, d, J 1 4 . M = 19 5, H14), 2 08 (3H, s, H18), 1 59 (3H, s, 
H16), 1 49 (3H, s, acetonide), 1 42 (3H, s, acetonide), 1 40 (3H, s, acetomde), 1 36 (3H, s, acetonide), 1 30 (3H, s, 
H17), 106(3H,s,H19) 
Mesylation of 28 -» 29. To a solution of compound 28 (0 10 g, 0 17 mmol) in pyridine (3 ml) at 0 °C 
methanesulfonyl chloride (80 μΐ, 1 0 mmol) was added The reaction mixture was stirred for 20 hours at rt after which 
CH2CI2 (25 ml) was added The mixture was washed with a solution of 10 % citric acid in water (15 ml), then with a 
NaHCOj-saturated solution, dried over Na2S04 and concentrated in vacuo After column chromatography 
(EtOAc/hexane 1/1), compound 28 was entirely recovered 
Dihydroxylation of 28 -• 30. To a solution of 28 (4 20 g, 7 32 mmol) in THF/H20 (80/40 ml), N-
methylmorphohne-JV-oxide monohydrate (0 90 g, б 7 mmol) and a solution of Os04, 2 5 % in f-BuOH (6 4 ml) were 
added The reaction mixture rapidly turned red After 20 hours, flonsil (2 0 g), water (26 ml) and Na2S204 (256 mg) 
were added The mixture was stirred for an additional 10 minutes and then filtered The filtrate was diluted with a 
concentrated solution of ammonium chloride in water (100 ml) and extracted twice with EtOAc (150 ml) The 
combined organic layers were washed with brine, dried over Na2S04 and concentrated in vacuo The residue was 
purified via chromatography (EtOAc), yielding 30 (3 33 g, 5 48 mmol, 75 %) mp 72 °C,[ct]d20 + 223 3° (c=0 95 in 
chloroform), 'H-NMR(400 MHz, CDCI,) δ 4 97 (IH, m, НИ"), 4 81 (IH, d, J 1 M = 9 3 Hz, H10), 4 55, (IH, m, Hll ), 
4 15 (IH, d, J^o = 9 3 Hz, H9), 4 09 (IH, d, J „ = 4 9 Hz, H2), 4 04 (IH, bs, H20), 3 87 (IH, m, H12"), 3 82 (IH, bs, 
H5), 3 77 (IH, m, H12"), 3 59 (IH, bs, H20), 3 50 (IH, m, H12'), 3 42 (IH, m, H12'), 3 23 (IH, d, J14 ,„ - 19 3 Hz, 
H14), 2 65 (IH, d, J 3 2 = 4 9 Hz, H3), 2 62 (IH, d, J1 4.,4= 19 3 Hz, H14), 2 03 (3H, s, H18), 1 56 (3H, s, H16), 1 46 (3H, 
s, acetonide), 1 43 (3H, s, acetonide), 1 34 (3H, s, H17), 1 08 (3H, s, H19), FAB-MS, 524 [M-THP+H]\ Anal Caled 
for C^HsoO, C, 65 11, H, 8 61 Found С, 64 72, H, 8 28 
Dihydroxylation of 9 -> 10. The same procedure was followed as for 30, using 9 (2 84 g, 6 37 mmol) Compound 
10 was isolated in 87 % yield (2 65 g, 5 50 mmol) 'H-NMR (400 MHz, CDCI,) δ 4 90 (IH, d, J10., = 9 2 Hz, НЮ), 
4 24 (Ш, d, J2 j = 5 7 Hz, H2), 4 19 (IH, d, J, 10 = 9 2 Hz, H9), 4 01 (IH, d, J 2 0. 2 0= 11 4 Hz, H20), 3 86 (IH, bs, H5), 
3 65 (IH, d, J 2 0. 2 0= 11 4 Hz, H20), 3 23 (IH, d, J 1 4 , 4 = 19 3 Hz, H14), 2 69 (IH, d, J 1 4 1 4 = 19 3 Hz, H14), 2 65 (IH, d, 
J 3 2 = 4 9 Hz, H3), 2 08 (3H, s, H18), 1 59 (3H, s, H16), 1 51 (3H, s, acetonide), 1 48 (3H, s, acetonide), 1 46 (3H, s, 
acetonide), 1 43 (3H, s, acetonide), 1 33 (3H, s, H17), I 09 (3H, s, H19) 
Silylation and Mesylation of 30 -* 31 -> 32. A solution of imidazole (5 10 g, 74 8 mmol) and /-butyldimethylsilyl 
chloride (4 64 g, 30 9 mmol) in DMF (30 ml) was stirred for 15 minutes Compound 30 (3 33 g, 5 48 mmol) was then 
added After 3 hours the reaction mixture was diluted with a solution of 10 % citric acid in water (200 ml) and extracted 
twice with EtOAc (100 ml) The combined organic layers were washed with brine, dried over Na2S04 and concentrated 
m vacuo The residue was purified via chromatography (EtOAc/hexane 2/5), yielding 31 (3 78 g, 5 23 mmol, 95 %) 
mp 52 °C,[a]d20 + 169 Г (c=l 00 in chloroform) FAB-MS, 746 [M+Na]\ Anal Caled for C j ^ O ^ S i H 2 0 C, 63 20, 
H, 9 27 Found C, 63 56, H, 8 95 
To a solution of 31 (3 78 g, 5 23 mmol) in pyridine (50 ml) at 0 °C methanesulfonyl chloride (2 5 ml, 32 mmol) was 
added The reaction mixture was stirred for 20 hours at rt after which CH2C12 (150 ml) was added The mixture was 
washed with a solution of 10 % citric acid in water (75 ml), with a NaHCO,-saturated solution, dried over Na2SO„ and 
concentrated m vacuo The residue was purified via chromatography (EtOAc/hexane 2/5), yielding 32 (3 70 g, 4 63 
mmol, 89 %) mp 57 °C, [a] d 2 0 + 211 Io (c=l 00 in chloroform), 'H-NMR (400 MHz, CDClj) δ 4 94 (IH, m, Hl 1"), 
4 86 (IH, bs, H5), 4 80 (IH, d, J10_, = 9 3 Hz, НЮ), 4 57 (IH, m, Hl Г), 4 18 (IH, d, J, ,„ = 9 3 Hz, H9), 4 12 (IH, d, 
J2 0.2 0= 10 4 Hz, H20), 4 02 (IH, d, J „ = 4 1 Hz, H2), 3 86 (IH, m, H12"), 3 74 (IH, m, H12"), 3 66 (IH, d, J 2 0 2 0 = 10 4 
Hz, H20), 3 51 (IH, m, H12'), 3 47 (IH, d, J , 4 , 4 = 19 4 Hz, H14), 3 38 (IH, m, H12'), 2 94 (3H, s, MeS02), 2 56 (IH, d, 
J 1 4 , 4 = 19 4 Hz, H14), 2 51 (IH, d, J3 2 = 4 1 Hz, H3), 2 07 (3H, s, H18), 1 55 (3H, s, H16), 1 47 (3H, s, acetonide), 1 43 
(3H, s, acetonide), 1 34 (3H, s, H17), 1 08 (3H, s, H19), 0 90 (9H, s, r-Bu), 0 08 (6H, s, Me2Si), FAB-MS, 823 
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[M+Na]*, Anal Caled for C ^ H ^ S i S C, 59 97, H, 8 56, S, 4 00 Found C, 60 14, H, 8 47, S, 2 69 
Silylation and Mesylation of 10 -> 11 -> 12. The same procedure was followed as for 32, using 10 (2 65 g, 5 50 
mmol) Compound 11 was isolated in 94 % (3 07 g, 5 20 mmol) 
Compound 12 was isolated in 86 % yield (3 0 g, 4 5 mmol) 'H-NMR (400 MHz, CDC13) δ 4 86 (IH, bs, H5), 4 80 
(lH,d,J1().9 = 9 2Hz,H10),4 19(lH,d,J 9 1 ( ) = 9 2Hz,H9),4 15 (IH, d, J 2 , = 5 7 Hz,H2),4 10 (IH, d, J 2 0 2 0 = 11 1 Hz, 
H20), 3 65 (IH, d, J 2 0. 2 0= 11 1 Hz, H20), 3 55 (IH, d, J,4 14 = 19 3 Hz, H14), 2 97 (3H, s, MeS02), 2 60 (IH, d, J14 14 = 
19 3 Hz, H14), 2 53 (IH, d, J, , = 4 9 Hz, H3), 2 08 (3H, s, H18), 1 56 (3H, s, H16), 1 49 (3H, s, acetonide), 1 44 (3H, s, 
acetonide), 1 42 (3H, s, acetonide), 1 37 (3H, s, acetonide), 1 31 (3H, s, H17), 1 09 (3H, s, H19), 0 90 ( 9H, s, f-Bu), 
0 07 (6H, s, Me2Si) 
Construction of the Oxetane Ring: 32 -> 33 (Route 1). To a solution of 32 (3 70 g, 4 63 mmol) in THF (75 ml), 
tetrabutylammonium fluoride (1 8 g, 6 9 mmol) was added The reaction mixture was stirred for one hour at rt after 
which EtOAc (150 ml) was added The organic layer was washed with a NaHCCysaturated solution, dried over Na 2S0 4 
and concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), yielding the desilylated 
compound (3 10 g, 4 52 mmol, 98 %) mp 89 °C, FAB-MS, 687 [M+H]*, 709 [M+Na]\ Anal Caled for C„H5 40,2S C, 
59 46, H, 7 92, S, 4 67 Found C, 59 35, H, 7 88, S, 3 31 
To a solution of the desilylated compound (3 10 g, 4 52 mmol) in butanone (75 ml) tetrabutylammonium acetate (12 0 
g, 39 9 mmol) was added The reaction mixture was stirred at reflux temperature, for 17 hours The mixture was then 
diluted with EtOAc (100 ml) and washed with a saturated solution of ammonium chloride in water The organic layer 
was dried over Na2S04 and concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 2/5), 
yielding 33 (2 04 g, 3 46 mmol, 77 %) mp 65 °C, [ct]d20 + 188 7° (c=l 0 in chloroform), 'H-NMR (400 MHz, CDC1,) δ 
4 94 (IH, m, НИ"), 4 86 (IH, bs, H5), 4 80 (IH, d, J 1 M = 9 3 Hz, НЮ), 4 57 (IH, m, Hl 1'), 4 18 (IH, d, J, ,0 = 9 3 Hz, 
H9), 4 12 (IH, d, J2 O.2 0- 10 4 Hz, H20),4 02 (IH, d, J „ = 4 1 Hz, H2), 3 86 (IH, m, H12"), 3 74 (IH, m, H12"), 3 66 
(IH, d, J 2 M 0 - 10 4 Hz, H20), 3 51 (IH, m, H12'), 3 47 (IH, d, J H l4 = 19 4 Hz, H14), 3 38 (IH, m, H12'), 2 94 (3H, s, 
MeS02), 2 56(1H, d, J , 4 1 4 = 19 4 Hz, HI4), 2 51 (IH, d, J 3 2 = 4 1 Hz, H3), 2 07 (3H, s, H18), 1 55 (3H, s, H17), 147 
(3H, s, acetonide), 1 43 (3H, s, acetonide), 1 34 (3H, s, H16), 1 08 (3H, s, H19), FAB-MS, 591 [М+НГ, 613 [M+Naf, 
Anal Caled for C33HS0O, C, 67 09, H, 8 53 Found С, 67 04, H, 8 47 
Acetylation of 33 -> 34. To a solution of 33 (0 10 g, 0 17 mmol) m CH2CI2 (3 ml), Ac20 (50 μΐ) and DMAP (55 mg, 
0 45 mmol) were added The reaction mixture was stirred at rt for 24 hours The reaction mixture was diluted with 
CHjClj (25 ml) and washed with water (15 ml), brine (10 ml), dried over NajSO,, and concentrated ¡n vacuo The 
residue was purified via chromatography (EtOAc/hexane 2/5), yielding 34 (0 89 g, 0 14 mmol, 83 %) mp 44 °C, 'H-
NMR (400 MHz, CDCI3) δ4 93 (2H, m, НИ", H5), 4 71 (IH, d, J 1 M = 94 Hz, H10), 4 58 (IH, m, Hl Г), 4 52 (2H, bs, 
H20), 4 27 (IH, d, J,
 l 0 = 9 4 Hz, H9), 4 08 (IH, d, J 2 3 = 4 8 Hz, H2), 3 87 (IH, m, H12"), 3 76 (IH, m, H12"), 3 52 
(IH, m, H12'), 3 40 (IH, m, H12'), 2 57 (2H, bs, H14), 2 52 (Ш, d, J 3 2 = 4 8 Hz, H3), 2 01 (3H, s, H4'), 1 91 (3H, s, 
H18), 1 58 (6H, bs, acetonide), 1 50 (3H, s, H16), 1 45 (3H, s, H17), 1 31 (3H, s, H19), FAB-MS, 633 [M+H]f, Anal 
Caled for Cj,H52Ol0 C, 66 43, H, 8 28 Found С, 66 74, H, 8 02 
Construction of the Oxetane Ring: 12 —> 14 (Route 1). The same procedure was followed as for 33, using 12 (3 0 
g, 4 5 mmol) The desilylated compound was isolated in 98 % (2 46 g, 4 40 mmol) 
Compound 14 was isolated in 56 % yield (1 14 g, 2 50 mmol) 'H-NMR (400 MHz, CDC13) δ 4 77 (IH, dd, J „ = 
7 9 Hz, J5 6 = 1 5 Hz, H5), 4 67 (IH, d, J № , = 9 4 Hz, H10), 4 57 (Ш, d, J 2 0 . 2 0= 8 0 Hz, H20), 4 34 (IH, d, J20_20= 8 0 
Hz, H20), 4 27 (IH, d, J^10 = 9 5 Hz, H9), 4 24 (IH, d, J2 3 = 5 4 Hz, H2), 3 06 (IH, d, J14 „ = 19 0 Hz, H14), 2 90 (IH, 
bs, OH4), 2 64 (IH, d, J 1 4 1 4 = 19 0 Hz, H14), 2 10 (2H, m, 2H6), I 93 (3H, s, H18), 1 78 (3H, d, J J 2 = 5 4 Hz, H3), 1 58 
(3H, s, H16), 1 56 (3H, s, acetonide), 1 50 (3H, s, acetonide), 1 45 (3H, s, acetonide), 1 43 (3H, s, acetonide), 1 38 (3H, 
s,H17), 1 32(3H,s,H19) 
2-Debenzoyl-l,2-(ditetrahydropyran-2-yl)-4-deacetyl-7-deoxy-lO-deacetyl-9,lO-0-(Propane-2,2-diyl)-9(Ä)-
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dihydrobaccatin HI (35) (Route 1). To a solution of 33 (2 04 g, 3 46 mmol) in CH2CI2 (15 ml) at -10 °C, a solution of 
DIBALH in CH2C12 (5ml, IM) was added The reaction mixture was stirred at 0 °C for 45 minutes Subsequently a 
solution of 10 % citric acid in water (30 ml) was carefully added The water layer was extracted twice with CH2C12 (75 
ml) The combined organic layers were washed with a NaHCO,-saturated solution, then with bnne, dried over Na2S04 
and concentrated m vacuo The residue was purified via chromatography (EtOAc/hexane 2/3), yielding 35 (1 02 g, 
1 72 mmol, 49 %) and 36 (0 23 g, 0 39 mmol, 11 %) 
35 mp 50 ° C, 'H-NMR (400 MHz, CDC1,) fi 4 91 (IH, m, НИ"), 4 79 (IH, dd, ¡^ = 8 0 Hz, J56 = 3 6 Hz, H5), 
4 65 (IH, d, J,M = 8 9 Hz, НЮ), 4 62 (IH, d, J20.20 = 8 0 Hz, H20), 4 54 (IH, m, HI Г), 4 49 (IH, d, J20.20 = 8 0 Hz, 
H20),441(lH,m,H13),4 10(lH,d,J ! M I ) = 8 9Hz,H9),3 98(lH,d,.J 2 , = 4 4Hz, H2), 3 91 (IH, m, H12"), 3 79 (IH, 
m, H12"), 3 73 (IH, s, OH4), 3 50 (IH, m, H12'), 3 41 (IH, m, H12'), 2 43 (IH, dd, J,4 ,4 = 16 0 Hz, Jl4_13 = 9 8 Hz, 
H14), 2 16 (2H, m, H3 and H14), 2 00 (2H, m, H6 and Н7), 1 93 (ЗН, s, Н18), 1 63 (ЗН, s, Н16), 1 49 (ЗН, s, 
acetonide), 1 46 (ЗН, s, acetonide), 1 42 (ЗН, s, H17), 1 13 (ЗН, s, H19), FAB-MS, 615 [M+Na]*, Anal Caled for 
C,jHî20, H20 С, 64 89, H, 8 91 Found С, 65 25, H, 8 83 
36, Ή-NMR (400 MHz, CDC!,) δ 4 93 (IH, m, НИ"), 4 80 (IH, dd, J « = 8 0 Hz, J M = 2 4 Hz, H5), 4 62 (IH, d, 
J 1 M = 9 2 Hz, НЮ), 4 59 (IH, d, Д№20 = 8 2 Hz, H20), 4 52 (IH, m, Hl Г), 4 44 (IH, d, J2o.20 = 8 2 Hz, H20), 4 11 (IH, 
d, J,
 ro
 = 9 2 Hz, H9), 3 98 (IH, d, J 2 , = 4.4 Hz, H2), 3 91 (IH, m, H13), 3 88 (IH, m, H12"), 3 79 (IH, m, H12"), 3 50 
(IH, m, H12·), 3 41 (IH, m, H12'), 2 46 (IH, dd, J,„ ,„= 15 9 Hz, J l 4 l3 = 10 0 Hz, H14), 2 00 (4H, m, H3, H6, H7 and 
H14), 1 93 (3H, s, H18), 1 60 (3H, s, H16), 1 50 (3H, s, acetonide), 1 44 (3H, s, acetonide), 1 40 (3H, s, H17), 1 13 
(3H,s, H19) 
2-DebenzoyH,2-O-(Propane-2,2-diyl)-4-deaceryl-7-deoxy-10-deacetyl-9,I0-O-(Propane-2,2-diyl)-9(Ä)-
dihydrobaccatin III (38) (Route 1) The same procedure was followed as for 35 (route 1), using 14 (1 14 g, 2 50 
mmol) Compound 38 and 39 were isolated in 44 % (0 51 g, 1 1 mmol) and 12 % (0 14 g, 0 30 mmol), respectively 
38 'H-NMR (400 MHz, CDC13) δ 4 80 (IH, dd, J,^ , = 7 9 Hz, J ^ = 3 7 Hz, H5), 4 63 (IH, d, J I Q , = 9 4 Hz, H10), 
4 61 (IH, d, J 2 O . 2 0 =8 0Hz, H20), 4 43 (IH, m, H13), 4 34 (IH, d, J 2 0 . 2 0 = 8 0 Hz, H20), 4 14 (IH, bd, J^„ = 9 5 Hz, 
H9), 4 Π (IH, d, J „ = 5 4 Hz, H2), 2 59 (IH, bd, J14.14 = 19 0 Hz, H14), 2 16 (IH, d, J14. l4 = 19 0 Hz, H14), 2 12 (IH, d, 
J,, = 5 4 Hz, H3), 2 05 (2H, m, 2H6), 1 93 (3H, s, H18), 1 56 (3H, s, H16), 1 52 (3H, s, acetonide), 1 50 (3H, s, 
acetonide), 1 47 (3H, s, acetonide), 1 43 (3H, s, acetonide), I 35 (3H, s, H17), 1 16 (3H, s, H19) 
39 'H-NMR (400 MHz, CDC1,) δ 4 80 (1 H, dd, J „ = 7 9 Hz, J
s 6 = 2 2 Hz, H5), 4 59 (2H, 2d, Jl0_, = 9 4 Hz, J20 20 = 
8 0 Hz, H10 and H20), 4 35 (IH, d, J20.20 = 8 0 Hz, H20), 4 14 (2H, 2d, J, 10 = 9 5 Hz, J 2 3 = 5 4 Hz, H2 and H10), 3 95 
(IH, m, HI3), 2 50 (IH, bd, J 1 4 1 4 = 19 0 Hz, H14), 2 10 (2H, m, 2H6), 2 01 (2H, m, H3 and H7), 1 96 (IH, m, H14), 
I 91 (3H, s, HI8), 1 55 (3H, s, H16), 1 51 (3H, s, acetonide), 1 49 (3H, s, acetonide), 1 47 (3H, s, acetonide), 1 43 (3H, 
s, acetonide), 1 35 (s, 3H, H17), 1 27 (3H, s, H19) 
Reduction оГ32-> 37 (Route 2). То a solution of 32(1 00 g, 1 25 mmol) in CH2C12 (10 ml) at-10 °C, a solution of 
DIBALH m CH2C12 (2 0 ml, IM) was added The reaction mixture was stirred at 0 °C for 3 hours Then a solution of 10 
% citric acid in water (20 ml) was carefully added The water layer was extracted twice with CH2C12 (50 ml) The 
combined organic layers were washed with a NaHCOj-sarurated solution, with brine, dried over Na2S04 and 
concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 2/5), yielding 37 (0 47 g, 0 59 
mmol, 45 %) mp 49 "C, 'H-NMR (400 MHz, CDCI,) δ 4 88 (2H, m, H5 and НИ"), 4 74 (IH, d, J 1 M = 94 Hz, НЮ), 
4 58 (IH, m, НИ'), 4 43 (IH, m, H13), 4 26 (IH, d, J2 0.2 0= 10 5 Hz, H20), 4 02 (IH, d, J,_10 = 9 4 Hz, H9), 3 86 (2Н, m, 
H2and HI2"), 3 74 (IH, m, H12"), 3 63 (IH, d, J 2 0 . M = 10 5 Hz, H20), 3 51 (IH, m, H12'), 3 47 (IH, s, OH4), 3 39 (IH, 
m, H12'), 3 06 (ЗН, s, MeS02), 2 69 (IH, d, J, 2 = 4 0 Hz, H3), 2 41 (2H, bd, J,4 „ = 6 3 Hz, 2H14), 2 06 (3H, s, H18), 
1 59 (3H, s, H16), 1 46 (3H, s, acetonide), 1 43 (3H, s, acetonide), 1 40 (3H, s, H17), 1 06 (3H, s, H19), 0 91 (9H, s, t-
Bu), 0 08 (6H, s, Me2Si), FAB-MS, 825 [M+Na]\ Anal Caled for C ^ ^ O u S i S C, 59 82, H, 8 53, S, 3 99 Found С, 
59 74, H, 8 78, S, 3 56 
2-Debenzoyl-l,2-(ditetrahydropyran-2-yl)-4-deacetyl-7-deoxy-10-deacetyI-9,10-O-(Propane-2,2-diyl)-9(Z))-
dihydrobaccatin III (35) (Route 2). То a solution of 37 (0 47 g, 0 59 mmol) m THF (10 ml), tetrabutylammomum 
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fluoride (0 23 g, 0 9 mmol) was added The reaction mixture was stirred for one hour at rt after which EtOAc (50 ml) 
was added The organic layer was washed with a NaHCOj-saturated solution, dried over Na2S04 and concentrated in 
vacuo The residue was not further purified 
To a solution of this residue in butanone (15 ml) tetrabutylammonium acetate (1 50 g, 5 0 mmol) was added The 
reaction mixture was stirred at reflux temperature for 17 hours The mixture was then diluted with EtOAc (50 ml) and 
washed with a saturated solution of ammonium chloride in water The organic layer was dried over Na2S04 and 
concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 2/5), yielding 35 (0 28 g, 0 47 
mmol, 79 %) mp 49 °C, 'H-NMR (400 MHz, CDC13) was the same as for 35 in route 1 
Hydrolysis of 33 -»· 40. Compound 33 (1 00 g, 1 69 mmol) was dissolved in a mixture of HOAc/H20/THF 
(68/34/17 ml) After 24 hours at it, the mixture was diluted with EtOAc (100 ml) The organic layer was washed with a 
NaHCOj-saturated solution (75 ml) and subsequently with brine The organic layer was dried over Na2S04 and 
concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), yielding 40 (770 mg, 1 52 
mmol, 89 %) mp 67 "С, Ή-NMR (400 MHz, CDClj) δ 4 94 (IH, t, J = 5 1 Hz, НИ"), 4 96 (IH, dd, J« = 8 5 Hz, J5 6 
= 2 2 Hz, H5), 4 67 (IH, d, J 1 M = 9 4 Hz, H10), 4 61 (IH, d, J2 M 0 = 8 1 Hz, H20), 4 37 (IH, d, J20.20 = 8 1 Hz, H20), 
4 26 (IH, d, J, ,o = 9 4 Hz, H9), 4 14 (IH, d, J2, = 5 4 Hz, H2), 3 67 (2H, m, 2H12"), 3 07 (IH, s, OH4), 3 05 (IH, d, 
J,414 = 19 2Hz,H14),2 59(IH,d,J, 4 1 4 - 19 2 Hz, H14),2 02 (3H,m,2H6and H7), 1 93 (3H, s, H18), 1 81 (lH,d,J 3 2 
= 5 3 Hz, H3), 1 62 (3H, s, H16), 1 58 (3H, s, acetonide), 1 49 (3H, s, acetomde), 1 45 (3H, s, H17), 1 33 (3H, s, H19), 
FAB-MS, 529 [M+Na]\ Anal Caled for C2,H42Os C, 66 38, H, 8 36 Found С, 66 79, Η, 8 46 
Benzoylation of 40 -> 41. To a solution of 40 (0 77 g, 1 5 mmol) in EtOAc (10 ml), Methylamine (0 62 ml, 4 4 
mmol), DMAP (11 6 g, 9 51 mmol) and benzoyl chloride (0 32 ml, 2 8 mmol) After 24 hours at rt, EtOAc (50 ml) was 
added The mixture was washed with a 10 % citric acid solution in water (50 ml), then with brine, dried over Na2S04 
and concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 2/5), yielding 41 (891 g, 
1 46 mmol, 96 %) mp 184 °C, [a]„M +1814°, , 'H-NMR (400 MHz, CDCI,) δ 8 04 (2H, dd, J = 7 4 Hz, J = 1 2 Hz, 
2H-Ph), 7 57 (IH, t, J = 7 4 Hz, H-Ph), 7 45 (2H, t, J = 7 6 Hz, 2H-Ph), 4 97 (IH, t, J = 5 1 Hz, Hll"), 4 78 (IH, dd, J« 
= 8 4 Hz, JM = 2 1 Hz, H5), 4 67 (IH, d, J,«., = 9 4 Hz, H10), 4 58 (IH, d, J20.„= 8 1 Hz, H20), 4 34 (3H, m, H20 and 
2H12'), 4 25 (IH, d, J, ,„ = 9 4 Hz, H9), 4 14 (IH, d, J23 = 5 4 Hz, H2), 3 05 (IH, d, Jl4 H = 19 2 Hz, H14), 2 90 (IH, s, 
OH4), 2 60 (IH, d, Jl4 ,«,= 19 2 Hz, H14), 2 02 (3H, m, 2H6 and H7), 1 93 (3H, s, H18), 1 82 (IH, d, J 3 2 = 5 5 Hz, H3), 
1 58 (3H, s, H16), 1 55 (3H, s, acetonide), 1 49 (3H, s, acetonide), 1 45 (3H, s, H17), 1 33 (3H, s, H19), FAB-MS, 611 
[M+H]\ 633 [M+Na]*, Anal Caled forC^H^O, C, 68 83, H, 7 59 Found С, 69 01, H, 7 26 
l-Bcnzoyl-2-debenzoyl-2-(tetrahydropyran-2-yl)-4-deacetyI-7-deoxy-10-deaceryl-9,10-O-(Propane-2,2-diyl)-
9(/c)-dihydrobaccatm III (42). To a solution of 41 (0 89 g, 1 5 mmol) m dry THF (20 ml), BH3 THF (20 ml, IM in 
THF) was added After 3 hours at rt, EtOAc (50 ml) was added The mixture was washed with a 10 % citric acid 
solution in water (50 ml), then with a NaHC03-saturated solution, dried over Na2S04 and concentrated in vacuo The 
residue was purified via chromatography (EtOAc/hexane 1/1), yielding 42 (192 mg, 0 314 mmol, 21 %) mp 127 "С, 
'H-NMR (400 MHz, CDC13) δ 8 05 (2H, d, J = 7 4 Hz, 2H-Ph), 7 56 (IH, t, J = 7 3 Hz, H-Ph), 7 45 (2H, t, J = 7 7 Hz, 
2H-Ph), 4 91 (IH, t, J = 5 1 Hz, Hll"), 4 80 (IH, dd, J^ =10 0 Hz, JM = 5 1 Hz, H5), 4 62 (IH, d, J1(w = 9 4 Hz, H10), 
4 61 (IH, d, J20.20 = 8 1 Hz, H20), 4 36 (4H, m, H13, H20 and 2H12'), 4 09 (IH, d, ¡%w = 9 4 Hz, H9), 3 98 (IH, d, J2 3 = 
5 4 Hz, H2), 3 26 (IH, s, OH4), 2 44 (IH, d, J14,4= 16 0 Hz, H14), 2 14 (2H, m, H3 and H14), 2 03 (3H, m, 2H6 and 
H7), 1 93 (3H, s, H18), 1 49 (3H, s, H16), 1 48 (3H, s, acetonide), 1 45 (3H, s, acetonide), 1 42 (3H, s, H17), 1 13 (3H, 
s, Η19), FAB-MS, 635 [M+Naf, Anal Caled for C3SH480, H20 C, 66 63, H, 8 01 Found C, 66 31, H, 7 96 
Other Procedures for the Reduction of 41: 
Reduction with Sodium Borohydnde (NaBH4). To a solution of 41 (47 mg, 0 077 mmol) in MeOH (5 ml), NaBH4 
(3,8 mg, 0 10 mmol) was added The mixture was stirred at rt After one hour an additional amount of NaBH4 (3 8 mg, 
0 10 mmol) was added In comparison to the identified products from the BH3-reduction, TLC (EtOAc/hexane 7/3) 
showed that the undesired C13ß-OH isomer was formed as the major product 
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Reduction with Lithium Borohydnde (LiBH4). To a solution of 41 (27 mg, 0 044 mmol) in DMF (3 ml), LiBH4 
(2 3 mg, 0 10 mmol) was added Unfortunately, the result was the same as for the NaBH4-reduction 
Reduction with Diphenylsilane (Ph2SiH2). To a solution of 41 (40 mg, 0 066 mmol) in toluene (5 ml), a catalytic 
amount of tns(tnphenylphosphme)-rhodium chloride was added This mixture was stirred for 5 minutes, whereafter 
Ph2SiHj (50 μΐ, 0 27 mmol) was added After 24 hours the mixture was diluted with EtOAc (25 ml) and washed first 
with a 10 % citric acid solution (20 ml) and then with brine (10 ml) The organic layer was dried over Na2S04 and 
concentrated in vacuo After purification by column chromatography (EtOAc/hexane 1/1), the starting material was 
recovered 
Reduction with 9-BBN. A solution of 41 (48 mg, 0 079 mmol) in THF (3 ml) was stirred at 0 °C 9-BBN (0 40 ml 
0 5M in THF, 0 20 mmol) was added After two hours the temperature of the reaction mixture was allowed to raise to 
room temperature After 24 hours the mixture was heated to 40 °C After the normal work up procedure the starting 
material was recovered 
Reduction with Potassium tri-sec-Butyl Borohydnde (K-selectnde). A solution of 41 (27 mg, 0 044 mmol) in 
THF (3 ml) was cooled to 0 °C K-selectride (0 06 ml 1 0 M) was added After two hours the reaction mixture was 
warmed up to rt After 24 hours the reaction was worked up by standard procedures The starting material was 
recovered 
Acetylation of 41-> 43. To a solution of 41 (0 25 g, 0 41 mmol) in dry CH2C12 (10 ml), Ac20 (110 μΐ) and DMAP 
(125 mg, 1 0 mmol) were added The reaction mixture was stirred for 48 hours at rt The reaction mixture was diluted 
with CH2C12 (50 ml) and washed with water (25 ml), then brine (25 ml), dried over Na 2S0 4 and concentrated in vacuo 
The residue was purified via chromatography (EtOAc/hexane 2/5), yielding 43 (235 mg, 0 360 mmol, 88 %) mp 179 
°C, [ct]„20 + 207 2°, 'H-NMR (400 MHz, CDCI,) δ 8 06 (2H, d, J = 7 9 Hz, H-Ph), 7 56 (IH, d, J = 7 4 Hz, H Ph), 7 45 
(2H, t, J = 7 6 Hz, H-Ph), 4 97 (IH, t, ¡
іл
 = 4 7 Hz, H5), 4 90 (IH, d, J = 8 7 Hz, HI 1 ), 4 71 (IH, d, V , = 9 4 Hz, 
H10), 4 51 (2H, s, H20), 4 35 (2H, t, J = 6 5 Нд H12'), 4 26 (IH, d, J, ,„ = 9 4 Hz, H9), 4 09 (IH, d, J 2 , = 4 8 Hz, H2), 
2 58 (IH, d, J„
 l 4 = 3 5 Hz, H14), 2 52 (IH, d, J3 2 = 4 7 Hz, H3), 2 25 (3H, m, H6, H7 and H14), 1 97 (ЗН, s, acetate), 
1 91 (ЗН, s, H18), I 60 (6H, s, H16 and acetonide), 1 49 (ЗН, s, acetonide), 1 45 (3H,s, H17), 1 31 (3H, s, H19), FAB-
MS, 653 [M+H]*, Anal Caled forC„H480,o C.68 07, H, 7 43 Found С, 68 25, H, 7 41 
l-Benzoyl-2-debenzoyl-2-(tetrahydropyran-2-yI)-7-deoxy-lO-deacetyl-9,lO-0-(Propane-2,2-diyl)-9(Ä)-
dihydrobaccatin III (44). To a solution of 43 (235 mg, 0 360 mmol) in dry THF (10 ml), BH3 THF (8 ml, IM in THF) 
was added After 3 hours at rt, EtOAc (50 ml) was added The mixture was washed with a 10 % citric acid solution in 
water (50 ml), then with a NaHCCysaturated solution, dried over Na2S04 and concentrated in vacuo The residue was 
purified via chromatography (EtOAc/hexane 1/1), yielding 44 (30 mg, 0 046 mmol, 13 %) mp 116 °C, 'H-NMR (400 
MHz, CDClj) δ 8 05 (2H, d, J = 7 2 Hz, 2H-Ph), 7 58 (IH, t, J = 7 0 Hz, H-Ph), 7 45 (2H, m, 2H-Ph), 4 94 (Ш, t, J = 
5 1 Hz, HI 1"), 4 83 (IH, dd, J « = 9 9 Hz, J « = 5 3 Hz, H5), 4 63 (IH, d, J 1 M = 9 2 Hz, H10), 4 61 (IH, d, J 2 M 0 - 8 3 
Hz, H20), 4 39 (4H, m, H13, H20 and 2H12'), 4 09 (IH, d, J,.,» = 9 2 Hz, H9), 4 05 (IH, d, J2 j = 5 2 Hz, H2), 2 58 (IH, 
d, J J 2 = 5 1 HZ.H3), 2 41 ( lH.d, J 1 4 ] 4 = 16 0 Hz, H14), 2 14 (IH, m, H14), 2 06 (3H, m, 2H6 and H7), 2 02 (3H, s, 
acetate), 1 94 (3H, s, H18), 1 50 (3H, s, H16), 1 49 (3H, s, acetonide), 1 45 (ЗН, s, acetonide), 1 41 (ЗН, s, H17), 1 19 
(ЗН, s, H19), FAB-MS, 655 [M+H]+ 
(2S,3R)-(-)-Methy.-2,3-dihydroxy-3-phenylpropionate (50). To a mixture of K2Os02(OH)4 (67 mg, 0 18 mmol), 
(DHQD)2Phal (0 72 g, 0 92 mmol), K3Fe(CN)6 (90 8 g, 276 mmol), K2CO, (38 1 g, 276 mmol) and 
methanesulfonamide (8 80 g, 92 6 mmol) in f-BuOH/H20 (900 ml, l/l(v/v)), methyl cinnamate (49) (15 0 g, 92 6 
mmol) was added The reaction mixture was stirred for 15 hours at rt, after which sodium sulfite (Na2S03) (93 g) was 
added After 15 minutes, EtOAc (300 ml) was added to the mixture The water layer was extracted twice with EtOAc 
(25 ml) The combined organic layers were washed with brine, dried over Na2S04 and concentrated in vacuo The 
residue was purified by column chromatography (EtOAc/hexane 2/5) yielding 50 (15 9 g, 81 1 mmol, 88 %) [a]¿° = -
10 Io (с = 1 00 in CHClj), Lit [a]„M = - 10 7" (c = 1 00 in CHCI3), 'H-NMR (100 MHz, CDCI,) δ 7 37 (5H, m, H-Ph), 
5 01 (IH, d, J 2, = 2 75 Hz, H2), 4 35 (IH, d, J, 2 = 2 75 Hz, Hl), 3 61 (ЗН, s, СООСН3), 3 21 (IH, bs, OH) 2 93 (IH, 
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bs, OH) 
(2S,3RM-)-Methyl 3-hydroxy-phenyl-2-((p-tolylsulfonyI)oxy)propnonate (51). To a stirred solution of 50 (15 9 
g, 81 1 mmol) in dry dichloromethane (270 ml), triethylamine (16 9 ml, 121 6 mmol) and p-toluenesulfonyl chloride 
(15 8 g, 83 3 mmol) were added The mixture was stirred for three days at 0 "C Subsequently 10 % solution of citric 
acid in water (100 ml) was added to the mixture The water layer was extracted twice with dichloromethane (75 ml) 
The combined organic layers were washed with brine, dried over Na2S04 and concentrated in vacuo The residue was 
purified by column chromatography (EtOAc/hexane 2/5) yielding 51 (23 6 g, 67 3 mmol, 83 %) 'H-NMR (100 MHz, 
CDC1,) δ 7 55 (2H, m, H-Ph), 7 22 (7H, m, H-Ph), 5 08 (IH, t, JH^H = 5 7 H A J 2 , = 4 5 Hz, H2), 4 89 (IH, d, J 3 2 = 4 5 
Hz, H2), 3 61 (3H, s, COOMe), 2 95 (IH, d, J 0 H 3 = 5 68 Hz, OH), 2 41 (3H, s, Ph-CH,) 
(2R,3SM+)-Methyl 3-phenyloxiranecarboxylate (52). Compound 51 (20 0 g, 57 1 mmol) was dissolved in N,N-
dimethylformamide (200 ml) H 2 0 (5 0 ml) and K2CO, (23 10 g, 167 8 mmol) were added to this solution The reaction 
mixture was stirred for 20 hours at rt, after which H 2 0 (40 ml) was added The mixture was extracted with diethyl ether 
The combined organic layers were washed with brine, dried over Na2S04 and concentrated in vacuo, yielding 52 (9 50 g 
(53 1 mmol, 93 %) [α]„20 = + 14 4° (с = 1 15 in CHC13), Lit [a]d 2 4 = + 14" (с = 1 6 in CHClj), 'H-NMR (100 MHz, 
CDClj) 6 7 33 (5H, m, H-Ph), 4 23 ( 1H, d, J,
 2 = 4 6 Hz, H3), 3 83 ( 1H, d, J 2 , = 4 6 Hz, H2), 3 53 (3H, s, COOCH,) 
(2R,3SH+)-Methyl 3-azido-2-hydroxy-3-phenyl-propionate (53). Compound 52 (9 00 g, 50 6 mmol) was dissolved 
in methanol/H20 (270 ml, 8/1 (v/v)) To this solution, methyl formate (42 ml) and sodium azide (16 4 g, 252 mmol) 
were added The mixture was stirred for two days at 50 °C, after which the mixture was concentrated H 2 0 was added to 
the residue and this water layer was extracted with diethyl ether The combined organic layers were washed with brine, 
dried over NajSO,, and concentrated in vacuo The residue was purified by column chromatography (EtOAc/hexane 
1/9) yielding 53 (10 7 g, 48 3 mmol, 96 %) [a]d 2 0 = + 140 2° (c = 1 08 in CHC1,), Lit [a]„M = + 142° (c = 1 00 in 
CHC1,), 'H-NMR (100 MHz, CDCI3) δ 7 42 (5H, m, H-Ph), 5 40 (IH, d, J, 2 = 5 0 Hz, H3), 5 09 (IH, d, J 2 , = 5 0 Hz, 
H2), 3 82 (3H, s, COOCH,) 
(2R,3S)-(-)-N-r-Butyloxycarbonyl-3-phenylisoserine methyl ester (54). Pd-C (10 %) (578 mg) was treated with 
H2 for 10 minutes, whereafter a solution of 53 (5 80 g, 26 2 mmol) and BOC20 (6 80 g, 31 0 mmol) in EtOAc (50 ml) 
was added The reaction was stirred for 3 days under hydrogen atmosphere Then the suspension was filtered over 
Hyflo The filtrate was diluted with EtOAc (50 ml) and washed with water (25 ml), then brine (25 ml), dried over 
Na2S04 and concentrated m vacuo, yielding 54 (7 60 g, 25 8 mmol, 98 %) [α], 2 0 - 7 2° (c = 1 05 in CHCI3), Lit [a]„20 -
7° (c = 1 2 in CHClj), 'H-NMR (100 MHz, CDCI3) δ 7 30 (5H, m, H-Ph), 5 39 (IH, d, J 3 2 = 8 4 Hz, НЗ), 5 17 (IH, d, 
J 2 3 = 8 7 Hz, H2), 4 44 (IH, bs, NH), 3 82 (3H, s, COOCH3), 3 10 (IH, bs, OH), 1 43 (9H, s, /-Bu) 
(2R,3S)-(-)-2-Ethoxyethoxy-N-r-Butyloxycarbonyl-3-phenylisoserin£ (55). То a solution of 54 (4 40 g, 14 9 
mmol) m dichloromethane (45 ml), pyndinium-/>toluenesulfonate (1 8 g, 0 70 mmol) and ethyl vinyl ether (6 9 ml, 
72 4 mmol) were added After stirring for I 5 hours the reaction mixture was washed with a NaHCOj-saturated 
solution, then brine, dried over Na2S04 and concentrated in vacuo, yielding ethoxyethoxy-protected compound 54 
(5 09 g, 13 9 mmol, 91 %), which was dissolved m MeOH (100 ml) To this solution H 2 0 (60 ml) and K2C03 (4 26 g, 
30 8 mmol) were added The mixture was stirred for 15 hours at rt, after which a 10 % citric acid solution was carefully 
added until the pH was neutral Then the mixture was extracted twice with dichloromethane (75 ml) The combined 
organic layers were washed with brine, dried over Na2S04 and concentrated in vacuo, yielding 55 (4 66 g, 13 2 mmol, 
95 %) 'H-NMR (100 MHz, CDClj) δ 7 25 (5H, m, H-Ph), 5 39 (IH, m, НЗ), 5 17 (IH, m, CH(CH3)), 4 70 (IH, m, 
H2), 4 34 (IH, m, NH), 3 10 (2H, m, CH2(CH3)), 1 43 (9H, s, i-Bu), 1 18 (6H, m, (CH)CH3and (CH2)CH3) 
(2R,3S)-(-)-N-benzoyl-3-phenyhsoserine methyl ester (57). A mixture of 53 (10 7 g, 48 3 mmol), benzoyl 
chloride (11 3 ml, 96 9 mmol), triethylamine (20 2 ml, 144 3 mmol) and DMAP (0 21 g, 1 8 mmol) in EtOAc (200 ml) 
was stirred at rt for 4 hours, after which methanol (10 ml) was added After being stirred for an additional two hours the 
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reaction mixture was filtered over Celite The filtrate was washed with a 10 % solution of citric acid m water, then 
brine, dried over Na2SO,, and concentrated in vacuo The residue was purified by column chromatography 
(EtOAc/hexane 1/9) yielding 56 (17 g) as a white powder This white powder was dissolved in fctOAc (200 ml) and 
treated with 10 % palladium on carbon (1 1 g) and then placed under hydrogen atmosphere The resulting mixture was 
stirred for 20 hours, and then it was filtered over Celite The filtrate was concentrated m vacuo The residue was 
purified by column chromatography (EtOAc/hexane 1/1), yielding 57 (11 7 g, 39 3 mmol, 81 %) [a] d 2 0 = - 44 2° (c = 
1 07 in methanol), Lit [a]„M = - 48° (c = 1 00 in methanol), 'H-NMR (100 MHz, CDC13) δ 7 72 (2H, m, H-Ph), 7 38 
(8H, m, H-Ph), 5 48 (IH, d, J3 2 = 3 9 Hz, H3), 4 49 (IH, d, J „ = 3 9 Hz, H2), 3 58 (3H, s, COOCH,) 
(2R,3SM-)-2-Ethoxyethoxy-N-benzoyl-3-phenylisoserine (45). То a solution of 57 (4 30 g, 14 4 mmol) in 
dichloromethane (90 ml), pyndinium-p-toluenesulfonate (3 61 g, 14 mmol) and ethyl vinyl ether (13 8 ml, 144 7 
mmol) were added After stirring for 1 5 hours the reaction mixture was washed with a NaHCCysaturated solution, 
brine, dried over Na^O, and concentrated in vacuo This yielded ethoxyethoxy-protected compound 57 (4 98 g, 13 4 
mmol, 93 %), which was solved in MeOH (120 ml) To this solution, 30 ml of H 2 0 (60 ml) and K2C03 (4 26 g, 30 8 
mmol) were added The mixture was stirred for 15 hours at rt, after which a 10 % citric acid solution was carefully 
added until the pH was neutral Then the mixture was extracted twice with dichloromethane (75 ml) The combined 
organic layers were washed with brine, dried over NajSO,, and concentrated in vacuo This yielded 45 (4 54 g, 12 7 
mmol, 95 %) [α]„Μ -20 8° (с = 1 08 in MeOH), Lit [a]d 2 S -21° (c = 0 7 in MeOH), 'H-NMR (100 MHz, CDC1,) δ 
7 79-7 96 (2H, m, H-Ph), 7 26-7 52 (8H, m, H-Ph), 7 17 (IH, bs, NH), 5 59-5 78 (IH, m, НЗ), 4 82 and 4 55 (IH, 2q, J 
= 5 7 Hz, CH(CHj)), 4 65 and 4 53 (IH, 2d, J 2 3 = 2 39 Hz, H2), 3 51-3 13 and 3 06-2 74 (2H, m CH2(CH3)), 1 22 and 
1 13 (3H, 2d, J = 5 67 Hz, (CH)CH3), 0 93 and 0 86 (3H, 2t, J = 7 46 Hz, (CH2)CH3) 
Os-2,4-diphenyl-5-(l-ethoxyethoxy)-4,5-dihydro-l,3-oxazin-6-one (46). To a stirred solution of 45 (2 10 g, 5 89 
mmol) in tetrahydrofurati (100 ml), K-Oí-Bu (1 22 g, HO mmol) was added After 30 minutes, methanesulfonyl 
chloride (0 681 g, 5 89 mmol) in tetrahydrofuran (17 ml) was added The reaction mixture was stirred for 2 hours at rt, 
after which a mixture of EtOAc/hexane (200 ml, l/l(v/v)) was added This solution was washed with a NaHC03-
saturated solution, then brine, dried overNa2S04 and concentrated in vacuo, yielding 46 (0 760 g, 2 24 mmol, 41%), as 
a yellow oil [ct]d2° - 21 5° (c = 1 20 in CHC13), Lit [a]/s - 22° (c = 1 55 in CHCl,), 'H-NMR (100 MHz, CDCI,) δ 
7 90-8 22 (2H, m, H-Ph), 7 76-7 00 (8H, m, H-Ph), 5 10 (IH, dd, J3 2 = 5 22 Hz, H3), 4 85 and 4 61 (IH, 2q, J = 5 45 
Hz, CH(CH3)), 4 71-4 55 (IH, dd, J 2 3 = 5 22 Hz, H3), 3 50-3 05 (2H, m, CH2(CH3)), 1 32-0 83 (6H, m, (CH)CH3 and 
(CH2)CH3) 
2-Debenzoyl-l,2-(ditetrahydropyran-2-yl)-4-deacetyl-7-deoxy-I0-deacetyl-9,10-O-(Propanc-2,2-diyl)-2'-
(ethoxyethyl)-9(Ä)-dihydropaclitaxel (58). To a solution of 35 (1 02 g, 1 72 mmol) in toluene (50 ml), DMAP (210 
mg, 1 72 mmol), pyridine (1 ml) and oxazinone 46 (2 75 g, 8 0 mmol) were added The reaction mixture was stirred for 
12 hours at rt The reaction mixture was then diluted with EtOAc (200 ml) This mixture was washed with a solution of 
10 % copper sulfate in water (50 ml) The organic layer was dried over Na2S04 and concentrated in vacuo The residue 
was purified via chromatography (EtOAc/hexane 2/5), yielding 58 (1 41 g, 151 mmol, 89 %) mp 63 °C, 'H-NMR 
(400 MHz, CDC13) δ 7 76 (2H, m, H-Ph), 7 48 (5H, m, H-Ph), 7 33 (3H, m, H-Ph), 7 08 (IH, d, JNH э = Ю 3 Hz, NH), 
6 12 (IH, d, J3 NH = 10 3 Hz, H3'), 5 88 (IH, m, H13), 4 95 (IH, m, H5), 4 79 (IH, m, HU"), 4 61 (3H, m, Hl Г, H10 
and H20), 4 47 (3H, m, H20, OH4 and HC(CH3)), 4 18 (2H, m, H9 and H2'), 3 94 (IH, bs, H2), 3 78 (IH, m, H12"), 
3 63 (IH, m, H12"), 3 47 (IH, m, H12'), 3 28 (2H, m, H12' and H-CH(CH3)), 3 08-2 95 (IH, dq, J = 7 03 Hz, H-
CH(CH3)), 2 24 (3H, m, 2H14 and H6), 2 06 (3H, m, H3, H6 and H7), 1 86 (3H, s, H18), 1 63 (3H, s, H16), 1 52 (3H, 
s, acetomde), 1 46 (3H, s, acetonide), 1 43 (3H, s, HI7), 1 26 (IH, d, J = 4 2 Hz, H3C-(CH)), 1 19 (3H, s, H19), 0 92-
0 85 (3H, dt, J = 7 03 Hz, H3C-(CH2)), FAB-MS, 955 [M+Naf, Anal Caled for CS3H73NO„ 0 5H20 C, 67 62, H, 7 94, 
N, 1 49 Found С, 67 47, H, 7 58, Ν, 1 90 
C4-acerylation of 58. To a solution of 58 (0 10 g, 0 11 mmol) in dry CH,CI2 (5 ml), Ac20 (40 μΐ) and DMAP (40 
mg, 0 33 mmol) were added The reaction mixture was stirred for 48 hours at rt The reaction mixture was diluted with 
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CH2C12 (25 ml) and washed with water (15 ml), then brine (15 ml), dried over N a ^ O , and concentrated m vacuo The 
residue was purified via chromatography (EtOAc/hexane 2/5) The starting material, 58, was entirely recovered 
2-Debenzoyl-l,2-O-(Propane-2,2-diyl)-4-deacetyl-7-deoxy-10-deacetyl-9,10-O4Propane-2J-diyl)-2'-
(ethoxyethyl)-9(R)-dihydropachtaxel (59). The same procedure was followed as for 58, using 38 (0 49 g, 1 1 mmol) 
Compound 59 was isolated in 66 % yield (0 58 g, 0 72 mmol) mp 65 °C, 'H-NMR (400 MHz, CDC13) δ 7 76 (2H, m, 
H-Ph), 7 42 (8H, m, H-Ph), 7 14 (IH, d, }
шз
 = 9 4 Hz, NH), 6 12 (IH, d, J,
 ш
 = 9 4 Hz, НЗ'), 5 87 (IH, m, Н13), 4 93 
(IH, t, J = 5 4 Hz, H5), 4 62 (3H, m, НЮ, Н20 and Н2'), 4 47 (ЗН, m, Н20, СН(СН3) and ОН4), 4 18 (IH, d, J = 9 6 
Hz, H9), 4 08 (IH, bs, H2), 3 25-2 95 (2H, m, СН2 (СН,)), 2 35 (IH, m, Н14), 2 24 (2Н, m, Н6 and Н14), 2 02 (ЗН, m, 
НЗ, Н6 and Н7), 1 83 (ЗН, ds, Н18), 1 52 (ЗН, s, Н16), 1 47 (ЗН, s, acetonide), 1 44 (ЗН, s, acetonide), 1 36 (ЗН, d, J = 
5 5 Hz, H,C-(CH)), 1 27 (6Н, bs, acetonide), 1 25 (ЗН, s, H17), 1 17 (ЗН, s, H19), 0 97-0 85 (ЗН, dt, J = 6 9 Hz, H3C-
(СН2)) FAB-MS, 804 [М+Н]\ 826 [M+Na)+, Anal Caled for C Ä N O , , Η 2 0 С, 67 20, Η, 7 74, Ν, 1 70 Found С, 
67 53, Η, 7 70, Ν, 1 98 
l-Benzoyl-2-debenzoyl-2-(tetrahydropyran-2-yl)-4-deacctyl-7-deoxy-10-deacetyl-9,10-O-(Propane-2,2-diyl)-
2'-(ethoxyethyl)-9(R)-dihydropaclitaxel (60). The same procedure was followed as for 58, using 42 (0 19 g, 0 31 
mmol) Compound 60 was isolated in 80 % yield (0 24 g, 0 25 mmol) mp 141 °C, 'H-NMR (400 MHz, CDC13) 6 8 01 
(2H, d, J = 7 7 Hz, 2H-Ph), 7 83 (2H, d, J = 7 2 Hz, H-Ph), 7 75 (2H, m, 2H-Ph), 7 40 (9H, m, 9H-Ph), 7 07 (IH, d, J ^ 
, = 96 Hz, NH), 6 13 (IH, d, Jj N„ = 9 7 Hz, H3'), 5 85 (IH, m, H13), 4 94 (IH, bd, J = 5 5 Hz, HI 1"), 4 81 (IH, m, 
H5), 4 65 (IH, d, J10., = 9 5 Hz, H10), 4 59 (IH, d, J20.20 = 7 9 Hz, H20), 4 48 (2H, m, H20 and H2'), 4 19 (4H, m, H9, 
2H12' and H-C(CH3)), 3 96 (IH, d, J 2 3 = 5 3 Hz, H2), 3 25-2 98 (2H, m, H2C(CH3)), 2 25 (2H, m, H3 and H14), 2 05 
(4H, m, 2H6, H7 and H14), 1 88 (3H, s, H18), 1 52 (3H, s, H16), 1 47 (3H, s, acetonide), 1 44 (3H, s, acetonide), 1 37 
(3H, dd, J = 5 5 Hz, H3C-(CH)), 1 26 (3H, s, H17), 1 19 (3H, s, H19), 0 92 (3H, dt, J = 7 0 Hz, H3C-(CH2)), FAB-MS, 
974 [M+Na]\ Anal Caled for C„H6,NO l 3 H 2 0 C, 68 08, H, 7 39, N, 1 44 Found C, 67 84, H, 7 13, N, 1 44 
I-Benzoyl-2-debenzoyl-2-(tetrahydropyran-2-yl)-7-deoxy-10-deacetyl-9,10-O-(Propane-2,2-diyl)-2'-
(ethoxyethyl)-9(A)-dihydropaclitaxel (61). The same procedure was followed as for 58, using 44 (30 mg, 0 046 
mmol) Compound 61 could not be isolated In the 'H-NMR spectrum the presence of 61 was deduced from the 
following signals 'H-NMR (400 MHz, CDC13) δ 8 03 (2H, d, J = 7 6 Hz, 2H-Bz), 6 10 (IH, m, H3'), 5 80 (IH, m, 
HI3), 4 80 (IH, t, J = 5 3 Hz, H5), 4 70 (IH, d, J 1 M = 9 5 Hz, H10), 4 30 (IH, d, J, ,„ = 9 4 Hz, H9), 3 85 (IH, bs, H2), 
2 07 (3H, s, C4-OC(0)CH3), 1 95 (3H, s, Η18) 
2-DebenzoyI-2-(tetrahydropyran-2-yl)-4-deacetyl-7-deoxy-10-deacetyl-9,10-O-(Propane-2^-diyl)-9-(Ä)-
dihydropaclitaxel (65). Compound 58 (0 25 g, 0 27 mmol) was dissolved in HOAc/THF/H20 (8/4/8 ml) After 20 
hours at rt the reaction mixture was diluted with fctOAc (50 ml) The organic layer was washed with a NaHCCy 
saturated solution (20 ml), dried over Na2S04 and concentrated in vacuo The residue was purified via chromatography 
(EtOAc/hexane 1/1), yielding 65 (0 16 g, 0 21 mmol, 76 %) mp 115 °C, 'H-NMR (400 MHz, CDC13) δ 7 72 (2H, d, J 
= 7 4 Hz, 2H-Ph), 7 58 (2H, d, J = 7 5 Hz, 2H-Ph), 7 40 (6H, m, 6H-Ph), 7 03 (IH, d, J M n = 9 5 Hz, NH), 5 98 (IH, 
bd, J = 10 0 Hz, H3'), 5 95 (IH, m, H13), 4 92 (IH, bd, J ^ = 7 4 Hz, H5), 4 86 (IH, t, J = 4 7 Hz, НП"), 4 60 (3H, m, 
H10, H20 and H2), 4 49 (IH, d, J2CU20 = 8 0 Hz, H20), 4 25 (IH, s, OH4), 4 15 (IH, d, J, ,0 = 9 5 Hz, H9), 3 98 (IH, d, 
J 2 3 = 5 3 Hz, H2), 3 59 (IH, bs, OH2'), 3 53 (2H, t, J = 5 5 Hz, 2HI2"), 2 39 (IH, dd, JM M = 15 9 Hz, J,4 „ = 3 7 Hz, 
H14), 2 23 (2H, m, H6 and H14), 2 07 (IH, d, J 3 2 = 5 3 Hz, H3), 2 00 (3H, m, H6, H7 and OHI), 1 73 (ЗН, s, H18), 
1 55 (ЗН, s, Н16), 1 53 (ЗН, s, acetonide), 1 46 (ЗН, s, acetonide), 1 42 (ЗН, s, H17), 1 46 (ЗН, s, H19), FAB-MS, 776 
[M+H]h, 798 [M+Na]\ Anal Caled for Ο ^ , Ν Ο , , H 2 0 C, 66 55, H, 7 49, N, 1 76 Found С, 66 51, H, 7 40, N, 
173 
2-Debenzoyl-2-(tetrahydropyran-2-yl)-4-deacetyl-7-deoxy-10-deacetyl-9(Ä)-dihydro-paclitaxel(66). 
Compound 58 (0 20 g, 0 21 mmol) was dissolved in HOAc/THF/H20 (12/3/6 ml) The reaction mixture was stirred for 
24 hours at 40 °C The reaction mixture was then diluted with EtOAc (50 ml) The organic layer was washed with a 
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NaHCOj-saturated solution (20 ml), dried over Na2SO„ and concentrated in vacuo The residue was purified via 
chromatography (EtOAc/hexane . 7/3), yielding 66 (97 mg, 0 13 mmol, 63 %) mp 198 "С, 'H-NMR (400 MHz, 
CDC1,) δ 7 74 (2H, d, J = 7 3 Hz, 2H-Ph), 7 56 (2H, d, J = 7 6 Hz, 2H-Ph), 7 40 (6H, m, 6H-Ph), 7 09 (IH, d, J ^ , = 
9 5 Hz, NH), 5 97 (IH, bd, J = 9 4 Hz, H3'), 5 89 (IH, m, H13), 4 91 (IH, dd, J M = 8 8 Hz, J S 6 = 2 1 Hz, H5), 4 86 
(IH, t, J = 5 3 Hz, HI Γ), 4 62 (3H, m, H10, H20 and H2'), 4 48 (IH, d, J20.20 = 8 0 Hz, H20), 4 15 (IH, bs, OH4), 3 97 
(IH, d, J^,„ = 9 5 Hz, H9), 3 93 (IH, d, J „ = 5 4 Hz, H2), 3 70 (IH, bs, OH2'), 3 54 (2H, t, J = 5 5 Н А 2H12"), 2 75 
(IH, bs, OH), 2 50 (IH, bs, OH), 2 36 (IH, dd, JM M = 15 8 Hz, J1(.„ = 3 5 Hz, H14), 2 27 (IH, d, J,.2 = 5 3 Hz, H3), 
2 22 (IH, dd, J14.„ = 15 7 Hz, J l 4.„ = 6 3 Hz, Η14), 2 00 (5H, m, 2H6, 2H7 and OHI), 1 67 (3H, s, H18), 1 55 (3H, s, 
H17), I 48 (3H, s, Н16), 1 16 (ЗН, s, Н19), FAB-MS, 736 [M+H]\ 758 [M+Na]*, Anal Caled for C4,HS JNOu H 2 0 С, 
65 32, H, 7 35, Ν, 1 86. Found С, 65 02, Η, 7 40, Ν, 1 80 
2-DebenzoyM,2-O-(Propane-2,2-diyl)-4-deacetyl-7-deoxy-9-(Ä)-dihydro-I0-deacetyl-paclitaxel(67). The same 
procedure was followed as for 66, using 59 (0 20 g, 0 25 mmol) Compound 67 was isolated in 66 % yield (114 mg, 
0 165 mmol) mp 150 °C, 'H-NMR (400 MHz, CDCI,) δ 7 74 (2H, d, J = 7 4 Hz, H-Ph), 7 58 (2H, d, J = 7 4 Hz, H-
Ph), 7 50 (IH, t, J = 7 4 Hz, H-Ph), 7 39 (4H, m, H-Ph), 7 30 (IH, t, J = 7 3 Hz, H-Ph), 7 09 (IH, d, J
m
, = 9 4 Hz, 
NH), 6 00(IH, bd, J, M, = 9 5 Hz, H3'), 5 87 (IH, m, H13), 4 88 (IH, dd, J ^ = 8 7 Hz, J S 6 = 2 3 Hz, H5), 4 66 (IH, bs, 
H2-), 4 60 (IH, d, J 1 0 9 = 9 6 Hz, H10), 4 59 (IH, d, J20.20 = 8 0 Hz, H20), 4 45 (IH, d, J 2 M 0 = 80 Hz, H20), 4 05 (IH, d, 
J „ = 5 5 Hz, H2), 3 98 (IH, d, J, ,„ = 9 6 Hz, H9), 3 94 (IH, s, OH), 3 80 (IH, bs, OH), 2 69 (IH, bs, OH), 2 25 (7H, 
m, H3, 2H6, 2H7, 2HI4), I 64 (3H, s, H18), 1 58 (3H, s, H16), 1 48 (3H, s, acetonide), 1 36 (3H, s, acetonide), I 31 
(3H, s, H17), 1 14 (3H, s, H19), FAB-MS, 692 [M+H]\ 714 [M+Na]*, Anal Caled for C„H 4,NO l 01 5H20 C, 65 15, 
H, 7 31, N, 1 95 Found C, 65 29, H, 7 22, N, I 92 
l-BenzoyI-2-debenzoyl-2-(tetrahydropyran-2-yl)-4-deacetyl-7-deoxy-10-deacetyl-9(/t)-d¡hydropacl¡taxel (68). 
Compound 60 (0 10 g, 0 12 mmol) was dissolved in HOAc/THF/H20 (36/3/6 ml) After 24 hours at 50 °C, the reaction 
mixture was diluted with EtOAc (50 ml) The organic layer was washed with a NaHCOj-saturated solution (20 ml), 
dried over Na2SO< and concentrated m vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), 
yielding 68 (61 mg, 0 073 mmol, 61 %) mp 122 "С, 'H-NMR (400 MHz, CDCI3) δ 8 02 (2H, dd, J = 7 8 Hz, J = 1 4 
Hz, 2H-Ph), 7 73 (2H, dd, J = 7 8 Hz, J = 1 6 Hz, 2H-Ph), 7 55 (3H, m, 3H-Ph), 7 37 (8H, m, 8H-Ph), 7 05 (IH, d, J ^ 3 
= 9 5 Hz, NH), 6 02 (IH, bd, J,
 m
 = 9 5 Hz, H3'), 5 88 (IH, m, H13), 4 91 (IH, dd, J 5 6 = 8 9 Hz, J 5 6 = 2 3 Hz, H5), 
4 86 (IH, t, J = 5 6 Hz, НИ"), 4 62 (ЗН, m, НЮ, Н20 and Н2'), 4 44 (IH, d, J20.,„= 7 9 Hz, H20), 4 24 (2H, m, 2Н12"), 
4 09 (IH, s, OH4), 3 98 (IH, d, JM0 = 9 4 Hz, H9), 3 93 (IH, d, J 2 , = 5 5 Hz, H2), 3 70 (IH, bs, OH2'), 2 66 (IH, bs, 
OH), 2 35-1 99 (8H, m, H3, 2H6, 2H7, 2H14 and OH), 1 68 (3H, s, H18), 1 58 (3H, s, H16), 1 48 (3H, s, HI7), 1 16 
(3H, s, H19), FAB-MS, 840 [M+H]\ 862 [M+Na]\ Anal Caled for C„H„NO l 2 C, 68 62, H, 6 85, Ν, I 67 Found С, 
68 38, H, 7 05, N, 141 
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4 Incorporation of the C2-benzoate Group 
4.1 Introduction 
In chapter 3, the synthesis and biological evaluation of the first 7-deoxypaclitaxel analogs, 
starting from crude taxine were described. The lack of activity of these analogs was attributed to the 
missing benzoate group at C2, in agreement with SAR studies which show that this group is 
absolutely necessary for activity.1 
In chapter 3 it was also shown that the usual protection and deprotection strategy cannot be used 
for the introduction of the benzoate group at C2. Therefore, a strategy had to be devised in which 
the CI- and C2-hydroxyl groups are protected with a group that is stable toward base and that can 
be converted directly into the desired benzoate group at C2. 
This chapter describes the search for a suitable method to incorporate the C2-benzoate group. 
4.2 The Cyclic Carbonate 
In the literature it has been reported that a cyclic carbonate at Cl, C2 can be opened by 
phenyllithium,2 resulting in the regioselective formation of the C2-benzoate (scheme 4.1). 
Scheme 4.1 
(a) 5 equiv of PhLi/THF/-78 °C/15 min; 70 %. 
This cyclic carbonate is relatively stable toward base. Therefore, several approaches to 
synthesize 4 from 3 (scheme 4.2) were examined. 
4.2.1 First Approach 
In the first approach, depicted in scheme 4.3, the first step is the hydrolysis of the cinnamoyl side 
chain at C5, followed by the introduction of the cyclic carbonate. 
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Scheme 4.2 
ОН з 
(derived from taxine В (see scheme 3 5 compd 27)) 
Scheme 4.3 
I, II, III, IV a 
(I) 20 N NaOH/THF, Δ (Π) 1 equiv NaOMe, Δ (III) LiOH, MeOH/H20 , 3/1 
(IV) NHjOH HCl/NaOAc/EtOH/H20 (56 %) (a) 1,1-carbonyldiimidazoIe 
Treatment of 3 with strong bases (see I, II and III, scheme 4 3) resulted in a mixture of at least 
seven compounds (according to TLC) Since there was no major product, the products were not 
separated or identified It is likely that in the case of an unprotected С1 -hydroxyl group, under the 
influence of strong base, retro-aldol or retro-Michael reactions can occur, leading to rearranged 
products Reaction of 3 with NH2OH HCl,
3
 however, yielded 5 in 56 % Unfortunately, treatment of 
5 with 1,1-carbonyldnmidazole gave a mixture of products, from which 4 could not be isolated and 
which could not be identified 
4.2.2 Second Approach 
In a second approach, first the cyclic carbonate was introduced, scheme 4 4 Treatment of 
compound 3 with l,l-carbonyldnmida7ole gave compound 6 in 85 % yield The hydrolysis of the 
cinnamoyl side chain was carried out under different conditions (see I and II, scheme 4 4) 
Unfortunately the desired product 4 could be isolated nor detected 
With NH2OH HCl the desired product 4 was not formed From the 'H-NMR spectrum, it is clear 
that the cyclic carbonate was opened probably by ethanol to give the ethyl carbonate at C2, because 
the proton at C2 shifted from 5 36 to 5 68 ppm The cinnamoyl side chain did not split off, as the 
phenyl protons were still present in the 'H-NMR, but an addition to the double bond m this chain 
had taken place, as can be concluded from the disappearance of the signals of the protons at C5' 
(7 64 ppm) and C6' (6 27 ppm), respectively Furthermore, the signals of the two double bond 
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protons at C20 had disappeared, showing that also a reaction at this double bond had occurred. 
From the NMR spectrum it is not clear which product was formed in this reaction. 
Scheme 4.4 
1,11 
-x—- * 
(a) 1,1-carbonyldiimidazole; 85 %. (I) NH2OH.HCl/NaOAc/EtOH/H20. (II) KCN/MeOH. 
Use of KCN in MeOH, lead to the formation of a new product without the cinnamoyl side chain, 
according to 'H-NMR. After careful examination of the mass spectrum and in agreement with 
combustion analysis, we concluded that the cinnamoyl side chain at C5 was substituted by cyanide. 
In addition, the cyclic carbonate was also removed, leading finally to compound 7 (figure 4.1) 
which was isolated in 93 %.A 
Figure 4.1 
As mentioned before, from the literature2 it was known that the cyclic carbonate can be opened 
by phenyllithium to the benzoate group at C2. Since it was not possible to remove the cinnamoyl 
side chain at C5 without opening or removal of the cyclic carbonate, it was thought that 
phenyllithium would be an appropriate reagent to open the cyclic carbonate to the desired C2-
benzoate group as well as to remove the cinnamoyl side chain under the same conditions. Treatment 
of compound 6 with 2.5 equivalents of phenyllithium, indeed, gave compound 8 in 28 % yield, with 
a 65 % recovery of 6. Treatment with 6 equivalents of phenyllithium gave 8 in 33 % yield, but 
compound 9 was also isolated in 12 % yield, with a 45 % recovery of 6 (scheme 4.5). 
Some remarks can be made about the peculiar course of this reaction. The conversion rate of this 
reaction with two equivalents of phenyllithium, is rather low. When more equivalents were added, 
the isolated yield becomes higher, but also the side product 9 is formed. Intermediate products, with 
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a benzoate group at C2 and the cinnamoyl side chain at C5 or with the cyclic carbonate still present 
and without cinnamoyl side chain, were not isolated. 
Scheme 4.5 
I) 2.5 equiv PhLi/-78 °C; 80 % (8), based on 35 % conversion. II) 6 equiv PhLi/-78 °C; 60 % 
(8) and 22 % (9), based on 55 % conversion. 
Therefore, the opening of the cyclic carbonate seems to depend on the presence or absence of the 
cinnamoyl side chain at C5. Attack of phenyllithium at the cyclic carbonate from the upper side is 
sterically hindered by the CH3-16, CH3-19 and the proton at C2 and at the bottom side the cyclic 
carbonate is shielded by the side chain (figure 4.2).5 Once the side chain is split off, the opening of 
the cyclic carbonate is possible. The configuration at C13 of 9 must be as indicated in scheme 4.5, 
because the singlet of CH3-17 in the 'H-NMR spectrum was shifted from 1.32 to 1.03 ppm under 
the influence of the induced field of the aromatic ring. 
Figure 4.2 Shielding of the cyclic carbonate from the upper and bottom side in compound 6 
CH.-16 
phenyl! 
CH5-I9 
C=0 (cyclic carbonate) 
To construct the oxetane ring in compound 8, the C4-C20 double bond of 8 was cis-
dihydroxylated with Os04, yielding 10 (scheme 4.6). 
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Scheme 4.6 
(a) Os04/NMMO; 61 %. (b) r-butyldimethylsilyl chloride/imidazole; 79 %. (c) Methanesulfonyl 
chloride/pyridine; 92 %. (d) TBAF; 51 %, based on 86 % conversion. 
Next, the primary alcohol was protected with a /-butyldimethylsilyl (TBDMS) group, followed 
by mesylation of the secondary alcohol, to give 11 (scheme 4.6). Removal of the TBDMS group via 
treatment with TBAF was expected to give 12. Ring closure should lead to an oxetane compound. 
However, after treatment with TBAF the isolated compound appeared not to be 12. Instead product 
13, in which the benzoyl group had migrated from C2- to the C20-hydroxyl group, was isolated. 
The formation of compound 13 frustrated this route. It was foreseen that removal of the benzoate 
group, closure of the oxetane ring, followed by introduction of the benzoate group at C2 via the 
cyclic carbonate would be rather cumbersome. 
4.2.3 Third Approach 
The third approach was based on the use of a masked cyclic carbonate. Treatment of 3 with a 
tetra-alkyl orthocarbonate should give compound 14 (scheme 4.7). Subsequent hydrolysis of the 
cinnamoyl side chain, followed by treatment with an aqueous acidic solution could yield 4. 
In order to protect the CI-, C2-hydroxyl groups as a diethyl orthocarbonate or dimethyl 
orthocarbonate, compound 3 was treated with tetraethyl and tetramethyl orthocarbonate, 
respectively, in the presence of a catalytic amount of /j-toluenesulfonic acid. All reactions were 
carried out in dichloromethane or chloroform. Variation of the temperature (from 25 to 40 °C), the 
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pressure (from 1 bar to 15 kbar) and the reaction time (from 5 to 90 hours) did not result in 
formation of compounds 14a and 14b. 
Scheme 4.7 
- * * о 
b,c 
14a R = Me 
14b R = Et 
(a) tetraethyl and tetramethyl orthocarbonate, respectively, under different reaction 
conditions, (b) 20 N NaOH. (c) H30*. 
In contrast, the reaction of 3 with triethyl orthoformate, which was carried out for the study of 
the hydrolysis of different cyclic protecting groups,6 went very smoothly and gave 15 in 82 % yield 
(scheme 4.8). 
Scheme 4.8 
-*• O: 
b,c 
YC ^ o 
(a) triethyl orthoformate/PTS; 82 %. (b) 20 N NaOH. (с) Н3<У. 
Hydrolysis of the cinnamoyl side chain, followed by hydrolysis of the orthoformate group will 
most probably lead to the C2-formate compound 16. Therefore, we tried to protect the CI-, C2-
hydroxyl groups as an orthobenzoate group. Analogously, this group can be hydrolyzed by acidic 
aqueous solutions to give the desired benzoate function, hopefully at C2. Unfortunately treatment of 
3 with triethyl orthobenzoate in the presence of a catalytic amount ofp-toluenesulfonic acid gave no 
reaction (scheme 4.9). 
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Scheme 4.9 
(a) triethyl orthobenzoate/PTS, 80 °C; no reaction. 
4.3 The Benzylidene Acetal 
In section 4.2 it was shown that the protection of the CI-, C2-hydroxyl groups with a cyclic 
function requires precision. Protection as an orthocarbonate or orthobenzoate function could not be 
accomplished. Until now, only the isopropylidene acetal (section 3.2.2)7 and the ethyl orthoformate 
group (section 4.2) were successfully applied for the cyclic diprotection of the CI-, C2-hydroxyl 
groups. Based on these results it was decided to study the cyclic benzylidene acetal as a protecting 
group in the synthetic strategy. In the literature several methods are described to convert this acetal 
into a benzoate group. Especially in sugar chemistry, the use of this acetal is an established method.8 
In the taxane chemistry, this function has not yet been applied.' 
4.3.1 Synthesis of the Benzylidene Protected Compound 28 
Compound 3 was not obtained pure and was contaminated with compound 18, as was mentioned 
before in chapter 3. It was expected that purification would be possible after protection of 3 as a 
benzylidene acetal. After some test reactions, it was found that the conversion of 3 into 19 
proceeded optimally using benzaldehyde dimethyl acetal (instead of benzaldehyde) with p-
toluenesulfonic acid as catalyst and toluene as the solvent (scheme 4.10). After column 
chromatography compound 19 was isolated in 85 % yield and compound 18 in 14 % yield. The 
synthesis of 1,7-dideoxypaclitaxel derivatives, starting from compound 18, will be discussed in 
chapter 6. 
Compound 19 was treated with 20 N NaOH in order to hydrolyze the cinnamoyl side chain to 
give compound 20. Before introduction of the oxetane ring, several methods for the oxidation of the 
benzylidene acetal to the C2-benzoate were tested in order to select the most satisfactory method. 
Therefore, the C5-hydroxyl group of 20 had to be protected. Treatment of 20 with allyl bromide or 
benzyl bromide, using various reaction conditions10'13 did not lead to the allylic or benzylic 
protected compounds 21a or 21b, respectively. In all reactions more than 75 % of the starting 
material was recovered. 
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Scheme 4.10 
0 H
 3 R = OH 
18 R = H 
"OR' 
-я 
+ 18 
V-° 4--Ö 
/ 21a R'= benzyl ; 20 
ph 21b R* = allyl Ph 
(a) 2 equiv benzaldehyde dimethyl acetal/PTS/toluene, 85 % (19) and 14 % (18) (b) 20 N NaOH, 76 % (c) Allyl and 
benzyl chloride, respectively, under various reaction conditions 
Introduction of the oxetane ring was achieved by established methods The C4-C20 double bond 
of compound 20 was c/s-dihydroxylated, using Os04, to give compound 22 (scheme 4 11) 
Scheme 4.11 
(a) OsO„/NMMO, 55 % (b) i-butyldimethylsilyl chlonde/imidazole, 94 % 
(c) methanesulfonyl chlonde/pyndine, 84 % (d) r-butylammonium fluoride, 99 % 
(e) tetrabutylammonium acetate, 64 % 
Incorporation of the C2-benzoate Group 
Protection of the primary hydroxyl group with r-butyldimethylsilyl chloride and mesylation of 
the secondary hydroxyl group afforded compound 23. Removal of the r-butyldimethylsilyl group 
with i-butylammonium fluoride followed by ring closure under the influence of 
tetrabutylammonium acetate yielded oxetane compound 24. The configuration at C4' of 24, was 
confirmed by NOE difference experiments. The S-configuration was assigned at C4' because of the 
NOE contact between H(4') and H(2). In the R-configuration, when these protons are in trans 
position, such a NOE contact is not possible. 
4.3.2 Opening of the Benzylidene Acetal 
Compound 24, having the required oxetane ring, seemed appropriate to test the regioselective 
opening of the benzylidene acetal leading to compound 25 (scheme 4.12). 
Scheme 4.12 
In the literature several methods are described how to accomplish the oxidation of a benzylidene 
acetal to a benzoyl and a free hydroxyl group. A number of these methods was investigated in order 
to find one that can be successfully applied in taxane chemistry. First, it was tried to open the 2-
phenyl-l,3-dioxolane ring by irradiation in the presence of N-bromosuccinimide (NBS).14 The 
mechanism for this reaction is depicted in scheme 4.13. 
Scheme 4.13 
NBS 
V -=•* 
H Ph 
24 
V 
Br Ph 
26 
4° -^ X 
Br" Ph H - 0 Ph 
27 28 
но о 
P h - ^ O 
25 
Compound 24 should be converted into intermediate 26 via a radical substitution reaction. The 
next step would be the formation of carbocation 27, followed by reaction with water to give 
intermediate 28, which would open very fast to the benzoate compound 25. When compound 24 
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was irradiated in the presence of NBS, many products were formed, probably due to several 
unwanted radical reactions. The desired C2-benzoate compound 25 was not isolated. 
Opening of the benzylidene acetal by ozone,15 2,3-dichloro-5,6-dicyano-l,4-benzoquinone 
(DDQ)16 or sodium perborate17 occurs by the same kind of mechanism. First, hemiorthoester 28 
should be formed, followed by ring opening to give product 25. 
The reaction of 24 with ozone resulted again in many products, from which the desired product 
could not be isolated. A significant problem with ozone for small scale reactions is the dosage of 
added ozone. Too much ozone leads to several unwanted oxidation reactions. 
Treatment of compound 24 with DDQ in the presence of water, however, gave the desired 
product 25. Although the ring opening was 100 % regioselective,18 the conversion rate was very 
low. The yield of 25 was only 14 %, with a recovery of 85 % of compound 24, although excess 
DDQ was used. 
In the reaction of compound 24 with sodium perborate in the presence of acetic anhydride, 
compound 25 was also isolated in 13 % yield. The recovery of 24, however, was only 28 %, 
together with several side products which were not identified. 
Another reagent that is capable of opening the benzylidene acetal oxidatively to the C2-benzoate 
group is trityl tetrafluoroborate" (scheme 4.14). 
Scheme 4.14 
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In the first step, hydride abstraction by the trityl carbocation should take place, followed by 
nucleophilic attack of water, this would lead via 29 to intermediate 28. Fast opening of this 
hemiorthoester then will give compound 25. In addition to the oxidative opening of the benzylidene 
acetal, this reagent also will be capable of opening the acetonide at C9,C10 to the acyloin function20 
(scheme 4.15). 
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Treatment of 24 with trityl tetrafluoroborate should give intermediate 30. Via intermediates 31 
and 32, followed by nucleophilic attack of water, the acyloin compound 33 should be formed. 
Therefore, in the ideal situation, the following overall conversion would, in principle, be possible 
(scheme 4.16). 
Scheme 4.16 
Pri ^ O 
When compound 24 was treated with trityl tetrafluoroborate, first, three major products were 
formed, together with some minor products, according to TLC. One of the three major products was 
compound 25, the other two were not identified. By adding more equivalents of trityl 
tetrafluoroborate, compound 25 disappeared completely. The two other major products were 
isolated by column chromatography. It was not possible to identify these two products by 'H-NMR 
spectroscopy, but from these spectra it was concluded that the desired compound 34 was not one of 
the two isolated products. The signal for the proton at C2 was not present in both spectra and 
moreover it was hard to detect other signals representative for an intact taxane skeleton. Therefore, 
also trityl tetrafluoroborate is clearly not a suitable reagent for our synthetic purposes. 
Finally, the oxidative opening with /-butyl hydroperoxide in the presence of a catalyst was 
studied. A palladium species is normally used as a catalyst.21 Other possible catalysts are copper(II) 
chloride, iron(II) chloride, nickel(II) chloride or ruthenium(III) chloride.22 The mechanism of the 
opening by r-butyl hydroperoxide catalyzed by palladium(II) acetate, is depicted in scheme 4.17. 
Scheme 4.17 
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This mechanism involves co-ordination of the acetal oxygen atom of compound 28 to 
palladium(II) followed by nucleophilic attack of /-butyl hydroperoxide on the acetal carbon atom. 
Elimination of/-butyl alcohol will give compound 25. 
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When compound 24 was treated with /-butyl hydroperoxide in the presence of palladium(II) 
acetate at 50 °C, the benzylidene acetal was opened to the benzoate group. The yield of compound 
25 was 51 %, with a recovery of 32 % of compound 24. The opening was 100 % regioselective 
according to 'H-NMR spectroscopy. 
According to Hosokawa et al.,2,c this kind of oxidative opening reaction is even better promoted 
by using Pd(OCOCF3)((00/-Bu)23 instead of Pd(OAc)2 as a catalyst, because the /-BuOO ligand of 
Pd(OCOCF3)(00/-Bu) may act as an alternative intramolecular nucleophile. However no better 
results were found using this catalyst. 
Treatment of compound 24 with /-butyl hydroperoxide in the presence of ruthenium(III) chloride 
hydrate gave no reaction at room temperature or at 50 °C. When the mixture was heated to 80 °C, 
destruction of compound 24 took place and several unidentified products were formed. 
4.4 The Regioselective Opening to the C2-benzoate Group 
The opening of the cyclic carbonate (section 4.2) as well as of the benzylidene acetal (section 
4.3) were accomplished with 100 % regioselectivity, leading to the formation of the benzoate group 
exclusively at C2. 
Holton et al. and Nicolaou et al. introduced the C2-benzoate group via opening of the cyclic 
carbonate in their total syntheses of paclitaxel.2 No explanation was given for the regioselectivity 
found in this ring opening reaction. 
First it was believed that formation of the C2-benzoate is favored in comparison with the 
formation of the CI-benzoate, because there is less room for a benzoate group at CI than at C2. If 
this is the only reason, a 100 % regioselectivity is somewhat surprising. In section 3.2.3, it was 
already mentioned that the CI-hydroxy 1 group can be very easily benzoylated in 96 % yield 
(scheme 3.10). 
Moreover, in their attempt to prepare 1-deoxypaclitaxel, Chaudhary et al.24 synthesized the 
compounds 37 and 38 (figure 4.3) by a reaction sequence in which a benzoate group migrated from 
C2toCl. 
Figure 4.3 
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The steric hindrance mentioned above, therefore, is not a reasonable explanation for the complete 
regioselectivity. Nevertheless it is possible that this regioselectivity is determined by steric factors, 
although it has nothing to do with the (size of the) benzoyl group itself. In the opening of the cyclic 
carbonate as well as of the benzy lidene acetal, one of the first important steps is the complexation of 
a metal atom to an carbonate or acetal oxygen, respectively. In the case of the cyclic carbonate two 
lithium ions are involved. One co-ordinates at the carbonyl and the other at the carbonate oxygen of 
compound 6 (figure 4.4). 
Figure 4.4 
Pd(II)--0 î HO 
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In the case of the benzylidene acetal, Pd(II) co-ordinates to the acetal oxygen of compound 24 
(figure 4.3). The carbonate oxygen or acetal oxygen, respectively, to which the metal atom is co­
ordinated ends up being the free hydroxyl group whereas the benzoyl is attached to the other 
hydroxyl group. Due to steric hindrance, co-ordination at the C2-oxygen is difficult so that after the 
opening reactions the benzoyl group will be attached to the C2-oxygen. This supposition is 
supported by molecular modeling, showing for compound 24 that indeed the C2-oxygen is much 
more shielded than the CI-oxygen.5 
In agreement with the above supposition, the same kind of explanation can be given for the 
failure of the deprotection of the C2-tetrahydropyranyl analogs and the Cl,C2-acetonide analogs in 
chapter 3. For the hydrolysis of the C2-tetrahydropyranyl group, it is necessary for H30
+
 to co­
ordinate at the C2-oxygen. Due to steric hindrance, this co-ordination is difficult and, therefore, the 
deprotection of the C2-hydroxyl group needs forced conditions. For the Cl,C2-acetonide function 
the same type of problem may play a rôle. 
4.5 Conclusions 
In the search for a suitable method for the incorporation of the C2-benzoate group, it appeared 
that selection of the C1-C2 protecting groups is crucial. Earlier described protecting groups, such as 
the cyclic carbonate, successfully used by Holton et al.2a and Nicolaou et al.,2b cannot be applied in 
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the planned strategy. In this study a method was developed, however, to incorporate the benzoate 
group via oxidation of the benzylidene acetal. This acetal, which has not yet been applied 
(successfully) in taxane chemistry, seems to be an excellent function for both the protection of the 
CI- and C2-hydroxyl groups as well as for the introduction of the benzoate group at C2. The most 
satisfactory method to convert this acetal into the C2-benzoate group is the oxidative opening, 
achieved by /-butyl hydroperoxide in the presence of palladium acetate as a catalyst In the next 
chapter this method will be applied in the synthetic routes toward 7-deoxypaclitaxel analogs, that 
possess the required C2-benzoate group 
The regioselectivity found in the C1-C2 ring opening reactions is ascribed to the shielding of the 
C2-oxygen Therefore, co-ordination to this oxygen is difficult. This can explain the regioselective 
opening of the benzylidene acetal and of the cyclic carbonate, as well as the failure in deprotection 
of the C2-hydroxyl group. 
4.6 Experimental Section 
Proton magnetic resonance spectra were measured on a Braker AC-100 or a Bruker AM-400 
spectrometer Chemical shift values are reported as δ-values relative to tetramethylsilane as an 
internal standard, deuterochloroform was used as solvent. Mass spectra were obtained with a double 
focusing VG 7070E spectrometer. Elemental analyses were carried out on a Carlo Erba Instruments 
CHNSO EA 1108 element analyzer. For the determination of optical rotations a Perkin-Elmer 241 
Polarimeter was used. Melting points were determined with a Reichert Thermopan microscope and 
are uncorrected. Thin layer chromatography was earned out on Merck precoated silica gel 60 F-254 
plates (thickness; 0.25 mm). All reactions mentioned were monitored by TLC. Spots were 
visualized with UV or a 6.2 % H2S04 aqueous solution, (IL) containing ammonium molybdate (42 
g) and eerie ammonium sulfate (3.6 g), followed by charring Column chromatography was carried 
out using silica 60 or silica 60H (Merck). Unless otherwise stated, materials were obtained from 
commercial sources and used without further purification. When necessary, solvents were distilled 
and dried according to standard procedures. 
Hydrolysis of 3 -> 5. (I) To a solution of 3 (0 50 g, 0 93 mmol) in dry THF (8 ml), 20 N NaOH (aq) (4 ml) was 
added The reaction mixture was stirred at reflux temperature The reaction was followed on TLC (EtOAc/hexane 
1/1) After two hours, according to TLC, more than seven products had been formed The reaction mixture was diluted 
with water (25 ml) and extracted twice with CH2CI2 (15 ml) The combined organic layers were washed with brine, 
dried over Na2S04 and concentrated m vacuo The residue was not further purified, because it still contained at least 
seven products without a clear major product 
(II) A solution of sodium methoxide prepared from 28 mg sodium (0 0012 g-atoms) in methanol (35 ml), was 
cooled to 0 °C under argon atmosphere After addition of 3 (0 50 g, 0 93 mmol), the reaction mixture was stirred for 5 
hours at 0 °C Subsequently the reaction mixture was acidified with 10 % citric acid (aq) and concentrated Water (35 
ml) was added This solution was extracted twice with ether (20 ml) The combined ether layers were washed with a 
saturated NaHCCysolution, dried over Na2S04 and concentrated m vacuo The residue was not further purified, 
94 
Incorporation of the C2-benzoate Group 
because on TLC no products could be distinguished, there was one stripe of products 
(III) A solution of LiOH (11 mg, 0 46 mmol) in water (2 ml) and methanol (3 ml), was cooled to 0 °C under argon 
atmosphere Next a solution of 3 (0 20 g, 0 37 mmol) in methanol (3 ml) was added After stirring for one hour no 
reaction had taken place, probably due to the bad solubility of LiOH The reaction mixture was stirred for an additional 
hour in an ultrasonic bath According to TLC more than eight products were formed The reaction mixture was 
acidified with 10 % citric acid (aq) This solution was extracted twice with EtOAc (15 ml) The combined organic 
layers were washed with brine, dried over Na2S04 and concentrated in vacuo The residue was not further purified, 
because it still contained more than eight products without a clear major product 
(IV) To a solution of 3 (0 50 g, 0 93 mmol) in ethanol (60 ml), NH2OH HCl (0 58 g, 8 4 mmol) was added Next a 
solution of sodium acetate (1 16 g, 14 2 mmol) in water was added The reaction mixture was stirred for 24 hours at 
reflux temperature After cooling to room temperature, the reaction mixture was diluted with water (200 ml) and 
extracted twice with CHC13 (100 ml) The combined organic layers were washed with brine, dried over Na2SO, and 
concentrated m vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), yielding 5 (0 21 g, 0 52 
mmol, 56 %) m ρ 84 °C, 'H-NMR (400 MHz, CDC13) δ 5 26 (IH, s, H20), 5 24 (IH, s, H20), 4 95 (IH, d, J 1 M = 9 3 
Hz, НЮ), 4 25 (IH, d, J, ,„ = 9 3 Hz, H9), 4 24 (IH, bs, H5), 4 05 (IH, d, J „ = 6 6 Hz, H2), 3 43 (IH, d, J,
 2 = 6 6 Hz, 
H3), 2 64 (2H, s, H14), 2 06 (3H, s, H18), 2 04 (2H, m, H6 and H7), 1 75 (2H, m, Н6 and Н7), 1 62 (ЗН, s, H16), 1 51 
(ЗН, s, acetonide), 1 45 (ЗН, s, acetonide), 1 35 (ЗН, s, H17), 1 05 (ЗН, s, H19), EI-MS, 406 [M]*, Anal Caled for 
C 2 3 H„0 6 C, 67 96, H, 8 43 Found С, 67 69, H, 8 41 
Synthesis of compound 4 from 5. The same procedure was followed as described for compound 6 (next 
procedure) Unfortunately a mixture of unknown products was formed, which were not identified and from which 4 
could not be isolated 
l,2-Carbonate-9,10-Acetonide-5a-cinnamoyltaxicin-I (6). To a solution of 3 (700 mg, 1 31 mmol) in butanone 
(20 ml), 1,1-carbonyldumidazole (850 mg, 5 25 mmol) was added, under argon atmosphere The reaction mixture was 
stirred at reflux temperature After 24 hours the reaction mixture was diluted with water (50 ml) and extracted twice 
with EtOAc (30 ml) The combined organic layers were washed with brine, dried over NajS04 and concentrated m 
vacuo The residue was purified via chromatography (EtOAc/hexane 2/5), yielding 6 (626 mg, 1 11 mmol, 85 %) 
m ρ 114 "С, 'H-NMR (400 MHz, CDC13) δ 7 71 (2H, d, J = 6 5 Hz, H-Ph), 7 64 (IH, d, ¡SJ6 = 15,9 Hz, H5'), 7 44 (3H, 
m, H-Ph), 6 27 (IH, d, J6 , = 15 9 Hz, H6'), 5 52 (IH, s, H20), 5 37 (IH, s, H20), 5 36 (IH, bs, H5), 4 93 (IH, d, J23 = 
5 8 Hz, H2), 4 88 (IH, d, J1M = 9 1 Hz, H10), 4 13 (IH, d, J^,0 = 9 1 Hz, H9), 3 22 (IH, d, JD2 = 5 6 Hz, H3), 2 96 (2H, 
s, 2H14), 2 17 (3H, s, H18), 2 01 (IH, m, H6), 1 80 (2H, m, H6 and H7), 1 68 (3H, s, H16), 1 50 (3H, s, acetonide), 
145 (3H, s, acetonide), 143 (3H, s, H17), 114 (3H, s, H19), FAB-MS, 563 [M+H]+, Anal Caled for 
C3JH38Oe 0 5H20 C, 69 33, H, 6 88 Found С, 69 37, H, 6 72 
Hydrolysis of 6 -• 4. (I) To a solution of 6 (50 mg, 0 090 mmol) in ethanol (6 ml) NH2OH HCl (58 mg, 0 84 
mmol) was added Next a solution of sodium acetate (120 mg, 1 47 mmol) in water (6 ml) was added The reaction 
mixture was stirred for 48 hours at reflux temperature After cooling to room temperature, the reaction mixture was 
diluted with water (20 ml) and extracted twice with CHC13 (20 ml) The combined organic layers were washed with 
brine, dried over Na2S04 and concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 
1/1), yielding one major unidentified product (22 mg) 
(II) To a solution of 6 (180 mg, 0 32 mmol) in methanol (5 ml), KCN (15 mg, 0 23 mmol) was added The reaction 
mixture was stirred at reflux temperature After 24 hours the reaction mixture was diluted with water (20 ml) and 
extracted twice with EtOAc (15 ml) The combined organic layers were washed with brine, dried over Na2SO„ and 
concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), yielding 7 (124 mg, 0 300 
mmol, 93 %) m ρ 77 "С, Ή-NMR (400 MHz, CDCl,) δ 5 40 (IH, s, H20), 5 01 (IH, s, H20), 4 75 (IH, d, J 1 M = 83 
Hz, H10), 4 65 (IH, dd, J M = 2 3 Hz, J M =10 6 Hz, H5), 4 33 (IH, bs, H2), 4 23 (IH, d, J*,» = 8 2 Hz, H9), 2 95 (3H, 
m, H3 and 2H14), 1 84 (3H, m, 2H6 and H7), 1 76 (3H, s, H18), 1 56 (3H, s, H16), 1 48 (3H, s, acetonide), 1 44 (3H, s, 
acetonide), 1 34 (3H, s, H17), 1 17 (3H, s, H19), FAB-MS, 416 [M+H]\ Anal Caled for C2,H3 3N05 H 2 0 C, 66 48, H, 
95 
8 15, Ν, 3 23 Found С, 66 73, Η, 7 77, Ν, 3 75 
Preparation of compound 8. (I) To a solution of 6 (1 70 g, 3 02 mmol) in THF (10 ml), stirred at -78 "C, PhLi (4 
ml, 1,8 M in cyclohexane/ether, 7 2 mmol) was added After 30 minutes the reaction was quenched with 10 % citric 
acid (aq) (50 ml) at -78 °C Next the temperature was allowed to raise to room temperature The solution was extracted 
twice with EtOAc (30 ml) The combined organic layers were washed with bnne, dried over Na2S04 and concentrated 
in vacuo The residue was purified via chromatography (EtOAc/hexane 2/5), yielding 8 (0 43 g, 0 85 mmol, 28 %) 
with a recovery of 6 (1 11 g, 1 98 mmol, 65 %) Compound 8 m ρ 134 "С, Ή-NMR (400 MHz, CDCl,) δ 8 04 (2H, d, 
J = 7 4 Hz, H-Bz), 7 59 (IH, t, J = 7 4 Hz, H-Bz), 7 46 (2H, t, J = 7 6 Hz, H-Bz), 5 88 (IH, d, J„ = 6 2 Hz, H2), 5 06 
(IH, s, H20), 5 02 (IH, d, J 1 M = 9 2 Hz, H10), 4 60 (IH, s, H20), 4 40 (IH, d, J, ,„ = 9 2 Hz, H9), 4 21 (IH, bs, H5), 
3 70 (IH, d, J,, = 6 2 Hz, H3), 2 97 (IH, d, J,4. 14b = 19 3 Hz, H 14a), 2 68 (IH, d, J,4b H . = 19 3 Hz, H 14b), 2 13 (3H, s, 
H18), 1 73 (3H, s, H16), 1 55 (3H. s, acetonide), 1 48 (3H, s, acetonide), 1 32 (3H, s, H17), 1 08 (3H, s, H19), FAB-
MS, 511 ГМ+НГ, Anal Caled for C,0H3,O7 C, 70 57, H, 7 50 Found С, 70 64, H, 7 51 
(II) Same procedure was followed as for entry I, using 10 ml (18 mmol) PhLi After purification via 
chromatography, the yield of 8 was 33 % (508 mg, 0 996 mmol), the recovery of 6 was 45 % (765 mg, 1 36 mmol) and 
the yield of 9 was 12 % (213 mg, 0 362 mmol) Compound 9 m ρ 154 °C, Ή-NMR (400 MHz, CDCI3) 8 8 10 (2H, d, 
J = 7 3 НА H-BZ), 7 60 (1 H, t, J = 7 4 Hz, H-Bz), 7 49 (2H, t, J = 7 6 Hz, H-Ph), 7 40 (2H, d, J = 7 4 Hz, H-Bz), 7 26 
(3H, m, H-Ph), 5 76 (IH, d, J„ = 6 3 Hz, H2), 5 47 (IH, bs, C13-OH), 5 06 (IH, s, H20), 5 01 (IH, d, J,„, = 9 3 Hz, 
H10), 4 56 (IH, s, H20), 4 39 (IH, bs, C4-OH), 4 36 (IH, d, J, ,„ = 9 3 Hz, H9), 3 79 (IH, bs, H5), 3 70 (IH, d, J,
 2 = 
6 3 Hz, H3), 3 10 (IH, d, J,4l ,4b = 15 7 Hz, H 14a), 2 45 (IH, d, J14b 14. = 15 7 Hz, H 14b), 2 12 (3H, s, H18), 2 04 (IH, s, 
Cl-OH), 1 60 (3H, s, H16), 1 53 (3H, s, acetonide), 1 48 (3H, s, acetonide), 1 03 (3H, s, H17), 1 01 (3H, s, H19), FAB-
MS.6II [M+Na]* 
Dihydroxylation of 8 -> 10. To a solution of 8 (835 mg, 1 64 mmol) in THF/H20 (7/3 5 ml), N-methylmorpholine-
N-oxide monohydrate (930 mg, 6 91 mmol) and a solution of Os04 (2 5 % m r-BuOH, 1 0 ml) were added The 
reaction mixture rapidly turned red After 3 hours the reaction mixture was diluted with water (50 ml) and extracted 
twice with EtOAc (30 ml) The combined organic layers were washed with brine, dried over Na2S04 and concentrated 
m vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), yielding 10 (545 mg, 1 00 mmol, 61 %) 
m ρ 144 "С, Ή-NMR (400 MHz, CDC13) 6 8 11 (2H, d, J = 7 4 Hz, H-Bz), 7 61 (IH, t, J = 7 4 Hz, H-Bz), 7 49 (2H, t, 
J = 7 6 Hz, H-Bz), 5 88 (IH, d, J2 } = 4 6 Hz, H2), 4 91 (IH, d, J 1 M = 9 3 Hz, H10), 4 38 (IH, d, J, 10 = 9 3 Hz, H9), 
3 82 (IH, d, J14l 14Ъ = 19 2 Hz, H14a), 3 76 (IH, s, C4-OH), 3 64(IH, bs, H5), 3 57 (IH, dd, J20,2№ = 10 8 Hz, J2IMC2IM)H) 
= 4 5 Hz, H20a), 3 39 ( 1 H, dd, J
m
 „, = 10 8 Hz, J^^O-OH) = 5 8 Hz, H20b), 3 00 ( 1 H, d, J3 2 = 4 6 Hz, H3), 2 83 ( I H, 
s, C5-OH), 2 61 (IH, d, J14b ,4, = 19 1 Hz, H 14b), 2 08 (3H, s, H18), 2 03 (IH, m, C20-OH), 1 89 (IH, s, Cl-OH), 1 71 
(3H, s, H16), 1 53 (3H, s, acetonide), 1 45 (3H, s, acetonide), 1 32 (3H, s, H17), 1 05 (3H, s, H19), FAB-MS, 567 
{M+Na]\ Anal Caled forC^^O, C, 66 16, H7 40 Found С, 65 72, H, 7 87 
Silylation and mesylation of 10 -* 11. A solution of imidazole (850 mg, 12 5 mmol) and í-butyldimethylsilyl 
chloride (772 mg, 5 15 mmol) in DMF (6 0 ml) was stirred for 15 minutes Then compound 10 (500 mg, 0 92 mmol) 
was added After two hours the reaction mixture was diluted with a solution of 10 % citric acid in water (60 ml) and 
extracted twice with EtOAc (30 ml) The combined organic layers were washed with brine, dried over Na2S04 and 
concentrated m vacuo The residue was purified via chromatography (EtOAc/hexane 2/5), yielding the silylated 
analog of 10 (480 mg, 0 73 mmol, 79 %) m ρ 124 "С, Ή-NMR (400 MHz, CDCl,) δ 8 08 (2H, d, J = 7 3 Hz, H-Bz), 
7 58 (IH, t, J = 7 4 Hz, H-Bz), 7 44 (2H, t, J = 7 6 Hz, H-Bz), 5 84 (IH, d, J„ = 4 6 Hz, H2), 4 91 (IH, d, J,„, = 9 3 Hz, 
H10), 4 39 (IH, d, J, ,0 = 9 3 Hz, H9), 3 93 (IH, d, J14, ,4b = 19 1 Hz, H14a), 3 86 (IH, s, C4-OH), 3 53 (IH, d, J20a20b = 
9 7 Hz, H20a), 3 47 (IH, bs, H5), 3 34 (IH, d, J20b.20l = 9 7 Hz, H20b), 2 99 (IH, d, J3 2 = 4 7 Hz, H3), 2 70 (IH, s, C5-
OH), 2 60(1H, d, J l 4 b M, = 19 0 Hz, H 14b), 2 09 (3H, s, HI8), 1 79 (IH, s, Cl-OH), 1 69 (3H, s, HI6), 1 53 (3H, s, 
acetonide), 1 45 (3H, s, acetonide), 1 32 (3H, s, H17), 1 07 (3H, s, H19), 0 68 (9H, s, Sir-Bu), -0 19 (3H, s, SiMe), -
0 47 (3H, s, SiMe), FAB-MS, 659 [M+H] , Anal Caled for C ^ H J A S I С, 65 62, H, 8 26 Found С, 65 67, H, 8 59 
То a solution of the silylated analog (450 mg, 0 68 mmol) in pyridine (10 ml) at 0 °C, methanesulfonyl chloride (0 5 
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ml) was added The reaction mixture was stirred for 20 hours at room temperature Next, CH2Cl2 (50 ml) was added 
The mixture was washed with a solution of 10 % citric acid in water (30 ml), with a saturated NaHCOj-solution, dried 
over Na2S04 and concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), yielding 
11 (460 mg, 0 625 mmol, 92 %) m ρ 132 "С, Ή-NMR (400 MHz, CDCIj) 8 8 07 (2H, d, J = 7 4 Hz, H-Bz), 7 60 (IH, 
t, J = 74 Hz, H-Bz), 7 46 (2H, t, J = 7 6 Hz, H-Bz), 5 85 (IH, d, J „ = 4 4 Hz, H2), 4 89 (IH, d, V , = 9 3 Hz, H10), 
4 67 (IH, bs, H5), 4 40 (IH, d, J, ,„ = 9 3 Hz, H9), 3 90 (IH, d, JM. 14b = 19 3 Hz, H 14a), 3 88 (IH, s, C4-OH), 3 56 
(IH, d, )2„,m= 10 2 Hz, H20a), 3 37 (IH, d, го, = 102 Hz, H20b), 3 03 (3H, s, mesyl), 2 92 (IH, d, J, 2 = 4 4 Hz, 
H3), 2 61 (IH, d, JH b .H . = 19 1 Hz, H14b), 2 14 (3H, s, H18), 1 80 (Ш, s, Cl-OH), 1 69 (3H, s, H16), 1 54 (3H, s, 
acetonide), 1 46 (3H, s, acetonide), 1 32 (3H, s, H17), 1 10 (3H, s, H19), 0 71 (9H, s, Stf-Bu), -0 14 (3H, s, SiMe), -
0 45 (3H, s, SiMe), FAB-MS, 737 [М+НГ, Anal Caled for С„Н
и
О„8і5 1 5H 20 C, 58 16, H, 7 80, S, 4 20 Found 
С, 58 14, H, 7 48, S, 5 34 
Preparation of compound 13. To a solution of 11 (0 43 g, 0 58 mmol) in THF (5 ml), tetrabutylammonium 
fluoride (1 0 ml, 1M in THF, 1 mmol) was added The reaction mixture was stirred for 20 minutes at room temperature 
EtOAc (50 ml) was added The organic layer was washed with a saturated NaHCCysolution, dried over Na 2S0 4 and 
concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), yielding 13 (0 16 g, 0 26 
mmol, 44 %) with a recovery of 11 (60 mg, 0 082 mmol, 14 %) Compound 13 m ρ 179 °C, 'H-NMR (400 MHz, 
CDC1,) δ 8 02 (2H, d, J = 7 3 Hz, H-Bz), 7 59 (IH, t, J = 7 4 Hz, H-Bz), 7 46 (2H, t, J = 7 6 Hz, H-Bz), 5 34 (IH, d, 
J 2 0. 2 № = 12 1 Hz, 20a), 5 10 (IH, bs, H5), 4 83 (IH, d, J I M = 9 3 Hz, H10), 4 46 (IH, d, J 2 № 2 0 1 = 12 1 Hz, H20b), 4 25 
(IH, d, J, ,„ = 9 3 Hz, H9), 4 22 (IH, d, J „ = 5 0 Hz, H2), 4 01 (IH, s, C4-OH), 3 22 (IH, d, J,,.
 t 4 b = 19 3 Hz, H14a), 
2 99 (3H, s, mesyl), 2 65 (IH, d, J j , = 4 8 Hz, H3), 2 63 (IH, d, J1 4 b.M. = 19 4 Hz, H14b), 2 08 (3H, s, H18), 1 61 (3H, 
s, H16), 1 50 (3H, s, acetonide), 1 44 (3H, s, acetonide), 1 37 (3H, s, H17), 1 24 (3H, s, H19), FAB-MS, 645 [M+Na]* 
l,2-(Dimethoxymethylene)-9,10-acetonide-5a-cinnamoyltaxicin-I (14a). To a solution of 3 (0 50 g, 0 93 mmol) 
in dry CH2CI2 (15 ml), terramethyl orthocarbonate (0 21 g, 1 5 mmol) and a catalytic amount of PTS were added This 
reaction was carried out under different reaction conditions The pressure was varied from 1 bar to 15 kbar, the 
temperature was varied from 25 to 40 °C After 16 hours the reaction mixture was diluted with EtOAc (30 ml), washed 
with a saturated NaHCCysolution, then washed with brine, dried over Na2SO„ and concentrated in vacuo The residue 
was purified via chromatography (EtOAc/hexane 2/5) The starting compound 3 was fully recovered 
l,2-(Diethoxymcthylene)-9,10-acetonide-5a-cinnamoyltaxicin-l (14b). The same procedure was followed as for 
14a, using tetraethyl orthocarbonate (0 36 g, 1 86 mmol) After purification, compound 3 was fully recovered 
l,2-(Ethyl-orthoformate)-9,10-acetonide-5a-cinnamoyltaxicin-I (15). To a solution of 3 (2 00 g, 3 73 mmol) in 
THF (20 ml), triethyl orthoformate (1 10 g, 7 43 mmol) and a catalytic amount of PTS were added After 24 hours the 
reaction mixture was diluted with EtOAc (100 ml), washed with brine, dried over Na2S04 and concentrated in vacuo 
The residue was purified via chromatography (EtOAc/hexane 2/5), yielding 15 (I 80 g, 3 04 mmol, 82 %) and the 1-
deoxy analog of 15 (0 33 g, 0 63 mmol, 17 %) Compound 15 m ρ 56 °C, 'H-NMR (400 MHz, CDC1,) δ 7 72 (2H, m, 
H-Ph), 7 62 (IH, d, JS J i = 15 9 Hz, H5'), 7 43 (3H, m, H-Ph), 6 32 (IH, d, J6 s = 15 9 Hz, H6'), 5 73 (IH, s, H-C(OEt)), 
5 55 (IH, bs, H20a), ^ 34 (IH, bs, H5), 5 30 (IH, bs, H20b), 4 89 (IH, d, J 1 M = 9 2 Hz, H10), 4 27 (IH, d, J „ = 5 6 
Hz, H2), 4 21 (IH, d, J, ,0 = 9 2 Hz, H9), 3 63 (2H, m, 0-CH2(CH3)), 3 14 (IH, d, J3 2 = 5 6 Hz, H3), 2 88 (2H, bs, 
2H14), 2 14 (3H, s, H18), 1 98 (IH, m, H6), 1 77 (2H, m, H6 and H7), 1 60 (3H, s, H16), 1 49 (3H, s, acetonide), 1 44 
(3H, s, acetonide), 1 38 (3H, s, HI7), 1 23 (3H, m, (0-CH2)-CH,), 1 11 (3H, s, H19), FAB-MS, 615 [M+Na]\ Anal 
Caled for CJSHHO,, 0 5H20 C, 69 85, H, 7 54 Found С, 70 00, H, 7 75 
l,2-(Ethyl-orthobenzoate)-9,10-acetonide-5o>cinnamoyltaxicin-I (17). (I) To a solution of 3 (0 10 g, 0 19 mmol) 
in tnethyl ortobenzoate (5g, 22,3 mmol), a catalytic amount of PTS was added The reaction mixture was slowly heated 
to 80 °C After 48 hours no reaction had taken place, according to TLC (EtOAc/hexane 2/5) The reaction mixture was 
diluted by EtOAc (50 ml), washed with a NaHCOj-saturated solution, then washed with brine, dried over Na2S04 and 
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concentrated m vacuo The residue was purified via chromatography (EtOAc/hexane 2/5) The starting compound 3 
was fully recovered 
(II)To a solution of 3 (1 00 g, 1 87 mmol) and a catalytic amount of PTS in CH2CI2 (50 ml), triethyl orthobenzoate 
(840 mg, 3 73 mmol) was added The reaction mixture was stirred at reflux temperature After 48 hours no reaction had 
taken place, according to TLC (EtOAc/hexane 2/5) The reaction mixture was diluted with CH2C12 (25 ml), washed 
with a NaHCOj-saturated solution, then washed with brine, dried over N a ^ O , and concentrated m vacuo The residue 
was purified via chromatography (EtOAc/hexane 2/5) The starting compound 3 was fully recovered 
I^-(Benzylidene-acetal)-9,10-acetonide-5a-cinnamoyltaxicin-I (19). To a solution of the mixture of 3 and 18 
(5 0 g, 9 4 mmol) and PTS (10 mg, 0 05 mmol) in CH2C12 (75 ml), dimethyl acetal of benzaldehyde (2 8 ml, 18 6 
mmol) m CH2CI2 (10 ml) was slowly added at room temperature After one day the reaction mixture was washed with 
saturated NaHCO, solution, then washed with brine, dried over Na2SO„, and concentrated m vacuo The residue was 
purified by chromatography (EtOAc/hexane 2/5), yielding 18 (0 68 g, 1 3 mmol, 14 % ) " and 19 (4 98 g, 7 98 mmol, 
85 %) m ρ 108-110 °C, Ή-NMR (400 MHz, CDC13) δ 7 72 (H, m, H-Ph), 7 42 (8H, m, H-Ph), 7 62 (IH, d, ¡S-e = 
15 9 Hz, H5'), 6 34 (IH, d, J„, = 15 9 Hz, H6'), 5 80 (IH, s, H-(CPh)), 5 65 (IH, bs, H20a), 5 35 (IH, bs, H5), 5 28 
(IH, bs, H20b), 4 93 (IH, d, V , = 9 2 Hz, H10), 4 40 (IH, d, J2, = 5 4 Hz, H3), 4 33 (IH, d, J, ,„ = 9 2 Hz, H10), 3 21 
(IH, d, J32 = 5 3 Hz, H3), 2 78 (2H, bs, 2H14), 2 16 (3H, s, H18), 1 69 (3H, s, H16), 1 53 (3H, s, acetomde), 1 46 (3H, 
s, acetomde), 1 39 (3H, s, H17), 1 16 (3H, s, H19), FAB-MS, 625 [M+H]*, 647 [M+Na]*, Anal Caled for С „ Н „ 0 , С, 
74 98, H, 7 10 Found С, 74 63, H, 7 23 
Hydrolysis of 19 -• 20. To a solution of 19 (4 98 g, 7 98 mmol) in dry THF (60 ml), 20 N NaOH (aq) (25 ml) was 
added The reaction mixture was stirred at reflux temperature for 2 days The reaction mixture was subsequently diluted 
with water (50 ml) and extracted twice with CH2C12 (150 ml) The combined organic layers were washed with brine, 
dried over Na2S04, and concentrated in vacuo The residue was purified by chromatography (EtOAc/hexane 1/1), 
yielding 20 (3 00 g, 6 07 mmol, 76 %) m ρ 180 "С, Ή-NMR (400 MHz, CDC13) δ 7 43 (2H, m, H-Ph), 7 37 (3H, m, 
H-Ph), 5 79 (IH, s, H-(CPh)), 5 54 (IH, s, H20a), 5 10 (IH, s, H20b), 4 95 (IH, d, V , = 9 2 Hz, НЮ), 4 36 (IH, d, J 2 3 
= 5 4 Hz, H2), 4 30 (IH, d, J,_10 = 9 2 Hz, H9), 4 19 (IH, bs, H5), 3 34 (IH, d, 3,2 = 5 3 Hz, ИЗ), 2 70 (2H, s, 2H14), 
2 09 (3H, s, H18), 1 74 (4H, m, 2H6 and 2H7), 1 68 (3H, s, H16), 1 52 (3H, s, acetomde), I 47 (3H, s, acetomde), 1 36 
(3H,s,H17), 1 11 (3H, s, H19), FAB-MS, 495 [М+НГ, Anal Caled for C30H38O6 C,72 85,H,774 Found С, 7251, 
H, 8 00 
Protection of allylic alcohol 20 -> 21a. Entry 1 To a solution of 20 (0 10 g, 0 21 mmol) and NaOH (0 110 g, 2 75 
mmol) in dry toluene (5 ml), allyl bromide (30 μΙ, 0 34 mmol) was added The reaction mixture was stirred at reflux 
temperature After 42 hours, the reaction mixture was diluted with EtOAc (25 ml), washed with brine, dried over 
Na2S04 and concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 1/1) The starting 
compound 20 was fully recovered 
Entry 2 A solution of 20 (0 10 g, 0 21 mmol) and NaH (60 % dispersion in oil, 10 mg, 0 25 mmol) in dry THF (5 
ml) was stirred for 10 minutes at room temperature After which allyl bromide (36μ1, 0 41 mmol) was added The 
reaction mixture was stirred at room temperature After 42 hours, the reaction mixture was diluted with EtOAc (25 ml), 
washed with brine, dried over Na 2S0 4 and concentrated in vacuo The residue was purified via chromatography The 
starting compound 20 was fully recovered 
Entry 3 The same procedure was followed as for entry 2 Instead of stirring at room temperature, the mixture was 
stirred at reflux temperature No reaction took place, the starting compound 20 was fully recovered 
Entry 4 A solution of 20 (70 mg, 0 14 mmol) and dibutyltin oxide (60 mg, 0 24 mmol) in dry toluene (7 ml) was 
stirred for 12 hours at reflux temperature After which, allyl bromide (250 μΐ, 2 86 mmol) and tetrabutylammonium 
bromide (22 mg, 0 07 mmol) were added After stirring for 48 hours at reflux temperature, the reaction mixture was 
diluted with EtOAc (25 ml), washed with brine, dried over Na2S04 and concentrated in vacuo The residue was purified 
via chromatography (EtOAc/hexane 1/1) The starting compound 20 was fully recovered 
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Protection of allylic alcohol 20 -» 21b. Entry 5 To a solution of 20 (0 10 g, 0 20 mmol) and NaH (60 % 
dispersion in oil, 8 5 mg, 0 21 mmol) in dry THF, tetrabutylammonium iodide (12 mg, 0 030 mmol) and benzyl 
bromide (30 μΙ, 0 25 mmol) were added The reaction mixture was stirred at reflux temperature After 4 days, the 
mixture was diluted with EtOAc (25 ml), washed with brine, dried over NajSOj and concentrated in vacuo The residue 
was purified via chromatography (EtOAc/hexane 1/1) The starting compound 20 was fully recovered 
Dihydroxylation of 23 -* 22. To a solution of 20 (3 00 g, 6 07 mmol) in THF/H20 (80/40 ml), N-
methylmorpholine-N-oxide monohydrate (900 mg, 6 70 mmol) and a solution of Os04 (2 5 % in f-BuOH, 6 4 ml) were 
added The reaction mixture rapidly turned red After 20 hours, Flonsil (2 0 g), water (26 ml) and NajS204 (256 mg) 
were added The mixture was stirred for an additional 10 mm and then filtered The filtrate was diluted with a saturated 
solution of NH„Cl in water (100 ml) and extracted twice with EtOAc (150 ml) The combined organic layers were 
washed with brine, dried over ^ Б О д , and concentrated m vacuo The residue was purified by chromatography 
(EtOAc), yielding 22 (1 77 g, 3 35 mmol, 55 %) m ρ 133 "С, Ή-NMR (400 MHz, CDC13) 5 7 41 (5H, m, H-Ph), 5 86 
(IH, s, H-(CPh)), 4 85 (IH, d, J10., = 9 3 Hz, H10), 4 35 (IH, d, J23 = 4 7 Hz, H2), 4 23 (IH, d, J,.,,, = 9 3 Hz, H9), 4 08 
( 1 H, dd, J20. г» = 11 3 Hz, J20l^„20 = 2 7 Hz, H20a), 3 78 ( 1 H, bs, H5), 3 65 ( 1 H, s, C4-OH), 3 55 ( 1 H, dd, J20b 20, = 11 3 
Hz, J2M,OH»= » 8 Hz, H20b), 3 37 (IH, d, J,„. 14b = 19 3 Hz, H14a), 2 77 (IH, d, J14b ,„,= 19 2 Hz, H14b), 2 74 (IH, d, J, 
j = 4 7 Hz, H3), 2 35 (IH, dd, JOI12„.2o. = 2 8 Hz, -Wo2«, = 8 8 Hz, C20-OH), 2 05 (3H, s, HI8), 1 85 (IH, m, H6), 1 70 
(2H, m, H6 and H7), 1 67 (3H s, H16), 1 49 (3H, s, acetomde), 1 45 (3H, s, acetonide), 1 40 (3H, s, H17), 1 15 (3H, s, 
H19),FAB-MS, 551 [M+NaV\Anal Caled for C3OH40O„ H20 C, 65 90, H, 7 75 Found С, 66 26, H, 7 57 
Silylation and Mesylation of 22 to 23. A solution of imidazole (3 19 g, 46 8 mmol) and TBDMSCl (3 05 g, 20 3 
mmol) m DMF (30 ml) was stirred for 15 min Compound 22 (1 77 g, 3 35 mmol) was subsequently added After 3 h 
the reaction mixture was diluted with a solution of 10 % citric acid in water (200 ml) and extracted twice with EtOAc 
(100 ml) The combined organic layers were washed with brine, dried over Na2S04, and concentrated in vacuo The 
residue was purified by chromatography (EtOAc/hexane 2/5), yielding the silylated compound (2 03 g, 3 16 mmol, 94 
%) ) m ρ 61 "С, Ή-NMR (400 MHz, CDCI,) δ 7 45 (2H, m, H-Ph), 7 35 (3H, m, H-Ph), 5 78 (IH, s, H-(CPh)), 4 84 
(lH,d, J,0, = 93Hz, H10), 4 26(2H, m, H2 and H9), 4 18 (IH, d, J2 0 l 2 0 b = 9 1 Hz, H20a), 3 81 (IH, d, J14.l41, = 19 3 
Hz, H14a), 3 71 (IH, s, C4-OH), 3 58 (IH, bs, H5), 3 46 (IH, d, J20(b2O. = 9 1 Hz, H20a), 2 73 (IH, s, C5-OH), 2 65 
(lH,d,J,2 = 45Hz,H3) ,263( lH,d,J l 4 b M l = 194 Hz, H14b),2 05 (3H,s, H18), 1 86(lH,m,H6), 1 65 (3H, s, H16), 
1 50 (3H, s, acetonide), 1 45 (3H, s, acetonide), 1 36 (3H, s, H17), 1 08 (3H, s, H19), 0 75 (9H, s, /-BuSi), -0 07 (3H, s, 
SiMe), -0 22 (3H, s, SiMe), FAB-MS, 665 [M+Na]\ Anal Caled for C36HS40,Si С, 67 26, H, 8 47 Found С, 67 07, 
H, 8 83 
То a solution of the silylated compound (2 03 g, 3 16 mmol) in pyridine (50 ml) at 0 °C, methanesulfonyl chloride 
(2 5 ml) was added The reaction mixture was stirred for 20 hours at room temperature, after which CH2C12 (150 ml) 
was added The mixture was washed with a solution of 10 % citric acid in water (75 ml), with saturated NaHCO, 
solution, dried over Na2S04, and concentrated in vacuo The residue was purified by chromatography (EtOAc/hexane 
2/5), yielding 23 (1 91 g, 2 65 mmol, 84 %) m ρ 199 "С, Ή-NMR (400 MHz, CDCI3) δ 7 44 (2H, m, H-Ph), 7 36 
(3H, m, H-Ph), 5 79 (IH, s, H-(CPh)), 4 84 (IH, d, J I M = 9 3 Hz, H9), 4 81 (IH, bs, H5), 4 26 (IH, d, J, ,„ = 9 3 Hz, 
H9), 4 25 (IH, d, J2 j = 4 0 Hz, H2), 4 16 (IH, d, J20,20b =10 0 Hz, H20a), 3 74 (IH, d, J,4, „„= 19 4 Hz, H14a), 3 57 
(IH, d, J20b.20l =10 0 Hz, H20b), 3 51 (IH, s, C4-OH), 2 97 (3H, s, mesyl), 2 69 (IH, d, J14b M . = 19 4 Hz, H14b), 2 63 
(lH,d,JJ 2 = 4 0Hz, H3),2 10(3H,s, H18),2 01(1H, m, H6), 1 86(lH,m, H6), 1 68 (2H, m, 2H7), 1 65 (3H, s, H16), 
1 49 (3H, s, acetonide), 1 45 (3H, s, acetonide), 1 38 (3H, s, Н17), 1 12 (ЗН, s, Н19), 0 75 (9Н, s, /-BuSi), -0 06 (3H, s, 
SiMe), -0 20 (ЗН, s, SiMe), FAB-MS, 743 [M+Na]\ Anal Caled for C37HS6Ol0SiS C, 61 64, H, 7 83, S, 4 45 Found 
С, 61 35, H, 8 09, S, 4 47 
Construction of the Oxetane Ring: 23 to 24. To a solution of 23 (1 91 g, 2 65 mmol) in THF (75 ml), 
tetrabutylammonium fluoride ( I 0 g, 3 8 mmol) was added The reaction mixture was stirred for one hour at room 
temperature, after which EtOAc (150 ml) was added The organic layer was washed with saturated NaHCO, solution, 
dried over Na2S04, and concentrated in vacuo The residue was purified by chromatography (EtOAc/hexane 1/1), 
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yielding the desilylated compound (1 60 g, 2 64 mmol, 99 %) m ρ 116-120 "С, Ή-NMR (400 MHz, CDC13) δ 7 43 
(5H, m, H-Ph), 5 87 (IH, s, H-(CPh)), 4 95 (IH, bs, H5), 4 85 (IH, d, J I M = 9 3 Hz, H10), 4 35 (IH, d, J 2 3 = 4 8 Hz, 
H2), 4 23 (IH, d, J^.o = 9 3 Hz, H9), 4 06 (IH, dd, J2Oa.20tl = 11 8 Hz, J20^mo = 1 9 Hz, H20a), 3 68 (IH, dd, J20b.20. = 
11 8 Hz, )
m o H 2 0 = 9 8 Hz, H20b), 3 58 (IH, s, C4-OH), 3 31 (IH, d, J14, 14b = 19 3 Hz, H14a), 2 96 (3H, s, mesyl), 2 80 
(IH, d, J 1 4 M 4 . = 19 3 Hz, H14b), 2 66 (IH, d, J 3 , = 4 7 Hz, H3), 2 29 (IH, dd, J O H 2 M O l =2 0 Hz, Jo^j«, = 9 8 HZ, C20-
OH), 2 12 (3H, s, H18), 1 95 (3H, m, 2H6 and Н7), 1 67 (ЗН, s, H16), 1 50 (3H, s, acetonide), 1 45 (ЗН, s, acetonide), 
1 42 (3H, s, H17), 1 19 (3H, s, H19), FAB-MS, 629 [M+Na]\ Anal Caled for C3 1H4 201 0S C, 61 37, H, 6 98, S, 5 28 
Found С, 61 06, H, 7 08, S, 4 63 
То a solution of the desilylated compound (1 60 g, 2 64 mmol) in butanone (75 ml), tetrabutylammonium acetate 
(7 00 g, 23 3 mmol) was added The reaction mixture was stirred at reflux temperature for 17 hours The mixture was 
diluted with EtOAc (100 ml) and washed with a saturated solution of NH„CI in water The organic layer was dried over 
NajS04 and concentrated in vacuo The residue was purified by chromatography (EtOAc/hexane 2/5), yielding 24 
(0 85 g, 1 7 mmol, 64 %) m ρ 109 "С, Ή-NMR (400 MHz, CDCl,) 5 7 41 (5H, m, H-Ph), 5 87 (IH, s, H-(CPh)), 4 78 
(IH, dd, J , ^ = 8 4 Hz, J
s
^, - 2 0 Hz, H5), 4 70 (IH, d, J 1 M = 9 5 Hz, НЮ), 4 67 (IH, d, J2 0.2 O b = 8 4 Hz, H20a), 4 38 
(IH, d, J „ = 5 2 Hz, H2), 4 35 (IH, d, J2M,20i = 8 4 Hz, H20b), 4 33 (IH, d, J„.l0 = 9 5 Hz, H9), 3 13 (IH, d, J,4, ,4b = 
19 3 Hz, H14a), 2 72 (IH, s, C4-OH), 2 69 (IH, d, J 1 4 b . M .= 19 3 Hz, H14b), 2 10 (3H, m, 2H6 and H7), 1 95 (3H, s, 
H18), 1 90 (IH, d, Jj j = 5 2 Hz, H3), 1 69 (ЗН, s, H16), 1 62 (ЗН, s, acetonide), 1 52 (ЗН, s, acetonide), 1 47 (3H, s, 
H17), 1 39 (3H, s, H19), FAB-MS, 533 [M+Naf, Anal Caled for C,0H„O7 H 2 0 C, 68 15, H, 7 64 Found С, 67 80, 
H, 7 59 
Opening of the benzylidene acetal: 24 -> 25. (1) N-bromosuccinimide (NBS) To a solution of 24 (39 mg, 0 076 
mmol) in CCI, (5 ml), BaCOj (0 13 g, 0 95 mmol) and NBS (32 mg, 0 18 mmol) were added While stirring the 
mixture, water (8 μΐ) was added The mixture was irradiated, using a 200 Watt lamp After 1 hour, according to TLC, 
several products were formed, but the starting material was still present After 18 hours, the starting material was 
completely converted in a lot of products, which were not isolated or identified 
(II) Ozone (Oj) A solution of 24 (37 mg, 0 073 mmol) in EtOAc (5 ml) was stirred at room temperature Next, 
ozone, generated by a Fischer ozone generator (type 0500), was led through the mixture (rate of ozone lmmol/min) 
The reaction was followed via TLC (EtOAc/hexane 1/1) The first 10 minutes it appeared that about 50 % of 24 had 
reacted The major product at that time was 25 After 25 minutes, starting compound 24 was completely converted 
Compound 25, however, was also no longer present in the reaction mixture Instead, a mixture of products was formed, 
which were not isolated or identified 
(HI) 2,3-Dichloro-5,6-dicyano-l,4-benzoqumone (DDQ) To a solution of 24 (27 mg, 0 053 mmol) in CH2CI2 (2 5 
ml), water (1 ml) and DDQ (55 mg, 0 24 mmol) were added After 24 hours, an additional amount of DDQ (55 mg, 
0 24 mmol) was added After 48 hours the mixture was diluted with CH2CI2(15 ml), washed with water, washed with a 
saturated NaHCCysolution, dried over Na2S04 and concentrated in vacuo The residue was purified via 
chromatography (EtOAc/hexane 1/1), yielding 25 (3 9 mg, 0 0074 mmol, 14 %) with a recovery of 24 of 85 % 
(IV) Sodium perborate (NaBO, 4H20) To a solution of 24 (36 mg, 0 071 mmol) and Na2C03 (32 mg, 0 30 mmol) 
m toluene (4 ml), Ac20 (45 μΐ, 0 47 mmol) and NaBO, 4H 20 (43 mg, 0 28 mmol) were added The reaction mixture 
was stirred for 48 hours at 75 °C The conversion of 24 to 25 was confirmed via TLC, but was not completed The 
mixture was, therefore, stirred for an additional 48 hours at 90 °C The reaction mixture was diluted with EtOAc (15 
ml), washed with water, washed with brine, dried over Na2S04 and concentrated in vacuo The residue was purified via 
chromatography (EtOAc/hexane 1/1), yielding 25 (5 mg, 0 0095 mmol, 13 %) with a recovery of 24 of 28 % 
(V) Trityl fluoroborate (Ph3CBF4) To a solution of 24 (51 mg, 0 10 mmol) in CH3CN (5 ml), Ph3CBF4 (29 mg, 
0 088 mmol) was added After stirring for 24 hours 25 was spotted next to two unknown products while 24 was also 
still present After addition of extra Ph3CBF4 (53 mg, 0 16 mmol), compounds 24 and 25 disappeared A saturated 
NaHCOj-solution (10 ml) was added and the mixture was stirred for 10 minutes and then extracted twice with EtOAc 
(10 ml) The combined organic layers were washed with brine, dried over Na 2S0 4 and concentrated m vacuo The 
residue was purified via chromatography (EtOAc/hexane 3/1), yielding two products (3 and 5 mg respectively), which 
could not be identified by 'H-NMR 
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(VI) /-Butyl hydroperoxide (f-BuOOH) Three different catalysts were used, Pd(OAc)2, Pd(OCOCF3XOO/-Bu) and 
RuCl3nH20 Pd(OAc)2 and RuCl3nH20 are commercially available, Pd(OCOCF,)(00/-Bu) was synthesized as 
follows22 r-BuOOH (1 ml, 5 0-6 0 M in decane) was added to Pd(OCOCF3)2 (100 mg, 0 301 mmol) The mixture was 
stirred for 3 hours The formed orange crystals were collected after filtration, washed with n-pentane and dried m 
vacuo, yielding Pd(COCF3XOOf-Bu) (89 mg, 0 29 mmol, 96 %) 
- The procedure with Pd(OAc)2 To a solution of 24 (1 69 g, 3 31 mmol) in toluene (30 ml), i-BuOOH (660 μΐ, 5 0-
6 0 M in decane) and Pd(OAc)2 (74 mg, 0 33 mmol) were added The reaction mixture was stirred at 50 °C After 3 and 
6 hours, respectively, an additional amount of Pd(OAc)2 (74 mg, 0 33 mmol) was added After 18 hours water (50 ml) 
and EtOAc (75 ml) were added This two layer system was filtered over Hyflo, to remove the palladium species The 
water layer was extracted twice with EtOAc (30 ml) The combined organic layers were washed with brine, dried over 
Na2S04 and concentrated m vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), yielding 25 
(888 mg, 1 69 mmol, 51 %) with a recovery of 24 of 32 % 
- The procedure with Pd(OCOCF3XOO/-Bu) The same procedure was followed as with Pd(OAc)2, using 24 (35 
mg, 0 069 mmol) and Pd(OCOCF3XOOf-Bu) (3 times 2 0 mg, 0 0065 mmol) The yield of 25 was 14 % (5 0 mg, 
0 0095 mmol), with a recovery of 24 of 71 % 
- The procedure with RuClj nH20 The same procedure was followed as with Pd(OAc)2, using 24 (25 mg, 0 049 
mmol) and RuCI3 nH20 (3 times 1 0 mg, 0 0048 mmol) At 50 °C no reaction took place When the temperature was 
raised to 80 °C, several products were formed, which were not isolated nor identified 
Compound 25 m ρ 101-102 "С, Ή-NMR (400 MHz, CDCI,) δ 8 04 (2H, d, J = 7 5 Hz, H-ph), 7 59 (IH, t, J = 7 4 
Hz, H-ph), 7 46 (2H, dd, J = 7 7 Hz, J = 7 7 Hz, H-ph), 5 88 (IH, d, J23 = 5 0 Hz, H2), 4.74 (IH, d, J 1 M = 9 4 Hz, H10), 
4 64 (IH, dd, J« = 4 0 Hz, J« = 4 5 Hz, H5), 4 48 (IH, d, J, ,0 = 9 4 Hz, H9), 4 39 (IH, d, J20,20b = 8 3 Hz, H20a), 4 11 
(IH, d, J,«,,,, = 8 4 Hz, H20b), 3 62 (IH, d, J l4 l 14„ = 192 Hz, H14a), 2 71 (IH, s, C4-OH), 2 62 (IH, d, J l4b M. = 19 2 
Hz, H14a), 2 34 (IH, d, J32 = 5 1 Hz, H3), 2 08 (2H, m, H6), 1 96 (3H, s, H18), 1 87 (IH, s, Cl-OH), 1 73 (3H, s, 
H16), 1 56 (3H, s, acetonide), 1 50 (3H, s, acetomde), 1 47 (3H, s, H17), 1 33 (3H, s, H19), FAB-MS, 527 [M+H]\ 549 
[M+Nar, Anal Caled for C30H38O8 2H20 C, 64 04, H, 7 52 Found С, 64 49, H, 7 34 
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5 Synthesis of 7-Deoxypaclitaxel Analogs that 
possess the C2-Benzoate Group 
5.1 Introduction 
The synthesis of oxetane compound 1, outlined in chapter 4 (see 4.3, scheme 4.10 and 4.11), and 
the newly developed conversion of the benzy lidene acetal to the C2-benzoate analog 2 (scheme 5.1) 
using i-BuOOH in the presence of a catalytic amount of Pd(OAc)2, were reasons to set up new 
strategies for the synthesis of paclitaxel analogs, starting from 1. These analogs possess the C2-
benzoate group required for cytotoxic activity.' 
Scheme 5.1 
1 
V-0 
Pii" Ph' 
(a) /-BuOOH/Pd(OAc)2; 75 %, based on 68 % conversion. 
During the course of the present synthetic study SAR studies became available which showed 
that the substituent at C4 is also important for cytotoxic activity.2 Fortunately, for the introduction 
of the C4-acetate, only slight modifications of earlier strategies will be necessary. 
In this section, therefore, the strategies toward 7-deoxypacIitaxel analogs 3a-f (figure 5.1) in 
which the C2-benzoate group is present in all analogs and the C4-acetate is present in some cases, 
will be described, where the starting material will be oxetane compound 1. 
In order to convert 1 into 3a-f, the following reactions, given in random sequence, have to be 
accomplished: 
- The oxidative opening of the benzylidene acetal at C1,C2 (opening). 
- Stereoselective reduction of the СІЗ-carbonyl (reduction). 
- Coupling of the paclitaxel side chain (coupling). 
- Deprotection of the C9- and C10-hydroxyl groups (deprot C9.C10). 
- Acetylation of the C9- and C10-hydroxyl groups (acetyl C9,C10). 
- Acetylation of the C4-hydroxyl group (acetyl C4). 
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Deprotection of the C2'-hydroxyl group of the side chain after coupling (deprot C2'). 
Figure 5.1 
Ph 
О 
A 
Ph 
NH 
OH 
Pri ^ O 
3a R,, R2 = isopropyhdene ; R3 = H 
3b R,, R2 = isopropyhdene , R3 = Ac 
3c Ri = R2
 =
 R3 = H 
3d R, = R2 = H , R3 = Ac 
3e R, = R2 = Ac , R3 = H 
3f R, = R2 = Rj = Ac 
It is clear that the sequence of these reactions is important, because it determines if and how 
certain conversions can be accomplished. To give a clear picture of possible reaction sequences, i.e., 
strategies, leading to reasonable synthetic routes for the synthesis of 3a-f, table 5.1 has been set up. 
Table 5.1 Reaction sequences, leading to reasonable synthetic routes 
for the conversion of 1 into 3a-f 
Entry 
I 
la 
II 
Ha 
III 
Ilia 
IV 
1 
reduction 
reduction 
reduction 
reduction 
opening 
opening 
opening 
2 
coupling 
coupling 
opening 
opening 
reduction 
reduction 
deprot 
C9,C10 
3 
acetyl C4a 
acetyl C4a 
coupling 
coupling 
coupling 
coupling 
acetyl C9, 
C10(C4)a 
4 
deprot C2' 
deprot C2' 
acetyl C4a 
acetyl C4a 
acetyl C4a 
acetyl C4a 
reduction 
5 
opening 
opening 
deprot C2' 
deprot C2' 
deprot C2' 
deprot C2' 
coupling 
6 
-
deprot C9,C 10 
-
deprot C9,C 10 
-
deprot C9,C 10 
deprot C2' 
Prod. 
3a (3b) 
3c (3d) 
3a (3b) 
3c (3d) 
3a (3b) 
3c (3d) 
3e(3f) 
a
 The reaction in italic leads to the product between brackets 
The strategies mainly differ from each other by the order of their important reactions in the 
sequence namely, the reduction of the C13-carbonyl, coupling to the paclitaxel side chain and the 
opening of the benzylidene acetal. 
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Entries I and la can be carried out in the same way as was described in chapter 3 for the THP-
analogs. Reduction of the СІЗ-carbonyl by DIBALH, coupling of the paclitaxel side chain, 
acetylation of the C4-hydroxyl group (if desired), deprotection of the C2'-hydroxyl group, followed 
by opening of the benzylidene acetal, should lead to 3a or the C4-acetate analog 3b. Additional 
deprotection of the C9- and C10-hydroxyl groups should give 3c or the C4-acetate analog 3d. 
Problems are foreseen for the acetylation of the C4-hydroxyl group (see 3.2.5) and also for the 
oxidative opening of the benzylidene acetal, in the presence of the paclitaxel side chain. 
In entries II and Ha, the opening of the benzylidene acetal takes place after reduction of the С13-
carbonyl, using DIBALH, but before coupling of the taxane part to the paclitaxel side chain. Next, 
the C4-hydroxyl group can be, if desired, acetylated. Deprotection of the C2'-hydroxyl group will 
yield 3a or, if desired, 3b. Furthermore, deprotection of the C9- and C10-hydroxyl groups will give 
3c or, if desired, 3d. 
In entries III, Ilia and IV, first the benzylidene acetal at C1,C2 will be opened to give the 
benzoate compound 2, scheme 5.1. Because of the presence of the benzoyl group at C2, DIBALH 
can no longer be used as a reducing agent. If a suitable reduction method could be found in entries 
III and Ilia the reduced compound then can be coupled to the paclitaxel side chain. If desired, 
acetylation of the C4-hydroxyI group, followed by deprotection of the C2'-hydroxyl group will 
afford 3a or 3b. Deprotection of the C9- and ClO-hydroxyl groups will give 3c or 3d. 
In entry IV, after opening of the benzylidene acetal at C1,C2 to 2, scheme 5.1, the isopropylidene 
functionality at C9,C10 will be hydrolyzed, followed by acetylation of the deprotected hydroxyl 
groups at these positions and, if desired, of the C4-hydroxyl group. Then the C13-carbonyl can be 
reduced. Coupling of the reduced compound to the paclitaxel side chain followed by deprotection of 
the C2'-hydroxyl group will result in 3e or, if desired, in 3f. 
5.2 The Different Strategies and The Resulting Synthetic 
Routes 
In this section, each strategy, i.e., each entry of table 5.1, with its synthetic route will be 
elaborated in detail in separate sub-sections. 
Based on the three important reactions mentioned above and the notion that coupling of the 
paclitaxel side chain can only take place after reduction of the СІЗ-carbonyl, there are three realistic 
strategies: 
- Reduction, Coupling and Opening (Entry 1(a)); section 5.2.1 
- Reduction, Opening and Coupling (Entry 11(a)); section 5.2.2 
- Opening, Reduction and Coupling (Entry 111(a)); section 5.2.3 
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A fourth strategy is a variant of the Opening, Reduction and Coupling Strategy (Entry IV) and 
will be discussed in section 5.2.4. 
In the sections 5.2.1-5.2.4, it will become clear that in all strategies, the reduction of the C13-
carbonyl is the key step. Because of the important role of these reduction reactions, the results of 
these reactions will be discussed and rationalized in section 5.3. 
5.2.1 Reduction, Coupling and Opening (Entry 1(a)) 
The synthetic route belonging to the first strategy is comparable to the one leading to the THP-
analogs, discussed in chapter 3.3 Reduction of 1, using DIBALH, yielded α-isomer 4a in 46 % and 
the ß-isomer 4b in 9 % (scheme 5.2). When the reduction was carried out with NaBH4, the α-isomer 
4a was not detected, while the p-isomer 4b was isolated in 70 % yield. 
Scheme 5.2 
(al) DIBALH/-10 °C; 46 % (4a); 9 % (4b). (all) NaBH4/MeOH/RT; 70 % (4b). (b) DCC/DMAP; 70 %. (ci) 
Ac20/DMAP; no reaction, (ell) AcCl/DMAP/pyridine; no reaction, (d) H20/HOAc/THF : 2/4/1,40 °C; 68 %. 
Coupling of 4a to the protected paclitaxel side chain 5, in the presence of DCC and DMAP, 
afforded protected 7-deoxypaclitaxel analog 6 in 70 % yield.4 
Treatment of 6 with a 2/4/1 mixture of H20/HOAc/THF at 40 °C gave 7 in 68 % yield. 
Compound 7 as such was tested for its cytotoxic activity (section 5.4). The structure of 7 is 
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presumed to be as depicted m scheme 5 2 The configurations at C4, C5, C13 and C4' (for 
numbering see 7, scheme 5 2) were confirmed by NOE difference experiments The following NOE 
contacts were observed H(2)-H(9), H(2)-CH3(16), H(2)-CH3(19), H(2)-H(4'), H(9)-CH,(19), 
H(13)-H(14ß), H(13)-CH3(17), H(14ß)-CH3(17) and CH3(19)-H(20p) The configuration at C13 
must be S, as no NOE contact is possible between H(13) and CH3(17) in the case of the R-
configuration5 The configuration at C4' must also be the S because of the NOE contact between 
H(4') and H(2) In the R-configuration these protons are in /raws-position, such a NOE contact, 
therefore, is not possible The S-configuration was assigned to C4 and the R-configuration to C5 
because of the NOE contact between CH3(19) and H(20ß) 
In order to synthesize the C4-acetate analogs 3b and 3d (figure 5 1) it was tried to acetylate the 
C4-hydroxyl group of compound 6, in which all the other hydroxyl groups are either protected or 
functionalized Using either Ac20 or AcCl in the presence of DMAP this acetylation could not be 
achieved As was stated in chapter 3, in this case also the formation of a hydrogen bond between the 
C4-hydroxyl group and the ester carbonyl of the side chain possibly prevents the acetylation of the 
C4-hydroxyl group6 
In order to introduce the C2-benzoate group, the C2'-hydroxyl group of 6 was first deprotected, 
using a 2/2/1 mixture of H20/HOAc/THF at room temperature, affording 8 in 73 % yield (scheme 
5 3) Otherwise the 1-ethoxyethoxy group, which is also an acetal, could be oxidized yielding the 
C2'-acetyl analog 
Scheme 5.3 
О 
Pri NH О 
-* P h ^ S ^ O - / ri γ ^ Ό"· 
OH 
О 
U 
Ρ Ι Γ Α Ν Η О 
P h ^ Y O . 
он 
(a) HjO/HOAc/THF 2/2/1, RT, 73 % (b) /-BuOOH/Pd(OAc)2, 62 %, based on 45 % conversion 
Oxidative opening of the benzylidene acetal at C1,C2 of 8, using r-BuOOH in the presence of a 
catalytic amount of Pd(OAc)2, resulted in compound 3a Compound 3a was not further converted to 
the C9,C10 deprotected analog 3c (figure 5 1, ρ 105) ' 
The conversion of 8 into 3a was accomplished in 62 % yield, based on 45 % conversion, whereas 
the conversion of 1 to 2 (scheme 5 1) was realized in 75 % yield, based on 68 % conversion These 
results may suggest that opening of the benzylidene acetal will proceed with higher conversion in 
the absence of the paclitaxel side chain In the next strategy, therefore, this opening will be carried 
out m an earlier stage 
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5.2.2 Reduction, Opening and Coupling (Entry 11(a)) 
In the strategy outlined in this section the opening of the benzylidene acetal is planned to be 
carried out immediately after the reduction of the СІЗ-carbonyl. In this way DIBALH still can be 
applied for the reduction of the C13-carbonyl of 1, leading to compound 4a (scheme 5.2). 
Subsequently the benzylidene acetal at C1.C2 of 4a has to be opened to give compound 9a 
(scheme 5.4). Next, compound 9a has to be coupled to the paclitaxel side chain, after which 
deprotection of the C2'-hydroxyl group and the C9-, ClO-hydroxyl groups should lead to 3a and 3c, 
respectively. Introduction of the C4-acetate group will not be possible in this strategy. Acetylation 
of 4a will lead to the C13-acetate compound and acetylation in the presence of the paclitaxel side 
chain is not possible as was mentioned before. 
Treatment of 4a with f-BuOOH in the presence of a catalytic amount of Pd(OAc)2 indeed 
afforded 9a, however in a yield of only 10 % (with 43 % recovery of 4a) (scheme 5.4). Coupling of 
9a to the protected paclitaxel side chain was not carried out since the synthesis of 3a and 3c is more 
successful (higher overall yields) via the strategy described in section 5.2.1. 
» 3a + 3c 
.0 
5.2.3 Opening, Reduction and Coupling (Entry 111(a)) 
In the previous sections (5.2.1 and 5.2.2) it appeared that reduction of СІЗ-carbonyl has a 
negative effect on the opening of the benzylidene acetal at C1,C2.8 In the third strategy, therefore, 
the reaction sequence will be started with the opening of the benzylidene acetal of compound 1, 
leading to compound 2 (scheme 5.1). Next, the reduction of the СІЗ-carbonyl of 2 affording 9a, 
which is of course the key step in this strategy, has to be achieved (scheme 5.5). 
Once compound 9a has been isolated, coupling of the protected paclitaxel side chain, followed 
by deprotection of the hydroxyl groups will result in the 7-deoxypaclitaxel analogs 3a and 3c, 
respectively (figure 5.1). If the route toward 3a and 3c is successful then the C4-acetate group in 2 
can be introduced which will lead to 10. Reduction of 10 will afford 11, which can be converted 
into the 7-deoxypaclitaxel analogs 3b and 3d in a similar way as is described for 3a and 3d. 
Scheme 5.4 
HO" 
(a) /-BuOOH/Pd(OAc)2/50 °C; 10 % (43 % recovery of 4a). 
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Scheme 5.5 
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For the reduction of the C13-carbonyl of 2, DIBALH cannot be used, because of the expected 
concomitant reduction of the C2-benzoate group. In the literature, NaBH4 has been successfully 
used in taxane chemistry for the selective reduction of the С13-carbonyl, whether or not in the 
presence of CeCl3.' 
Although in section 5.2.1 it was shown that compound 1 was selectively reduced by NaBH4 to 
the undesired ß-isomer 4b (scheme 5.2), NaBH„ was tried for the reduction of 2. It was hoped that 
the opening of the benzylidene aceta! to the corresponding C2-benzoate would make the taxane 
skeleton less rigid and therefore less flat and that this would influence the stereoselectivity of the 
reduction.10 
Treatment of 2 with NaBH4 yielded the α-isomer 9a in 18 % and the ß-isomer 9b in 26 % yield 
with 24 % recovery of 2 (scheme 5.6), showing that the opening of the benzylidene acetal indeed 
had some influence on the a/ß-ratio. 
Scheme 5.6 
a! 
HO" 
all 
+ HO' 
(al) NaBH/0 °C; 24 % (9a); 34 % (9b); based on 76 % conversion, (all) NaBH/CeCt/O °C; 11 % (9a); 49 % 
(9b); based on 70 % conversion. 
Addition of CeClj to the mixture prior to NaBH4, can have a tremendous effect on the 
stereoselectivity of the reduction reaction in general." Moreover, in taxane chemistry it has been 
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found that CeCl3 often leads to an inversion of the α/β-ratio.
12
 However, for the reduction of 2, in 
the presence of CeCl3, the ratio of 9a/9b (α/β) became even worse. In the presence of CeCl3, 9a was 
isolated in only 8 % yield, while the yield of 9b was increased to 34 %. The recovery of 2 was 30 
%. As the results of these reduction reactions, which were carried out on a small scale, were 
disappointing, the reduction of 2 using NaBH4 was not scaled up and also the reaction sequence, 
depicted in scheme 5.5, was not completed. 
5.2.4 Variant of the Opening, Reduction and Coupling Strategy (Entry IV) 
It was shown in the preceding sections that opening of the benzylidene acetal had a positive 
influence on the α/β-ratio in the reduction of the СІЗ-carbonyl, using NaBH4. It, therefore, was 
reasoned that removal of the isopropylidene acetal at C9,C10 of 2, before the reduction of the С13-
carbonyl (scheme 5.7), might make the taxane skeleton even less rigid and therefore again might 
influence the α/β-ratio in the reduction reaction. 
Treatment of 2 with a 5/1/2 mixture of HOAc/THF/H20 at 55 °C yielded 12 in 60 %, with 29 % 
recovery of 2. Prior to reduction of the СІЗ-carbonyl, the C9- and C10-hydroxyl groups have to be 
protected again, otherwise the reduction would lead to the product in which three secondary 
hydroxyl groups viz. at C9, CIO and С13, are present, which will complicate the coupling to the 
paclitaxel side chain. Acetyl groups were used for the protection of the C9- and C10-hydroxyl 
groups, for the following reasons: 
- It is known from the literature that an acetate at CIO has minor effects on the selectivity of the 
reduction of the C13-carbonyl.' 
- It would be possible to introduce the C4-acetyl group simultaneously with the protection of the 
C9- and C10-hydroxyl groups. 
- SAR studies suggest that acetoxy groups at the C9- and C10-position have no negative effects on 
cytotoxic activity. 
To achieve this acetylation, compound 12 was treated with Ac20 in the presence of DMAP. By 
adding 1 equivalent of Ac20 at room temperature it was hoped to acetylate selectively the more 
acidic C10-hydroxyl group."13 Unfortunately, TLC indicated that a mixture of three products had 
been formed, probably a mixture of the two mono-acetylated products and the C9,C10-di-acetylated 
product. By adding more equivalents of Ac20, the two proposed mono-acetylated products 
disappeared and the di-acetylated product 13 was isolated in 96 % yield. When the reaction was 
performed at 40 °C for 24 hours, in addition to compound 13 (28 %), the C4-acetylated compound 
14 (36 %) was also isolated.14 
The next step in this route is the selective reduction of the СІЗ-carbonyl of the compounds 13 
and 14. These reduction reactions were first explored on a test scale using the following reducing 
agents: NaBH4 (whether or not in the presence of CeCl3),9 L-selectride,15 K-selectride,15 
NaB(OCH3)3H16 and NaB(OCOCH3)jH.5 With exception of the NaBHrexperiments, no reaction 
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took place in the other cases, probably because the substituents at the boron atom are too bulky and 
therefore these substituted boron hydrides cannot approach the C13-carbonyl. The reduction 
reactions using NaBH4 whether or not in the presence of CeCl3 showed some selectivity as was 
observed by TLC. For that reason, these reactions were repeated on a larger scale. 
Scheme 5.7 
HO OH 
(a) AcOH/THF/HjO : 5/1/2, 55 °C; 85 %; based on 71 % conversion. (Ы) Ac20/DMAP; 96 %. (ЫІ) Ac2O/DMAP/40 
°C; 28 % (13); 36 % (14). (ci) NaBH«/MeOH/0 °C; 19 % (15a); 33 % (15b). Cell) NaBH4/CeCl,/MeOH/0 °C; 63 % 
(15a); 24 % (15b). (d) ΝβΒΗ,/ΜβΟΗ/Ο °C; 28 % (16a); 22 % 15a; 16b was not detected; based on 72 % conversion. 
When reduction of 13 was carried out under Luche conditions'0"1 (NaBH, in methanol) the 
desired α-isomer 15a was isolated in only 19 % yield, whereas the undesired ß-isomer 15b was 
obtained in 33 % yield. As in the case of 2, the reduction of 13 was repeated in the presence of 
CeCl3, which was added prior to NaBH4. In contrast to the results of analogous reduction of 2, the 
diastereoselectivity and therefore the α/β-ratio was completely reversed and in favor of the a-
isomer. Compound 15a (α-isomer) was isolated in 63 % yield and compound 15b (ß-isomer) in 24 
% yield. The configuration at C13 of 15a was determined by NMR-spectroscopy. From the 
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literature it is known that the proton absorption signal of H13 of the α-isomer is shifted for about 
0.5 ppm to low field with respect to the absorption of HI 3 of the ß-isomer.12' Indeed, proton 
absorption of H13 was observed at 4.55 ppm for 15a and at 4.21 for 15b. The configuration at C13 
for 15a was confirmed by a NOE difference experiment. A NOE contact was observed between 
H(13) and CH3(17), which is only possible for the α-isomer 15a.17 
Reduction of the C4-acetylated compound 14 was accomplished by NaBH4, yielding a mixture of 
at least five products, from which the α-isomer 16a was isolated in 20 % yield, and the diacetylated 
α-isomer 15a in a yield of 16 % with 28 % recovery of 14. The other products, which could not be 
identified by 'H-NMR, did not contain the ß-isomer, indicating that the reduction of 14 proceeded 
completely diasteroselectively favoring the α-isomer. This reaction, therefore, was not repeated in 
the presence of CeCl3. The formation of 15a is probably due to the excess NaBH4, which caused 
also removal of the C4-acetate group.18' Unfortunately, the isolated amount of 16a was only 23 mg. 
After the necessary analysis, the amount of 16a was too small, to continue the reaction sequence 
toward 7-deoxypaclitaxel analogs possessing the C4-acetate group.18b 
Therefore, another route was also tried in which 16a is synthesized from 15a (scheme 5.8), 
analogous to the acetylation of the C4-hydroxyl group of baccatin III analogs described in 
literature.2"·5·619 
Scheme 5.8 
15a ». EUSiO 
AcO OAc 
AcO 
AcO OAc 
•%+- Et3SiO" 16a 
(a) EtjSiCI/imidazole/DMF; 100 %. (b) Ac20 and AcCl, respectively, under various reaction conditions, (c) HF. (d) 
AcCl/2.5 eq of LiN(SiMe3)2; 66 %; based on 15 % conversion. 
Before acetylation of the C4-hydroxyl group of 15a, first the C13-hydroxyl group was protected, 
using triethylsilyl chloride in the presence of imidazole,20 yielding compound 17 quantitatively. 
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Then the acetylation of the C4-hydroxyl group of 17 using various reaction conditions to obtain 
compound 18 was investigated. No reaction took place when 17 was treated with Ac20 in the 
presence of DMAP13 or with AcCl in the presence of 1 equivalent 1,1,1,3,3,3-hexamethyldisilazane 
lithium salt (LiN(SiMe3)2),21. Treatment of 17 with AcCl in the presence of 2.5 equivalents 
LiN(SiMe3)2 resulted in partial deprotection, followed by acetylation of the C13-hydroxyl group, 
yielding compound 19 in a yield of 10 %, with a 85 % recovery of 17.22 
In the recent literature another method is described that is appropriate for the acetylation of 
hindered tertiary hydroxyl groups.23 In analogy herewith, compound 17 was treated with Ac20 in 
the presence of a catalytic amount of scandium(IH)triflate (Sc(OS02CF3)j), resulting in a mixture of 
many products, which were not further identified. 
To obtain new 7-deoxypaclitaxel derivative(s), having at least the C2-benzoate group, 
compound 15a was coupled to the protected paclitaxel side chain 5 (scheme 5.9). 
Scheme 5.9 
AcO OAc AcO OAc 
PIT NH О 
HO ¿ 'НО ^ Ph-^ -NH О 
1 15а " Ч " 4 " ^ 
Р п ^ О s 
PIT ^ f 'ОН 
OŒ 
h |—20 R = EE 
L»>21 R = H 
(a) DIPC/DMAP; 79 % (20). (b) AcOH/THF/H20 : 2/1/2; 85 % (21) 
In the presence of diisopropylcarbodiimide (DIPC)24 and DMAP compound 20 was formed and 
isolated in 79 % yield. Deprotection of the C2'-hydroxyl group afforded compound 21 in 85 % 
yield. 
Coupling of compound 15b to the protected paclitaxel side chain 5, in the presence of DCC and 
DMAP resulted in protected 7-deoxy-13-epi-paclitaxel analog 22 (scheme 5.10). The yield of the 
13-epi-isomer 22 is higher than that of compound 20 (79 %) shown in scheme 5.9, which can be 
ascribed to the better accessibility of the paclitaxel side chain toward the ß-hydroxyl group of 15b.5 
Treatment of 22 with a mixture of AcOH/THF/H20 : 2/1/2 yielded 7-deoxy-13-epi-paclitaxel 
analog 23 in 56 % yield with 19 % recovery of 22. 
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Scheme 5.10 
AcO OAc AcO OAc 
Pri NH О 
о 
U 
Ph"^NH О 
. ÔEE 
.1—22 R = ЕЕ 
b L»-23 R = H 
(a) DCC/DMAP; 95 %. (b) AcOH/THF/H20 : 2/1/2; 69 %; based on 81 % conversion. 
5.3 The Reduction of the C13-carbonyI and Acetylation of 
the C4-hydroxyl Group; Discussion 
Reduction 
In all strategies described in section 5.2, the reduction of the СІЗ-carbonyl appeared to be a key 
step. Because of the importance of this reaction, in this section the results of the several reduction 
reactions will be compared. 
In general, the approach of the C13-carbonyl by a reducing agent is less sterically hindered from 
the upper side due to the inverted cup shape of the molecules, than from the bottom side. For this 
reason α-isomer 4a was the major product in the reduction of 1, using DIBALH (scheme 5.2). 
When compound 1 was reduced with NaBH„, however, only ß-isomer 4b was isolated. Although 
NaBH4 is smaller than DIBALH and some formation of the ß-isomer could be expected, complete 
ß-stereoselectivity was surprising. In the literature it is known that a hydroxyl group in the 
neighborhood of a carbonyl that has to be reduced may be able to assist in the hydride transfer, due 
to co-ordination of this hydroxyl group to the reducing agent.25 For the reduction of 1 with NaBH4, 
this means that the C4-hydroxyl group co-ordinates on the boron atom (figure 5.2). 
Figure 5.2 Transition state model of the reduction of 1, using NaBH4. 
A-
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The space between the C4-hydroxyl group and the C13-carbonyl must be such that the co-
ordinated boron hydride can be rotated toward the C13-carbonyl to deliver the hydride, resulting in 
the complete stereoselective reduction of the C13-carbonyl, leading to the ß-isomer. In the case of 
DIBALH, co-ordination to the C4-hydroxyl group does not take place or, most likely, the co-
ordinated DIBALH does not fit in the space between the C4-hydroxyl group and the C13-carbonyl. 
Therefore, this reduction is determined by steric hindrance, as mentioned above. 
Compound 13 (scheme 5.7), with the benzylidene acetal opened as well as the isopropylidene 
acetal removed, is supposed to be flatter than compound 1. This means also that the space between 
the C4-hydroxyl group and the СІЗ-carbonyl is larger and that the co-ordinated boron hydride is 
further removed from the СІЗ-carbonyl, so that delivery of a hydride by the co-ordinated boron 
hydride may be less efficient than in the case of 1. Therefore, some reduction may also take place 
from the upper side, leading to a mixture of the a- and the ß-isomer, in which the latter is still the 
major compound. However, when CeCl3 was added prior to NaBH4, the α/β-ratio was reversed, 
which may indicate that CeCl3 was co-ordinated to the C4-hydroxyl group
26
 and that this co­
ordinated CeCI3 fits well in the space between the C4-hydroxyl group and the C13-carbonyl group 
so that the bottom side of the C13-carbonyl is shielded. That can explain why in this reduction 
reaction the α-isomer 15a was the major compound. 
For compound 2 (scheme 5.6) in which the benzylidene acetal is opened but with the 
isopropylidene acetal still present, the inverted cup shape is proposed to be flatter than for 
compound 1, but less flat than for compound 13. For the reduction of 2 with NaBH4 the same 
explanation can be given as in the analogous reduction of 13, for the formation of a mixture of the 
a- and the ß-isomer, again in favor of the ß-isomer. However, the addition of CeCl3 to 2 prior to 
NaBH4, did not give the expected reversion of the α/β-ratio. On the contrary, it had even a slight 
negative influence, indicating a more complicated behavior of CeCl3 with 2 than with 13. 
In the reduction of 14, using NaBH4, the C4-acetate group apparently functions like CeCl3 in the 
reduction of 13, giving even better shielding of the bottom side of the C13-carbonyl, leading 
exclusively to the α-isomer 16a. The yield of 16a was somewhat disappointing (28 %, based on 72 
% conversion), although this reaction still has to be optimized. 
Acetylation 
The disappointing results of the acetylation of the C4-hydroxyI group of 17, which should have 
given 18 (scheme 5.8), are in contrast with the C4-acetylation of 24, carried out by Chen et al,21 
which produced 25 in 75 % (scheme 5.11), 
116 
Synthesis of 7-Deoxypaclitaxel Analogs that possess the C2-Benzoate Group 
Scheme 5.11 
AcO О OSiEt·. 
Et3SiO" 
AcO О 
Et3SiO" 
MeîHSiO
 0 HO 
iv 24 
P h ^ O 
OSiEta 
Me2HSiO ¿ О 
25 
Ph·" ^ O 
(a) LiN(Si(CH3)3)2/0 °C, cyclopropanecarbonyl chloride; 75 %. 
χ χ 
It is assumed that the protecting group at the Cl-hydroxyl group, as well as the protected 7-
hydroxyl group in 24, does not have any influence on the C4-acetylation. Therefore, the difference 
in reactivity of 17 and 24 is determined by the substitution pattern at C9. It seems that the cc-acetoxy 
group at C9 instead of a carbonyl at this position prevents the acetylation of C4-hydroxyl group. An 
explanation could be that in compound 17 a hydrogen bond between the C4-hydroxyl group and the 
carbonyl of the C9-acetoxy group prevents the acetylation of the C4-hydroxyl group. The presence 
of this hydrogen bond is supported by model studies.27 In 24 such a hydrogen bond is not possible. 
5.4 Evaluation of 7-Deoxypaclitaxel Analogs 3a, 7, 8, 21 and 
23 
To determine their cytotoxic activity, the analogs prepared in the preceding sections were tested 
against seven well-characterized human tumor cell lines: MCF7 (breast cancer), EVSA-T (breast 
cancer), WIDR (colon cancer), IGROV (ovarian cancer), Ml9 MEL (melanoma), A498 (renal 
cancer), H226 (Non-small cell lung cancer). The determination of the cytotoxicity was carried out 
by Kolker H.J.; Verweij, J.; Stoter, G. and Schellens, J.H.M, from the laboratory of Experimental 
Chemotherapy and Pharmacology, Department of Medical Oncology. Rotterdam Cancer Institute 
(Dr. Daniel den Hoed Kliniek).28 
The benzylidene analogs 7 ( scheme 5.2) and 8 (scheme 5.3), side products in the synthetic route 
toward analog 3a, were tested for their activity because of the two acetal oxygens at C1,C2 which 
are in about the same spatial position as the two oxygens of the benzoate group in paclitaxel. 
Furthermore, the hydrophobic phenyl group may act as a substitute for the phenyl group of the 
benzoate function.29 These analogs, however showed very low cytotoxic activity against the cell 
lines mentioned above. The IDJ0-values of these analogs were 10,000-20,000 times higher than the 
ID50 of paclitaxel, which was < 3ng/ml for all cell lines. Similar to the analogs in chapter 3, the 
absence of activity for the analogs 7 and 8 was therefore attributed to the missing C2-benzoate 
group. 
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However, recent SAR studies showed (concurrent with our investigations), that the C4-acetyl 
group of paclitaxel also has a significant influence on cytotoxic activity. 4-Deacetylpaclitaxel 
appeared to be about 100 times less active than paclitaxel2,3° 
With the exception of the C4-acetate group, the analogs 3a and 21 possess all other functions, 
important for activity. These include the oxetane ring, the paclitaxel side chain, a free C2'-hydroxyl 
group and a C2-benzoate group. The absence of the 7-hydroxyl group is thought not to have a 
negative effect on cytotoxic activity, because 7-deoxypaclitaxel is slightly more active than 
paclitaxel31 (figure 5.3). Furthermore, in compound 3a the isopropylidene acetal, and in compound 
21 the acetyl groups at the C9- and ClO-hydroxyl groups are most likely not responsible for the low 
cytotoxic activity since 9-0-methyl-9(R)-dihydropaclitaxel is even more active than 10-deacetyl-
9(R)-dihydropaclitaxel and paclitaxel, respectively.32 It was hoped that the positive effects of the 
substitution pattern at position 7,9 and 10 could balance the negative effect of the missing acetate at 
C4. 
Although, 3a and 2133 also showed improvement they still have very low cytotoxic activity with 
ID30-values which were at least 5,000 times higher than for paclitaxel. It seems that the missing 
acetate at C4 is the major factor that accounts for the low cytotoxic activity. 
Figure 5.3 
Ph 
О 
Л 
R,0 
NH О 
Ph AAvT-
OH 
R, = OH, paclitaxel 
Ri = Η , 7-deoxypaclitaxel 
R2 = Ac, R3 = Me, R4 = Ac , 9-0-methyl-9(R)dihydropachtaxel 
R2 = H, R3 = H, R4 = Ac, 10-deacteyl-9(R)-dihydropachtaxel 
R2 = Ac, R3 = H, R4 = Η , 4-deacetyl-9(R)-dihydropaclitaxel 
R2 = Ac, R3 = H, R4 = Ac , 9(R)-dihydropachtaxel 
Compound 
paclitaxel 
7-deoxypaclitaxel 
9-0-methyl-9(R)-dihydropaclitaxel 
10-deacetyl-9(R)-dihydropaclitaxel 
4-deacetyl-9(R)-dihydropaclitaxel 
9(R)-dihydropaclitaxel 
IDM 
P-388 
9.0 
2.0 
7.8 
140 
> 1000 
49 
(ng/ml) 
A549 
2.5 
-
-
11 
>1000 
-
Reference 
30 
31 
31 
32 
32 
'ID ;o Drug concentration required to inhibit cell proliferation to 50 % vs untreated cells (37 
°C, 72 h) bP-388 mouse lymphocytic leukemia, A549 human breast cancer 
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Recently a similar result was reported by Klein et al. who had synthesized 4-deacetyl-9(R)-
dihydropaclitaxel34 (figure 5.3), which has a structure very similar to 3a and 21. Also, 4-deacetyl-
9(R)-dihydropaclitaxel showed very low cytotoxic activity, with an ID50 of > 1000 ng/ml, compared 
to paclitaxel, with an ГО^ of 9.0 ng/ml against P-388 cells. Because 9(R)-dihydropaclitaxel has an 
ID50 of 49 ng/ml against P-388 cells, the low activity of 4-deacetyl-9(R)-dihydropaclitaxel was 
ascribed to the missing C4-acetate group. 
In line with the literature concerning 13-epi-paclitaxel analogs,5 23 showed no cytotoxic activity, 
due to the missing C4-acetyl group as well as to the R-configuration at C13. 
5.5 Conclusions 
In this chapter it has been shown that it is possible to apply the benzylidene acetal for both the 
protection of the CI- and C2-hydroxyl groups as well as for the introduction of the benzoate 
functionality at C2, in the syntheses of 7-deoxypaclitaxel analogs that possess the C2-benzoate 
group, starting from crude taxine. For this purpose four strategies were studied. 
The reduction of the C13-carbonyl group appeared to be the key step in the synthetic routes, 
thereby determining whether or not a synthetic route is successful. The results, such as selectivity 
and yield, of the reduction reactions depend on the substitution pattern of CI, C2, C4, C9 and CIO. 
Therefore, from the four outlined strategies in section 5.2, only two were successfully completed. 
Strategy I, the Reduction, Coupling and Opening strategy resulted in the analogs 3a, 7 and 8. 
Strategy IV, the Opening, Reduction and Opening strategy resulted in the analogs 21 and 23. 
The unexpected low cytotoxic activity of 3a and 21, demonstrates that it is difficult to predict the 
cytotoxic activity of paclitaxel analogs that have modifications at several positions, by combining 
results of the cytotoxic activity tests of single-modified analogs (also see 2.2.2). The absence of 
activity of 3a and 21 is attributed to the missing C4-acetate group, which is in line with recent 
results reported in the literature.2'30·3,1 
As is shown in section 5.2.4, strategy IV will enable the synthesis of analogs that possess the C4-
acetate group which is important for cytotoxic activity. During the writing of this thesis the repeat 
of the reaction sequence of strategy IV on a larger scale was ongoing. The increase in scale will 
enable the optimization of the reduction of 14 to 16a (scheme 5.7) which then can be converted to 
7-deoxy-9-acetyl-9(R)-dihydropaclitaxel. 
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5.6 Experimental Section 
Proton magnetic resonance spectra were measured on a Bruker AC-100 or a Braker AM-400 
spectrometer Chemical shift values are reported as δ-values relative to tetramethylsilane as an 
internal standard; deuterochloroform was used as solvent. Mass spectra were obtained with a double 
focusing VG 7070E spectrometer. Elemental analyses were carried out on a Carlo Erba Instruments 
CHNSO EA 1108 element analyzer. For the determination of optical rotations a Perkin-Elmer 241 
Polarimeter was used. Melting points were determined with a Reichert Thermopan microscope and 
are uncorrected. Thin layer chromatography was carried out on Merck precoated silica gel 60 F-254 
plates (thickness; 0.25 mm). All reactions mentioned were monitored by TLC. Spots were 
visualized with UV or a 6.2 % H2S04 aqueous solution, (IL) containing ammonium molybdate (42 
g) and eerie ammonium sulfate (3.6 g), followed by charring. Column chromatography was carried 
out using silica 60 or silica 60H (Merck). Unless otherwise stated, materials were obtained from 
commercial sources and used without further purification. When necessary, solvents were distilled 
and dried according to standard procedures. 
Opening of the benzylidene acetal: 1 -> 2. This procedure is described in section 4 6 for the conversion of 28 into 
29, entry VI 
2-Debenzoyl-l,2-O-benzylidene-4-deacetyl-7-deoxy-lO-deacetyl-9,lO-0-(propane-2,2-diyi)-9(R)-
dihydrobaccatin III (4a); Reduction with DIBALH: To a solution of 1 (0 85 g, I 7 mmol) in CH2CI2 (10 ml) at -10 
°C, a solution of DIBALH in CH2C12 (3 0 ml, IM, 3 0 mmol) was added The reaction mixture was stirred at 0 °C for 3 
hours, after which a solution of 10 % citric acid in water (20 ml) was carefully added The water layer was extracted 
twice with CH2C12 (50 ml) The combined organic layers were washed with saturated NaHCO, solution, with brine, 
dried over NaS04, and concentrated m vacuo The residue was purified by chromatography (EtOAc/hexane 2/5), 
yielding 4a (0 40 g, 0 78 mmol, 46 %) m ρ 105-108 °C, Ή-NMR (400 MHz, CDCI3) 8 7 41 (5H, m, H-Ph), 5 82 (IH, 
s, H-(CPh)), 4 81 (IH, dd, J M = 8 3 Hz, J « = 2 8 Hz, H5), 4 72 (IH, d, J 2 0 l M b= 8 4 Hz, H20a), 4 66 (IH, d, J 1 0 9 = 9 6 
Hz, H10), 4 46 (IH, m, H13), 4 39 (IH, d, ]
ш л
 = 8 5 Hz, H20b), 4 23 (IH, d, J „ = 4 8 Hz, H2), 4 17 (IH, d, J„ ,„ = 
9 6 Hz, H9), 3 03 (IH, s, C4-OH), 2 57 (IH, bd, J14, M b = 16 0 Hz, H14a), 2 23 (IH, d, J3 2 = 4 8 Hz, H3), 2 18 (IH, d , 
Wi4.= 16 0 Hz, J14b.,j = 2 5 Hz, H14b), 2 03 (3H, m, H6 and H7), 2 01 (3H, s, H18), 1 66 (3H, s, H16), 1 56 (3H, s, 
acetonide), 1 49 (3H, s, acetonide), 1 44 (3H, s, H17), 1 19 (3H, s, H19), FAB-MS, 535 [M+Na]*, Anal Caled for 
C,0H„O7 C, 70 29, H, 7 86 Found С, 70 27, H, 8 00 
And yielding 4b (78 mg, 0 15 mmol, 9 %) m p. 116 °C, 'H-NMR (400 MHz, CDCI,) δ 7 39 (5H, m, H-Ph), 5 85 
(IH, s, H-(CPh)), 4 78 (IH, bd, J = 7 8 Hz, H5), 4 66 (IH, d, J 2 0 . 2 O b = 8 0 Hz, H20a), 4 58 (IH, d, J 1 M = 9 5 Hz, H10), 
4 37 (IH, d, J20b.20, = 8 0 Hz, H20b), 4 26 (IH, d, J 2 3 = 5 3 Hz, H2), 4 18 (IH, d, J, ,„ = 9 5 Hz, H9), 3 91 (IH, m, H13), 
2 94 (IH, s, C4-OH), 2 41 (IH, dd, J14, , 4 b = 15 1 Hz, JIWIÌ = 95 Hz, H14a), 2 12 (IH, dd , J,4b.,4l- 15 0 Hz, J14b 13 = 9 5 
Hz, H14b), 2 05 (4H, m, H3, 2H6 and H7), 1 91 (3H, m, H18), 1 61 (3H, s, H16), 1 49 (3H, s, acetonide), 1 47 (3H, s, 
acetonide), 1 44 (3H, s, H17), 1 21 (3H, s, H19), FAB-MS, 535 [M+Na]*, Anal Caled for C)0H40O7 C, 70 29, H, 7 86 
Found С, 70 19, H, 8 04 
Reduction with NaBH4: To a solution of 1 (20 mg, 0 039 mmol) in MeOH (4 ml) at room temperature, NaBH4 (10 
mg, 0 26 mmol) was added After 3 hours the reaction is quenched by adding a saturated NH4Cl-solution (2ml) After 
additional stirring for 15 minutes, water (10 ml) was added The water layer was extracted twice with CH2C12 (10 ml) 
The combined organic layers were washed with brine, dried over NajSO,, and concentrated m vacuo The residue was 
purified via chromatography (EtOAc/hexane 1/1), yielding 4b (14 mg, 0 027 mmol, 70 %) 
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2-Debenzoyl-l,2-O-benzyhdene-4-deacetyl-7-deoxy-I0-deacetyl-9,10-O-(propane-2,2-diyl)-2,-(ethoxyethyl)-
9(RH'hydropaclitaxel (6). To a solution of 4a (0 40 g, 0 78 mmol) in toluene (30 ml), DMAP (105 mg, 0 86 mmol), 
pyridine (1 ml) and protected paclitaxel side chain 5 (400 mg, 1 12 mmol) were added This mixture was cooled to 0 
°C, after which DCC (241 mg, 101 mmol) The reaction mixture was brought to room temperature and stirred for 12 
hours, after which the reaction mixture was diluted with EtOAc (200 ml) This mixture was washed with a solution of 
10 % CuS04 in water (50 ml) The organic layer was dried over NajS04 and concentrated in vacuo The residue was 
purified by chromatography (EtOAc/hexane 2/5), yielding 6 (465 mg, 0 546 mmol, 70 %) m ρ 73 °C, Ή-NMR (400 
MHz, CDCl,) δ 7 72 (IH, m, H-Ph), 7 37 (14 H, m, H-Ph), 7 02 (IH, d, }
m
, = 7 6 Hz, NH), 6 06 (IH, m, H3'), 5 80 
(IH, m, H13), 5 67 (IH, s, H-(CPh)), 4 94 (IH, m, H2'), 4 81 (IH, m, H5), 4 66 (2H, m, H10 and H20a), 4 56 (IH, bs, 
H20b), 4 44 (IH, m, H-(C(CH3)OEt)), 4 24 (2H, m, H2 and H9), 3 98 (IH, s, C4-OH), 3 29 (2H, m, H2(C(CH3)), 2 55 
(IH, d, Jj
 2 = 5 1 Hz, H3), 2 50-2 05 (4H, m, 2H14), 2 08 (3H, s, H18), 1 63 (3H, s, H16), 1 50 (3H, s, acetonide), 1 45 
(3H, s, acetonide), 1 43 (3H, s, H17), 1 24 (3H, s, H19), 1 18 (3H, d, J = 5 4 Hz, H,(CH(OEt)), 0 88 (3H, l, J = 7 I Hz, 
H3(CH2), FAB-MS, 874 [M+Na]+, Anal Caled for CS0H61N 0 „ H20 C, 69 01, H, 7 31, N, 1 61 Found С, 68 94, H, 
6 92,Ν, 1 90 
Acetylation of 6; With Ac20: To a solution of 6 (42 mg, 0 049 mmol) in CH2CI2 (3 ml), Ac20 (15 μΐ, 0 14 mmol) 
and DMAP (15 mg, 0 12 mmol) were added The mixture was stirred at reflux temperature After 24 hours, the mixture 
was diluted with CH2CI2 (15 ml) and washed with water and brine The organic layer was dried over Na2S04 and 
concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 2/5) The starting compound 6 
was fully recovered 
With AcCI: To a solution of 6 (50 mg, 0 059 mmol) in pyridine (5 ml), AcCI (10 μΐ, 0 12 mmol) and DMAP (15 
mg, 0 12 mmol) were added The same procedure was followed as with Ac,0 Again compound 6 was fully recovered 
2-Debenzoyl-l,2-O-benzylidene-4-deacetyl-7-deoxy-10-deacetyl-9(R)-dihydropaclitaxel (7). Compound 6 (0 10 
g, 0 12 mmol) was dissolved in HOAc/THF/H20 (12/3/6 ml) The reaction mixture was stirred for 24 hours at 40 °C 
The reaction mixture was diluted with EtOAc (50 ml) The organic layer was washed with saturated NaHC03 solution 
(20 ml), dried over Na2S04, and concentrated in vacuo The residue was purified by chromatography (EtOAc/hexane 
7/3), yielding 7 (60 mg, 0 081 mmol, 68 %) m ρ 144 °C, Ή-NMR (400 MHz, CDC13) δ 7 74 (2H, d, J = 4 2 Hz, H-
Ph), 7 53-7 13 (13H, m, H-Ph), 7 14 (IH, d, J™, = 7 6 Hz, NH), 5 96 (IH, bd, J,
 N H = 7 8 Hz, H3'), 5 86 (IH, m, H13), 
5 73 (IH, s, H-(CPh)), 4 89 (IH, dd, J M = 8 5 Hz, J5^ = 2 3 Hz, H5), 4 68 (IH, d, J20.20b = 8 1 Hz, H20a), 4 62 (2H, m, 
H10 and OH), 4 42 (IH, d, J20b20a = 8 1 Hz,120bH), 4 19 (IH, d, J„ = 5 2 Hz, H2), 4 02 (IH, dd, J, ,0 = 9 6 Hz, J,0 H, = 
3 2 Hz, H9) 3 89 (IH, bs, OH), 3 79 (s, C4-OH), 2 73 (IH, d, JOH99 = 3 3 Hz, C9-OH), 2 44 (2H, m, 2H14), 2 39 (IH, 
d, J,
 2 =5 2 Hz, H3), 2 12 (4H, m, 2H6 and 2H7), 1 64 (3H, s, H18), 1 60 (311, s, H16), 1 58 (3H, s, H17), 121 (3H, s, 
H19), NOE difference contacts H(2)-H(9), Η(2ΚΗ,(16), H(2)-CH3(19), H(2)-H(4'), H(9)-CH3(19), Η(13)-Η(14β), 
H(13)-CH3(17), H(14ß)-CH3(17) and CH,(19)-H(20ß), FAB-MS, 740 [M+H]*, 762 [M+Na]\ Anal Caled for C43H49N 
O,0 H20 C, 68 14, H, 6 80, N, 1 85 Found С, 67 81, H, 6 57, Ν, 2 15 
2-Debenzoyl-l,2-O-benzylidene-4-deacetyl-7-deoxy-10-deacetyl-9,10-O-(propane-2,2-diyl)-9(R)-
dihydropaclitaxel (8). Compound 6 (0 20 g, 0 24 mmol) was dissolved in HOAc/THF/H20 (8/4/8 ml) After 2 hours at 
room temperature the reaction mixture was diluted with EtOAc (50 ml) The organic layer was washed with saturated 
NaHCOj solution (20 ml), dried over Na2S04, and concentrated m vacuo The residue was purified by chromatography 
(EtOAc/hexane 1/1), yielding 8 (136 mg, 0 175 mmol, 73 %) m ρ 99 °C, Ή-NMR (400 MHz, CDCI3) δ 7 71-7 15 
(15H, m, H-Ph), 7 10 (IH, d, JNH3 = 7 9 Hz, NH), 5 95 (IH, bd, J = 92 Hz, H3'), 5 90 (IH, m, H13), 5 74 (IH, s, H-
(CPh)),490(lH,dd,J56 = 6 7Hz,J 5 6 = 1 8 Hz, H5), 4 67 ( 111, d, J20.20b = 8 1 Hz, 1H),4 62 (IH, bs, H2'),4 59 (IH, d, 
J I M = 9 5 Hz, H10), 4 44 (IH, d, J2 0 b 2 0 l = 8 2 Hz, H20), 4 25 (IH, d, J23 = 5 2 Hz, 112), 421 (IH, d, J, ]0 = 9 5 Hz, H9), 
3 91 (IH, s, C4-OH), 3 75 (IH, bs, C2'-OH), 2 45 (2H, m, 2H14), 2 24 (2H, m, 2H6), 2 20 (IH, d, J3 2 =5 2 Hz, H3), 
1 67 (3H, s, HI8), 1 63 (3H, s, H16), 1 59 (3H, s, acetonide), I 49 (3H, s, acetonide), 1 43 (3H, s, H17), I 23 (3H, s, 
H19), FAB-MS, 802 [M+Na]+, Anal Caled for C„H„N O l 0 0 5H20 C, 70 03, H, 6 89, N, 1 78 Found С, 69 93, H, 
6 54, N,2 13 
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4-Deacetyl-7-deoxy-10-deacetyl-9,10-O-(propane-2,2-diyl)-9(R)-dihydropaclitaxel (За). To a solution of 8 (0 10 
g, 0 13 mmol) in toluene (5 ml), a solution of f-BuOOH in decane (26 μΙ, 5 0-6 ОМ) and Pd(OAc)2 (2 4 mg, 0 011 
mmol) were added The reaction mixture was stirred at 50 °C for 24 hours The reaction mixture was diluted with 
EtOAc (20 ml) and filtered over Hyflo The filtrate was washed with water and brine The organic layer was dried over 
Na2S04 and concentrated in vacuo The residue was purified by chromatography (EtOAc/hexane 1/1), yielding 3a (29 
mg, 0 036 mmol, 28 %) (With a recovery of 55 % of 8) m ρ 125-128 "С, Ή-NMR (400 MHz, CDClj) δ 8 23 (2H, d, J 
= 7 5 Hz, H-Ph), 7 78 (2H, d, J = 7 3 Hz, H-Ph), 7 60 (2H, d, J = 7 4 Hz, H-ph), 7 42 (9H, m, H-Ph), 7 07 (IH, d, JN H 3 
= 9 6 Hz, NH), 6 16 (IH, d, J,
 ш
 = 9 5 Hz, H3'), 6 01 (IH, m, H13), 5 87 (IH, d, J 2 , = 5 2 Hz, H3), 4 89 (IH, dd, J ^ = 
6 7 Hz, }
ίΛ
 = 1 8 Hz, H5), 4 70 (IH, d, J l 0 9 = 9 5 Hz, H10), 4 67 (IH, bs, H2'), 4 40 (IH, d, J, 10 = 9 6 Hz, H9), 4 34 
(IH, d, J20,2Ob = 7 9 Hz, H20a), 4 19 (IH, d, ¡m M. = 7 9 Hz, H20b), 3 41 (IH, bs, OH), 2 91 (IH, dd, J,4, l4b - 15 7 Hz, 
Jl4l „ = 36 Hz, H 14a), 2 55 (IH, d, J, 2 = 5 2 Hz, H3), 2 30 (IH, dd, J14b l4. = 15 7 Hz, Jl4b „ = 6 4 Hz, HI4b), 2 05 (4H, 
m, 2H6 and 2H7), 1 90 (IH, s, CI-OH), 1 85 (3H, s, HI8), 1 53 (3H, s, HI6), 1 52 (3H, s, acetonide), 1 46 (3H, s, 
acetonide), 143 (3H, s, H17), 1 19 (3H, s, H19), FAB-MS, 796 [M+H]*, 818 [M+Na]*, Anal Caled for C„HS)N 
О,, 1 5H20 C, 67 08, H, 6 85, N, 1 78 Found С, 66 77, H, 6 67, Ν, 2 00 
4-Deacetyl-7-deoxy-10-deaceryl-9,10-O-(propane-2,2-diyl)-9(R)-dihydrobaccatin III (9a). 
From 4a: To a solution of 4a (50 mg, 0 098 mmol) in toluene (3 ml), a solution of/-BuOOH in decane (19 μΐ, 5 0-
6 0M) and Pd(OAc)2 (1 8 mg, 0 008 mmol) were added The reaction mixture was stirred for 24 hours at 50 °C The 
reaction mixture was diluted by EtOAc (15 ml) and filtered over Hyflo The filtrate was washed with water and brine 
The organic layer was dried over Na2S04 and concentrated in vacuo The residue was purified by chromatography 
(EtOAc/hexane 1/1), yielding 9a (5 2 mg, 0 0098 mmol, 10 %) (With a recovery of 43 % of 4a) m ρ 250 "С, Ή-
NMR (400 MHz, CDCI,) δ 8 08 (2H, d, J = 7 3 Hz, H-Ph), 7 58 (IH, t, J = 7 4 Hz, H-Ph), 7 46 (2H, m, H-Ph), 5 77 
(IH, d, J2 j = 4 7 Hz, H2), 4 71 (IH, bd, J = 4 2 Hz, H5), 4 69 (IH, d, J 1 M = 9 4 Hz, H10), 4 56 (IH, m, HI3), 4 39 (IH, 
d, Jjo.2«, = 8 4 Hz, H20a), 4 32 (IH, d, J, ,„ = 9 5 Hz, H9), 4 15 (IH, d, J20b 20, = 8 3 Hz, H20b), 3 59 (IH, bs, C4-OH), 
3 26 (IH, d, J0 H 1 3 „ = 8 6 Hz, C13-OH), 2 68 (IH, d, J, 2 = 4 8 Hz, H3), 2 63 (IH, dd, J,4,1 4 b = 15 9 Hz, J,4s „ = 2 4 Hz, 
H14a), 2 46 (IH, dd, J H b ,«,.-158 Hz, J l 4 b „ = 10 0 Hz, H14b), 2 06 (3H, m, 2H6 and H7), 1 96 (3H, s, H18), 1 63 (3H, 
s, H16), 1 52 (3H, s, acetonide), 1 47 (3H, s, acetonide), I 45 (3H, s, H17), 1 10 (3H, s, H19), NOE-difference contacts 
H(2)-H(9), H(2)-CH3(16), H(2)-CH1(19), H(9)-CH,(19), H(I3>CH,(I7) and CH3(19)-H(20p), FAB-MS, 551 [M+Na]\ 
Anal Caled for C,0H40O8 H 2 0 C, 65 91, H, 7 74 Found С, 65 75, H7 45 
From 2 (reduction using NaBH4): To a solution of 2 (50 mg, 0 095 mmol) in a mixture of THF/MeOH (3/1 5 ml), 
stirred at 0 "C, NaBH4 (18 mg, 0 47 mmol) was added After 30 minutes an additional amount of NaBH4 (18 mg, 0 47 
mmol) was added After 2 hours, the reaction was quenched by carefully adding a saturated NH4CI-solution (10 ml) and 
stirred for an additional 15 minutes When the solution reached room temperature, it was diluted by water (30 ml) and 
extracted thrice with EtOAc (25 ml) The combined organic layers were washed with brine, dried over Na2S04 and 
concentrated in vacuo The residue was purified by chromatography (EtOAc/hexane 1/1), yielding 9a (9 2 mg, 0 017, 
18 %) and 9b ( 13 0 mg, 0 025 mmol, 26 %) (With a recovery of 2 of 24 %) Analysis of 9a see above Analysis of 9b 
m ρ 117 "С, 'H-NMR (400 MHz, CDC13) 6 8 01 (2H, d, J = 7 3 Hz, H-Ph), 7 60 (IH, t, J = 7 4 Hz, H-Ph), 7 48 (2H, 
m, H-Ph), 5 80 (IH, d, J 2 , = 5 2 Hz, H2), 4 71 (IH, dd, i^ = 4 0 Hz, J5^ = 9 9 Hz, H5), 4 62 (IH, d, J 1 0 , = 9 5 Hz, 
H10), 4 39 (IH, d, J 2 0, 2 0 b = 8 0 Hz, H20a), 4 34 (IH, d, J, 10 = 9 5 Hz, H9), 4 17 (IH, m, H13), 4 07 (IH, d, J20b.2Ol = 79 
Hz, H20b), 3 74 (IH, dd, J,4l ,4b = 14 5 Hz, J,4. „ = 2 8 Hz, H14a), 2 86 (IH, dd, J l 4 b ,4, = 146 Hz, J l 4 b „ = 95 Hz, 
H14b), 2 10 (IH, d, J 3 2 = 5 2 Hz, H3), 2 02 (3H, m, 2H6 and H7), 1 92 (3H, s, H18), 1 63 (3H, s, H16), 1 53 (3H, s, 
acetonide), I 46 (3H, s, acetonide), 1 43 (3H, s, H17), 1 25 (3H, s, H19), FAB-MS, 551 [M+Naf, Anal Caled for 
C30H40O, H20 C, 65 91, H, 7 74 Found С, 65 85, H7 39 
From 2 (reduction using NaBH4 in the presence of CeCI3): Same procedure as without CeCI3, only prior to 
adding NaBH4, CeCl3 (149 mg, 0 400 mmol) was added to the solution Compound 9a was isolated in 8 % (4 0 mg, 
0 0076 mmol) and compound 9b in 34 % (17 0 mg, 0 032 mmol, 34 %) (With a recovery of 2 of 30 %) 
4-Deacetyl-7-deoxy-10-deacetyl-13-oxo-9(R)-dihydrobaccatin III (12). Compound 2 (0 95 g, 18 mmol) was 
dissolved in AcOH/THF/H20 (125/25/50 ml) After 9 hours at 55 °C, the reaction mixture was diluted with EtOAc (150 
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ml) The organic layer was washed with a NaHCOj-saturated solution (20 ml), dried over Na2S04 and concentrated m 
vacuo The residue was purified via chromatography (EtOAc/hexane 2/1), yielding 12 (528 mg, 1 09 mmol, 60 %) 
(With a recovery of 2 of 29 %) m ρ 153-154 °C, 'H-NMR (400 MHz, CDC13) δ 8 04 (2H, d, J = 7 5 Hz, H-Ph), 7 60 
(IH, t, J = 74 Hz, H-Ph), 7 47 (2H, dd, J = 7 7 Hz, J = 7 7 Hz, H-Ph), 5 86 (IH, d, J „ = 5 4 Hz, H2), 4 78 (IH, d, J I M 
= 9 7 Hz, H10), 4 65 (IH, dd, J 5 J 6 = 3 8 Hz, J M = 9 1 Hz, H5), 4 40 (IH, d, J 2 0 r i № = 8 4 Hz, H20a), 4 33 (IH, d, J, ,0 = 
9 5 Hz, H9), 4 12 (IH, d, J20b_20l = 8 4 HZ, H20b), 3 62 (IH, d, J14l.14b =19 2 Hz, H14a), 2 90 (IH, bs, OH), 2 73 (IH, bs, 
OH), 2 68 (IH, s, OH), 2 62 (IH, d, J,4b.,4l = 19 2 Hz, H14b), 2 59 (IH, d, J 3 2 = 5 4 Hz, H3), 2 15 (3H, m, 2H6 and 
H7), 1 94 (3H, s, H18), 1 85 (IH, s, Cl-OH), 1 71 (3H, s, H16), 1 52 (3H, s, HI6), 1 32 (3H, s, H19), FAB-MS, 509 
[M+Nar\Anal Caled for C27H340„ 0 5H 20 C, 65 44, H, 7 12 Found C, 65 20, H7 46 
4-Deacetyl-7-deoxy-9-acetyl-13-oxo-9(R)-dihydrobaccatin III (13). To a solution of 12 (528 mg, 1 09 mmol) m 
CHjClj (45 ml), Ac20 (200 μΐ) and DMAP (0 37 g, 3 0 mmol) were added The mixture was stirred at room 
temperature After 4 hours additional amounts of Ac20 (200 μΙ) and DMAP (0 20 g) were added After which the 
mixture was stirred for another 2 hours The reaction mixture was diluted by CH2CI2 (50 ml) and washed with brine 
The organic layer was dried over Na2S04 and concentrated m vacuo The residue was purified by chromatography 
(EtOAc/hexane 1/1), yielding 13 (596 mg, 1 05 mmol, 96 %) m ρ 112 "С, Ή-NMR (400 MHz, CDCl,) δ 8 04 (2H, 
d, J = 7 5 Hz, H-Ph), 7 59 (IH, t, J = 7 5 Hz, H-Ph), 7 48 (2H, dd, J = 7 7 Hz, J = 7 7 Hz, H-Ph), 6 02 (2H, s, H9 and 
НЮ), 5 93 (IH, d, J 2 3 = 5 5 Hz, H2), 4 67 (IH, dd, J « = 3 5 Hz, J ^ = 9 2 Hz, H5), 4 36 (IH, d, J 2 0 l 2 0 b = 8 5 Hz, H20a), 
4 12 (IH, d, J20b.20i = 8 5 Hz, H20b), 3 61 (IH, d, J,4, ,4b =19 3 Hz, H14a), 2 63 (2H, m, H3 and H14b), 2 56 (IH, s, C4-
OH), 2 14 (3H, s, OCOCHj), 2 09 (3H, s, OCOCH3), 2 08 (3H, s, H18), 1 89 (IH, s, Cl-OH), 1 78 (3H, s, H16), 1 34 
(3H, s, H16), 1 25 (3H, s, H19), FAB-MS, 593 [M+Na]*, Anal Caled for C3,H380,o 0 5H20 C, 64 24, H, 6 78 Found 
С, 63 97, H6 99 
7-Deoxy-9-acetyl-13-oxo-9(R)-dihydrobaccatin HI (14). The same procedure was followed as for 13, using 12 
(121 mg, 0 249 mmol) Compound 14 was isolated in 36 % (55 mg, 0 090) and compound 13 was isolated in 28 % (43 
mg, 0 070) Analysis of 14 m ρ 97 "С, Ή-NMR (400 MHz, CDCI3) δ 8 10 (2H, d, J = 7 4 Hz, H-Ph), 7 63 (IH, t, J = 
7 4 Hz, H-Ph), 7 50 (2H, dd, J = 7 7 Hz, J = 7 7 Hz), 6 05 (IH, d, J10.9 = 10 7 Hz, H10), 6 00 (IH, d, J,.10 = 10 7 Hz, 
H9), 5 92 (IH, d, J 2 3 = 6 1 Hz, H2), 4 94 (IH, bd, J = 8 6 Hz, H5), 4 35 (IH, d, J 2 0 l 2 0 b = 8 4 Hz, H20a), 4 10 (IH, d, 
¡mm. = 8 4 Hz, H20b), 3 26 (IH, d, J3 2 = 6 1 Hz, H3), 2 92 (IH, d, J,4l 14b = 19 7 Hz, H14a), 2 65 (IH, d, Jl4b ,„. = 19 7 
Hz, H14b), 2 27 (3H, m, 2H6 and H7), 2 18 (3H, s, OCOCH3), 2 15 (3H, s, OCOCH3), 2 12 (3H, s, OCOCH3), 2 07 
(3H, s, H18), 1 92 (IH, s, Cl-OH), 1 78 (3H, s, H16), 1 41 (3H, s, H17), 1 22 (3H, s, H19), FAB-MS, 613 [M+H] , 635 
[M+Na]', Anal Caled for C33H4ûO„ C, 64 69, H, 6 58 Found С, 64 51, H, 6 82 
4-Deacetyl-7-deoxy-9-acetyl-9(R)-dihydrobaccatin III (15a). 
Reduction, using NaBH4: To a solution of 13 (166 mg, 0 291 mmol) in MeOH (15 ml), stirred at 0 °C, NaBH, (77 
mg, 2 1 mmol) was added After 4 hours an additional amount of NaBH„ (75 mg) was added and the reaction mixture 
was stirred for another hour The reaction was quenched by carefully adding a saturated NH4CI-solution (15 ml) After 
stirring for 15 minutes, the mixture was diluted with water (50 ml) and extracted thrice with CH2C12 (30 ml) The 
combined organic layers were washed with brine, dried over Na2S04 and concentrated in vacuo The residue was 
purified by chromatography (CHCl3/MeOH 9/1), yielding 15a (31 mg, 0 054, 19 %) and 15b (55 mg, 0 096, 33 %) 
Analysis of 15a m ρ 87 °C, 'H-NMR (400 MHz, CDCI3) δ 8 08 (2H, d, J = 7 4 Hz, H-Ph), 7 59 (IH, t, J = 7 3 Hz, 
H-Ph), 7 47 (2H, dd, J = 7 7 Hz, J = 7 7 Hz, H-Ph), 5 95 (IH, d, J l w ) = 10 8 Hz, H10), 5 90 (IH, d, J,_l0 =10 8 Hz, H9), 
5 82 (IH, d, J 2 3 = 5 3 Hz, H2), 4 75 (IH, dd, J M = 3 9 Hz, J,^ = 9 5 Hz, H5), 4 55 (IH, m, H13), 4 35 (IH, d, J2 0.2 0 b = 
8 4 Hz, H20a), 4 18 (IH, d, J20b.20l = 8 5 Hz, H20b), 3 52 (IH, s, C4-OH), 3 17 (IH, d, i m n ,3 = 8 5 Hz, C13-OH), 2 96 
(IH, d, J 3 , = 5 5 Hz, H3), 2 64 (IH, dd, J1 4.1 4 b =15 8 Hz, J14. ,, = 2 4 Hz, H14a), 2 45 (IH, dd, J,4b ,4, = 158 Hz, J14b.,3 = 
110Hz,H14b),2 16 (3H, m, 2H6 and H7), 2 11 (6H, s, OCOCH3),2 04 (3H, s, H18), 1 78 (IH, s, Cl-OH), 1 69 (3H, 
s, H16), 1 31 (3H, s, H17), 1 25 (311, s, H19), FAB-MS, 595 [M+Na]*, Anal Caled for C 3 lH 4 0O 1 0H 2O C, 63 04, H, 
7 17 Found C, 62 88, H, 7 05 
Analysis of 15b m ρ 140 "С, Ή-NMR (400 MHz, CDC13) δ 8 00 (2H, d, J = 7 4 Hz, H-Ph), 7 60 (IH, t, J = 7 4 
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Hz, H-Ph), 7 47 (2H, dd, J = 7 7 Hz, J = 7 7 Hz, H-Ph), 5 93 (2H, s, H9 and H10), 5 85 (IH, d, J 2 , = 5 7 Hz, H2), 4 71 
(IH, dd, J « = 3 7 Hz, J M = 9 3 Hz, H5), 4 37 (IH, d, J2 0 t 2 M ) = 8 2 Hz, H20a), 4 21 (IH, dd, J„ ,„ = 95 Hz, J„ H b = 4 6 
Hz, H13), 4 09 (IH, d, и 2 0 , = 8 2 Hz, H20b), 2 87 (IH, dd, J,4. ,4„ = И 7 Hz, J l 4. „ = 9 5 Hz, H14a), 2 82 (IH, bs, 
C13-OH), 2 36 (IH, d, J,, = 5 8 Hz, H3), 2 18 (3H, m, 2H6 and H7), 2 11 (3H, s, OCOCH,), 2 09 (IH, s, C4-OH), 2 06 
(3H, s, OCOCH,), 2 04 (3H, s, H18), 1 94 (IH, dd, J,4b ,«. = 15 1 Hz, J l 4 b „ = 4 9 Hz, H 14b), 1 72 (IH, bs, Cl-OH), 
1 68 (3H, s, H16), 1 31 (3H, s, H17), 1 30 (3H, s, H19), FAB-MS, 595 [M+Na]+, Anal Caled for C„H 4 0O l 0 2H 20 C, 
61 17, H, 7 29 Found C,61 55, H, 7 08 
Reduction, using NaBH4, in the presence of CeClj·. Same procedure as without CeCI,, using 13 (547 mg, 0 96 
mmol), only prior to adding NaBH4, CeCl, (1 07 g, 2 88 mmol) was added to the solution Compound 15a was isolated 
in 63 % (346 mg, 0 605 mmol) and compound 15b in 24 % (131 mg, 0 229 mmol) 
7-Deoxy-9-acetyl-9(R)-dihydrobaccatin III (16a). To a solution of 14 (115 mg, 0 189 mmol) in MeOH (5 ml), 
stirred at 0 °C, NaBH4 (80 mg, 2 2 mmol) was added After 4 hours an additional amount of NaBH„ (80 mg) was added 
and the reaction mixture was stirred for another hour The reaction was quenched by carefully adding a saturated 
NH4Cl-solution (15 ml) After stirring for 15 minutes, the mixture was diluted with water (50 ml) and extracted thrice 
with CH2C12 (30 ml) The combined organic layers were washed with brine, dried over Na2S04 and concentrated in 
vacuo The residue was purified by chromatography (CHCl,/MeOH 9/1), yielding 16a (23 mg, 0 037, 20 %) and 15a 
(17 mg, 0 030 mmol, 16 %) (With a recovery of 14 of 28 %) Analysis of 16a: m ρ 213 "С, 'H-NMR (400 MHz, 
CDCl,) 5 8 12 (2H, d, J = 7 4 Hz, H-Ph), 7 60 (IH, t, J = 7 3 Hz, H-Ph), 7 48 (2H, bt, J = 7 7 Hz, H-Ph), 5 97 (2H, s, 
H9 and НЮ), 5 79 (IH, d, J 2 , = 6 3 Hz, H2), 4 98 (IH, bd, J = 8 8 Hz, H5), 4 79 (IH, m, H13), 4 32 (IH, d, J 2 0 l 2 0 b = 
8 5 Hz, H20a), 4 12 (IH, d, J 2 0 b 2 0, = 84 Hz, H20b), 3 21 (IH, d, J, 2 = 6 3 Hz, H3), 2 29-2 09 (5H, m, 2H6, H7 and 
2H14), 2 25 (3H, s, OCOCH,), 2 12 (6H, s, OCOH,), 2 05 (3H, s, H18), 1 73 (3H, s, H16), 1 60 (IH, s, Cl-OH), 1 42 
(3H, s, H17), 1 09 (3H, s, H17), FAB-MS, 615 [M+H]\ 637 [M+Na]+, Anal Caled for C„H4 20,, H 2 0 C, 62 63, H, 
7 02 Found С, 62 81, H, 6 89 
4-Deacetyl-7-deoxy-9-acetyl-13-tnethylsilyl-9(R)-dihydrobaccatin III (17). To a solution of 15a (390 mg, 0 680 
mmol) m DMF (20 ml), imidazole (370 mg, 5 40 mmol) and triethylsilyl chloride (920 μΙ, 5 40 mmol) were added 
After stirring for 1 hour at room temperature, the mixture was diluted with EtOAc (100 ml) and washed with brine The 
organic layer was dried over Na2S04 and concentrated in vacuo The residue was purified by chromatography 
(EtOAc/hexane 1/1), yielding 17 (469 mg, 0 680 mmol, 100 %) m ρ 108 "С, Ή-NMR (400 MHz, CDCl,) 6 8 15 
(2H, d, J = 7 5 Hz, H-Ph), 7 57 (IH, t, J = 7 4 Hz, H-Ph), 7 45 (2H, dd, J = 7 7 Hz, J = 7 7 Hz, H-Ph), 5 93 (IH, d, J1(M 
= 10 6 Hz, H10), 5 87 (IH, d, J t l 0 =10 6 Hz, H9), 5 78 (IH, d, J 2 , = 5 1 Hz, H2), 4 71 (IH, dd, ¡^ = 3 7 Hz, J,6 = 9 4 
Hz, H5), 4 61 (IH, bd, J = 9 6 Hz, H13), 4 32 (IH, d, J20l20b = 7 8 Hz, H20a), 4 22 (IH, d, J2ob20s = 7 8 Hz, H20b), 3 81 
(IH, s, C4-OH), 2 90 (IH, d, J , , 5 2 Hz, H3), 2 68 (IH, dd, Jl4l_l4b = 15 6 Hz, J,4l „ = I 7 Hz, H14a), 2 35 (IH, dd, J14b 
14, = 15 5 Hz, J14b „ = 1 0 1 Hz, H14b), 2 21-2 13 (3H, m, 2H6 and H7), 2 11 (3H, s, H18), 2 04 (6H, s, 2(OCOCH,)), 
1 78 (IH, s, Cl-OH), 1 68 (3H, s, H16), 1 30 (3H, s, H17), 1 06 (9H, t, J - 7 9 Hz, 3H,C(H2CSi)), 1 01 (3H, s, H19), 
0 76 (6H, m, 3(H,C)H2C(Si)), FAB-MS, 709 [M+Na]+, Anal Caled for C,7HS4O10Si 0 5 H20 C, 63 68, H, 7 97 Found 
С, 63 78, H, 7 55 
7-Deoxy-9-acetyl-13-triethylsilyl-9(R)-dihydrobaccatin III (18). 
- Ac20, DMAP To a solution of 17 (319 mg, 0 465 mmol) in CH2C12 (15 ml), Ас20 (351 μΙ, 3 72 mmol) and DMAP 
(851 mg, 6 98 mmol) were added The reaction mixture was stirred at room temperature After three hours the 
reaction temperature was brought to reflux temperature After 24 hours, the mixture was diluted by CH2CI2 (50 ml) 
and washed with brine The organic layer was dried over Na2S04 and concentrated in vacuo The residue was purified 
by chromatography (EtOAc/hexane 1/1) The starting material 17 was fully recovered 
- AcCl, LiN(SiMe,)2 A solution of LiN(SiMe,)2 (32 μΐ, 0 15 mmol) and BuLi (1 6 M in hexane, 87 μΙ, 0 14 mmol) in 
THF (2 ml) was stirred at 0 °C After 10 minutes a solution of 17 (87 mg, 0 13 mmol) in THF (2 ml) was added This 
mixture was stirred for 15 minutes, after which AcCl (10 μΐ, 0 14 mmol) was added After 24 hours, the mixture was 
diluted by a saturated NH4Cl-solution (15 ml) and extracted thrice with EtOAc (20 ml) The combined organic layers 
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were washed with brine, dried over Na2S04 and concentrated in vacuo The residue was purified by chromatography 
(EtOAc/hexane 1/1) The starting material 17 was fully recovered 
- Repeating this procedure, using 2 2 equivalents of AcCI, instead of 1 1 equivalents, gave the same result 
- Repeating this procedure, using 2 5 equivalents of LiN(SiMej)2, yielded compound 19 (8 0 mg, 0 013 mmol, 10 %) 
(With a 85 % recovery of 17) Analysis of 19 m ρ 96 "С, Ή-NMR (400 MHz, CDCl,) δ 8 07 (2H, d, J = 7 9 Hz, H-
Ph), 7 59 (IH, t, J = 7 4 Hz, H-Ph), 7 47 (2H, dd, J = 7 7 Hz, J = 7 7 Hz, H-Ph), 5 94 (2H, s, H9 and H10), 5 88 (IH, 
d, J = 10 Hz, H13), 5 84 (IH, d, J 2 3 = 5 5 Hz, H2), 4 76 (IH, dd, J 5 4 = 3 5 Hz, J « = 9 4 Hz, H5), 4 28 (IH, d, J 2 0 l 2 M ) = 
8 1 Hz, H20a), 4 20 (IH, d, W * = 8 1 Hz, H20b), 2 74 (IH, d, J 3 2 = 5 5 Hz, H3), 2 61 (IH, s, C4-OH), 2 58 (IH, 
dd, J,4. ,4b = 15 5 Hz, J,4.1 3 = 3 2 Hz, H14a), 2 55 (IH, m, H6), 2 43 (IH, dd, J14),,4. = 15 5 Hz, J,4b „ = 10 5 Hz, 
H14b), 2 36 (IH, m, H6), 2 20 (3H, s, OCOCHj), 2 11 (3H, s, OCOCH3), 2 05 (3H, s, OCOCH3)l 98 (3H, s, H18), 
1 72 (3H, s, H16), 1 33 (3H, s, H17), 1 10 (3H, s, H19), FAB-MS, 637 [M+Na]\ Anal Caled for С3 3Н4 20„ С, 
64 48, H, 6 89 Found С, 64 94, H, 6 79 
- Ac20, SC(OS0 2 CFJ)J То a solution of 17 (52 mg, 0 076 mmol) in THF (3 ml), Ас20 (11 μΐ, 0 12 mmol) and 
Sc(OS02CFj)j (3 7 mg, 0 0076 mmol) were added The mixture was stirred at room temperature After stirring for 2 
hours, 17 had completely disappeared, according to TLC The mixture was diluted with EtOAc (20 ml) and washed 
with brine The organic layer was dried over Na2S04 and concentrated in vacuo, yielding a mixture of many products 
This mixture was not further purified 
2'-Ethoxyethoxy-4-deacetyl-7-deoxy-9-acetyl-9(R)-d<hydropacl1tax*l (20). To a solution of 15a (52 mg, 0 091 
mmol) in toluene (5 ml), DMAP (18 mg, 0 15 mmol) and protected pachtaxel side chain (5) (49 mg, 0 14 mmol) were 
added This mixture was stirred at 0 °C Dnsopropyl carbodnmide (44 μΙ, 0 29 mmol) was added After 5 minutes the 
mixture was warmed up till room temperature After 18 hours the mixture was diluted with EtOAc (30 ml), washed 
with a IM KHSCysolution and washed with brine The organic layer was dried over NajS04 and concentrated in 
vacuo The residue was purified by chromatography (EtOAc/hexane 1/1), yielding a mixture of 20 (66 mg„ 0 072 
mmol, 79 % The 1H-NMR spectrum is similar as for 21 FAB-MS, 912 [M+Hf, 934 [M+Na]*, Anal Caled for 
C51H6lO l4N H 20 C, 65 86, H, 6 83, N, 1 51 Found C, 65 89, H, 6 72, N, 1 68 
4-Deacetyl-7-deoxy-9-acetyl-9(R)-dihydropaclitaxel (21). Compound 20 (66 mg, 0 072 mmol) was dissolved in a 
mixture of AcOH/THF/H20 (4/2/4 ml) After stirring for 4 hours at room temperature, the mixture was diluted by 
EtOAc (50 ml) and washed by a saturated NaHCCysolution The organic layer was washed with brine, dried over 
NajS04 and concentrated in vacuo The residue was purified by chromatography, using a chromatotron (CHCl3/MeOH 
98/2), yielding 21 (51 mg, 0 061, 85 %) m ρ 158 "С, Ή-NMR (400 MHz, CDCIj) δ 8 24 (2H, d, J = 7 5 Hz, H-Ph), 
7 78 (2H, d, J = 7 4 Hz, H-Ph), 7 42 (1 IH, m, H-Ph), 7 07 (IH, d, J^,, = 9 6 Hz, NH), 6 18 (IH, d, J,
 m
 = 9 6 Hz, H3'), 
5 97 (2H, s, H9 and H10), 5 96 (IH, m, H13), 5 92 (IH, d, J „ =5 7 Hz, H2), 4 91 (IH, dd, J 5 6 = 3 3 Hz, J M = 9 4 Hz, 
H5), 4 72 (IH, s, C4-OH), 4 68 (IH, d, J = 2 6 Hz, H2'), 4 31 (IH, d, ¡10,m = 80 Hz, H20a), 4 20 (IH, d, J20b2o, = 80 
Hz, H20b), 3 391H, d, JOH2.2 = 3 4 Hz, C2'-OH), 2 93 (IH, dd, Jl4, ,4b = 15 6 Hz, J,4. „ = 4 0 Hz, H14a), 2 84 (IH, d, J3, 
= 5 7 Hz, H3), 2 34 (IH, dd, J,4b 14l = 15 7 Hz, J14b 13 = 10 5 Hz, H 14b), 2 25 (IH, m, H6), 2 12 (3H, s, OCOCHj), 2 04 
(3H, s, OCOCHj), 2 00 (3H, s, H18), 1 92 (IH, m, H7), 1 81 (IH, s, Cl-OH), 1 74 (3H, s, H16), 1 35 (3H, s, H17), 1 11 
(3H, s, H19), FAB-MS, 840 [M+H]\ 862 [M+Na]\ Anal Caled for C47H„013N 0 5H20 C, 66 50, H, 6 41, N, 1 65 
Found С, 66 44, H, 6 63, Ν, 1 92 
2'-Ethoxyethoxy-4-deacetyl-7-deoxy-9-acetyl-9(R)-dihydro-13-epi-paclitaxcl (22). To a solution of 15b (54 mg, 
0 094 mmol) m toluene (3 ml), DMAP (25 mg, 0 20 mmol) and protected pachtaxel side chain (5) (50 mg, 0 14 mmol) 
were added The mixture was stirred at 0 °C Next DCC (33 mg, 0 14 mmol) was added After 5 minutes the reaction 
temperature was brought to room temperature After stirring for 20 hours, additional amounts of DMAP (25 mg, 0 20 
mmol), 5(17 mg, 0 048 mmol) and DCC (17 mg,, 0 071 mmol) were added After another 24 hours, the mixture was 
diluted by EtOAc (30 ml) and washed with a 1 M KHS04-soIution and with brine The organic layer was dried over 
Na2S04 and concentrated in vacuo The residue was purified by chromatography (EtOAc/hexane 1/1), yielding 22 (81 
mg, 0 089 mmol, 95 %) m ρ 98 °C, The Ή-NMR spectrum is very similar to the spectrum of 23 (next procedure), 
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FAB-MS, 934 [M+Naf. 
4-Deacetyl-7-deoxy-9-acetyl-9(R>-dihydro-13-epi-paclitaxel (23). Compound 22 (70 mg, 0 077 mmol) was 
dissolved in a mixture of HOAc/THF/H20 (4/2/4 ml) The mixture was stirred at room temperature After 5 hours, the 
mixture was diluted with EtOAc (30 ml) and washed with a saturated NaHCCysolution The organic layer was dried 
over Na2S04 and concentrated in vacuo The residue was purified by chromatography (EtOAc/hexane 1/1), yielding 
23 (36 mg, 0 043 mmol, 56 %) (With a 19 % recovery of 22). m ρ 107 °C, 'H-NMR (400 MHz, CDCI,) δ 8 00 (2H, d, 
J = 7 2 Hz, H-Ph), 7 78 (2H, d, J = 7 3 Hz, H-Ph), 7 72 (IH, m, H-Ph), 7 39 (10H, m, H-Ph), 6 93 (IH, d, і
ш
, = 8 9 
Hz,NH), 6 00 (IH, d, J 1 M = 10 6 Hz, H10), 5 92 (IH, d, J , „ = 1 0 7 Hz, H9), 5 85 (IH, d, J „ = 5 5 Hz, H2), 5 72 (IH, 
dd, Jj NH = 9 8 Hz, J,
 r
 = 1 6 Hz, H3'), 5 33 (IH, dd, J„ ,4. = 9 6 Hz, J„ 14b = 4 2 Hz, H13), 4 72 (IH, dd, J,^ , = 4 3 Hz, 
J M = 9 7 Hz, H5), 4 64 (IH, d, J 2 , = I 6 Hz, H2'), 4 35 (IH, d, J 2 0 a 2 0 b = 8 4 Hz, H20a), 4 17 (IH, d, J 2 0 b 2 0 l = 8 4 Hz, 
H20b), 3 98 (IH, bs, C4-OH), 3 39 (IH, bs, C2-OH), 3 29 (IH, dd, J l 4 l 14b = 15 0 Hz, J1 4 l 13 = 9 6 Hz, H14a), 2 38 (IH, 
d, J, j = 5 5 Hz, H3), 2 11 (3H, s, OCOCH,), 2 09 (3H, m, 2H6 and H 14b), 2 08 (3H, s, OCOCH3), 2 00 (3H, s, H18), 
1 81 (IH, s, Cl-OH), 1 71 (3H, s, H16), 1 27 (3H, s, H17), 1 26 (3H, s, H19), FAB-MS, 862 [M+Na]\ Anal Caled for 
C47H530,3N 2 5H20 C, 63.79, H, 6 61, N, 1 58 Found С, 63 60, H, 6 81, Ν, 1 82 
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6 Some Approaches to the Semisynthesis of 
1,7-Dideoxypaclitaxel Analogs 
6.1 Introduction 
In chapter 3 (section 3.2.1), it was mentioned that in crude taxine В isolated from Taxus boccata, 
1-deoxytaxine В analogs la and lb (figure 6.1) were also present.' 
Figure 6.1 
F^O OR2 
W IN 
" O - ^ ^ P h 
OH 
1a R, = Ac, R2 = H 
1 b R 1 = H , R 2 = Ac 
For that reason, the first steps in the synthesis of 7-deoxypaclitaxel analogs led to a mixture of 2 
and 3 (scheme 6.1) which were not separated via column chromatography, as was described in 
section 3.2.2.2 
In chapter 4, it was shown that introduction of the benzoyl group at C2 was achieved by 
oxidative opening of a benzylidene acetal at the Cl,C2-hydroxyl groups, prepared by treatment of 
the mixture of 2 and 3 with benzaldehyde dimethyl acetal (scheme 6.1). Benzylidene acetal 4 was 
isolated in 85 % yield, with a 14 % recovery of 1-deoxycompound 3. 
Scheme 6.1 
2 R = OH 
3 R = H 
(a) 2 equiv benzaldehyde dimethyl acetal/PTS/toIuene; 85 % (4) and 14 % (3). 
+ 3 
The absence of the hydroxyl group at CI makes compound 3 an interesting precursor for the 
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development of a synthetic route leading to 1 -deoxypaclitaxel analogs. Currently, neither isolation 
nor (successful) synthesis3 of 1-deoxypaclitaxel and/or analogs thereof have been reported. The 
synthesis of 1-deoxypaclitaxel analogs allows for biological evaluation of the influence of the Cl-
hydroxyl group on the cytotoxic activity of paclitaxel. 
In this chapter, some synthetic approaches toward 1,7-dideoxypacIitaxel analogs, starting from 
compound 3 will be described. 
6.2 General Strategy for the Synthesis of l,7-Dideoxy-9-
acetyl-9(R)-dihydropaclitaxeI 
Taking into account the results of chapters 3,4 and 5, a strategy was outlined for the synthesis of 
l,7-dideoxy-9-acetyl-9(R)-dihydropaclitaxel 12 which is depicted in scheme 6.2. In this strategy 
protection of the C2-hydroxyl group is necessary for the construction of the oxetane ring in 
compound 6, which will be synthesized via established methods,4 as described in chapters 3 and 4. 
Acetylation of the C4-hydroxyl group will afford compound 7. Subsequently, deprotection of the 
C2-hydroxyl group (compound 8), followed by benzoylation of this hydroxyl group should result in 
compound 9. 
Scheme 6.2 
'''''°^^Y^\ ~* "OH 
Ρ = protective group 
Ac 2 0 
DMAP -*> α 
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AcO OAc 
Next, compound 10 can be synthesized from 9, after successive removal of the isopropylidene 
functionality at C9,C10, and acetylation of the deprotected hydroxyl groups. Reduction of the С13-
carbonyl with NaBH4 should afford compound 11. Coupling of 11 to the protected paclitaxel side 
chain, followed by deprotection of the C2'-hydroxyl group should result in 1,7-dideoxy-9-acetyl-
9(R)-dihydropaclitaxel 12. 
6.3 Synthesis of Oxetane Compound 6 
6.3.1 Via (Selective) Protection of the C2-hydroxyI Group 
It was difficult to obtain compound 3 completely pure from the mixture of 3 and 4 (scheme 6.1). 
Although purification was possible via conversion of 3 into 13 (scheme 6.3), the impure compound 
3 was used in further synthesis. 
Scheme 6.3 
(a) EtjSiCl/imidazole; 93 %. 
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For the protection of the C2-hydroxyl group, the first choice was not an acid labile protective 
group, because deprotection problems were expected in a later stage of the synthetic route, similar 
to those described in section 3.2.5. Therefore protection of the C2-hydroxyl group with an allyl- or 
benzyl ether was considered (scheme 6.4). 
Scheme 6.4 
OR 
3 14 R = allyl 
15 R = benzyl 
I (a) Allyl bromide/NaOH/toluene/KT and 80 °C, respectively; no reaction, (b) Allyl bromide/NaH/THF/KT and 
80 °C, respectively; no reaction. 
II Benzyl bromide/NaH/Bu4NI/THF/KT, 40 and 80 °C, respectively; no reaction. 
Treatment of 3 with allyl5 or benzyl bromide6 under different reaction conditions, however, did 
not afford compounds 14 or 15, respectively, but instead the starting compound 3 was completely 
recovered. The low reactivity of compound 3 under the reaction conditions described in scheme 6.4, 
was unexpected because silylation of the C2-hydroxyl group proceeded very smoothly7 (scheme 
6.3). Then it was decided to go on with the synthesis without protection of the C2-hydroxyl group. 
Treatment of compound 3 with 20 N NaOH, afforded compound 16 in 79 % yield (scheme 6.5). 
Scheme 6.5 
(a) 20 N NaOH/80 °C; 79 %. 
Before the construction of the oxetane ring the C2-hydroxyl group must be protected, otherwise, 
during the mesylation of the C5-hydroxyl group, concomitant mesylation of the C2-hydroxyl group 
may take place. It may be expected that selective protection of the C2-hydroxyl group is possible 
because the C5-hydroxyl group of 16 does not react in the presence of the C4-C20 double bond.8 
The failure of the allylation and benzylation of the C2-hydroxyl group of 3 may be due to partial 
shielding of this hydroxyl group by the cinnamoyl side chain. Therefore, in the absence of the 
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cinnamoyl side chain, it was hoped that the C2-hydroxyl group of 16 could be selectively protected 
as an allyl- or benzyl ether (scheme 6.6). 
Scheme 6.6 
OR 
17 R = allyl 
18 R = benzyl 
19 R = benzoyl 
I (a) Allyl bromide/NaOH/toluene/KT and 80 °C, respectively; no reaction, (b) Allyl 
bromide/NaH/THF/KT and 80 °C, respectively; no reaction. 
II Benzyl bromide/NaH/Bu4NI/THF/KT, 40 and 80 °C, respectively; no reaction. 
III Benzoyl chloride/DMAP/Et,N; no reaction. 
Unfortunately, treatment of compound 16 with benzyl or allyl bromide under different reaction 
conditions did not lead to the corresponding ethers 17 and 18, respectively. Compound 16 was 
completely recovered. Also treatment of 16 with benzoyl chloride' in the presence of DMAP and 
Et,N gave no reaction. 
Next, selective silylation of the C2-hydroxyl group was investigated using i-butyldimethylsilyl 
chloride, isopropyldimethylsilyl chloride and triethylsilyl chloride (scheme 6.7). 
Scheme 6.7 
R. R, Product Yield (%) 
/-PrMe2SiCl 
EtjSiCl 
i-PrMe2Si 
H 
Et3Si 
EtjSi 
;-PrMe2Si 
EtjSi 
H 
Et3Si 
20 
21 
22 
23 
99 
34 (21 or 22) 
62 
With /-butyldimethylsilyl chloride no reaction took place and with isopropyldimethylsilyl 
chloride the undesired disilylated product 20 was isolated in 99% yield. In the reaction with 
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triethylsilyl chloride, monosilylated product 21 (or 22) was isolated in 34 % yield and the 
disilylated product 23 in 62 % yield.10 Treatment of 23 with Bu„NF gave monosilylated product 21 
(or 22) in 74 % yield and 16 in 18 % yield. The nature of the monosilylated product could be 
established after completing the sequence of reactions shown in scheme 6.8. It was found that the 
silyl group was introduced selectively at C5. The procedure shown in scheme 6.8 involves 
dihydroxylation of the C4-C20 double bond (24), silylation of the primary hydroxyl group at C20 
(25) and mesylation of the free secondary hydroxyl group. The thus obtained product 26 was 
analyzed by 'H-NMR which showed that the mesyloxy group was located at C2, while the initial 
silylation had taken place at C5. Going from 25 to 26 the C2 proton was shifted from 4.13 to 5.29 
ppm while the resonance of the C5 proton did not change. 
Apparently, in silylation reactions the C5-hydroxyl group in 16 is more reactive than the C2-
hydroxyl group. The mesyloxy group has thus been introduced at the wrong position with the 
consequence that no oxetane ring could be prepared anymore. Hence this route to the target 
molecule was abandoned. 
Scheme 6.8 
'OSiEt3 
•*• О 
'OSiEtg 
H І
н
но^-он 
24 
'OSiEt3 
HÒ λ — OS¡íBuMe2 
0 = S = 0 26 
CH, 
OH 
"OSiEt3 
НО
 л
—OS¡fBuMe2 
25 
(a) OsCyNMMO; 68 %. (b) f-BuMe2SiCl/imidazole; 100 %. (c) Mesyl chloride/pyridine; 96 %. 
6.3.2 Via Protection of the C4,C5-hydroxyI Groups as a Cyclic Carbonate 
As no suitable protective group for the C2-hydroxyl group could be found a strategy had to be 
derived in which this protection could be avoided. A possibility could be the synthesis of compound 
27b starting from compound 16 (scheme 6.9). 
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In compound 27b the C4- and C5-hydroxyl groups are protected by a cyclic carbonate group, 
which could also serve as a leaving group at C5 in treatment with base (i.e. Bu4NOAc), resulting in 
intermediate 28." From 28 C0 2 can be released to give compound 29. 
Scheme 6.9 
Bu4NOAc 
"O (27b) 
H I " Г'0—k. 
27aR = TBDMS°H ¿R ° 
27b R = H 
Δ, H20 
29 
By successive benzoylation of the C2-hydroxyl group and acetylation of the C4-hydroxyl group, 
compound 29 can be converted into compound 9 (scheme 6.2). The conversion of 9 into 1,7-
dideoxy-9-acetyl-9(R)-dihydropaclitaxel (12), has already been described in scheme 6.2. 
In the first step of the synthesis of 27a from 16 the C4-C20 double bond was c/i-dihydroxylated 
using Os04 in the presence of 4-methylmorpholine N-oxide monohydrate (NMMO) (scheme 6.10). 
The isolated compound 30 was then treated with /-butyldimethylsilyl chloride in the presence of 
imidazole to protect the primary hydroxyl group at C20 to give compound 31 in 82 % yield. 
Treatment of 31 with 1,1-carbonyldiimidazole was thought to give 27a, but instead compounds 32 
and 33 were isolated in yields of 28 and 43 %, respectively.12 
It was decided to carry on with 32 to construct the oxetane ring. For that purpose compound 32 
was treated with mesyl chloride in pyridine producing 34 and 3513 in a yield of 46 and 44 %, 
respectively (scheme 6.11). 
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Scheme 6.10 
OH 
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1 OSifBuMe2 
(a) Os04/NMMO; 50 %. (b) í-BuMe2SiCl/¡m¡dazole; 82 %. (с) 1,1-carbonyldiimidazole; 28 % (32) and 43 % (33) 
Scheme 6.11 
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32 
(a) Mesyl chloride/pyridine; 46 % (34) and 44 % (35). 
"«-ГО 
35 R = S0 2 CH 3 
The next step in the formation of the oxetane ring would be the deprotection of the primary 
hydroxyl group at C20, followed by treatment with base to close the ring. However, in section 4.2.2 
it was shown that instead of closure to the oxetane ring, the benzoyl group at C2 migrated to the 
primary C20-hydroxyl group. To avoid a similar problem with compound 34, the protecting 
function at C2 must be removed, before deprotection of the C20-hydroxyl group. 
It is known that an imidazole-N-carbamate function can be removed with a mixture of 
pyridine/H20 (3/1, v/v) or with 0.5 M NaOH in a mixture of dioxane/H20 (1/1, v/v).12b Treatment of 
34 with the pyridine/H20 mixture, however, gave no reaction. Compound 34 was completely 
recovered. Treatment of 34 with 0.5 M NaOH in dioxane/water gave a mixture of at least five 
products, which could not be isolated or identified. Therefore, compound 34 was also not 
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investigated further. 
Because of the relative stability of the imidazole-N-carbamate function at C2, it was decided to 
deprotect the C20-hydroxyl group of 33 in the presence of the carbamate group. Surprisingly, 
treatment of 33 with Bu„NF afforded compound 27, in which the C20-hydroxyl as well as the C2-
hydroxyl group was deprotected (scheme 6.12). Contrary to what was expected from models, 
treatment of 27 with Bu4NOAc in butanone at reflux temperature led to the formation of compound 
36 in 56 % yield.14 
Scheme 6.12 
H i " /о-Ч 
0 I о 
1 OSirBuMe2 
33 27 36 
(a) Bu<NF; 75 %. (b) Bu4NOAc/A; 56 %. 
6.3.3 Using an Acid-Labile Function for the Protection of the C2-
hydroxyl Group 
It was demonstrated in the preceding section that the C2-hydroxyl group does not react under 
basic conditions. Therefore, acid-labile protecting groups were considered next. It should be 
reminded that the THP-group at the C2-hydroxyl group cannot be removed (see chapter 3) in the 
case of related taxanes. The ethoxyethyl group is more acid-labile15 and therefore considered as an 
attractive alternative for the protection of the C2-hydroxyl group in compound 3.16 
Treatment of compound 3 with ethyl vinyl ether in the presence of PTS gave compound 37 in 72 
% yield (scheme 6.13), after purification via chromatography using silicagel pretreated with Et3N 
and eluent to which also Et3N was added. To avoid premature removal of the ethoxyethyl group, 
Et3N was used in the chromatographic purification of all products described in this section. 
In the next step, compound 37 was converted to 38 with 20 N NaOH in THF at reflux 
temperature. For the construction of the oxetane ring the C4-C20 double bond was cis-
dihydroxylated with Os04 in the presence of NMMO giving compound 39. The primary hydroxyl 
group of 39 was then silylated using /-butyldimethylsilyl chloride in the presence of imidazole, 
yielding 40. Mesylation of the secondary hydroxyl group at C5 resulted in compound 41. 
Deprotection of the primary hydroxyl group with Bu4NF afforded 42 in a yield of 85 %. Oxetane 
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compound 43 was isolated in 77 %, when 42 was treated with Bu4NOAc in butanone at reflux 
temperature. 
Following the synthetic route depicted in scheme 6.2 but now with the ethoxyethyl group as 
protecting group, compound 43 can be converted to l,7-dideoxy-9-acetyl-9(R)-dihydropaclitaxel 
(12) Due to lack of time, this conversion could not be completed, however, the prospects are very 
good.17 
Scheme 6.13 
(a) Ethyl vinyl ether/PTS, 72 % (b) 20 N NaOH/Δ, 76 % (c) Os04/NMMO, 66 % (d) /-BuMe2SiCl/imidazole, 100 % 
(e) Mesyl chlonde/pyndine, 75 % (f) Bu4NF, 85 % (g) Bu4NOAc/A, 77 % 
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6.4 Conclusions 
Some synthetic routes toward 1,7-dideoxypaclitaxel analogs starting from taxine B, have been 
studied. A key step in these routes was the (selective) protection of the C2-hydroxyl group. 
Protection of the C2-hydroxyl group with an allyl or benzyl group, before or after the removal of 
the cinnamoyl side chain at C5 (schemes 6.4 and 6.6) was not possible. Silylation of the C2-
hydroxyl group in the presence of the C5-cinnamoyl side chain, however, was readily accomplished 
(scheme 6.3). 
It should be noted that selective silylation of the C2-hydroxyl group was not possible in the 
presence of the free C5-hydroxyl group. On the contrary, it was the latter which was selectively 
silylated. This finding made it impossible to follow the standard protocol for the introduction of the 
oxetane ring. 
The approach in which the C4,C5-hydroxyl groups were protected as a cyclic carbonate, which 
in a later stage should act as a leaving group in the construction of the oxetane ring (under release of 
C02), was also not successful. The C20-hydroxyl group did not attack at C5, but instead reacted 
with the carbonyl of the cyclic carbonate, which therefore migrated from the C4.C5- to the C4-C20-
hydroxyl groups, yielding compound 36 (scheme 6.12). 
Finally, the ethoxyethyl group appeared to be a suitable protective group for the protection of the 
C2-hydroxyl group in the synthesis of 1,7-dideoxypaclitaxel analogs (scheme 6.2), because the 
introduction of the oxetane ring (scheme 6.13) proceeded very smoothly. The route toward 1,7-
dideoxypaclitaxel analogs can now be completed as is depicted in scheme 6.2. 
6.5 Experimental Section 
Proton magnetic resonance spectra were measured on a Bruker AC-100 or a Bruker AM-400 
spectrometer. Chemical shift values are reported as δ-values relative to tetramethylsilane as an 
internal standard; deuterochloroform was used as solvent. Mass spectra were obtained with a double 
focusing VG 7070E spectrometer. Elemental analyses were carried out on a Carlo Erba Instruments 
CHNSO EA 1108 element analyzer. For the determination of optical rotations a Perkin-Elmer 241 
Polarimeter was used. Melting points were determined with a Reichert Thermopan microscope and 
are uncorrected. Thin layer chromatography was carried out on Merck precoated silica gel 60 F-254 
plates (thickness; 0.25 mm). All reactions mentioned were monitored by TLC. Spots were 
visualized with UV or a 6.2 % H2S04 aqueous solution, (IL) containing ammonium molybdate (42 
g) and eerie ammonium sulfate (3.6 g), followed by charring. Column chromatography was carried 
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out using silica 60 or silica 60H (Merck) Unless otherwise stated, materials were obtained from 
commercial sources and used without further purification When necessary, solvents were distilled 
and dried according to standard procedures 
9,10-O-(Propane-2,2-diyl)-5a-cinnamoyltaxicin-II (3). The synthesis and isolation of compound 3 was already 
discussed in chapter 4 m the synthesis of compound 19, section 4 6 
2-Tnmethylsilyl-9,10-O-(propane-2,2-diyl)-Sa-cinnanioyltaxicin-H (13). To a stirred solution of imidazole (190 
mg, 2 79 mmol) and trimethylsilyl chloride (153 μΐ, 1 21 mmol) in DMF (5 ml), after 15 minutes compound 3 (100 mg, 
0 192 mmol) was added The reaction mixture was stirred for one hour at room temperature The reaction mixture was 
diluted with a 10 % citric acid solution (aq) (25 ml) and extracted twice with EtOAc (30 ml) The combined organic 
layers were washed with brine, dried over NaiSOj and concentrated in vacuo The residue was purified via 
chromatography (EtOAc/hexane 2/5), yielding 13 (106 mg, 0 179 mmol, 93 %) m ρ 72 °C Ή-NMR (400 MHz, 
CDCIj) δ 5 24 (IH, s, H20a), 5 22 (IH, s, H20b), 4 92 (IH, d, J 1 M = 9 2 Hz, НЮ), 4 25 (2H, m, H2 and H5), 4 19 (IH, 
d, J, ,0 = 9 2 Hz, H9), 3 28 (IH, d, J, 2 = б 2 Hz, НЗ), 2 81 (IH, dd, J,4l l 4 b = 19 7 Hz, J, 4 l, = 7 0 Hz, H14a), 2 36 (IH, 
dd, J, „. = 7 0 Hz, J,, = 2 2 Hz, HI), 2 19 (IH, d, J14b.,4l = 19 7 Hz, H14b), 2 08 (3H, s, H18), 2 02 (IH, d, J™, = 7 3 
Hz, C5-OH), 1 69 (4H, m, 2H6 and 2H7), 1 67 (3H, s, H16), 1 49 (3H, s, acetonide), 1 44 (3H, s, acetonide), 1 25 (3H, 
s, H17), 1 03 (3H, s, H19), FAB-MS, 615 [M+Na]\ Anal Caled for C„H4,06Si 0 5H20 C, 69 85, H, 8 21 Found С, 
69 51, H, 8 19 
Attempted synthesis of 2-allyl-9,10-O-(propane-2,2-diyl)-5a-cinnamoyltaxicin-II (14). 1(a) To a solution of 3 
(50 mg, 0 096 mmol) in toluene (2 ml), NaOH (powder) (50 mg, 1 3 mmol) and allyl bromide (12 5 μΙ, 0 14 mmol) 
were added The reaction mixture was stirred for 5 hours at RT Then the mixture was heated to 80 °C After 24 hours, 
the mixture was diluted with EtOAc (25 ml) and washed with water, then with brine, dried over Na2S04 and 
concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), recovering the starting 
compound 3 
1(b) To a solution of 3 (50 mg, 0 096 mmol) in THF (2 ml), NaH (3 9 mg, 60 % dispersion in oil, 0 10 mmol) and 
allyl bromide (10 0 μΐ, 0 12 mmol) were added The reaction mixture was stirred at RT for 4 hours Then the reaction 
mixture was heated to 80 °C After stirring for 24 hours at this temperature, the mixture was diluted with EtOAc (25 ml) 
and washed with water, then with brine, dried over Na 2S0 4 and concentrated in vacuo The residue was purified via 
chromatography (EtOAc/hexane I/I), recovering the starting compound 3 
Attempted synthesis of 2-benzyl-9,10-O-(propane-2,2-diyl)-5a-cinnamoyltaxicin-II (15). To a solution of 3 (50 
mg, 0 096 mmol) in THF (2 ml), NaH (3 9 mg, 60 % dispersion in oil, 0 10 mmol), Bu4NI (3 5 mg, 0 0097 mmol) and 
benzyl bromide (I I 5 μΙ, 0 097 mmol) were added The reaction mixture was stirred at RT for 4 days Then the reaction 
mixture was heated to 40 °C After stirring for 1 hour, the mixture was heated to 80 °C After stirring for 24 hours at 
this temperature, the mixture was diluted with EtOAc (25 ml) and washed with water, then with brine, dried over 
NajS04 and concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), recovering the 
starting compound 3 
Hydrolysis of 3 -> 16. To a solution of 3 (300 mg, 0 577 mmol) m THF (4 ml), 20 N NaOH (2 5 ml) was added 
The reaction mixture was stirred at reflux temperature for 18 hours Then the mixture was diluted with CH2C12 (25 ml) 
and washed with water and the with brine The organic layer was dried over Na2S04 and concentrated m vacuo The 
residue was purified via chromatography (EtOAc/hexane 1/1), yielding 16 (177 mg, 0 454 mmol, 79 %) m ρ 119 °C 
Ή-NMR (400 MHz, CDCl,) δ 5 24 (IH, s, H20a), 5 22 (IH, s, H20b), 4 92 (IH, d, J10., = 9 2 Hz, НЮ), 4 25 (2H, m, 
H2 and H5), 4 19 (IH, d, J,.,0 = 9 3 Hz, H9), 3 29 (IH, d, J, 2 = 6 2 Hz, НЗ), 2 81 (IH, dd, J14, ,4b =19 7 Hz, J,4. , = 7 0 
Hz, H14a), 2 37 (IH, dd, J, ,4 l = 7 0 Hz, J, 2 = 2 3 Hz, HI), 2 19 (IH, d, J14b l 4 a = 19 7 Hz, H14b), 2 08 (3H, s, H18), 
2 01 (IH, d, J 0 H 5 = 7 3 Hz, OH), 1 69 (4H, m, 2H6 and 2H7), 1 67 (3H, s, H16), 1 49 (3H, s, acetonide), 1 44 (3H, s, 
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acetomde), 1 23 (3H, s, H17), 1 03 (3H, s, H19), FAB-MS, 391 [M+H]+, 413 [M+Na]\ Anal Caled for C
a
H M 0 5 C, 
70 74, H, 8 78 Found C, 70 83, H, 8 50 
Attempted allylation of 16 -» 17. The same procedures were followed as for 14, using 16 (50 mg, 0 128 mmol) 
Compound 17 was not isolated, instead for both methods, 16 was fully recovered 
Attempted benzylation of 16 -> 18. The same procedure was followed as for 15, using 16 (50 mg, 0 128 mmol) 
Compound 18 was not isolated, instead, 16 was fully recovered 
Attempted benzoylation of 16 -> 19. To a solution of 16 (50 mg, 0 128 mmol) in EtOAc (3 ml), Et3N (21 4 μΙ, 
0 154 mmol), DMAP (1 6 mg, 0 013 mmol) and benzoyl chloride (16 3 μΐ, 0 141 mmol) were added The reaction 
mixture was stirred at RT for 24 hours Then the mixture was heated to reflux temperature and stirred for another 24 
hours The reaction mixture was diluted with EtOAc (20 ml) and washed with water, then with brine, dried over 
Na2S04 and concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), recovering the 
starting compound 16 
Reaction of 16 with r-butyldimethylsilyl chloride. To a solution of imidazole (125 mg, 1 84 mmol) and t-
butyldimethylsilyl chloride (114 mg, 0 771 mmol) in DMF (3 ml), 16 (50 mg, 0 128 mmol) was added The reaction 
mixture was stirred for 24 hours at RT Subsequently the mixture was diluted with a 10 % citric acid solution (aq) (15 
ml) and extracted twice with EtOAc (20 ml) The combined organic layers were washed with brine, dried over Na^C^ 
and concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane I/I), recovermg starting 
compound 16 
Preparation of compound 20. The same procedure was followed as mentioned above, using isopropyldimethylsilyl 
chloride (120 μ|, 0 775 mmol) Compound 20 was isolated in 99 % yield (75 mg, 0 127, 99 %) m ρ 116 "С Ή-NMR 
(400 MHz, CDCI,) δ 5 15 (IH, s, H20a), 5 04 (IH, s, H20b), 4 88 (IH, d, J 1 M = 9 3 Hz, H10), 4 33 (IH, dd, J 2 , = 5 3 
Hz, J 2 , = 2 0 Hz, H2), 4 18 (IH, d, J, 10 = 9 3 Hz, H9), 4 05 (IH, bs, H5), 3 04 (IH, d, J, 2 = 5 7 Hz, H3), 2 70 (IH, dd, 
Ji«.i4b= 197Hz, J „ . , = 7 1 Hz,H14a),240(lH,d,J 1 4 b . l 4 .= 19 7 Hz, H14b),2 18 (lH.dd, J, 1 4 l = 69Hz, J, 2 = I 8 Hz, 
Hl), 2 06 (3H, s, H18), 1 65 (3H, s, H16), 1 49 (3H, s, acetonide), 1 43 (3H, s, acetomde), 1 18 (3H, s, H17), 1 01 (3H, 
s, H19), 0 95 (14H, m, SiCH(CH,)2), 0 11 (6H, m, Si(CHj)2), -0 13 (6H, m, Si(CH,)2), FAB-MS, 591 [M+H]\ 613 
[M+Na]* 
Preparation of compound 21 and 23. The same procedure was followed as mentioned above, using triethylsilyl 
chloride (63 μΐ, 0 384 mmol) Compound 21 was isolated in 34 % yield (22 mg, 0 0437, 34 %) and compound 23 was 
isolated in 62 % yield (49 mg, 0 0793 mmol, 62 %) 
Compound 21 m ρ 97 "С Ή-NMR (400 MHz, CDCI,) δ 5 22 (IH, s, H20a), 5 08 (IH, s, H20b), 4 88 (IH, d, J I M 
= 9 3 Hz, H10), 4 18 (3H, m, H2, H5 and H9), 3 17 (IH, d, J,
 2 = 6 9 Hz, H3), 2 78 (IH, dd, J,4. ,4b = 19 6 Hz, J l 4 . , = 
7 2 Hz, H14a), 2 39 (IH, dd, J,
 l 4 l = 7 1 Hz, J,, = 2 4 Hz, HI), 2 16 (IH, d, J14b „. = 19 8 Hz, H14b), 2 06 (3H, s, HI8), 
1 66 (3H, s, H16), 1 49 (3H, s, acetonide), 1 43 (3H, s, acetonide), 1 22 (3H, s, H17), 1 02 (3H, s, H19), 0 90 (9H, m, 
Si(CH£H,),), 0 55 (6H, m, SifÇHjCH,),), FAB-MS, 505 [M+H]+, 527 [M+Na]\ Anal Caled for C»H„OjSi C, 
69 00, H, 9 58 Found С, 68 69, H, 9 28 
Compound 23 m ρ 72 "С Ή-NMR (400 MHz, CDCI3) δ 5 18 (IH, s, H20a), 5 08 (IH, s, H20b), 4 91 (IH, d, J I M 
= 9 3 Hz, НЮ), 4 39 (IH, dd, J 2 3 = 5 9 Hz, J2, = 2 0 Hz, H2), 420 (IH, d, J, l 0 = 9 3 Hz, H9), 4 08 (IH, bs, H5), 3 07 
(IH d, J3 2 = 5 8 Hz, H3), 2 73 (IH, dd, J ] 4 l 14b = 19 7 Hz, J l 4 . , = 7 2 Hz, H14a), 2 45 (IH, d, J,4b l 4 l = 19 7 Hz, HI4b), 
2 22 (IH, dd, J,
 1 4 l = 7 0 Hz, J, 2 = 1 8 Hz, Hl), 2 09 (3H, s, H18), 1 68 (3H, s, HI6), 1 52 (3H, s, acetonide), 1 46 (3H, 
s, acetonide), 1 21 (3H, s, H17), 1 05 (3H, s, H19), 0 97 (18H, m, Si(CH,CH,U 0 58 (6H, m, Si(CH,CH,U 0 57 (6H, 
m, Si(CH,CH,U. FAB-MS, 619 [М+НГ\ 641 [M+Na]\ Anal Caled for C35H6205Si2 0 5H20 C, 66 93, H, 10 11 
Found С, 66 84, H, 9 81 
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Desilylation of 23 -• 21 and 16. To a solution of 23 (30 mg, 0 0485 mmol) in THF (3 ml), Bu4NF (97 μΙ 1 M in 
THF, 0 097 mmol) was added The reaction mixture was stirred for 5 minutes at RT Subsequently the mixture was 
diluted with EtOAc (20 ml) and washed with a saturated NaHCOj solution, then with brine The organic layer was dried 
over Na2S04 and concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 2/5), yielding 
21 (18 mg, 0 0357 mmol) and 16 (3,4 mg, 0 00871 mmol) 
Dihydroxylation of 21 -* 24. To a solution of 21 (1 01 g, 2 00 mmol) in a mixture of THF/H20 (2/1, v/v), NMMO 
(1 38 g) and Os04 (2 0 ml 2 5 % Os04 in i-BuOH) was added The reaction mixture was stirred for 24 hours at RT 
Subsequently the mixture was diluted with EtOAc and washed with water and then with brine The organic layer was 
dried over NajSO« and concentrated m vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), 
yielding 24 (730 mg, 1 36 mmol, 68 %) m ρ 61 "С Ή-NMR (400 MHz, CDCl,) δ 4 74 (IH, d, J 1 M = 9 3 Hz, H10), 
4 29 (IH, d, J 2 0 l 2 0 6 = 11 6 Hz, H20a), 4 18 (3H, m, H2, H9 and H20), 3 91 (IH, bs, H5), 3 55 (IH, bs, OH), 3 41 (IH, 
bs, OH), 2 78 (IH, dd, J,4, ,4b =19 8 Hz, J H . , = 6 8 Hz, H14a), 2 55 (IH, d, J l 4 b l 4. = 19 8 Hz, H14b), 2 36 (IH, m, Hl), 
2 23 (IH, d, J,, = 4 8 Hz, H3), 2 00 (3H, s, H18), 1 64 (3H, s, H16), 1 47 (3H, s, acetonide), 1 42 (3H, s, acetonide), 
1 24 (3H, s, H17), 1 09 (3H, s, H19), 0 94 (9H, m, Si(CH,CH,U 0 65 (6H, m, Si(CH7CH,),ì. FAB-MS, 539 [M+H]+, 
561 [M+Na]*, Anal Caled for C2,HS0O7Si 0 5H20 C, 63 58, H, 9 38 Found С, 63 55, H, 9 22 
Silylation of 24 -> 25. To a solution of imidazole (1 4 g, 20 mmol) and f-BuMe2SiCI (1 2 g, 8 1 mmol) m DMF (10 
ml), a solution of 24 (0 73 g, 1 36 mmol) in DMF (10 ml) was added The reaction mixture was stirred for 1 hour at RT 
Then the mixture was diluted with EtOAc (100 ml) and washed with a 10 % citric acid solution (aq) (50 ml) and then 
with brine The organic layer was dried over Na2S04 and concentrated m vacuo The residue was purified via 
chromatography (EtOAc/hexane 2/5), yielding 25 (887 mg, 1 36 mmol, 100 %) m ρ 37 "С Ή-NMR (400 MHz, 
CDCl,) δ 4 75 (IH, d, J 1 M = 9 3 Hz, H10), 4 69 (IH, d, J 2 O l 2 0 b = 10 6 Hz, H20a), 4 24 (IH, d, J 2 0 b 2 O l =10 5 Hz, H20b), 
4 17 (IH, d, J,
 10 = 9 4 Hz, H9), 4 13 (IH, bd, J = 5 5 Hz, H2), 3 80 (IH, bs, H5), 3 67 (IH, bs, OH), 3 51 (IH, bs, OH), 
2 86 (IH, d, J l4b.,4l = 19 6 Hz, H 14b), 2 73 (IH, dd, J,4. „„ = 19 5 Hz, J 1 4 l , = 6 7 Hz, H14a), 2 37 (IH, d, Jj 2 = 5 01 Hz, 
H3), 2 28 (IH, dd, J, ,4l = 6 5 Hz, J, 2 = 1 8 Hz, Hl), 2 02 (3H, s, H18), 1 62 (3H, s, H16), 1 47 (3H, s, acetonide), 1 42 
(3H, s, acetonide), 1 20 (3H, s, H17), 1 07 (3H, s, H19), 0 94 (18H, m, 9xSit-Bu and 9xSi(CH2ÇHJ)J), 0 57 (6H, m, 
Si(CH,CH,U 0 08 (6H, s, SiMe2), FAB-MS, 653 [M+H]\ 675 [M+Na]+, Anal Caled for C,sHH07Si2 0 5H20 C, 
63 49, H, 9 90 Found С, 63 62, H, 9 77 
Mesylation of 25 -> 26. A solution of 25 (800 mg, I 23 mmol) in pyridine (15 ml) was cooled to 0 °C After 
stirring for 15 minutes, mesyl chloride (1 1 ml) was added The reaction mixture was warmed up to RT and then stirred 
for 2 hours The mixture was diluted with CH2C12 (50 ml) and washed with a 10 % citric acid solution (aq) (40 ml) and 
then with brine The organic layer was dried over Na2SO„ and concentrated in vacuo The residue was purified via 
chromatography (EtOAc/hexane 2/5), yielding 26 (862 mg, 1 18 mmol, 96 %) m ρ 61 °C Ή-NMR (400 MHz, 
CDCIj) δ 5 29 (IH, dd, J 2 , = 4 3 Hz, J 2, = 1 6 Hz, H2), 4 76 (IH, d, J 1 M = 9 3 Hz, H10), 4 20 (IH, d, J, ,0 = 9 3 Hz, 
H9), 4 02 (IH, d, J 2 0 l m = 10 7 Hz, H20a), 3 80 (IH, bs, H5), 3 65 (IH, d, J20tb2O, = 10 7 Hz, H20b), 3 42 (IH, d, J l 4 b ,4. 
= 19 6 Hz, H14b), 3 17 (IH, bs, OH), 3 05 (3H, s, mesyl), 2 74 (IH, dd, J, 4 b l 4 b = 19 8 Hz, J l 4 l , = 4 3 Hz, H14a), 2 59 
(IH, bd, J = 8 02 Hz, Hl), 2 53 (IH, d, J,
 2 = 4 3 Hz, H3), 2 03 (3H, s, H18), 1 69 (3H, s, H16), 1 48 (3H, s, acetonide), 
1 43 (3H, s, acetonide), 1 22 (3H, s, H17), 1 13 (3H, s, H19), 0 93 (18H, m, 9xSit-Bu and 9xSi(CH2ÇHJ)1), 0 60 (6H, 
m, SitÇJLCHj),), 0 08 (6H, s, SiMe2), FAB-MS, 753 [M+Na]+, Anal Caled for C^H^OçSijS C, 59 14, H, 9 10, S, 
4 39 Found С, 59 20, H, 9 04, S, 3 98 
Dihydroxylation of 16 -» 30. The same procedure was followed as for 24, using 16 (217 mg, 0 556 mmol) 
Compound 30 was isolated in 50 % yield (117 mg, 0 276 mmol) m ρ 102 "С Ή-NMR (400 MHz, CDCl,) δ 4 82 
(IH, d, J,,,., = 9 3 Hz, НЮ), 4 28 (IH, d, J 2 0 > 2 № = 10 7 Hz, H20a), 4 23 (IH, m, H2), 4 18 (IH, d, J, ,„ = 9 3 Hz, H9), 
3 71 (IH, s, OH), 3 67 (2H, m, H5 and H20b), 2 80 (2H, m, H14aand H14b), 2 55 (IH, d, J, 2 = 4 7 Hz, H3), 2 31 (IH, 
m, Hl), 2 04 (3H, s, H18), 1 65 (3H, s, H16), 1 47 (3H, s, acetonide), 1 42 (3H, s, acetonide), 1 24 (3H, s, H17), 1 09 
(3H, s, H19), FAB-MS, 447 [M+Na]*, Anal Caled for C2,H,607 0 5H20 C, 63 72, H, 8 60 Found С, 63 40, H, 8 18 
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Silylation of 30 -* 31. The same procedure was followed as for 25, using 30 (108 mg, 0 254 mmol) Compound 31 
was isolated in 82 % yield (112 mg, 0 208 mmol) m ρ 172 °C 'H-NMR (400 MHz, CDC13) 8 4 82 (IH, d, J , M = 93 
Hz, H10), 4 62 (IH, d, JC 2 0 H j = 9 0 Hz, C20H), 4 41 (IH, s, OH), 4 26 (IH, d, J 2 0 , m = 9 8 Hz, H20a), 4 18 (2H, m, H2 
and H9), 3 56 (IH, d, J2№.20t = 9 8 Hz, H20b), 3 53 (IH, bs, H5), 2 81 (2H, m, H14a and H14b), 2 56 (IH, d, J3 2 = 5 2 
Hz, H3), 2 42 (IH, s, OH), 2 32 (IH, m, Hl), 2 04 (3H, s, H18), I 64 (3H, s, H16), 1 47 (3H, s, acetonide), 1 42 (3H, s, 
acetonide), 1 23 (3H, s, H17), 1 06 (3H, s, H19), 0 91 (9H, s, Sit-Bu), 0 10 (6H, s, SiMe2), FAB-MS, 539 [M+H]*, 561 
[M+Na]\Anal Caled for C2,HTO0,Si C, 64 65, H, 9 35 Found С, 64 31, H, 9 03 
Preparation оГ compounds 32 and 33. To a solution of 31 (74 mg, 0 138 mmol) in butanone (3 ml), 1,1-
carbonyldumidazole (134 mg, 0 820 mmol) was added The reaction mixture was stirred for 24 hours at reflux 
temperature Then the mixture was diluted with EtOAc (50 ml) and washed with water The organic layer was dried 
over NajS04 and concentrated in vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), yielding 
32 (24 mg, 0 0380 mmol, 28 %) and 33 (39 mg, 0 0593 mmol, 43 %) 
Compound 32 m ρ 113 "С 'H-NMR (400 MHz, CDC1,) δ 8 15 (IH, s, H(im)), 7 43 (IH, s, H(im)), 7 08 (IH, s, 
H(im)), 5 72 (IH, m, H2), 4 87 (IH, d, J 1 M = 9 2 Hz, H10), 4 29 (IH, d, J, ,„ = 9 2 Hz, H9), 3 83 (IH, s, OH), 3 49 (4H, 
m, H5, H14b, H20a and H20b), 2 89 (IH, d, J3 2 = 4 6 Hz, H3), 2 77 (IH, dd, JM, l 4 b = 19 7 Hz, J M t , = 6 5 Hz, H14a), 
2 71 (IH, s, OH), 2 24 (IH, m, Hl), 2 09 (3H, s, H18), 1 76 (3H, s, H16), 1 52 (3H, s, acetonide), 1 45 (3H, s, 
acetonide), 1 26 (3H, s, H17), 1 04 (3H, s, H19), 0 83 (9H, s, Sit-Bu), -0 04 (3H, s, SiMe), -0 17 (3H, s, SiMe), FAB-
MS, 1266 [2M+2H]*, 655 [M+Na]*, Anal Caled for C„H5 208N2Si 0 5H20 C, 61 75, H, 8 32, N, 4 36 Found С, 
61 45, H, 8 05, Ν, 3 95 
Compound 33 m ρ 96 "С 'H-NMR (400 MHz, CDC13) δ 8 22 (IH, s, H(im)), 7 48 (IH, s, H(im)), 7 15 (IH, s, 
H(im)), 5 77 (IH, dd, J 2 3 - 6 2 Hz, J 2 , = 2 6 Hz, H2), 4 93 (IH, bs, H5), 4 85 (IH, d, J 1 M = 9 3 Hz, H10), 4 32 (IH, d, 
J, ,0 = 94 Hz, H9), 3 84 (IH, d, J2 0,2 O b = 11 9 Hz, H20a), 3 66 (IH, d, J 2 0 b 2 O l = 12 0 Hz, H20b), 2 93 (IH, dd, J H . ,„„ = 
20 0 Hz, J H . , = 5 6 Hz, H14a), 2 82 (IH, d, J14b M l = 20 0 Hz, H14b), 2 47 (IH, d, J, 2 = 6 1 Hz, H3), 2 37 (IH, m, Hl), 
2 05 (3H, s, H18), 1 78 (3H, s, H16), 1 53 (3H, s, acetonide), 1 46 (3H, s, acetonide), 1 26 (3H, s, H17), 1 23 (3H, s, 
H19), 0 78 (9H, s, Sit-Bu), -0 14 (3H, s, SiMe), -0 15 (3H, s, SiMe), FAB-MS, 659 [M+H]*, 681 [M+Na]\ Anal 
Caled for C„H50O,N2Si 0 5H20 C, 61 15, H, 7 70, N, 4 19 Found С, 61 09, H, 7 52, Ν, 3 97 
Mcsylation of 32 -> 34 and 35. The same procedure was followed as for 26, using 32 (297 mg, 0 470 mmol) 
Compound 34 was isolated in 46 % (155 mg, 0 218 mmol) and compound 35 was isolated in 44 % yield (145 mg, 
0 209 mmol) 
Compound 34 m ρ 102 °C 'H-NMR (400 MHz, CDC13) 6 8 14 (IH, s, H(im)), 7 42 (IH, s, H(im)), 7 08 (IH, s, 
H(im)), 5 70 (IH, m, H2), 4 84 (IH, d, J10_, = 9 2 Hz, H10), 4 73 (IH, bs, H5), 4 29 (IH, d, J, l 0 = 9 3 Hz, H9), 3 89 
(IH, s, OH), 3 49 (ЭН, m, H3, H20a and H20b), 3 03 (3H, s, mesyl), 2 78 (2H, m, H14a and H14b), 2 26 (IH, m, HI), 
2 13 (3H, s, H18), 1 75 (3H, s, H16), 1 51 (3H, s, acetonide), 1 44 (3H, s, acetonide), 1 26 (3H, s, H17), I 07 (3H, s, 
Η19), 0 85 (9H, s, Sit-Bu), 0 07 (3H, s, SiMe), -0 16 (3H, s, SiMe), FAB-MS, 711 [M+H]+, 733 [M+Na]*, Anal Caled 
for C34H„O10N2SiS I 5H 20 C, 55 34, H, 7 79, N, 3 80, S, 4 35 Found C, 55 08, H, 7 50, N, 3 45, S, 4 26 
Compound 35 m ρ 109 °C 'H-NMR (400 MHz, CDC13) δ 5 33 (IH, m, H2), 4 83 (IH, d, J 1 M = 9 2 Hz, H10), 
4 68 (IH, bs, H5), 4 24 (IH, d, J, ,0 = 9 3 Hz, H9), 4 20 (IH, d, J 2 0 l 2 0 b = 1 0 5 Hz, H20a), 3 84 (IH, s, C4-OH), 3 48 
(IH, d, V 2 0 , = 10 5 Hz, H20b), 3 46 (IH, d, JM„ „, = 19 7 Hz, H14b), 3 08 (3H, s, mesyl), 3 02 (3H, s, mesyl), 2 80 
(IH, dd, J,„
 Mb = 19 7 Hz, J,^, = 7 0 Hz, H14a), 2 69 (IH, d, J 3 2 = 4 2 Hz, H3), 2 63 (IH, m, Hl), 2 13 (3H, s, H18), 
1 73 (3H, s, H16), 1 51 (3H, s, acetonide), 1 45 (3H, s, acetonide), 1 28 (3H, s, H17), 1 13 (3H, s, H19), 0 95 (9H, s, 
Sit-Bu). 0 16 (3H, s, SiMe), 0 15 (3H, s, SiMe), FAB-MS, 695 [M+H]*, 617 [M+Na]*, Anal Caled for C3,H„0„SiS 
C, 53 57, H, 7 83, S, 9 23 Found С, 53 48, H, 7 83, S, 8 11 
Deprotection of 34 (1) To a solution of 34 (141 mg, 0 199 mmol) m pyridine, water (1 ml) was added The 
reaction mixture was stirred for 24 hours at RT Then the mixture was diluted with CH2C12 (40 ml) and washed with a 
10 % citric acid solution (20 ml) The organic layer was washed with brine, dried over Na 2S0 4 and concentrated m 
vacuo The residue was purified via chromatography (EtOAc/hexane 1/1), recovering the starting compound 34 
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(2) To a solution of 34 (94 mg, 0 132 mmol) in dioxane (2 ml), 1 M NaOH (aq) (2 ml) was added The reaction 
mixture was stirred for 4 hours at RT According to TLC (EtOAc/hexane 1/1), more than five products had been 
formed, without a clear major product After 24 hours the situation had not changed The reaction was not worked up 
The products were not isolated or identified 
Desilylation of 33 -» 27. The same procedure was followed as in the desilylation of 22, using 33 (39 mg, 0 0S93 
mmol) Compound 27 was isolated in 75 % yield (21 mg, 0 0445 mmol) m p. 238 °C 'H-NMR (400 MHz, CDC1,) δ 
4 32 (IH, d, J,«., = 9 2 Hz, HIO), 4 77 (IH, bs, H5), 4 33 (IH, m, H2), 4 32 (IH, d, }20,.ш =13 4 Hz, H20a), 4 21 (IH, 
d, J,.,» = 9 4 Hz, H9), 3 96 (IH, d, J2 № 2 0 t = 13 4 Hz, H20b), 2 88 (IH, dd, J,^M = 19 8 Hz, J 1 4., = 7 1 Hz, H14a), 2 54 
(IH, d, J l 4 b.1 4. = 19 8 Hz, H14b), 2 40 (IH, dd, J, l 4 l = 7 0 Hz, J, 2 = 2 6 Hz, HI), 2 20 (IH, d, J, 2 = 6 1 Н А H3), 2 00 
(3H, s, H18), 1 67 (3H, s, H16), 1 49 (3H, s, acetonide), 1 43 (3H, s, acetonide), 1 24 (3H, s, H17), 1 18 (3H, s, H19), 
FAB-MS, 473 [M+H]*. Anal Caled for C 2 4 H„0 8 2H 20 C, 59 25, H, 7 87 Found C, 59 68, H, 7 22 
Preparation of 36. To a solution of 27 (30 mg, 0 0636 mmol) in butanone (2 ml), Bu<NOAc (72 mg, 0 24 mmol) 
was added The reaction mixture was stirred for 1 hour at reflux temperature Then the mixture was diluted with EtOAc 
(40 ml) and washed with a saturated NH„CI solution The organic layer was washed with brine, dried over Na 2S0 4 and 
concentrated in vacuo The residue was purified via chromatography (EtOAc), yielding 36 (16 mg, 0 0356, 56 %) m ρ 
292 "С Ή-NMR (400 MHz, CDC13) δ 4 82 (IH, d, J10., = 9 4 Hz, НЮ), 4 79 (IH, d, J2 0,2 0 Ь = 7 7 Hz, H20a), 4 46 (IH, 
m, H2), 4 16 (IH, d, J,
 10 = 9 5 Hz, H9), 3 90 (IH, d, J20b.2Ol = 13 4 Hz, H20b), 3 74 (IH, bs, H5), 2 94 (2H, m, H3 and 
H14b), 2 83 (IH, dd, J14, 14b = 20 0 Hz, J H l , = 6 8 Hz, H14a), 2 60 (IH, s, OH), 2 11 (IH, m, Hl), 2 04 (3H, s, H18), 
1 65 (3H, s, H16), 1 47 (3H, s, acetonide), 1 42 (3H, s, acetonide), 1 24 (3H, s, H17), 1 02 (3H, s, H19), FAB-MS, 451 
[M+H]*, 473 [M+Na]\ Anal Caled for C2„H,40„ 2H 20 C, 59 25, H, 7 87 Found С, 59 78, H, 7 38 
2-Ethoxyethyl-9,lO-0-(propane-2,2-diyl)-5a-cinnamoyltaxicin-II (37). То a solution of 3 (880 mg, I 69 mmol) 
in CH2C12 (10 ml), ethyl vinyl ether (2 4 ml, 25 1 mmol) and a catalytic amount of PTS were added The reaction 
mixture was stirred for 4 hours at RT Then 2 drops of pyridine were added and the mixture was diluted with CH2C12 
(75 ml) and washed with water and then with brine The organic layer was dried over Na,S04 and concentrated in 
vacuo The residue was purified via chromatography (EtOAc/hexane 2/5), yielding 37 (720 mg, I 22 mmol, 72 %) 
m ρ 56 °C Ή-NMR (400 MHz, CDC13) δ 7 74 (2H, m, H-Ph), 7 56 (IH, m, H5'), 7 42 (3H, m, H-Ph), 6 41 (IH, m, 
H6'), 5 73 (IH, bs, H5), 5 32 (2H, m, Н20а and H20b), 4 90 (IH, d, J,»., = 9 2 Hz, НЮ), 4 71 (IH, q, J = 5 2 Hz, 
HC(CHj)), 4 23 (IH, m, H9), 4 12 (IH, m, H2), 3 55 (2Н, m, Н2С(СН3)), 3 05 (IH, m, НЗ), 2 87 (IH, m, H14a), 2 62 
(IH, m, Hl), 2 45 (IH, m, H14b), 2 14 (3H, s, HI8), 1 67 (3H, s, H16), 1 51 (3H, s, acetonide), 1 44 (3H, s, acetonide), 
1 25 (3H, s, H17), 1 13 (3H, m, (CH)CH,), 1 10 (3H, s, H19), 0 86 (3H, m, (CH2)CH3), FAB-MS, 593 [M+H]*, 615 
[M+Na]*, Anal Caled for C 3 6H 4 90, H 2 0 C, 70 79, H, 8 25 Found С, 70 96, H, 7 95 
Hydrolysis of 37 -> 38. The same procedure was followed as for 16, using 37 (670 mg, 1 14 mmol) Compound 38 
was isolated in 76 % yield (400 mg, 0 867 mmol) m ρ 45 °C Ή-NMR (400 MHz, CDCI3) δ 5 35 (IH, bs, H20a), 5 11 
(IH, s, H20b), 4 92 (IH, d, J 1 0 9 = 9 2 Hz, НЮ), 4 70 (IH, q, J = 5 2 Hz, HC(CH,)), 4 25 (IH, d, J, ,„ = 9 3 Hz, H9), 
4 15 (2H, m, H2 and H5), 3 55 (2H, m, Н2С(СН3)), 3 20 (IH, m, НЗ), 2 80 (IH, dd, J1 4 l „„ = 19 8 Hz, J,4,, = 6 0 Hz, 
H14a), 2 52 (IH, dd, J,
 l 4 l = 6 0 Hz, J, 2 = 2 2 Hz, Hl), 2 26 (IH, d, J l 4 b „. = 19 7 Hz, H14b), 2 08 (3H, s, H18), 1 65 
(3H, s, H16), 1 49 (3H, s, acetonide), 1 44 (3H, s, acetonide), 1 21 (3H, s, Н17), 1 09 (ЗН, m, (СН)СН3), 1 02 (ЗН, s, 
H19), 0 91 (ЗН, m, (СН2)СН3), FAB-MS, 463 [М+Н]+, 485 [M+Na]\ Anal Caled for С27Н420„ 0 5Н20 С, 68 76, Н, 
9 19 Found С, 68 64, H, 9 01 
Dihydroxylation of 38 -> 39. The same procedure was followed as for 24, using 38 (396 mg, 0 857 mmol) 
Compound 39 was isolated in 66 % yield (280 mg, 0 565 mmol) m ρ 82 °C Ή-NMR (400 MHz, CDCI,) δ 4 83 (IH, 
d, J 1 M = 9 3 Hz, H10), 4 77 (IH, m, HC(CH3)), 4 34 (IH, bs, 20a), 4 16 (IH, bs, H20b), 4 13 (IH d, J, ,„ = 9 3 Hz, H9), 
3 97 (IH, bs, OH), 3 79 (IH, bs, H5), 3 56 (2H, m, H2C(CH3)), 2 87 (1 H, m, H 14a), 2 66 (1 H, m, H 14b), 2 59 (1 H, m, 
H3), 2 41 (IH, m, Hl), 2 05 (3H, s, H18), 1 66 (3H, s, H16), I 47 (3H, s, acetonide), 1 42 (3H, s, acetonide), I 24 (3H, 
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s, H17), 1 12 (3H, m, (CH)CH3), 1 07 (3H, s, H19), 0 88 (3H, m, (CH2)CH,), FAB-MS, 519 [Μ+Η]+, Anal Caled for 
C„H„0,0 5H20 C, 61 93, H, 9 05 Found C, 62 24, H, 8 43 
Silylation of 39 -> 40. The same procedure was followed as for 25, using 39 (280 mg, 0 565 mmol) Compound 40 
was isolated in 100 % yield (344 mg, 0 564 mmol) m ρ 61 "С Ή-NMR (400 MHz, CDC13) δ 4 82 (IH, d, J 1 M = 9 1 
Hz, HI0), 4 54 (IH, m, HC(CHj)), 4 41 (IH, bs, H20a), 4 25 (IH, m, H2), 4 15 (IH, d, J,.,0 = 9 2 Hz, H9), 4 05 (IH, bs, 
H20b), 3 60 (3H, m, H5 and H2C(CH3)), 3 00 (IH, m, H3), 2 58 (2H, m, H14a and H14b), 2 48 (IH, m, Hl), 2 04 (3H, 
s, H18), 1 60 (3H, s, H16), 1 47 (3H, s, acetonide), l 42 (3H, s, acetonide), 1 22 (3H, s, H17), 1 11 (3H, m, (CH)CH3), 
1 06 (3H, s, H19), 0 93 (3H, m, (CH2)CH3), 0 88 (9H, m, Sif-Bu), 0 05 (6H, m, SiMeJ, FAB-MS, 633 [M+Na]\ Anal 
Caled for C33Hs,0,Si 0 5H20 C, 63 94, H, 9 59 Found С, 64 14, H, 9 37 
Mesylation of 40 -> 41. The same procedure was followed as for 26, using 40 (300 mg, 0 492 mmol) Compound 
41 was isolated in 75 % yield (254 mg, 0 369 mmol) m ρ 79 °C Ή-NMR (400 MHz, CDClj) δ 4 88 (IH, bs, H5), 
4 81 (IH, d, J1 M = 9 2 Hz, НЮ), 4 57 (IH, q, J = 5 1 Hz, HC(CH3)), 4 33 (IH, d, Jjo, „„ = 11 0 Hz, H20a), 4 21 (IH, m, 
H2), 4 14 (IH, d, ¡%l(¡ = 9 2 Hz, H9), 3 73 (IH, d, J2M,20l = 11 0 Hz, H20b), 3 52 (2H, m, H2C(CH3)), 3 36 (IH, s, C4-
OH), 3 16 (IH, d, JMb ,4l = 19 7 Hz, H14b), 2 98 (3H, s, mesyl), 2 69 (IH, dd, J14l ,4b =19 7 Hz, J,4., = 6 9 Hz, H14a), 
2 45 (IH, d, J3 j = 4 4 Hz, H3), 2 16 (IH, m, Hl), 2 10 (3H, s, H18), 1 62 (3H, s, H16), 1 48 (3H, s, acetonide), 1 42 
(3H, s, acetonide), I 25 (3H, s, H17), 1 19 (3H, m, (CH)CH3), 1 11 (3H, s, H19), 0 93 (3H, m, (CH2)CH3), 0 88 (9H, m, 
Si/ Bu), 0 07 (6H, m, SiMe2), FAB-MS, 711 [M+Na]+, Anal Caled for C34HMO10SiS H20 C, 57 76, H, 8 84, S, 4 54 
Found С, 58 03, H, 8 41, S, 4 69 
Desilylation of 41 -» 42. The same procedure was followed as in the desilylation of 23, using 41 (225 mg, 0 327 
mmol) Compound 42 was isolated in 85 % yield (160 mg, 0 279 mmol) m ρ 115 "С Ή-NMR (400 MHz, CDC13) δ 
4 93 (IH, bs, H5), 4 82 (IH, d, J 1 M = 9 3 Hz, НЮ), 4 64 (IH, q, J = 5 1 Hz, HC(CH3)), 4 33 (IH m, H2), 4 33 (IH, d, 
J,„. г» = 11 6 Hz, H20a), 4 26 (IH, s, C4-OH), 4 24 (IH, m, H2), 4 18 (IH, d, J,.l0 = 9 3 Hz, H9), 3 95 (IH, d, J20b20. 
= 11 5 Hz, H20b), 3 53 (2H, m, H2C(CH3)), 3 02 (3H, s, mesyl), 2 88 (IH, d, J14b 14l = 19 7 Hz, H14b), 2 81 (IH, dd, J14t. 
14b = 19 7 Hz, J,,,., = 6 2 Hz, H14a), 2 44 (IH, d, J3 2 = 4 9 Hz, H3), 2 31 (IH, m, Hl), 2 08 (3H, s, H18), 1 65 (3H, s, 
H16), 1 47 (3H, s, acetonide), 1 42 (3H, s, acetonide), 1 26 (3H, s, H17), 1 18 (3H, m, (CH)CH3), 1 11 (3H, s, H19), 
0 92 (3H, m, (CH2)CH3), FAB-MS, 597 [M+Na]h, Anal Caled for C2eH46Ol0S 0 5H20 C, 57 60, H, 8 13, S, 5 49 
Found С, 57 62, H, 7 71, S, 5 02 
Construction of the Oxetane Ring: 42 -» 43. The same procedure was followed as for 36, using 42 (150 mg, 
0 261 mmol) Compound 43 was isolated in 77 % yield (96 mg, 0 201 mmol) m ρ 63 "С Ή-NMR (400 MHz, CDC13) 
δ 4 88 (IH, d, J20a20b = 8 1 Hz, H20a), 4 73 (IH, d, J I M = 9 4 Hz, H9), 4 64 (IH, q, J = 5 1 Hz, HC(CH3)), 4 36 (IH, bs, 
H5), 4 29 (IH, d, J20M0, = 8 6 Hz, H20b), 4 24 (IH, d, J, 10 = 9 3 Hz, H9), 4 09 (IH, m, H2), 3 50 (2H, m, H2C(CH3)), 
2 93 (IH, s, C4-OH), 2 73 (IH, d, J,4b 14l = 23 2 Hz, H 14b), 2 60 (IH, m, H3), 2 25 (IH, m, Hl), 2 02 (4H, m, H 14a, 
2H6 and H7), I 93 (3H, s, H18), 1 66 (3H, s, H16), 1 51 (3H, s, acetonide), 1 44 (3H, s, acetonide), 1 31 (3H, s, H17), 
1 22 (9H, m, (CH)CHj), (CH2)CH3) and H19), FAB-MS, 501 [M+Na]\ Anal Caled for C27H4207 0 75H20 C, 65 88, 
H, 8 93 Found С, 65 98, H, 8 76 
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Summary 
The diterpenoid paclitaxel (1) (figure 1), first isolated from the bark of the western yew Taxus 
brevi/olia, is a new and very promising antitumor compound. It has been approved by the FDA for 
the treatment of patients with advanced ovarian or breast cancer. 
Figure 1 
The structural complexity of 1, as well as its unique mechanism of action, have stimulated 
extensive research toward the synthesis of paclitaxel and new analogs. The synthesis of paclitaxel 
has been achieved both by semisynthesis, starting from 10-deacetylbaccatin III (2), and by total 
synthesis. 
The synthesis of analogs for Structure Activity Relationship (SAR) studies have mostly been 
accomplished by structural modification of paclitaxel itself. In several cases precursors isolated 
from the needles of different Taxus species were used, in the semisynthesis of paclitaxel analogs. 
Little attention has been given to taxine В (3), which is the most abundant precursor present in 
the needles of Taxus baccalà (figure 1), as a precursor for either the synthesis of paclitaxel or its 
analogs. A retrosynthetic analysis showed that the synthesis of paclitaxel itself from taxine В would 
require more than 20 steps. Especially, the incorporation of the 7-hydroxyl group was expected to 
be difficult. In this thesis the main efforts were directed toward the synthesis of 7-deoxypaclitaxel 
analogs, because in vitro assays showed that the 7-hydroxyl group had practically no effect on the 
cytotoxic activity. 
From SAR studies it is known that the oxetane ring, the paclitaxel side chain, and the hydroxyl 
group at C2' are important for cytotoxic activity and that the functional groups at the upper side of 
paclitaxel, viz. at C7, C9, and CIO, are of less importance for cytotoxic activity. At the start of the 
research described in this thesis the importance of substituents at the bottom side of paclitaxel, viz. 
at CI, C2, and C4, was virtually unknown. 
This thesis deals with the synthesis of some 7-deoxypaclitaxel analogs with structural changes at 
CI, C2, and C4. At positions C9 and CIO, all the analogs have either free hydroxyl groups or 
hydroxyl functions protected by an isopropylidene group. 
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In chapter 3. the isolation of crude taxine В (3a-f) and the conversion of this crude taxine В into 
the new 7-deoxypaclitaxel analogs 6, 7, 8, and 9 via oxetane compounds 4 and 5, respectively, is 
described (scheme 1). 
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The analogs 6, 7, 8 and 9 were tested for their cytotoxic activity against seven well-characterized 
human tumor cell lines. All analogs showed very low cytotoxic activity. The lack of activity can be 
attributed to the missing benzoate group at C2, which is in agreement with recent SAR studies. The 
removal of the THP group at C2 and the isopropylidene acetal at C1,C2 could not be achieved 
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without destruction of other parts of the molecule. Therefore an alternative strategy is needed for the 
synthesis of 7-deoxypaclitaxel analogs having the C2-benzoate functionality, necessary for 
cytotoxic activity. 
Chapter 4 is devoted to a strategy for the synthetic modification of taxine В whereby the CI- and 
C2-hydroxyl groups are protected simultaneously in such manner that the protecting group can be 
converted directly into the C2-benzoate group which is essential for the cytotoxic activity. For this 
purpose the cyclic carbonate was first selected. The starting material was compound 10 in which the 
hydroxyl groups at C9 and CIO are protected by an isopropylidene group. The desired benzoate was 
readily introduced by reaction of 10 with 1,1-carbonyldiimidazole (scheme 2). Subsequent 
treatment with phenyllithium resulted in the formation of 12 in which the cyclic carbonate has been 
opened regioselectively to the C2-benzoate group with concomitant removal of the cinnamoyl group 
atC5. 
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The construction of the oxetane ring, however, could not be accomplished, because the benzoyl 
group at C2 migrated to the primary C20-hydroxyl group during the deprotection of the C20-
hydroxyl group of 13, which is an essential intermediate in the formation of the four-membered 
ring, leading to the undesired product 14. 
As an alternative a masked carbonate function was considered. However, treatment of 10 with 
tetramethyl or tetraethyl orthocarbonate, in the presence of p-toluenesulfonic acid did not result in 
the protected substrate 15 or 16, respectively (scheme 2). Hence, this method had to be abandoned 
as well. 
The third possibility for this strategy involved the use of a benzylidene acetal for the protection 
of the CI- and C2-hydroxyl groups. This group was readily introduced by treatment of 10 with 
benzaldehyde dimethyl acetal (scheme 3). The starting material also contained some 17 which was 
recovered during this transacetalization. Cyclic acetal 18 was converted in compound 19 containing 
the oxetane ring. The standard methodology for the introduction of this four-membered ring 
proceeded without any difficulties. For the opening of cyclic acetal 19 to the desired C2-benzoate 
the use of tert-butyl hydroperoxide in the presence of a catalytic amount of Pd(OAc)2 was most 
successful in producing compound 20. In the literature there is no precedent for the use of the 
benzylidene acetal in taxane chemistry. In view of the results presented in chapter 4, this group may 
have interesting prospects for the protection of the CI- and C2-hydroxyls and for the introduction of 
the essential C2-benzoate group. 
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In chapter 5, four different strategies, involving the use of the benzylidene acetal at C1,C2 for the 
synthesis of 7-deoxypaclitaxel analogs containing the C2-benzoate group are described. The 
essential differences between these strategies are the variations in the sequence of three events, viz. 
the reduction of the C13-carbonyl group, the coupling to the paclitaxel side chain and the oxidative 
opening of the benzylidene group played a key role and in fact, determined the success of this 
method to prepare paclitaxel analogs. Two of the four strategies were completed successfully. The 
first one involving successive reduction, coupling and opening resulted in the analogs 21, 22 and 23 
(figure 2). 
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The second strategy involving successive opening, reduction and coupling led to the analogs 24 
and 25. The assays of benzylidene analogs 21 and 22 showed a very low cytotoxic activity, which 
again can be attributed to the absence of the essential C2-benzoate group. However, the analogs 23 
and 24 also exhibited very low cytotoxic activity in spite of the presence of the C2-benzoate group. 
Recent SAR studies of structural variations at C4 revealed that the substituent at C4 is also of 
crucial importance for cytotoxic activity. Therefore, the lack of activity of 23 and 24 (and 21 and 
22) most likely must be attributed to the absence of the acetate at C4. It should be noted that the 
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last-mentioned strategy allows the acetylation of the C4-hydroxyl function This reaction is 
currently under investigation 
Compound 17 which lacks the Cl-hydroxyl group (vide supra) served as precursor for the 
preparation of 1,7-dideoxypachtaxel analogs, which until now have not been reported In chapter 6 
the first approaches to the synthesis of such 1,7-dideoxy analogs are described The most successful 
route appeared to be the one in which the C2-hydroxyl group of 17 was protected with an 
ethoxyethyl function to give compound 26 (scheme 4) Using the standard methodology for the 
introduction of the oxetane nng compound 27 was obtained 
Scheme 4 
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1 7-dideoxy 9-acetyl 9(R)-
dihydropaclitaxel (28) 
To complete the synthesis of l,7-dideoxy-9-acetyl-9(R)-dihydropachtaxel 28 a senes of 
operations has to be carried out, viz reduction of the СІЗ-carbonyl, introduction of the benzoate at 
C2, the acetate at C4, and the side chain at CI3 and transformation of the C9,C 10-isopropyhdene 
group to the bis-acetate These reactions could not be completed in the context of this thesis, but 
will be carried out by other members of the research group 
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Het diterpeen paclitaxel (1) (figuur 1), dat wordt geïsoleerd uit de schors van de Noord-
Amerikaanse taxusboom, Taxus brevifolia, is een nieuwe en veelbelovende antitumor-verbinding. 
Het is goedgekeurd door de Amerikaanse overheid voor de behandeling van patiënten met 
vergevorderde eierstok- of borstkanker. 
Figuur 1 
De complexe structuur van 1 alsmede het unieke werkingsmechanisme vormen de stimulans 
voor uitgebreid onderzoek naar de synthese van paclitaxel en nieuwe analoga. Onlangs is de 
synthese van paclitaxel gerealiseerd, zowel via semisynthese, uitgaande van 10-dcacetylbaccatine 
III (2) als via totaalsynthese. 
De Structuur Activiteit Relatie (SAR) studies zijn veelal uitgevoerd met analoga die 
gesynthetiseerd zijn door het structureel modificeren van paclitaxel zelf. In sommige gevallen zijn 
uitgangsstoffen gebruikt die geïsoleerd zijn uit verschillende soorten taxusbomen. 
Taxine В (3), het meest voorkomende taxaanderivaat in de naalden van de Taxus taccata (figuur 
1), is nauwelijks onderzocht als een uitgangsstof voor de synthese van paclitaxel en analoga ervan. 
Uit een retrosynthetische analyse bleek dat voor de synthese van paclitaxel, uitgaande van taxine B, 
meer dan 20 reactiestappen nodig zijn. Vooral de introductie van de 7-hydroxylgroep bleek erg 
moeilijk te zijn. Echter uit in vitro testen werd duidelijk dat de 7-hydroxylgroep niet belangrijk is 
voor de cytotoxische activiteit, derhalve werd het onderzoek toegespitst op de synthese van 7-
deoxypaclitaxel analoga. 
Uit SAR studies is tevens bekend dat de oxetaanring, de paclitaxel zijketen en de hydroxylgroep 
op C2' belangrijk zijn voor de cytotoxische activiteit en dat de functionele groepen aan de 
"bovenzijde" van paclitaxel op de posities C7, C9 en CIO van mindere betekenis zijn. De 
"onderkant" van paclitaxel met name de posities Cl, C2 en C4, was aan het begin van het 
onderzoek nauwelijks onderzocht. 
In dit proefschrift wordt de synthese van enkele 7-deoxypaclitaxel analoga, met structuurvariaties 
op posities Cl, C2 and C4 beschreven. Op de posities C9 en CIO, hebben alle analoga vrije 
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hydroxylgroepen of hydroxylgroepen die beschermd zijn in de vorm van een isopropylideenacetaal. 
In hoofdstuk 3 wordt de isolatie van ruwe taxine В (3a-f) en de omzetting ervan in de nieuwe 7-
deoxypaclitaxel analoga 6, 7, 8, en 9, via de oxetaanverbindingen 4 en 5 beschreven (schema 1). 
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De cytotoxische activiteit van de analoga 6, 7, 8 en 9 werd getest in zeven goed 
gekarakteriseerde menselijke tumorcellijnen. Deze analoga vertoonden een zeer lage cytotoxische 
activiteit in deze cellijnen. Deze vinding is in overeenstemming met recente SAR-studies, op grond 
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waarvan de afwezigheid van activiteit kan worden toegeschreven aan het niet aanwezig zijn van de 
benzoaatgroep op C2. Omdat noch de THP-groep op C2 noch het isopropylideenacetaal op C1,C2 
verwijderd kon worden zonder dat andere delen van het molecuul beschadigd werden, moest er een 
alternatieve strategie gevonden worden voor de synthese van 7-deoxypaclitaxel analoga met de voor 
de cytotoxische activiteit noodzakelijke C2-benzoaatgroep. 
In hoofdstuk 4 wordt een strategie beschreven voor de modificatie van taxine В door een 
gelijktijdige bescherming van de beide hydroxylgroepen op Cl en C2. In eerste instantie werd 
gekozen voor een cyclische carbonaatgroep omdat met een geschikte reactie hiermee de benzoaat op 
C2 kan worden verkregen. De benodigde uitgangsstof 11 kan goed worden bereid uitgaande van 10 
door reactie met 1,1-carbonyldiimidazool (schema 2). 
Schema 2 
У C(OR)4, PTS 
R = Me, Et 
H . OS(0)2CH3 
HO I HO Îj-OfBDMS 
P h ^ O 
Behandeling van 11 met fenyllithium gaf 12, waarin het cylisch carbonaat regioselectief geopend 
is tot de C2-benzoaatgroep en waarin ook de kaneelzure zijketen is verwijderd. 
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Het bleek helaas niet mogelijk om de oxetaanring te introduceren. Tijdens de ontscherming van 
de primaire hydroxylgroep in verbinding 13 migreerde de benzoylgroep van de C2- naar de C20-
hydroxylgroep, met verbinding 14 als ongewenst eindresultaat. 
Vervolgens werd geprobeerd om het cyclische carbonaat in een latere fase van de syntheseroute 
te introduceren, namelijk via een gemaskeerd cyclisch carbonaat. Behandeling van 10 met 
tetramethyl- of tetraethyl orthocarbonaat, in de aanwezigheid van p-tolueensulfonzuur, zou 
verbinding 15 of 16 hebben moeten opleveren (schema 2). Echter de synthese van 15 of 16 kon niet 
worden gerealiseerd. 
Als derde mogelijkheid voor de gelijktijdige bescherming van de hydroxylgroepen op Cl en C2 
werd een benzylideenacetaal gekozen. Behandeling van het mengsel van 10 en 17 met het 
dimethylacetaal van benzaldehyde, in de aanwezigheid van p-tolueensulfonzuur, leverde verbinding 
18 op, waarbij 17 werd teruggewonnen (schema 3). Verbinding 18 werd verder omgezet, via 
bekende methodes, in de oxetaanverbinding 19. 
Schema 3 
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Vervolgens werden een aantal, uit de literatuur bekende, methoden onderzocht voor de opening 
van het benzylideenacetaal van 19 tot de benzoaatgroep op C2. De meest geschikte methode 
hiervoor bleek te zijn de behandeling van 19 met tert-butylhydroperoxide, in de aanwezigheid van 
een katalytische hoeveelheid Pd(OAc)2 waarbij verbinding 20 werd verkregen. 
Het benzylideenacetaal, dat nog niet eerder werd toegepast in de taxaanchemie, lijkt interessante 
perspectieven te bieden voor de gelijktijdige bescherming van de Cl- en C2-hydroxylgroep en de 
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invoering van de benzoaatgroep op C2. 
In hoofdstuk 5. werden vier strategieën, gebaseerd op de opening van de benzylideenacetaal tot 
de C2-benzoaatgroep, beschreven voor een syntheseroute naar 7-deoxypacIitaxel analoga die een 
C2-benzoaatgroep bezitten. Deze strategieën verschillen voornamelijk in de volgorde van drie 
belangrijke reacties, namelijk de reductie van de C13-carbonyl, het koppelen van de paclitaxel 
zijketen en de opening van het benzylideenacetaal. De reductie van de СІЗ-carbonyl bleek hierbij 
een sleutelstap te vervullen en daarmee tegelijkertijd bepalend voor het succes van een strategie. 
Van de vier benaderingen werden er twee met succes voltooid. In de eerste werd als volgorde 
gekozen, de reductie, koppeling en acetaalopening, waarbij de analoga 21, 22 en 23 werden 
verkregen (figuur 2). Door de volgorde anders te kiezen, namelijk eerst acetaalopening vervolgens 
de reductie en als laatste de koppeling, werden de analoga 24 en 25 bereid. 
Figuur 2 
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De benzylideenanaloga 21 en 22 vertoonden een erg lage cytotoxische activiteit, hetgeen werd 
toegeschreven aan de afwezigheid van de C2-benzoaatgroep. Echter ook de analoga 23 en 24 
vertoonden een lage cytotoxische activiteit, ondanks de aanwezigheid van de C2-benzoaatgroep. 
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Recente SAR-studies van paclitaxel analoga met variaties op C4 hebben aangetoond, dat ook de 
substituent op C4 belangrijk is voor de cytotoxische activiteit. Daarom wordt verondersteld, dat het 
ontbreken van activiteit voor 23 en 24 (en misschien zelfs ook voor 21 en 22) veroorzaakt wordt 
door de afwezigheid van de acetylgroep op C4. De laatstgenoemde reactiesequentie laat de 
introductie van de acetylgroep aan de C4-hydroxyl goed toe, waardoor een potentieel actief analoog 
binnen bereik is. 
Boven werd vermeld dat de verbinding 17 werd verkregen bij de transacetalisering. Deze 
verbinding kan dienen als uitgangsstof voor de bereiding van 1,7-dideoxypaclitaxel analoga, die nog 
niet eerder in de literatuur zijn vermeld. In hoofdstuk 6 worden een aantal mogelijke routes voor de 
semisynthese van 1,7-dideoxypaclitaxel analoga beschreven. Het meest succesvol bleek de route te 
zijn waarin de C2-hydroxylgroep van 17 werd beschermd als een ethoxyethylacetaal, resulterend in 
verbinding 26 (schema 4). Invoering van de oxetaanring gebruikmakend van standaard-
methodologie, leverde verbinding 27 op. 
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1,7-dideoxy-9-acetyl-9(R)-
dihydropaclitaxel (28) 
Een verdere bewerking van deze verbinding 27, namelijk reductie van de C13-carbonyl, de 
introductie van de benzoaatgroep op C2, de acetaatgroep op C4 en de zij keten op C13 en de 
omzetting van het C9,C10-isopropylideenacetaal in het C9,C10-bisacetaat zal naar verwachting 
kunnen leiden tot l,7-dideoxy-9-acetyl-9(R)-dihydropaclitaxel 28. Deze experimenten worden thans 
uitgevoerd in de Nijmeegse onderzoeksgroep. 
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